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Abstract
Current pharmacological therapies fail to address the final end-point of cardiac
ischaemia — the death and dysfunction of cardiomyocytes. Advances in stem
cell biology have provided hope, for the first time, of addressing this underly-
ing pathology. The work performed here was designed to further understanding
of the mechanisms by which bone marrow derived cells improve damaged my-
ocardium.
In situ hybridisation was used to detect sex chromosomes within ex-planted,
human, sex-mismatch hearts. Host derived cells were found at low frequency in
donor hearts, suggesting ongoing post-natal cardiac tissue repair.
Human mesenchymal stem cells were examined in vitro and in a rat model
of ischaemia-reperfusion injury. Cardiomyocytes were not formed when cultured
with either 5-azacytidine or ascorbic acid, and the cells failed to home to the is-
chaemic heart or improve cardiac function.
In the same model, rat mononuclear cells significantly reduced infarct size
when administered immediately upon reperfusion. Cells were rarely identified
within the myocardium. No functional improvement was seen acutely, but at
seven days cardiac function had improved. The low frequency of cells retained
in the heart suggested that a process other than transdifferentiation accounted
for the observations.
Hence, evidence for paracrine actions was sought. In the same model, apop-
tosis and necrosis in cardiomyocytes were found to be significantly reduced.
Western blots demonstrated activation of the reperfusion salvage kinase path-
way, analogous to that seen in ischaemic pre- and post-conditioning. Blocking
this pathway abolished the infarct size reduction. Global proteomic analysis con-
firmed alterations in protein expression consistent with known cardioprotective
pathways.
In conclusion, endogenous myocardial repair processes are inadequate to
compensate for pathological insults. Supplementation with mononuclear cells in
an ischaemia-reperfusion model produced significant benefit to infarct size and
cardiac function. The mechanism of benefit appears to be induced by paracrine
effects activating pro-survival pathways.
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CHAPTER 1
Introduction
This thesis describes the experiments, methods and results obtained dur-
ing my PhD studies. It begins with a review of cardiovascular heart dis-
ease (CHD) pathology and epidemiology. This naturally leads to a look
at cardiovascular pharmacology, outlining failings of present day phar-
maceutical treatments, providing an understanding of why developments
in stem cell biology are needed and why they may one day produce im-
proved clinical therapies. I hope this thesis, which describes adult stem
cell (ASC) and progenitor cell biology and their therapeutic application
in cardiovascular disease, will help improve our current understanding of
their biology and potential uses.
1.1 Cardiac Epidemiology
Cardiovascular disease (CVD) is the leading cause of death in the world
today and the need for ongoing research in this field is essential. Ischaemic
heart disease (IHD) and cerebrovascular disease (stroke) were the leading
causes of death in both low and high income countries in 2001, respon-
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Table 1.1: Leading causes of death in high income countries (2001)
Rank Cause Deaths (millions) Percentage of total Deaths
1 Ischaemic heart disease 1.36 17.3
2 Cerebrovascular disease 0.78 9.9
3 Trachea, bronchus, and lung cancers 0.46 5.8
4 Lower respiratory infections 0.34 4.4
5 Chronic obstructive pulmonary disease 0.30 3.8
6 Colon and rectal cancers 0.26 3.3
7 Alzheimers and other dementias 0.21 2.6
8 Diabetes mellitus 0.20 2.6
9 Breast cancer 0.16 2.0
10 Stomach cancer 0.15 1.9
Table 1.2: Leading causes of death in low and medium income countries (2001)
Rank Cause Deaths (millions) Percentage of total Deaths
1 Ischaemic heart disease 5.70 11.8
2 Cerebrovascular disease 4.61 9.5
3 Lower respiratory infections 3.41 7.0
4 HIV/AIDS 2.55 5.3
5 Perinatal conditions 2.49 5.1
6 Chronic obstructive pulmonary disease 2.38 4.9
7 Diarrhoeal diseases 1.78 3.7
8 Tuberculosis 1.59 3.3
9 Malaria 1.21 2.5
10 Road traffic accidents 1.07 2.2
sible for 12 million deaths globally, accounting for almost one-quarter of
all deaths worldwide. In the same period, IHD accounted for 1.36 mil-
lion deaths in high income countries (17.3% of all deaths) and 5.7 million
deaths in low and medium income countries (11.8% of all deaths). In both
income categories, IHD was ranked the number one cause of death. See
Table 1.1 and Table 1.2 (Mathers et al., 2006). Therefore, IHD is clearly the
world’s number one health problem in terms of deaths caused and, con-
trary to popular opinion, is an important cause of mortality in developing
countries as well as westernised nations.
1.1.1 The Spread Of Cardiovascular Disease
Cardiovascular disease is predicted to remain the leading cause of global
mortality for the foreseeable future. Despite improvements in health ser-
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vices and pharmaceutical treatments that have reduced mortality from
IHD in developed countries (see Figure 1.1), mortality prediction models
forecast an increase in mortality in the near future. The reduced mortality
in developed countries does not compensate for the increasing mortality in
developing countries as their populations age and socioeconomic changes
expose the populace to increasing levels of cardiovascular risk factors such
as smoking, hypertension, hypercholesterolaemia, diabetes, and a seden-
tary lifestyle. The World Health Organisation (WHO) has predicted 25 mil-
lion CVD deaths worldwide by 2020 (Chockalingam & Balaguer-Vintro,
1999; WHO, 2002). These predictions have been made taking into consid-
eration the advances in medical treatment and an overall decline in mor-
tality rate in Western countries (Boersma et al., 2003; Reitsma et al., 1999;
Tunstall-Pedoe et al., 1999).
Thus, CVD is currently the leading cause of death worldwide and this
situation is predicted to escalate with global mortality increasing from 7
million in 2001 to 25 million in 2020, a rise of more than 350%.
The predicted rise in CVD in developing countries is a based on several
observations. Firstly, increasing life expectancy due to reduced infant and
childhood deaths and an improvement in nutrition combined with a de-
cline in infectious diseases. Secondly, industrialisation and urbanisation in
developing countries has increased the levels of traditional CV risk factors
amongst the populace and the duration of exposure has also increased due
to extended life expectancy. This combination of events will drive the in-
creasing levels of cardiovascular mortality of the next few decades (Reddy
& Yusuf, 1998).
The increasing prevalence of CV risk factors is not well documented in
the majority of developing countries, but data has been collected in India
and China and can be used as a broad marker for the pattern of change in
CV risk factors during industrialisation. Within a small number of years,
body weight, blood pressure and cholesterol levels were all seen to in-
crease in the China from 1984–86 to 1988–89 (Yao et al., 1993). This trend
has also been observed in India when urban populations were compared
with their rural contemporaries (Reddy, 1993).
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decrease in death rates
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+30% +53%
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+26% +20%
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Figure 1.1: Percentage change in coronary heart disease death rates, in people
aged 35 to 74, years 1988–1998, in selected countries. Reproduced from (Mackay
et al., 2004).
The prevalence of diabetes is also noted to be on an upward trend.
Projections suggest that in China, diabetes will increase from 1.4% to 2.4%
between 1995 and 2025. In India, the equivalent figures are from 2.1% to
3%. (Leeder et al., 2004).
Tobacco use is also projected to increase. The WHO predict that by the
year 2020, tobacco will become the largest single cause of death, account-
ing for 12.3% of global deaths (WHO, 1996). In India alone, the tobacco
attributable death toll will rise from 1.4% in 1990 to 13.3% in 2020. It is es-
timated that by 2025, tobacco-attributable deaths in China will be a stag-
gering 2 million annually (Peto et al., 1996). A significant proportion of
the tobacco related mortality, in India and China, will be attributable to
cardiovascular deaths.
28
Introduction 1.2 The Burden of Cardiac Disease
1.2 The Burden of Cardiac Disease
The burden of cardiac disease cannot be completely described by docu-
menting the number of deaths it causes. True comprehension of the im-
pact of CVD must take into account a wider range of personnel and social
measures. For example: the cost of treatment both in staff and drugs, the
impact on the quality of life of patients, and the economics of lost working
hours due to poor health.
In purely financial terms, CVD is costly, estimated costs to the U.K. are
30.7 billion pounds a year, 47% of this is due to direct health care costs, 27%
to productivity losses, and 26% to the informal care of people with CVD.
As a separate entity, CHD is estimated to cost the U.K. nearly 9 billion
pounds a year, 36% is attributable to direct health care costs, 43% to pro-
ductivity losses, and 21% to the informal care of patients (Allender et al.,
2008a).
At the European level, CVD estimated expenses for the European
Union (EU) economy are 192 billion pounds a year, and CHD is estimated
to cost the EU economy 49 billion pounds a year (Allender et al., 2008b).
CVD is also a significant economic burden in low- and middle-income
countries. CVD and diabetes are estimated to reduce gross domestic prod-
uct by 1–5% in low- and middle-income countries. For the period of 2006–
2015, China is expected to lose $558 billion in national income due to the
combination of heart disease, stroke and diabetes (WHO, 2009).
Apart from monetary cost there is also a burden on clinical services,
428,000 inpatient cases were treated for CHD in National Health Service
hospitals in 2006–07 in England, and a further 49,000 in Scotland. These
represent 4% of all inpatient cases in men and 2% in women for England
(Allender et al., 2008a). The number of inpatient cases treated for CHD has
increased by over 13% in the last six years.
In human terms, CVD has also been documented to cause a substantial
burden. The WHO prefer to use the disability-adjusted life year (DALY) as
a summary measure of population health, this measure combines years of
life lost from premature death and years of life lived in less than full health.
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Table 1.3: Leading causes of burden of disease in low and medium income coun-
tries (2001)
Rank Cause DALYS (millions of years) Percentage of total DALYS
1 Perinatal Disease 89.07 6.4
2 Lower respiratory infections 83.61 6.0
3 Ischaemic heart disease 71.88 5.2
4 HIV/AIDS 70.80 5.1
5 Cerebrovascular disease 62.67 4.5
Table 1.4: Leading causes of burden of disease in high income countries (2001)
Rank Cause DALYS (millions of years) Percentage of total DALYS
1 Ischaemic heart disease 12.39 8.3
2 Cerebrovascular disease 9.35 6.3
3 Unipolar depressive disorder 8.41 5.6
4 Alzheimer’s and other dementias 7.47 5
5 Trachea, bronchus, and lung cancers 5.40 3.6
DALYs for a specific cause are calculated as the sum of the years of life lost
due to premature mortality (YLL) from that cause and the years of healthy
life lost as a result of disability (YLD) for incident cases of the health con-
dition as follows: DALY = YLL + YLD. The YLL are essentially calculated
as the number of cause-specific deaths multiplied by a loss function spec-
ifying the years lost as a function of the age at which death occurs.
In low and medium income countries IHD is the third largest cause of
disease burden (71.88 million DALYs, 5.2% of total DALYs, see Table 1.3).
In high income countries CVD causes the highest burden of DALYS with
IHD ranked as the number one cause (12.39 million DALYs, 8.3% of to-
tal DALYs) and cerebrovascular disease is ranked second (9.35 million
DALYs, 6.3% of total DALYs, see Table 1.4).
1.3 Heart Failure
The global rise of CVD will not only be constituted by acute problems such
as myocardial infarction but also by the chronic sequelae of these events.
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Heart failure will be the most significant chronic condition that increases
as a result of the world rise in CVD. This is a notable issue as heart failure
is associated with high rates of mortality and morbidity, it is also a major
drain on health care funding, infrastructure and personnel.
Heart failure is a clinical syndrome that arises due to impaired func-
tion of the left ventricle and is characterised clinically by the presence of
dyspnoea, oedema and fatigue. The commonest cause, in about 2/3rds
of cases, of impaired function of the left ventricle is loss of, or impaired
function of, cardiomyocytes secondary to ischaemic insults McMurray &
Stewart (2000).
The final common pathway of all cases of heart failure is loss or im-
paired function of cardiomyocytes. This is a fundamental concept in un-
derstanding the approach of cellular therapy — to replace lost or damaged
cells with new fully functional cells. The importance of this point is further
underlined by the knowledge that no other treatment addresses the un-
derlying primary pathology of heart failure. All modern pharmacological
treatments do not treat cell loss, but more commonly the neurohormonal
sequelae of the cell loss and consequent haemodynamic changes. Only,
one current treatment does treat cell loss directly, and that is heart trans-
plantation, which could be considered the ultimate cell therapy. The im-
portance of developing a treatment that confronts the fundamental pathol-
ogy of heart failure is essential to combat the current and predicted epi-
demic of heart failure and its devastating effects on the individual, the
population and the economy.
1.3.1 Heart Failure Epidemiology
The outlook for patients with heart failure has improved in recent years,
but mortality remains high especially compared to other diseases. Patients
with heart failure have one-year survival rates that are comparable, if not
worse, than patients suffering with cancer. For example, one year from di-
agnosis of breast cancer 92% of patients are expected to be alive compared
with only 62% of patients with a diagnosis of heart failure — even with
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current treatments (Cowie et al., 2000; MacIntyre et al., 2000; Quinn et al.,
2001). For men diagnosed with heart failure, median survival is only 1.7
years, whilst for women it is 3.2 years (Kannel, 2000).
As well as causing a significant mortality, heart failure also has a ma-
jor impact on the quality of life of those afflicted. A recent American
study of patients with advanced heart failure (New York Heart Associ-
ation (NYHA) functional classification III–IV) demonstrated they experi-
ence numerous symptoms, significant symptom distress, and a compro-
mised quality of life. Quality of life was strongly associated with symptom
distress, psychological well-being and functional status. The most preva-
lent symptoms were lack of energy (66%), dry mouth (62%), shortness of
breath (56%), and drowsiness (52%). Pain was reported by about one-third
of patients. Quality of life was moderately compromised (Multidimen-
sional Index of Life Quality composite)(Blinderman et al., 2008). A larger
U.K. based study, also documented that those with a diagnosis of heart
failure had significant impairment of all the measured aspects of physical
and mental health, in addition to declines in physical functioning. Notably,
the physical health burden was significantly greater than that suffered in
other serious common chronic disorders, such as osteoarthritis or chronic
obstructive pulmonary disease (Hobbs et al., 2002).
In the last decade heart failure has emerged as a major health problem
in developed countries, imposing an escalating burden on their health care
systems because of the high mortality and morbidity combined with the
high prevalence of the condition. For example, in the U.K. there are about
68,000 new cases of heart failure each year, about 38,000 in men and 30,000
in women, and the total prevalence of heart failure in the UK is estimated
at 707,000 in people age 45 and older (Allender et al., 2008a).
The overall prevalence of clinically identified heart failure is estimated
to be 3–20 cases/1000 population, but rises to >100 cases/1000 popula-
tion in those aged >65 years. The overall annual incidence of clinically
overt heart failure in middle aged men and women is approximately 0.1–
0.2%. However, with each additional decade of life there is an approxi-
mate doubling of this rate and the incidence of heart failure in those aged
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>85 years is approximately 2–3% (McMurray & Stewart, 2000). Given the
prevalence of heart failure, and the morbidity and mortality it causes it
is unsurprisingly a frequent cause of hospital admission. Statistics from
the United States in 1991 established that heart failure was the primary
discharge diagnosis in approximately 790,000 hospitalisations and consti-
tuted the leading diagnostic related group among hospitalised patients
aged over 65 years of age (Lenfant, 1994).
The economic burden for caring for chronic heart failure is significant.
The cost of managing heart failure in the early 1990s was estimated to be
1–2% of total health care expenditure. As hospital care consumes a signif-
icant proportion of this expenditure, and rates of heart failure related hos-
pitalisation have risen, and new costly device therapies are emerging this
will be an an underestimate of the current cost of heart failure (McMurray
& Stewart, 2000).
For the UK in 1995, it is estimated that 988,000 patients needed treat-
ment for heart failure, the ’direct’ cost of health care for these patients was
estimated to be £716 million, or 1.83% of total NHS expenditure. Hospi-
talisations and drug prescriptions accounted for 69 and 18% of this expen-
diture, respectively. The additional costs associated with long-term nurs-
ing home care and secondary heart failure admissions accounted for a
further £751 million (2.0 % of total NHS expenditure). By the year 2000,
these costs were estimated to rise so that the combined total direct cost of
heart failure would have risen to £905 million — equivalent to 1.91% of
total NHS expenditure — the predominant cost component being hospi-
talisation (Stewart et al., 2002). Similar costs, are incurred throughout Eu-
rope, data suggest that approximately 1% of national health care budgets
is spent on individuals with heart failure (Eriksson, 1995).
1.3.2 Future Burden of Heart Failure
Despite a decline in age adjusted mortality from CHD in developed coun-
tries overall, the number of patients with chronic CHD is increasing. Con-
sequently, heart failure is expected to become an increasingly prevalent
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cause of mortality and morbidity in then next two to three decades. The
central causes of this trend are threefold. Firstly, the rise of cardiovascular
disease in low and medium income countries, without the facilities and
infrastructure to provide best care, will lead to an increase in chronic se-
quelae of CVD.
Secondly, in high income countries chronic conditions as a result of
IHD, e.g., heart failure will rise due to improvements in health care that
are reducing acute mortality from IHD and resulting in an increase in
those surviving but suffering from long term debilitating illnesses such
as heart failure (Reitsma et al., 1999). In particular, it has been shown that
survival after acute myocardial infarction has increased notably over the
past decade, at least in part because of better medical treatment (Rosa-
mond et al., 1998). As coronary artery disease is the most powerful risk
factor for heart failure (and its most important precursor) it is likely that
the aforementioned trends will lead to an increase its future prevalence.
Thirdly, the rise in heart failure will also be driven by the changing
demographics of the population. Age has a significant influence on the
incidence of heart failure as shown in Figure 1.2 (Cowie et al., 1999). Thus,
the effect of the increasing mean age of the population, the inversion of the
“population pyramid”, as shown in Figure 1.3, from greater numbers of
young people to greater numbers of older people will cause an increasing
incidence of heart failure over the next half a century (Schafer et al., 2009).
Heart failure will be a significant health care issue in the future due
to these circumstances and will become a more common manifestation of
chronic heart disease and contribute to many more deaths (McMurray &
Stewart, 2000).
Formal projections of the future burden of heart failure have been un-
dertaken. For example, an analysis of demographic trends in the Nether-
lands has predicted that the prevalence of heart failure caused by coronary
heart disease will rise by approximately 70% from 1985 to 2010 (Bonneux
et al., 1994).
An additional factor increasing prevalence of heart failure is improved
long-term trends in the survival of patients with HF, with an overall de-
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Figure 1.2: Prevalence of heart failure in men and women is significantly in-
creased with age, from Cowie et al. (1999).
cline in mortality of approximately 12% per decade from 1950 to 1999 in
the Framingham Study (Ho et al., 1993). Moreover, reports from Scotland,
Sweden, and the U.K. have also suggested that survival rates may also be
improving following hospital discharge (Cowie, 1999; Cowie et al., 1999).
The knock on effect of an increased prevalence of chronic conditions such
as heart failure will have a measurable impact on health care services. For
example, hospital admissions for HF are projected to increase by 50% over
the next 25 years (Allender et al., 2006).
The epidemiology of HF in Scotland has been well documented, from
this data HF is predicted to rise in men (31%) and women (17%) by 2020.
The annual number of male and female GP visits is likely to rise by 40%
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Figure 1.3: Predicted change in world population age distribution in men and
women between 1950 and 2030, from Schafer et al. (2009).
and 16% in the longer term (124,000 and 126,000 visits), respectively. By
2020 the annual number of hospital admissions associated with a princi-
pal diagnosis of heart failure is expected to increase by 34% (from 5,500 to
7,500) in men and by 12% (from 7,800 to 8,500) in women (Stewart et al.,
2003). Historical records from Scotland reveal that the number of hospital
discharges with heart failure coded as the primary diagnosis rose by 60%
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between 1980 and 1990 (McMurray et al., 1993). The pattern in Scotland of
steadily increasing admissions appears to be repeated in all industrialised
countries, especially among older individuals. Overall, annual admission
rates for 1990 ranged from 10–40 admissions/ 10,000 population and in-
creased to >75 admissions/10,000 population in those aged >65 years
(McMurray & Stewart, 2000). Data for developing countries is limited but
some predict the burden of heart failure will increase dramatically in the
emerging economies (Levy et al., 2002).
The epidemiological data and predictive models suggest significant in-
creases in the prevalence of HF in the future with major financial, health
care and humanitarian costs. Unless major unexpected changes occur in
the incidence of heart failure, the burden of this disorder will continue to
increase. Future health service and research planning must take this into
account — a major argument for funding to develop new treatments such
as cellular therapy that can for the first time address the primary pathol-
ogy of heart failure.
1.3.3 Heart Failure and the Hope for Stem Cell Treatment
Heart failure is as a progressive disorder, which is most commonly initi-
ated after a primary event that damages the heart muscle, with a resultant
loss of functioning cardiac myocytes that impairs the ability of the my-
ocardium to contract and generate force. Thus, the primary initiating aeti-
ology of heart failure is loss of functioning cardiomyocytes, it is this deficit
that stem cell therapy is attempting to address.
The primary cell injury or index event is usually ischaemic in origin,
and may be acute, as in myocardial infarction, or in the case of less com-
mon causes of HF, may be gradual as with hypertensive or valvular heart
disease induced HF.
The impaired contraction of the heart leads to the symptoms of HF,
but also to the activation of neurohormonal and cytokine responses that
are initially helpful in the course of the disease, but eventually produce
negative effects on the function of the heart and lead to HF progression
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with worsening clinical symptoms and signs.
Compensatory systems activated by HF that lead to deleterious effects
on the heart include the adrenergic system and the renin angiotensin sys-
tem (RAS). These systems initially compensate for reduced cardiac func-
tion by maintaining cardiac output through increased retention of salt
and water, peripheral vasoconstriction, and increasing contractility of the
heart. However, with time the sustained activation of these systems can
lead to secondary end-organ damage within the ventricle, with worsen-
ing LV remodelling and subsequent cardiac decompensation (Jessup &
Brozena, 2003; McMurray & Pfeffer, 2005; Triposkiadis et al., 2009).
There is expectation that stem cell treatment to replace dead or func-
tionally impaired myocytes and vascular cells will treat the underlying
pathology of heart failure. The aim being the restoration of LV mass
and function, with subsequent abolishment of the secondary maladaptive
adrenergic and neurohormonal responses. The progress towards such an
achievement will now be reviewed.
1.4 Stem Cell Potential — An Overview
Anyone who has pondered the cellular necessities of reproduction will
understand the inherent potential of a limited number of stem cells to pro-
duce multiple differentiated tissue types, eventually resulting in the birth
of a new organism. The stem cells containing this potential have been la-
belled embryonic stem cells (ESCs). They can be isolated from the inner
cell mass of the developing embryo at about five days following fertil-
isation. These cells are pluripotent and can produce all the tissue types
needed to form a functional organism. Given that multiple cell types are
generated from a single embryonic stem cell origin during embryonic de-
velopment, the potential of such a cell for cardiac repair is self-evident.
The adult organism has no ESCs, only adult stem cells (ASCs) and pro-
genitor cells. ASCs like ESCs share important stem cell defining character-
istics — capacity to self-renew and to produce specialised daughter cells
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while maintaining the integrity of their own DNA and phenotype. Unlike
ESCs, ASCs have a more limited menu of daughter cells appropriate to
the tissue they reside in, which they can serve up when required. For ex-
ample, haematopoietic stem cells being multipotent have the capacity to
produce all blood cell lineages. In contrast, progenitor cells, such as en-
dothelial progenitor cells, are not true stem cells — they are only able to
undergo several cycles of cell division to produce one type of daughter cell
and are unable to undergo indefinite growth, i.e., they lack clonogenicity.
ESCs have the greatest potential for regenerating the myocardium, as
with the correct protocol their differentiation can be controlled to pro-
duce any cell type needed for therapeutic use. The potential of ESCs is
counter balanced by several significant drawbacks: collection of cells from
embryos raises serious ethical considerations thus limiting their availabil-
ity; implanted cells would be allogeneic and require immunosuppression
to prevent rejection; and lastly; the potential of growth and differentiation
that makes the ESCs desirable as a cellular repair tool can become unreg-
ulated after transplantation, resulting in tumour formation.
Hence, although ESCs are an attractive option for use in cardiac repair,
researchers have turned to ASCs in an attempt to bypass the issues of ESC
use noted above.
A wide range of adult cells have been reported to induce cardiac repair
or functional improvement. These include bone marrow derived mononu-
clear cells (BMMNCs) that consist of haematopoietic stem cells (HSCs),
mesenchymal stem cells (MSCs) and endothelial progenitor cells (EPCs).
Other adult derived progenitor cells include skeletal myoblasts, cardiac
resident stem cells, and umbilical cord blood stem cells.
The potential for cell therapy to develop as a new treatment has created
a new field of research — Regenerative Medicine.
1.4.1 Regenerative Medicine
Regenerative Medicine is a new field encompassing the direct transplanta-
tion of ESC and ASCs, or the use of products and new molecules derived
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from their study with the aim of restoring tissue and organ function in
the face of diverse pathologies. The field is rapidly expanding and has at-
tracted a wide portfolio of scientists and clinicians from within all areas
of research, with varied interests encompassing: the study of cells in tis-
sue culture and in complex in vitro models; the study of the animals with
intrinsic regenerative ability (e.g., the zebrafish can regenerate lost my-
ocardium with new cardiomyocytes and adult salamanders can regener-
ate limbs); the use of complex large and small animal models investigating
the fate of transplanted cells; and finally, to the implementation of clinical
trials in regenerative medicine.
The foundation of stem cell therapy as a treatment for cardiac disease is
based around the concept that myocardial infarction results in large-scale
cell loss, and heart failure is a direct result of loss of these cells. The idea
that stem cells could be used to replace lost or damaged cells to reverse
the effects of cardiomyocyte loss has evolved over the last one and a half
decades. The different cell types that may effect this repair are introduced
below and the discussion will be further expanded in the following sec-
tions.
1.4.2 Embryonic Stem Cells
A major step towards the use of human ESCs for transplantation was
taken in 1998 with the first report of embryonic cell line derivation in hu-
mans (Thomson et al., 1998). Since this time, multiple independent centres
have derived cardiomyocytes from ESCs that hold up to close scrutiny
when examined histologically, physiologically and genetically. Further
progress has been delayed due to the problems previously discussed in-
cluding observation of a dose-dependent induction of teratomas with im-
plantation of undifferentiated human ESCs, albeit at the same time as pro-
ducing significant cardiac muscle regeneration (Behfar et al., 2005). For
the time being, the issue of tumour formation has been addressed by pre-
differentiating ESCs into a cardiomyocyte phenotype prior to their trans-
plantation (Laflamme et al., 2007). Currently, ESC research is focusing on
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refining techniques for differentiation, selection, and purification of car-
diomyocytes and industrialisation of these techniques prior to attempting
clinical trials.
1.4.3 Inducible Pluripotent Stem Cells
Several independent investigators have produced a pluripotent autolo-
gous stem cell alternative to ESCs, which retains the differentiation po-
tential of ESCs, but without the risk of tissue rejection following trans-
plantation or causing ethical concerns — as the cells can be produced
from a patients own cells, e.g., from the mouth (Park et al., 2008), or
even from a few plucked hairs (Aasen et al., 2008). These cells have been
termed inducible pluripotent stem cells (iPSCs). They were first identified
in 2006 when mouse fibroblasts were reprogrammed back to an undiffer-
entiated pluripotent state by inserting four genes, Oct3/4, Sox2, KL4 and
c-Myc, into differentiated somatic cells (Takahashi & Yamanaka, 2006). The
treated cells subsequently took on the morphological phenotype of ESCs
and were demonstrated in vivo and in vitro to have the same differentia-
tion potential as ESCs, able to form all three germ layers, i.e, mesoderm,
endoderm and ectoderm.
Following the demonstration of iPSC production in mice, the results
were replicated in humans. Just as in mice, when human adult cells were
reprogrammed by retroviral transduction of the same four genes, they re-
turned to an undifferentiated pluripotent state with the ability to differen-
tiate into all three germ layers (Aasen et al., 2008; Park et al., 2008; Taka-
hashi et al., 2007).
The potential of an autologous pluripotent cell derived from adult tis-
sue is considerable. Research has already progressed towards practical
applications of this emerging technology. So far functioning cardiomy-
ocytes (Zhang et al., 2009) and vascular cells (Taura et al., 2009) have
been produced demonstrating potential uses in cardiovascular regener-
ative medicine.
Despite the potential inherent in the ability to produce patient spe-
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cific iPSCs, problems remain that must be solved before they can be used
in clinical trials. The main concern is tumour genesis. The majority of
iPSC lines have been derived by inserting putative oncogenes using in-
tegrating retroviruses, e.g., lentiviruses, into the host genome which have
the potential to cause cancer. One study demonstrated up to 20% of off-
spring derived using iPSCs developed tumours (Okita et al., 2007). Ad-
vances have been made in circumventing this issue, such as the use of
non-integrating adenoviruses for gene delivery (Okita et al., 2008), or us-
ing small molecules to produce the same outcome without the need for
gene insertion (Shi et al., 2008), and one sophisticated study demonstrated
the possibility of excising the inserted genes after the iPSCs had been
formed with no impact on differentiation potential of the cells (Soldner
et al., 2009). Once the tumour genesis problem has been resolved, and the
complete mechanism of reprogramming is understood, there are consid-
erable expectations that iPSCs can provide a patient specific source of car-
diovascular cells for use in regenerative medicine.
Soon after the initial advances in human ESCs were made, and before
the discovery of iPSCs, the first evidence for a contribution to cardiac re-
pair by ASCs was made.
1.4.4 Adult Stem Cells and the Path to Clinical Trials
The first steps taken towards the promotion of adult cell therapy for car-
diovascular disease included animal experiments that demonstrated that
circulating endothelial cells of bone marrow origin could contribute to
neovascularisation in adult tissues (Takahashi et al., 1999). Evidence of
bone marrow cells contributing to skeletal muscle (Ferrari et al., 1998),
and for HSCs contributing to cardiac muscle and vasculature were also
seen (Jackson et al., 2001). Furthermore, human MSCS were shown to have
multilineage potential (Pittenger et al., 1999) and were able to form car-
diomyocytes in vitro when chemically treated (Makino et al., 1999).
Evidence from cardiac sex-mismatch transplants demonstrating car-
diomyocyte and vascular chimerism supported the idea of a circulating
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progenitor able to contribute to cell repair of endothelium and cardiac
muscle at a low frequency. Testing for the presence of the Y chromosome in
ex-planted hearts of male patients who had received female donor hearts
revealed male derived myocytes and endothelial cells. This finding was
interpreted as representing cardiac repair affected by circulating progeni-
tor cells (Quaini et al., 2002). A second similar study in which the hearts of
females, who had received male bone marrow transplants, were examined
for presence of the Y chromosome, concluded that bone marrow progeni-
tor cells were capable of transit to the heart and its subsequent repair (Deb
et al., 2003). The concept of cellular repair of the heart using bone marrow
stem cells was beginning to evolve.
Others were already successfully demonstrating that exogenously de-
rived cells could be transplanted into the heart and improve cardiac func-
tion (Li et al., 1996) (e.g., foetal cardiomyocytes (Soonpaa et al., 1994)).
Progress was also being made with skeletal myoblasts, the native stem
cell of striated muscle (Collins et al., 2005), with functional benefits being
shown when used to treat cryoinjured mouse hearts (Taylor et al., 1998).
Experiments with foetal and skeletal myoblasts had proved the con-
cept of functional improvement following cell therapy. However, both cell
types had drawbacks. Foetal cell therapy for humans would be fraught
with ethical issues and the need for immunotherapy after transplantation,
whilst studies of skeletal myoblasts were demonstrating that transplanted
cells were not able to integrate into the host myocardial syncitium (Leobon
et al., 2003).
An autologous source of cells for transplantation was extremely de-
sirable and, as all three stem cell or progenitor lines of the bone marrow
had been shown to form muscle or vascular cells (Deb et al., 2003; Jackson
et al., 2001; Makino et al., 1999; Takahashi et al., 1999) bone marrow cells
began to be investigated as a treatment for dysfunctional hearts.
Multiple animal studies initially suggested that all three cell lines from
bone marrow were able to contribute to cardiac regeneration in models
of myocardial ischaemia. MSCs were able to engraft into ischaemic my-
ocardium, and express muscle proteins in models of myocardial infarction
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(Shake et al., 2002; Toma et al., 2002). Human EPCs were able to simu-
late neoangiogenesis within the infarcted vascular bed, reducing apopto-
sis and improving cardiac function in a mouse model (Kocher et al., 2001).
In one study, bone marrow derived cells were shown to regenerate sub-
stantial amounts of myocytes, endothelial cells and smooth muscle cells,
when injected into the hearts of mice following myocardial infarction. The
authors felt that a subpopulation of primitive bone marrow cells regener-
ated myocardium in vivo, replacing dead tissue, and promoted success-
ful treatment of large myocardial infarcts (Orlic et al., 2001a). Strikingly,
positive animal studies such as this quickly spurred on the initial clinical
studies.
The first in man feasibility study published in 2001 documented the
successful administration of intracoronary autologous bone marrow cells
to a 46 year old male following primary percutaneous coronary interven-
tion (PCI) for an anterior infarct (Strauer et al., 2001). Two larger case se-
ries, with a combined total of 30 subjects, followed the year after, demon-
strating selective intracoronary cell transplantation to be safe and effective
under clinical conditions (Assmus et al., 2002; Strauer et al., 2002).
After the initiation of clinical trials, basic science studies began to ques-
tion the proposed mechanism of action of the transplanted cells. Muscle
generation or transdifferentiation were not seen in two high profile stud-
ies of bone marrow progenitor therapy, although functional benefit was
still seen (Balsam et al., 2004; Murry et al., 2004). The rare observed events
that were thought to be de novo muscle or vessel formation could be at-
tributed to donor and host cell fusion (Alvarez-Dolado et al., 2003; Nygren
et al., 2004).
The need for a new explanation for the benefits gained with stem cell
treatment lead to the proposal that local release of paracrine factors was
the key mechanism of effect of transplanted cells rather than myogenesis.
Supporting this, it is clear ASCs are capable of secreting a wide range of
cytokines (Xu et al., 2007). The released paracrine factors have been shown
to induce a number of beneficial effects, including induction of angiogen-
esis in host tissues (Kocher et al., 2001), reduced apoptosis (Xu et al., 2007)
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and immunomodulation of injury (Burchfield et al., 2008). A further doc-
umented paracrine benefit is the proposed stimulation of the recently de-
scribed resident cardiac progenitor cells (Rota et al., 2008).
1.4.5 Cardiac Progenitor Cells
Until recently the adult heart was understood to be a postmitotic organ,
i.e., it consists of a constant number of cells from birth to death unless
cells are lost to pathological insults. The only adaptive cellular response
was considered to be cardiomyocyte hypertrophy. This view is now being
challenged. The first suggestion of a new understanding of cardiac cellu-
lar homoeostasis was the discovery of ongoing cell division in adult hearts
which appeared to be stimulated by cardiac injury such as myocardial in-
farction, LVH and heart failure (Beltrami et al., 2001).
The discovery of chimeras, as discussed previously, further increased
the suspicion that there may be a local pool of cardiac progenitor cells
(CPCs) within the adult heart. Several independent investigators have
now located and defined a cardiac progenitor cell that meets standard
stem cell defining characteristics and is capable of differentiating to multi-
ple cardiac cell lineages, such as cardiomyocytes, endothelial and vascular
cells (Beltrami et al., 2003; Messina et al., 2004; Oh et al., 2003). In animal
models, CPC treatment has been shown to repair and improve cardiac
function following myocardial ischaemia (Beltrami et al., 2003; Messina
et al., 2004).
CPCs are an attractive option for use in clinical trials, as they are intrin-
sically more aligned to producing all the cells needed to repair the dam-
aged heart. However, they are significantly more difficult to harvest and
isolate compared to BMMNCs and the way ahead may be activation and
stimulation of the patients own intrinsic CPCs rather than transplantation.
Currently, the results of early safety studies using CPCs are awaited.
The body of evidence from basic science studies suggests that a signif-
icant benefit in LV function can be produced with the use of almost any
type of ASC in the setting of myocardial ischaemia. Despite doubts over
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the mechanism of action of ASCs, clinical trials have continued, as major
concerns over safety have not been raised and the clinical imperative to
improve treatment for heart failure is compelling. There is also evidence
from two recent meta-analysis that the transplantation of ASC is not only
safe, but efficacious beyond the benefits achieved using traditional ther-
apy (Abdel-Latif et al., 2007; Lipinski et al., 2007).
1.5 Stem Cells for Cardiac Repair
1.5.1 Basic Concepts
The defining characteristic of a stem cell is the ability to self-renew, and if,
appropriate to form daughter cells of one or more differentiated cell types.
The ”ultimate” cell that meets this definition is found in the embryo. Sev-
eral days after fertilisation the embryo develops into the blastocyst with
an outer shield of cells, the trophoblast, and an inner clump of undifferen-
tiated cells known as the inner cell mass. This inner ball of cells contains
the pluripotent ESCs. These are thought to represent the ultimate stem cell
as they have the ability to organise and produce all of the specialised cells
and organs needed to form a fully functioning adult, including the heart
and blood vessels (Wobus & Boheler, 2005). ESCs gradually disappear and
are replaced towards the end of term with ASCs. ASCs like ESCs have the
defining stem cell trait — an endless capacity to self-renew — but have a
more limited repertoire of specialised cells that they can produce.
The most well known example of an ASC is the haematopoietic stem
cell (HSC) that resides in the bone marrow and continuously replaces all
the cells of the blood. Thus, each adult organ contains its own reservoir of
stem cells that can produce daughter cells appropriate to its location (Poul-
som et al., 2002). Hence, adult stem cells are also known as tissue specific
or somatic stem cells. It is thought that their purpose is to replace cells lost
from adult organs during physiological and pathological cell turnover. As
such, ASCs are most obvious and consequently best characterised within
highly proliferative organs such as the bone, skin and gut. It has taken
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longer for tissue specific stem cells to be recognised within less prolifera-
tive organs such as the heart, but their presence within adult cardiac tis-
sue has now been documented in a variety of species, including rats, mice,
dogs and humans (Beltrami et al., 2003). It is hoped that the proliferative
and regenerative capacity of both ASCs and ESCs can be harnessed to pro-
duce cardiomyocytes and vascular cells for transplantation into ischaemic
and failing hearts. In contrast to current pharmacological therapy, such a
treatment would directly address the fundamental problems of myocyte
loss and lack of an adequate blood supply.
Stem cells are a population of cells defined by their ability to self-renew
and to form one or more differentiated cell types. Cells with these charac-
teristics can be usefully categorised in a number of ways; anatomically,
functionally, by cell surface markers, transcription factors and proteins.
One clear division of the stem cell family is between those isolated from
the embryo, and known as embryonic stem cells, and those that are found
in adult somatic tissue, known as adult stem cells. Within these categories,
stem cells can be further divided, according to the number of differentiated
cell types they can produce. Thus, totipotent stem cells are able to form all
fully differentiated cells of the body and trophoblasts of the placenta.
Pluripotent cells are able to differentiate into almost all cells that arise
from the three germ layers, but are unable to give rise to the placenta and
supporting structures. The zygote and the descendants of the first two di-
visions are the only cells considered to be totipotent. Embryonic stem cells
isolated at about day five after fertilisation, from the inner cell mass of the
blastocyst, are considered to be pluripotent.
Multipotential stem cells are capable of producing a limited range of
differentiated cell lineages appropriate to their location, usually found in
adult tissues. For example, small intestinal stem cells can produce four in-
digenous lineages. At the bottom of the tree of potential are unipotential
stem cells, otherwise known as progenitor cells, which are only capable of
generating one specific cell type. A stereotypical example would be epi-
dermal stem cells in the basal skin layer that produce only keratinised
squames.
47
Introduction 1.5 Stem Cells for Cardiac Repair
1.5.2 Embryonic Stem Cells
In 1998, two papers reported that ESCs could be isolated from human em-
bryos. This technological advance heralded tremendous interest and ex-
citement in the field of stem cell research, leading to claims that stem cell
therapy would revolutionise the treatment of chronic conditions, such as
cardiovascular disease and cancer (See Figure 1.4).
This claim was initially born from the observation of the potential of
human embryonic stem cells (hESCs) to spontaneously form functioning
cardiomyocytes, smooth muscle cells and endothelial cells in vitro (Kehat
et al., 2001). Furthermore, cardiomyocytes derived in this manner were
successfully used to treat myocardial infarction in animal studies, signifi-
cantly improving cardiac function (Behfar et al., 2005). However, consid-
erable development is still needed before these exciting techniques can be
trialled in man.
Technical issues that need to be overcome include the eradication of an-
imal products that are currently used in the cell culture of hESCs and the
assessment of the tumour potential of transplanted hESCs. The last point
also reflects the need for techniques of selecting ESCs as they start to dif-
ferentiate, so that they can be delivered to the relevant site. For example,
if only cells that were going to form ventricular type myocytes were de-
livered to the left ventricle instead of a heterogeneous population of cells
with the potential for multiple phenotypes, the problems related to subse-
quent arrhythmogenesis induced by non-relevant cell differentiation may
be overcome (Behfar et al., 2005). Another question is that of transplant
rejection. In theory, all recipients of hESC derived cells will need to receive
immunomodulatory therapy with the subsequent risk of complications.
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Figure 1.4: Differentiation of embryonic stem (ES) cells into a cardiovascular phe-
notype. Following fertilisation, ES cells isolated from the inner cell mass, part
of the blastocyst, can be maintained in a undifferentiated pluripotent state indefi-
nitely. When required, specialised differentiated cells can be produced by forming
droplet suspensions of ES cells, known as embryoid bodies, which induce differ-
entiation to diverse tissue types, including multiple cardiovascular cell types.
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Finally, it should be remembered that the use of any form of embry-
onic tissue carries with it moral and ethical issues that society is strug-
gling to address. For example, many people believe that early human em-
bryos should be accorded the same status as a sentient being and thus their
harvesting for stem cells is morally unjustifiable. With this in mind, other
sources of stem cells with the potential of ESCs are being looked for.
ESCs were initially isolated in mice and more recently in humans
(Evans & Kaufman, 1981; Reubinoff et al., 2000; Thomson et al., 1998).
ESCs are derived from the inner cell mass of the pre-implantation or peri-
implantation blastocyst-stage embryo. After mouse derived ESCs have
been isolated, they can be cultured for prolonged periods in an undifferen-
tiated state in the presence of leukaemia inhibitory factor (LIF) or mouse
embryonic fibroblasts (MEFs). In contrast, human ESCs (hESCs) remain in
an undifferentiated state only when cultured on a feeder layer of mitoti-
cally inactivated MEFs.
For the safe use of hESCs in clinical scenarios, an important step in the
culture of these cells is the removal of xenoproducts such as MEFs from
the process of isolation and culture. To this end, some progress has been
made to replace MEFs. Thus far, hESCs have been shown to remain undif-
ferentiated when grown in the presence of either human foetal fibroblasts,
adult epithelial cells, foreskin cells or a matrigel/laminin matrix in media
conditioned by MEFs (Amit et al., 2003a,b; Richards et al., 2002; Xu et al.,
2001).
Undifferentiated hESCs can be identified due to characteristic markers.
These include stage-specific embryonic antigens, SSEA-3, SSEA-4 and the
glycoproteins TRA-1-60, TRA-1-81. Undifferentiated ESCs also express al-
kaline phosphatase, high telomerase activity and the transcription factor
Oct-4. Human ESCs are pluripotent and can be induced into the differenti-
ation process on removal from feeder layers. The multicellular aggregates
of differentiated and undifferentiated cells that form as a consequence are
termed embryoid bodies (EBs) and resemble early post-implantation em-
bryos. Within EBs, cellular derivatives of all three primary germ layers
can be found (Itskovitz-Eldor et al., 2000). The technique of feeder layer or
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LIF withdrawal, and formation of EBs has been successfully used to ob-
tain cells with a cardiomyocytic phenotype from mouse and human ESCs
(Doetschman et al., 1985; Kehat et al., 2001)(See Figure 1.4).
After the formation of an EB, most ES cell lines will spontaneously dif-
ferentiate into a wide variety of cell lineages that include spontaneously
beating cells. These beating cells have been extensively characterised
and carry a cardiomyocytic phenotype. Morphology and ultrastructure of
these cells is organised with sarcomeric structures, formation of interca-
lated discs, desmosomes and gap junctions, all characteristic of cardiomy-
ocytes (Kehat et al., 2001; Westfall et al., 1997). These gap junctions have
been demonstrated to function by transference of Lucifer yellow dye be-
tween cells and microelectrode array mapping demonstrating the pres-
ence of a functional syncitium with action potential propagation (Kehat
et al., 2002; Westfall et al., 1997). Immunohistochemistry and in situ hy-
bridisation have demonstrated the presence of appropriate proteins in car-
diomyocytes and furthermore these are expressed in a time course that is
analogous to that seen in cardiomyocytes developing in vivo (Guan et al.,
1999).
Normal functioning of the cells is suggested by their spontaneous con-
traction, but also by their electrophysiological profile and response to
pharmacological agents (Maltsev et al., 1999; Wobus et al., 1991). Car-
diomyocytes formed in EBs are heterogeneous. By examining the electro-
physiological profiles of spontaneously contracting cells, three distinct cell
lines have been isolated; atrial, ventricular and purkinje cells (He et al.,
2003). This finding underlines the pluripotent nature of ESCs. However,
this attractive property of stem cells is also a hindrance to their potential
clinical application.
Therapeutic transplantation of cells that retain pluripotent capability
can lead to undesirable effects, such as oncogenesis. Equally transplanta-
tion of predifferentiated cells, such as atrial or non-cardiac lineage cells,
into the ventricle could act to destabilise the electrical milieu and lead to
arrhythmogenesis. Isolation and expansion of specific cells types from EBs
is crucial for a therapeutic role to be realised. Two approaches can be ap-
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plied to this problem, either solely or in combination. One approach, of-
ten described as enrichment, involves addition of growth factors or other
metabolically active agents to the culture medium to preferentially direct
differentiation of ESCs to a cardiac lineage.
Several factors alone and in combination have been shown to enrich
cardiac differentiation: hepatocyte growth factor (HGF), epidermal growth
factor (EGF), basic fibroblast growth factor (bFGF), transforming growth
factor b1 (TGFb1), platelet-derived growth factor (PDGF), sphingosine-1-
phosphate, retinoic acid, 5-azacytidine, vitamin C and over expression of
GATA-4 (Grepin et al., 1997; Sachinidis et al., 2003; Schuldiner et al., 2000;
Takahashi et al., 2003; Xu et al., 2002). Besides addition of factors to culture
medium, co-culture with visceral-endoderm-like cells helps direct hESCs
to differentiate into cardiomyocytes (Mummery et al., 2003). Other vari-
ables that may also be altered to enhance cardiomyocyte formation from
ESCs are the use of different cell lines, culture mediums or feeder layers,
timing of EB plating and altering the initial number of cells plated (Wobus
et al., 2002).
The process of enrichment is yet to yield a collection of cardiomyocytes
pure enough to consider for use in clinical therapy. An alternative avenue
that promises a purity of cell line necessary for clinical application is to
isolate cells after they have differentiated down a cardiac lineage by us-
ing a cell marker and separation technique. The key to this process is to
use a marker that is specific for the cardiac lineage and ideally able to
distinguish ventricular cardiomyocytes from atrial or purkinje cells. One
such method involves the transfection of ESCs with a fusion gene of a
MHC promoter linked to a cDNA encoding aminogylcoside phospho-
transferase. Following differentiation, selection of cells of cardiac lineage is
possible due to expression of the antibiotic resistant gene. Using this pro-
tocol, up to a 99% pure cardiomyocyte sample has been obtained (Klug
et al., 1996).
Another method, used to isolate ventricular type cells only, involves
the transfection of ESCs with enhanced green fluorescent protein under
transcriptional control of ventricular-specific myosin light chain-2v. This
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reporter gene based approach in conjunction with fluorescent assisted
cell sorting has allowed isolated collection of ventricular cardiomyocytes
(Mller et al., 2002). These methods of purification are highly effective, but
both insert a foreign epitope into the ESCs that may lead to immunolog-
ical rejection following transplantation. An alternative strategy that cir-
cumvents this problem, and has been applied to hESCs, is the use of a Per-
coll gradient that separates cells based on their density. This technique has
produced a four-fold enrichment of cardiomyocyte yield, with no undif-
ferentiated hES cells detected following separation (Xu et al., 2002). Using
these strategies to purify and enrich cardiomyocyte cultures, animal work
has been conducted to establish the effect of these ESC derived cells.
Transplanted ESC derived cardiomyocytes have been shown to engraft
in infarcted myocardium and improve cardiac function. Differentiated car-
diomyocytes, derived from mouse ESCs (mESC), have been transplanted
using epicardial injection in myocardial infarction models and in animals
with a muscular dystrophy. Results from these studies consistently show
a significant improvement in cardiac function using echocardiography or
left ventricular pressure transduction. Engraftment of transplanted car-
diomyocytes has been confirmed by donor cell tracking, using transfection
with green fluorescent protein, and immunohistochemistry (Behfar et al.,
2002; Klug et al., 1996; Min et al., 2002b; Yang et al., 2002).
In the failing heart, in addition to the replenishment of cardiomyocytes
by ES derived cells, a simultaneous increase in the blood supply is neces-
sary for optimal and prolonged engraftment. Hence, it is of interest that
ESCs differentiate to all cell lines necessary for formation of new blood
vessels. Both mESCs and hESCs spontaneously differentiate to form en-
dothelial and smooth muscle cells in vitro, and blood vessel-like struc-
tures can be seen within EBs (Levenberg et al., 2002; Vittet et al., 1996;
Yamashita et al., 2000). ES cell-derived endothelial cells express endothe-
lial cell markers, including CD31, Flk-1, VE-cadherin, PECAM, Tie-1 and
Tie-2. They also take up acetylated-LDL, a functional characteristic of the
endothelial cell phenotype. Enrichment and purification strategies, similar
to those applied to cardiomyocytes, have been developed for endothelial
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cells (Marchetti et al., 2002; Yamashita et al., 2000). A range of transplant
studies demonstrate that these cells can form vessels in vivo (Levenberg
et al., 2002; Marchetti et al., 2002; Yamashita et al., 2000). Encouragingly,
human ES cell-derived endothelial cells have been shown to anastomose
with host tissue following transplantation in immunodeficient mice and
the structures so formed have been found to contain red blood cells (Lev-
enberg et al., 2003).
Despite the progress made in transplantation, enrichment, purification,
and eradication of xenoproducts in the derivation and culture of human
stem cells, several issues still remain. The issue of rejection of donor cells
still necessitates the use of immunosuppressive therapy with the accom-
panying hazards. A way round the issue of immunogenicity of the donor
cell may be achieved using techniques such as somatic cell nuclear transfer
(SCNT) or parthenogenesis (see §1.5.4.1 and §1.5.4.2 respectively).
1.5.3 Cord Blood Derived Cells
Umbilical cord blood (CB) is blood that remains in the placenta and in
the attached umbilical cord after childbirth. It has been shown to be
a potent source of haematopoietic stem cells. Single cord blood units
can reconstitute the entire adult lympho-haematopoietic systems (Laugh-
lin et al., 2001). The collected CB, so far, has been used successfully to
treat haematopoietic and genetic disorders. Umbilical cord blood is a rich
source of haematopoietic stem cells for transplantation in children and
adults and has a long-standing and successful clinical history. Recent years
have seen our understanding of the stem cell repertoire of CB expand and
bring with it the hope of extending the successful uses of this source of
cells.
Cord blood has several benefits as a cell choice for clinical therapy. It
is easily collected without the need for an invasive procedure, and it lacks
any ethical baggage and can be stored for many years until required (Brox-
meyer et al., 2003). It is a more enriched source of haematopoietic progen-
itor cells, with greater growth potential and proliferation than adult bone
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marrow (Lewis & Verfaillie, 2000). There are also beneficial immunologi-
cal differences between CB and bone marrow. Better tolerance for HLA-
mismatches between donor and recipient is seen with CB transplants and
there is also a decreased incidence of graft-versus-host disease (Gluckman
et al., 1997).
In addition to the established benefits of CB, new ones have been dis-
covered over the last decade, including myogenic and vasculogenic capac-
ity. These newly discovered traits of CB have been harnessed to produce
beneficial effects on left ventricular function in myocardial infarction mod-
els.
Aside from haematopoietic activity, CB has now been demonstrated
to contain cells with endothelial progenitor and mesenchymal stem cell
activity. In addition to these, cells labelled unrestricted somatic stem cells
(USSCs) have also been revealed.
Cord blood derived MSCs are multipotent with osteogenic, chondro-
genic and adipogenic differentiation potential (Bieback et al., 2004; Erices
et al., 2000). Endothelial progenitor cells cultured from CB express ap-
propriate cell surface antigens, CD31, CD105, CD144, CD146, vWF and
KDR. They also uptake acetylated low-density lipoprotein and demon-
strate clonogenic capacity (Ingram et al., 2004).
Unrestricted somatic cells are a CD45 negative population of cells ob-
tained by selective culture of CB. USSCs are highly proliferative while
maintaining their pluripotential to differentiate in vitro to osteoblasts,
chondroblasts, adipocytes, and haematopoietic and neural cells.
In vivo differentiation of USSCs along mesodermal and endodermal
pathways was demonstrated in animal models. Transplantation of human
USSCs in a non-injury model, the preimmune foetal sheep, resulted in sub-
stantial numbers of human cardiomyocytes in both atria and ventricles of
the sheep heart. No tumour formation was observed in any of these ani-
mals.
The flourishing potential of CB led some to examine its ability to form
muscle and blood vessels, and hence whether CB could be used as a cellu-
lar therapy for IHD and heart failure. In co-culture with feline cardiomy-
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ocytes after five days, CB derived cells were seen to spontaneously con-
tract and stained positive for troponin-I and connexin 43 suggesting a
cardiomyocyte-like phenotype. This experiment was then repeated with
murine cardiomyocytes in co-culture with CB separated by a collagen
membrane. Again approximately half of the CB cells obtained a cardiomy-
ocyte like phenotype. The mechanism of fusion was excluded by the pres-
ence of the collagen membrane (Nishiyama et al., 2007).
Cardiomyocyte formation following transplantation of CB had initially
been demonstrated in a non-injury model. Following this, in a chronic
porcine model of MI, transplanted CB cells (100×106) survived for up to 1
month after intra-myocardial transplantation while adopting cardiac phe-
notypes. Cell lineage was traced with human mitochondrial DNA probes
and phenotype with troponin-I or myosin heavy chain antibodies. Fusion
events were not assessed in any manner. The number of engrafted cells
was not quantified, but increased numbers of blood vessels were counted
in the treated animals. Cardiac function and perfusion were found to be
significantly better in the CB treated group when assessed with echocar-
diography or MIBI (Kim et al., 2005). Similar results were obtained with a
rat MI model, when intra-myocardial injection of CB cells (5×106) labelled
with fluorescent dye (CM-Dil) again showed significant improvement in
LV function in the treated group. It was also claimed that cells were seen
to differentiate into cardiomyocytes and endothelial cells, but fusion was
once again not excluded, and the total number of engrafted cells was not
quantified (Wu et al., 2007).
A second study, using a porcine model of MI with intra-myocardial
injection of USSCs (1.3 ×107), demonstrated no donor cells within the
porcine myocardium 8 weeks after transplantation. However, LVEF was
significantly better in the USSC group (52%) compared to the control
group (27%). As there was no evidence of myocyte formation the bene-
ficial effects of USSC treatment were proposed to be paracrine induced
(Ghodsizad et al., 2008).
Currently, the use of CB finds itself in much the same situation as
BMMNCs. Many pre-clinical experiments have shown functional bene-
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fit after CB treatment, but in vivo myogenesis remains to be proved be-
yond doubt, and thus the mechanism of action is still unclear (Kgler et al.,
2009; Yu et al., 2008). Before CB cells are used clinically for cardiovascular
interventions, the optimisation of transplant regimens should proceed in
tandem with mechanism based investigations in order to fully appreciate
the therapeutic potential of CB cell therapy. A strategy for dealing with
the immunological issues of CB transplantation should also be developed
(Riordan et al., 2007).
1.5.4 Pluripotent Alternatives to Embryonic Cells
ES cells have the potential to provide all cell types that will ever be needed
for cellular therapy and tissue engineering. However, their use in clinical
practise is a long way from fruition due to multiple issues, as previously
discussed in §1.5.2. In brief, the main areas of concern are tissue rejection
after ES cell derived tissue implantation, as derived tissues will be allo-
geneic, the ethical debate regarding embryo use for ES cell derivation, and
finally tumour formation following implantation.
Tissue rejection of transplanted organs or cells derived from ES cells
could be ameliorated by the use of immunosuppressive drugs. Alterna-
tively, the problem could be entirely avoided by generating syngenic pa-
tient specific tissues or cells for transplantation. A number of methods for
producing syngenic cells have been discovered. These include somatic cell
nuclear transfer, parthenogenesis and production of inducible pluripotent
stem cells (iPSC). These techniques will now be discussed.
1.5.4.1 Somatic Cell Nuclear Transfer
Somatic cell nuclear transfer (SCNT), also known as therapeutic cloning,
involves introduction of an adult cell nucleus from the potential recipient,
into an enucleated oocyte to generate a cloned embryo (Hochedlinger &
Jaenisch, 2003). Embryonic stem cells may then be isolated from the resul-
tant blastocyst. ES cells isolated in this way are pluripotent, and differen-
tiated cells such as cardiomyocytes can be obtained (Kawase et al., 2000;
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Figure 1.5: Current methods for pluripotent stem cell derivation from adult so-
matic or germ cells. Three methods have been reported to generate pluripotent
stem cells from somatic cells: nuclear transfer, fusion, and forced expression of
defined factors. Also reported is the generation of chimera-competent pluripotent
stem cells after the long-term culture of bone marrow cells. In addition, pluripo-
tent stem cells can be established from mouse adult germ cells: multipotent GS
cells and parthenogenetic ES cells. Adapted from Yamanaka (2007).
Munsie et al., 2000). Viability of cardiac tissue produced by SCNT has been
demonstrated in vivo (Lanza et al., 2002). The benefit of this process is that
cells derived by nuclear transfer are genetically identical to the recipient
cells (which would be obtained from the patient requiring treatment), thus
eliminating the risk of organ rejection and requirement for immunosup-
pressive therapy.
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1.5.4.2 Parthenogenesis
Alternatively, a similar technique that has the same benefits of SCNT is
parthenogenesis. This technique allows formation of an embryo from an
egg without sperm. Understanding of this process is not as advanced as
SCNT, but pluripotent ES cells have nevertheless been produced. Car-
diomyocytes have been produced in vitro, whilst in vivo teratomas con-
taining tissue from all three germ layers have formed following implanta-
tion in immunodeficient mice (Cibelli et al., 2002).
1.5.4.3 Inducible Pluripotent Stem Cells
Somatic cell nuclear transfer demonstrates that differentiated cells can be
reprogrammed to an ESC-like state by transfer of nuclear contents into
oocytes or by fusion with ESCs. This suggested to some investigators that
unfertilised eggs and ESCs contain factors that can induce totipotency or
pluripotency in somatic cells.
The proof of this concept was first provided by the induction of
pluripotent stem cells from mouse embryonic and adult fibroblast cultures
by defined factors (Takahashi & Yamanaka, 2006). Twenty-four candidate
genes, selected for known pivotal maintenance roles in ES cell identity,
were investigated for their ability to induce pluripotency in somatic cells.
Using a pluripotent detection system, a βgeo cassette (a fusion of β-
galactosidase and neomycin resistance genes) inserted into the Fbx15 gene
by homologous recombination, any cells entering a pluripotent state ex-
press Fbx15 and hence the neomycin resistant gene and allow identifica-
tion by the survival of pluripotent colonies in culture after treatment with
G4181.
The 24 factors were sequentially tested in different combinations by
retroviral transduction into embryonic fibroblasts or adult fibroblasts from
Fbx15βgeo/βgeo mice. The performance of each combination was judged by
the number of pluripotent colonies produced. Using this approach, four
candidate genes were identified as providing the optimum balance be-
1Also known as Geneticin™ an aminoglycoside antibiotic from Gibco
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tween the number of genes needed to be transduced and the number of
pluripotent colonies produced. The four genes identified were Oct3/4,
Sox2, c-Myc, and klf4.
The produced cells were designated inducible pluripotent stem cells
(iPSCs). The iPSCs were seen to exhibit the morphology and growth
properties of ES cells. Comparison of iPSCs with ES cells using RT-PCR,
chromatin immunoprecipitation and global gene expression profiles from
DNA microarrays suggested that the cell types were similar. Pluripotency
was then examined by injecting iPSCs into nude mice. Teratoma forma-
tion was observed and the histology demonstrated evidence that all three
germ layers had been produced. When injected into blastocyts, the iPSCs
were able to contribute to embryonic development, but the chimeras were
abnormal and did not survive to term. Differentiation was then tested, in
vitro, using EB formation and after 3 days, culture immunostaining de-
tected cells from all three germ layers — α-smooth muscle actin (meso-
derm), α-fetoprotein (endoderm) and βIII tubulin (ectoderm).
Thus, the possibility of inducing pluripotent stem cells from adult cells
by introducing four factors, Oct3/4, Sox2, c-Myc and Klf4 had been suc-
cessfully demonstrated (Takahashi & Yamanaka, 2006). At this juncture in
the new field of iPSC research, important questions remained. Why did
only a fraction of transduced cells become iPSCs? Did this low response
rate suggest that only rare tissue stem cells that were present in the trans-
duced tissues account for the cells able to form iPSCs? The authors did
not think so as the same low response rate was independent of the density
of stem cells, e.g., the rate of transduction was no better when performed
with bone marrow stroma which should be enriched for stem cells. An-
other important question that would prove prescient was what are the
long term effects of retroviral transduction of putative oncogenes?
Soon, following the initial discovery of iPSCs, several independent lab-
oratories had replicated the results of Takahashi & Yamanaka (2006). In
a similar study, except for the detection system, which was a neomycin-
resistance marker inserted into either endogenous Oct4 or Nanog, iPSCs
were again produced (Wernig et al., 2007). The iPSCs, as before, resem-
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bled ES cells and assumed an epigenetic state consistent with ES cells.
However, unlike the initial iPSC study, when injected into blastocyts, the
reprogrammed cells generated viable chimeras. This approach may have
been more successful as identification of pluripotent cells by activation of
Oct3 or Nanog is a more stringent way of selecting reprogrammed cells
than by the use of Fbx15. Their data also suggested that iPSC induction
is brought about by the virally inserted factors, but viral-controlled tran-
scripts are down-regulated in iPSCs, and maintenance of the pluripotent
state is maintained by activity of endogenous pluripotent factors includ-
ing Oct4, Nanog, and Sox2.
A second independent study, again using Nanog rather than Fbx15
as the reporter of pluripotency, demonstrated similar results (Maherali
et al., 2007). iPSCs and ES cells were shown to be highly similar us-
ing a genome-wide analysis of two key histone modifications. Viable
high-degree chimeras with contribution to the germline were also pro-
duced. A third study in 2007 confirmed Nanog as a better reporter choice
over Fbx15, with resultant iPSCs comparable to ES cells in morphology,
proliferation, teratoma formation, gene expression and competency for
chimeras (Okita et al., 2007). However, this study also demonstrated that
20% of derived offspring developed tumours attributable to reactivation
of the c-Myc transgene.
Following the publication of iPSC production in mice, the results were
replicated in humans. Just as in mice, after adult cells were reprogrammed
by retroviral transduction of Oct3/4, Sox2, Kl4, and c-Myc, the adult hu-
man cells returned to a undifferentiated pluripotent state with the ability
to subsequently differentiate into all three germ layers (Aasen et al., 2008;
Park et al., 2008; Takahashi et al., 2007).
An alternative set of 4 genes, Oct4, Sox2, Nanog and Lin28, were also
shown to be sufficient to reprogram human somatic cells to a pluripotent
stem cell state when inserted into fibroblasts using a lentiviral vector. The
derived iPSCs had normal karyotype and appropriate telomerase activity,
cell-surface markers and gene expression for that of an ES cell (Yu et al.,
2007).
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The advent of a pluripotent autologous stem cell alternative to ES cells,
that retains the differentiation potential of ES cells, but without the risk of
tissue rejection after transplantation or ethical issues (as the cells can be
produced from a patients own cells, e.g., easily collected from the mouth
(Park et al., 2008), or even from a few plucked hairs (Aasen et al., 2008)) is
highly desirable.
The potential of an autologous iPSC derived from adult tissue is con-
siderable. Much success has already been made in working towards prac-
tical applications of this emerging technology. Already, production of car-
diomyocytes has been demonstrated (Mauritz et al., 2008; Narazaki et al.,
2008; Zhang et al., 2009).
Cardiomyocytes were derived from iPSCs using the EB technique. Car-
diomyocytes produced in this way were noted to have both appropriate
cardiac gene expression by real-time polymerase chain reaction (RT-PCR),
and sarcomeric structure using immunohistochemistry. Electrophysiolog-
ical studies clearly defined three distinct phenotypes within the differ-
entiated cardiomyocytes: nodal-, atrial- and ventricular-like phenotypes.
Furthermore, appropriate responses were seen to adrenergic stimulation
(Zhang et al., 2009).
As touched on previously, the cardiovascular regenerative repertoire
would not be complete without access to vascular cells. This issue has also
begun to be addressed. Mouse iPSCs were induced to form endothelial
and mural cells (pericytes and vascular smooth muscle cells) by culture
on type IV collagen coated dishes with cell media containing vascular en-
dothelial growth factor (VEGF) and serum. After differentiation, the cells
were found to express appropriate markers of endothelial cells such as
CD31 and VE-cadherin, or markers of mural cells, e.g., α-smooth mus-
cle actin. When grown in type I collagen gel, allowing three dimensional
growth, vascular tube-like structures were formed (Narazaki et al., 2008).
More recently, differentiation of human iPSCs to vascular cells has been
achieved (Taura et al., 2009). A system that had been successful in the di-
rected differentiation of ES cells to vascular cells was applied to human iP-
SCs. Immunofluorescent staining or RT-PCR of the differentiated progeny
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revealed a population of cells (1–5% of the total population) that was pos-
itive for Flk1, VE-cadherin, CD31, CD34, von Willebrand factor and en-
dothelial NO synthase at levels comparable to adult endothelial cells. Mu-
ral cell production was also investigated. Following directed differentia-
tion with PDGF-BB, cells were found to be calponin and α-smooth muscle
actin positive and thus coherent with mural cells.
Many are now viewing iPSCs as a gateway to fulfilling the potential
promised by regenerative medicine. Evidence towards this view has been
provided by another study aiming to differentiate vascular cells from iP-
SCs. In a proof of principle study, iPSCs were generated from human aortic
vascular cells and then differentiated back to a smooth muscle cell pheno-
type (Lee et al., 2010). Human aortic smooth muscle cells (HASMCs) were
induced to iPSCs with lentiviral transduction of the transcription factors
Oct4, Sox2, Nanog, Klf4 and Lin28. The iPSC phenotype was confirmed af-
ter induction, with cell surface markers, global mRNA expression, micro
RNA expression, epigenetic status and differentiation capacity equivalent
to that of ES cells. Then, the iPSCs were used to derive smooth muscle cells
and compared to the parental HASMCs gene expression, epigenetics and
in vitro function (cytosolic Ca2+ flux in response to vasoconstrictors) were
similar. This study demonstrates that human iPSCs can be generated from
diverse origins, not only fibroblasts. Indeed, others have produced iPSCs
from keratinocytes (Aasen et al., 2008), hepatocytes (Aoi et al., 2008), lym-
phocytes (Hanna et al., 2008), neural stem cells (Kim et al., 2008) and der-
mal cells from the mouth (Lowry et al., 2008). Furthermore, this study indi-
cates that iPSC derived daughter cells exhibit similar molecular signatures
and functional abilities as their parent cells. This confirms the promise of
this approach to provide an autologous cell source for patient specific cell
therapy.
Despite the potential inherent ability to produce patient individualised
iPSCs, problems remain that must be solved before they can be used in
clinical trials. The main concern is tumour genesis. The majority of iPSC
lines have been derived by inserting putative oncogenes using integrating
retroviruses, e.g., lentiviruses, into the host genome which have the po-
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tential to cause cancer. One study demonstrated up to 20% of off-spring
derived using iPSCs developed tumours (Okita et al., 2007).
The problem of tumour formation does not appear to be insurmount-
able. Progress has already been made in circumventing this issue for ex-
ample: the use of non-integrating adenoviruses for gene delivery (Okita
et al., 2008), using small molecules to produce the same outcome without
the need for gene insertion (Shi et al., 2008) and reducing the number of
inserted genes (Kim et al., 2008; Nakagawa et al., 2008). One sophisticated
study, using the Cre-Lox recombination system, demonstrated the possi-
bility of excising the inserted genes after the iPSCs had been formed with
no impact on differentiation potential of the cells (Soldner et al., 2009).
For now, until the tumour genesis problem is resolved, iPSC derived
cells will be invaluable in models of human tissue in health and disease.
Already, cardiomyocytes and vascular cells have been derived in normal
subjects. If this approach could be used to generate in vitro cardiomy-
ocytes from people afflicted with genetic diseases such as hypertrophic
cardiomyopathy, the understanding of this and other similar conditions
could be significantly improved.
This concept has already been successfully tested. Dermal fibroblasts
from patients with Parkinson’s disease were transfected with Oct4, Sox2,
Klf4, with and without c-Myc and iPSCs were obtained (Soldner et al.,
2009). Using a Cre-Lox recombination system, induced transgenes were
excised. The iPSCs retained ES cell like characteristics and were able to
differentiate into dopaminergic neurons. The ability of iPSCs to maintain
their pluripotential state following transgene excision is another step in
the right direction towards clinical use. Additionally, the demonstration of
neuron derivation from patients with underlying disease and of advanced
age underlines the theory that iPSCs can become a realistic research and
clinical tool.
One further practical barrier to clinical use of iPSCs will be the ability to
produce sufficient cells for therapeutic purposes. Experiments to date have
shown low conversion rates in the percentage of cells treated compared to
those that are successfully induced into a iPSC phenotype. The percentage
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of conversion to iPSCs in the literature varies from 1–0.0006% (See Table
1.5). To make matters more difficult, steps taken to combat tumour gene-
sis, e.g., the use of adenoviruses, significantly impair the conversion rate
(Stadtfeld et al., 2008).
Once the complete mechanism of reprogramming is understood, and
the tumour genesis problem has been resolved, there are considerable ex-
pectations that iPSC production can be up-scaled to provide a patient spe-
cific source of cardiovascular cells for use in regenerative medicine. Until
these aims are accomplished, the main cell types in use for cellular ther-
apy are adult derived tissue specific stem and progenitor cells, such as
haematopoietic stem cells (HSCs), mesenchymal stem cells (MSCs) and
endothelial progenitor cells (EPCs).
1.5.5 Adult Derived Cells
Adult stem cells are found in many tissues and organs where they have the
capacity to replenish cells that are lost during physiological homoeostasis.
Unearthing of an unrecognised property of adult stem cells, in which they
may undergo a process of transdifferentiation or exhibit plasticity, has led
to much interest in these cells. Plasticity describes a property of adult stem
cells whereby they are able to produce specialised cells that are outside of
their normal lineage commitment (Poulsom et al., 2002). In vitro and in
vivo studies have demonstrated that these cells can transdifferentiate into
brain, gut, lung, liver, pancreas, kidney and cardiac cells, when placed un-
der specific conditions (Alison et al., 2000; Deb et al., 2003; Ianus et al.,
2003; Krause et al., 2001; Makino et al., 1999; Mezey et al., 2000; Pittenger
et al., 1999; Poulsom et al., 2001)(see Figure 1.6). Within cardiovascular re-
search, most progress in the use of adult stem cells for cellular transplanta-
tion and end organ recovery has been seen with skeletal myoblasts, HSCs,
MSCs and EPCs. In addition, recent evidence has exposed the existence
of a hitherto unknown tissue resident stem cell within the heart known as
the cardiac stem cell (CSC) and this cell type has also proved beneficial for
cardiovascular cellular therapy. These cell types will now be reviewed.
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Figure 1.6: Adult stem cell plasticity. Bone marrow derived stem cells have been
shown to engraft and transdifferentiate into a variety of cell types other than
haematopoietic lineages.
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1.5.6 Skeletal Myoblasts
Myofibers, the contractile units of skeletal muscle, are giant syncytial cells,
each containing several hundred myonuclei within continuous cytoplasm.
They are, at least in mammals, terminally differentiated and cannot repli-
cate. Postnatal growth of skeletal muscle is carried out by satellite cells,
and they are the primary means by which adult muscle is formed (Schultz,
1996).
Skeletal muscle satellite cells were first described in frog muscle
(Mauro, 1961) and were later isolated in adult mammalian muscle
(Schultz, 1976). They reside beneath the basal lamina of adult skeletal mus-
cle, closely hugging the skeletal muscle fibres. The satellite cell has potent
myogenic potential and archetypal stem cell properties that suits its es-
sential roles of muscle regeneration, muscle hypertrophy and postnatal
muscle growth (Collins et al., 2005; Darr & Schultz, 1987; Rosenblatt et al.,
1994; Schultz, 1996).
Satellite cells in adult skeletal muscle are normally mitotically quies-
cent but are activated (i.e., initiate multiple rounds of proliferation) in re-
sponse to injury. Activated satellite cells produce progenitor cells. Both
asymmetric and symmetric division has been observed, called myogenic
precursor cells or myoblasts, which undergo multiple cycles of division
prior to fusing with existing or new myofibres to provide the myonuclei
required to repair or replace damaged myofibres (Moss & Leblond, 1971;
Snow, 1978).
Satellite cells have long been considered to have monopotential, with
the ability to give rise only to cells of the myogenic lineage. However, ev-
idence for a bi-directional differentiation potential between muscle and
bone marrow appeared in the late 1990s. Initially, bone marrow was shown
to contribute to muscle regeneration. Bone marrow from mice carrying a
transgene, in which β-galactosidase was under the control of a muscle-
specific promoter (myosin light chain 3F promoter), was transplanted into
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irradiated immunodeficient scid/bg2 mice. Following chemically induced
(thioglycollate) muscle damage, small numbers of LacZ-stained nuclei
were detected in regenerating muscle fibres (Ferrari et al., 1998).
Recruitment of donor-derived bone marrow cells to both skeletal and
cardiac muscles of immunodeficient mice suffering with muscular dystro-
phy was demonstrated using sex-mismatch bone marrow transplants and
tracking of donor Y chromosome in female hosts combined with muscle
specific immunohistochemistry to identify phenotype (Bittner et al., 1999).
Chimeric endothelial cells of blood vessels in both cardiac and skeletal
muscle were also seen. These observations strengthened the suggestions
that bone marrow-derived cells could contribute to muscle regeneration
(Ferrari et al., 1998) and also to endothelial progenitor cells for angiogene-
sis (Asahara et al., 1997). The results also offered the hope that bone mar-
row cells could be used as cellular substitutes or as shuttles in gene ther-
apy strategies for conferring the wild type gene to dystrophic or necrotic
muscle, in both skeletal and cardiac muscle (Bittner et al., 1999).
Two studies demonstrated the bi-directional plasticity of muscle and
bone marrow when muscle-derived cells were shown to repopulate whole
bone marrow in lethally irradiated mice. Firstly, muscle cells fractionated
on the basis of their efflux of Hoechst dye could rescue lethally irradiated
recipients (Gussoni et al., 1999). Secondly, unfractionated mono-nuclear
muscle cells were able to repopulate all major blood lineages of lethally
irradiated mice up to 12 weeks after transplant (Jackson et al., 1999).
However, when muscle cells from mice were isolated on the basis
of haematopoietic markers, Sca-1 and CD45, haematopoiesis was shown
to be exclusive to this population. Thus, muscle-derived haematopoietic
stem cells are probably derived from the haematopoietic system and are
not a result of transdifferentiation of myogenic stem cells, but instead
are derived from haematopoietic stem cells present in muscle (McKinney-
Freeman et al., 2002). The origin of these cells and their role within muscle
2The scid/bg mouse combines scid (severe combined immunodeficiency) animals,
which lack functional B and T cells, with beige (bg) animals that have low natural killer
(NK) cell activity.
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remains to be determined.
1.5.6.1 Cell Therapy with Skeletal Myoblasts
Satellite cells were one of the first cells to be considered for use in cell ther-
apy in cardiac disease. The favourable characteristics that led to its early
use included: their muscle phenotype with hope for contractile function
when transplanted into the heart; autologous source of cells avoiding im-
mune rejection; lineage restricted cells, with minimal risk of tumour for-
mation after transplantation; accessibility, as they are easy to harvest, with
no ethical concerns; adequate cell supply, as cell numbers can be increased
significantly prior to transplantation; and finally, they are relatively resis-
tant to ischaemia which may help long term survival in the hostile envi-
ronment within the diseased heart.
1.5.6.2 Pre-clinical Studies of Skeletal Myoblasts
Extensive pre-clinical studies of satellite cells or myoblasts have been per-
formed in a variety of animal models. The ability for skeletal myoblasts
to establish long term transplants within the heart was the first step to es-
tablishing potential for their use in cellular repair (Murry et al., 1996). En-
grafted myoblasts demonstrate a skeletal muscle-type phenotype, and ul-
timately differentiate into multi-nucleated myotubes (Maurel et al., 2005).
It is now recognised that the expression of cardiac markers by a few of the
transplanted cells resulted from fusion with host cardiomyocytes, and not
from transdifferentiation (Reinecke et al., 2004).
Functional benefits were then sought. In rabbit hearts inflicted with a
cryoinjury, autologous transfer of skeletal myoblasts improved contractil-
ity and compliance of the damaged region. Implanted cells were found to
still be in situ when assessed six weeks after transplantation (Taylor et al.,
1998). In rats, similar findings were seen in a coronary ligation model of
infarction, with implanted skeletal myoblasts forming viable grafts in in-
farcted myocardium, resulting in enhanced post-MI exercise capacity and
contractile function with attenuated ventricular dilation.
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Not all of the pre-clinical studies have provided encouraging results.
For example, studies have consistently demonstrated significant cell loss:
up to 84% loss in the first 24 hours and death of the transplanted myoblasts
within a few days (Maurel et al., 2005; Suzuki et al., 2004). Furthermore,
transplanted cells down regulate the major adhesion and gap junction pro-
teins, N-cadherin and connexin43, of the intercalated disk (Reinecke et al.,
2000) and are functionally isolated from the host myocardium with no ev-
idence of electromechanical coupling (Leobon et al., 2003). This may ac-
count for the increased incidence of arrhythmias seen in hearts after my-
oblast transplantation (Fernandes et al., 2006).
1.5.6.3 Clinical Experience with Skeletal Myoblasts
The multitude of positive findings in animal models following transplan-
tation of myoblasts led to their use in clinical trials. It should be noted that
this transition occurred at a point when arrhythmic side-effects were yet
to be documented in animal models.
Only patients with chronic heart failure were considered as suitable
candidates for myoblast transplantation as the process to obtain a clini-
cally useful amount of cells takes 2–3 weeks, over which time one billion
cells can be yielded from an initial small biopsy (Menasch, 2008).
The first use of myoblast implantation in man occurred at the turn of
the millennium in 2000. The single patient was 72 years old, with NYHA
III heart failure and evidence of previous posterior-inferior myocardial
infarction. Echocardiography demonstrated severe LV dysfunction, esti-
mated EF 21%. Viability using PET and stress echocardiography was sug-
gested in antero-lateral territories but not within the posterior or inferior
walls. A biopsy from vastus lateralis was cultured for two weeks to pro-
duce 800 x 106 cells, of which 65% were defined as myoblasts due to CD56
positivity as detected with flow cytometry. During two vessel coronary
artery bypass grafting (CABG), myoblasts were injected into 33 separate
areas in the posterior and inferior walls under direct vision. At five month
follow-up, no arrhythmias had been documented, and NYHA class had
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fallen to two. Evidence of viability was seen in the posterior wall, and EF
had increased to 30%. One case study does not allow critical interpretation
of the functional benefits of myoblast implantation, especially in the face
of concomitant CABG. However, feasibility of the use of myoblasts in man
was established (Menasch et al., 2001).
A randomised, double blind, placebo-controlled trial was then begun
(Myoblast Autologous Grafting in Ischaemic Cardiomyopathy, acronym
MAGIC). Inclusion criteria were severe left ventricular dysfunction, post-
infarction non-viable scar, and an indication for CABG. Out of 120 ran-
domised patients, 97 were effectively treated. At six months, myoblast
transplantation did not cause significantly more adverse cardiac events
than injections of placebo medium. Myoblast injections failed to increase
regional or global LV function beyond what was seen in the placebo group.
However, the highest dose of cells resulted in a significant decrease in
LV end diastolic and end systolic volumes (a pre-specified secondary end
point) (Menasche et al., 2008).
Prior to the MAGIC trial, the issue of arrhythmias had been flagged
up by the occurrence of postoperative episodes of sustained ventricular
tachycardia, reported in some early-phase clinical trials. For example in
one study, five out of nine patients required internal cardioversion de-
fibrillator (ICD) insertion for ventricular tachycardia. These 5 patients re-
ceived 14 shocks during the trial (Hagge et al., 2006). To clarify this issue,
ICDs were inserted in every patient included in the MAGIC trial. At the six
month study point, the burden of arrhythmias was not significantly differ-
ent between the myoblast-treated groups and the placebo group. The only
difference was seen in the time course of arrhythmias, which tended to
cluster in the early postoperative period in the myoblast group, but were
more evenly distributed over time in the placebo group. As neither the
burden of arrhythmias or adverse events were significantly different be-
tween the two groups, the clustering of early arrhythmias is notable and
remains to be fully explained but does not signify that skeletal myoblasts
should be withdrawn from the cellular therapy arena.
It is more troublesome that no significant benefit to LV function was
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seen in the MAGIC trial. This coupled with the low rate of transplanted
cell retention, high rate of cell death, and inability of the remaining cells to
form functional connections with the host cardiomyocytes signifies that
we are still some way from establishing an effective skeletal myoblast
based cell therapy.
Strategies must now be developed to optimise skeletal myoblast trans-
plantation before attempting further large scale clinical trials. Work has
already begun to address the important issues such as refining cell selec-
tion prior to transplantation and reducing transplanted cell death by us-
ing cells encoded with transgenes containing anti-apoptotic factors such
as bcl2 (Kutschka et al., 2006). Alternatively some have pre-conditioned
cells prior to transplantation to reduce cell death with some success using
potassium channel agonists (Niagara et al., 2007) or with physical stim-
uli such as heat shocking prior to cell delivery (Maurel et al., 2005; Zhang
et al., 2001).
1.5.7 Haematopoietic Stem Cells
The haematopoietic stem cell (HSC) is the common predecessor of all types
of blood cells, and is the most studied stem cell in the body. The HSC
is the only stem cell commonly applied clinically with great success, for
haematopoietic cell transplantation, for patients with malignancies, bone
marrow failure states, and immunodeficiencies (Bonnet, 2002).
Bone marrow HSCs are functionally defined by their unique capacity
to self-renew and to differentiate to produce all mature blood cell types.
The clonal origin of haematopoietic cells was first demonstrated in 1963,
in Swiss mice, by identifying clones due to unique radiation induced chro-
mosome aberrations within donor cells found in host mice spleens (Becker
et al., 1963).
The study of HSCs is hampered by our inability to perform their suc-
cessful long-term culture. Thus, in vivo models have developed as the
definitive assessment of whether a cell has HSC capacity or not. All in
vivo tests of HSC function are based on their capacity to repopulate the en-
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tire haematopoietic system in conditioned recipients after transplantation
(Phillips, 1991; Spangrude et al., 1988). In fact some believe that the defini-
tion of a HSC should require the fulfilment of two criteria: 1) the stem cell
must be capable of giving rise to progeny in all defined haematolymphoid
lineages, and 2) limiting numbers of stem cells must be capable of fully re-
constituting lethally irradiated mice, leading to their long-term survival.
Human HSCs have been extensively characterised in animal models.
The required models should not eliminate the human donor cell via im-
mune rejection, and ideally should also provide a conducive microenvi-
ronment for engraftment and differentiation of donor cells. Early studies
were thus, done in severe combined immunodeficiency (SCID) mice that
display a T and B cell defect (Bosma & Carroll, 1991; McCune et al., 1988)
and in beige/nude/xid3 (bnx) mice that display an NK, T, and B cell de-
fect (Kamel-Reid & Dick, 1988). However, both strains can mediate donor
cell rejection as a result of residual macrophages and NK cells. Therefore,
SCID mice were back-crossed to non-obese diabetic (NOD) mice that dis-
play partially deficient NK cell, antigen-presenting cell, and macrophage
functions (Shultz et al., 1995). Engraftment capacity is 10–20 times bet-
ter than pure SCID mice, hence, the NOD-SCID mouse is currently used
by most groups studying human haematopoiesis in vivo models, and en-
grafting cells are termed SCID repopulating cells (SRCs) (Larochelle et al.,
1996).
In addition to murine models, large animal transplantation models
have been developed, e.g., in which human HSCs are transplanted into
early gestational sheep foetuses (Flake et al., 1986; Srour et al., 1992). In
this model, low numbers of selected progenitors can engraft, and myelo-
erythroid as well as T and B lymphoid development can be monitored
over several years, compared to months in mouse models.
For practical purposes, HSCs are now most often isolated and defined
with respect to cell surface markers, or ability to efflux Hoechst dye. The
generation of monoclonal antibodies against the sialomucin CD34 (Civin
et al., 1984), which identifies the majority of HSCs, has led to the CD34
3X-linked immunodeficiency mutation
75
Introduction 1.5 Stem Cells for Cardiac Repair
antigen becoming the major positive marker used for human haematopoi-
etic stem and progenitor cell isolation.
In human cord blood, and bone marrow, CD34+ cells harbour virtu-
ally all in vitro clonogenic potential (Civin et al., 1984; DiGiusto et al.,
1994; Krause et al., 1994, 1996). However, the CD34+ population is hetero-
geneous. For example, CD34+CD38- cells and not CD34+CD38+ cells are
highly enriched for long-term culture-initiating cells (LTC-IC) and contain
SCID-hu-repopulating (Baum et al., 1992) and NOD-SCID-repopulating
cells (Bhatia et al., 1997; Larochelle et al., 1996).
Furthermore, the highest LTC-IC activity in NOD-SCID mice, and in
foetal sheep repopulating assays, resides in a CD34+KDR+4 fraction (0.1–
0.5% of CD34+ cells) in cord blood, bone marrow, and in G-CSF-mobilised
peripheral blood. CD34+KDR+ cells but not CD34+KDR- cells generated
myeloid, T, B, and NK cells in mice and myeloid/T cells in primary and
secondary foetal sheep transplants. These results show a >100 times en-
richment of SRC in CD34+KDR+ cells compared with CD34+CD38- cells
(Ziegler et al., 1999).
Other markers of HSC function include Thy-1, and specifically in mice
only Sca-1. CD34+Thy-1+ cells have been shown to be highly successful in
multiple clinical trials of autologous and allogeneic transplants to recon-
stitute and maintain haematopoiesis (Michallet et al., 2000; Negrin et al.,
2000). For mice, all HSC activity in bone marrow can be produced by
Lin-/lo, c-Kit+, Sca-1+ cells (Osawa et al., 1996a,b).
1.5.7.1 Haematopoietic Stem Cell Plasticity
The idea that the developmental potential of HSCs may expand beyond
the haematopoietic lineages emerged after reports indicating that cells de-
rived from bone marrow were capable of giving rise to multiple unex-
pected cell types. These include neural cells (Brazelton et al., 2000; Mezey
& Chandross, 2000), skeletal muscle (Ferrari et al., 1998; Gussoni et al.,
1999), cardiac muscle (Bittner et al., 1999; Jackson et al., 2001; Orlic et al.,
4Also known as VEGFR-2 or FLK2.
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2001a,b), and hepatic cells (Alison et al., 2000; Lagasse et al., 2000; Petersen
et al., 1999), as well as the epithelium of the buccal mucosa (Tran et al.,
2003) and gut (Brittan et al., 2002).
The plasticity of HSCs, has led to considerable excitement in using
HSCs in cell-based therapies and as vectors to deliver therapeutic agents.
This is particularly attractive clinically because bone marrow can be read-
ily obtained from patients by mobilising HSCs into the peripheral circula-
tion with cytokines such as G-CSF. Moreover, if a patients own stem cells
were taken for ex vivo expansion and directed to differentiate into, e.g,
cardiac cells, no immune rejection problems would arise.
However, the issue of HSC plasticity is highly contentious, with several
conflicting reports having been published, and evidence arising that cell
fusion rather than stem cell plasticity is the mechanism of the observed
HSC lineage diversity.
For example, the most convincing proof of principle demonstration
of the clinical potential of bone marrow was subsequently shown to be
due to cell fusion rather than plasticity (Lagasse et al., 2000). Female mice
deficient in the enzyme fumarylacetoacetate hydrolase (fah−/−, a model
of fatal hereditary tyrosinaemia type 1), a key component of the tyrosine
catabolic pathway, can be rescued biochemically by 1× 106 unfractionated
bone marrow cells that are wild-type for Fah. The salient point to arise
from this powerful demonstration of the therapeutic potential of bone
marrow cells was that although the initial engraftment was low (approx-
imately one bone marrow cell for every million indigenous hepatocytes),
the strong selection pressure exerted by liver failure on the engrafted bone
marrow cells resulted in their clonal expansion to eventually occupy al-
most half the liver. However, subsequently the new healthy liver cells in
the fah−/− mouse were found to contain chromosomes from both the re-
cipient and donor cells, i.e., donor and host cell fusion had occurred (Wang
et al., 2003). The fusogenic partners in the Fah setting have now been
identified and are not the HSCs themselves, but are bone marrow-derived
macrophages and granulocyte/macrophage progenitors (Camargo et al.,
2004; Willenbring et al., 2004).
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1.5.7.2 Controversy of Haematopoietic Stem Cell Plasticity in the Heart
As in liver, some of the most striking findings within the heart have been
questioned. The possibility of bone marrow contributing to ongoing post-
natal cardiac repair was initially suggested by demonstrations of cardiac
chimerism in either sex-mismatch cardiac transplants or in sex-mismatch
bone marrow transplants (Bittner et al., 1999; Caplice et al., 2003; Deb et al.,
2003; Hcht-Zeisberg et al., 2004; Laflamme et al., 2002; Minami et al., 2005;
Mller et al., 2002; Quaini et al., 2002). In both scenarios, the Y chromosome
was used to track “donor” cell lineage. This led to the use of Lin-c-kit+
HSCs, from GFP mice, in a mouse model of myocardial infarction. Donor
cells were able to engraft within the infarcted myocardium constituting
68% of the LV and significantly improving ventricular function. (Orlic
et al., 2001a). In a different study HSCs identified using the side population
phenotype, expressing CD34-/lowc-kit+Sca-1+, were shown to differentiate
into cells that bear a cardiomyocytic and endothelial cell phenotype in a
mouse model of myocardial infarction (Jackson et al., 2001). This regenera-
tive capacity was also seen with human HSCs in a rat model of myocardial
infarction. In this model intravenous injection of human CD34+ cells lead
to a significant reduction in scar tissue formation, improved neovasculari-
sation and resulted in an overall improvement in cardiac function (Kocher
et al., 2001). These initial findings have not been replicated in other labo-
ratories.
Two extensive studies have failed to demonstrate HSC transdifferen-
tiation into cardiac myocytes in myocardial infarction models in mice. In
145 separate transplantation experiments neither Lin-c-kit+ (100,000 dose
of cells) or Lin-c-kit+Sca-1+ cells (average dose approx 50,000 cells) when
injected 5 hours after coronary ligation or after cautery induced injury
demonstrated HSC transdifferentiation. Transgenic mouse lines in which
the cardiac-specific α-myosin heavy chain promoter drove expression of
either β-galactosidase or a GFP reporter were used to monitor cardiomyo-
genic transdifferentiation events. Furthermore, in vitro transdifferentia-
tion was not witnessed even once in over a thousand assessments when
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Lin-c-kit+ cells were co-cultured in embryoid bodies with mouse ES cells
(Murry et al., 2004). However, transdifferentiation was seen at low-levels
(2–4 cells per heart) when mice, whose bone marrow had been reconsti-
tuted with HSCs containing the α-MHC reporter gene, were subjected to
myocardial infarction and their hearts subsequently dual stained, 1 week
to 2 months later, for GFP and α-MHC to demonstrate fluorescent transd-
ifferentiated cardiomyocytes.
A similar study also failed to demonstrate transdifferentiation of HSCs
to cardiomyocytes. In a mouse MI model, Lin-c-kit+ (1 × 106 cells) or c-
kit+Thy1.1loLin-Sca-1+ (4×103 cells) cells isolated from transgenic mice ex-
pressing GFP were directly transplanted into the ischaemic myocardium
of wild-type mice. At ten days post MI, large numbers of GFP positive
cells were found within the mouse myocardium, but at 30 days post MI,
very few cells were detected. Phenotype assessment at either time point
failed to demonstrate any GFP marked cells staining positive for cardiac
markers. In fact, most of the donor cells retained a haematopoietic pheno-
type expressing CD45 and the myeloid marker Gr-1. Despite the lack of
observed transdifferentiation, there was evidence of a modest, although
statistically significant, improvement in LV function when assessed by
echocardiography compared to control animals at six weeks post MI (Bal-
sam et al., 2004). These results where further underlined using an alterna-
tive strategy, in which no detectable cardiac regeneration was seen using a
parabiotic mouse model, with one wild-type mouse, subjected to myocar-
dial infarction, paired to a GFP transgenic mouse.
1.5.7.3 Haematopoietic Stem Cell Fusion in the Heart
The observation of transdifferentiation of HSCs has been further ques-
tioned by the observation of donor HSC fusion with differentiated host
cells. As discussed above, fusion has been shown to be the primary mecha-
nism of what was once thought to be bone marrow to hepatocyte differen-
tiation (Wang et al., 2003). Fusion has also been seen within the heart. For
example, the Cre-Lox recombination system was used to detect cell fusion
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in a mouse model, in the absence of ischaemia or other injury. Bone mar-
row from mice constitutively expressing Cre recombinase and GFP was
used to reconstitute the bone marrow of a Cre-dependent LacZ reporter
mouse strain (R26R) following their lethal irradiation. Thus, any fusion
events would be eloquently demonstrated by the expression of LacZ. This
approach demonstrated that small quantities of bone marrow derived cells
fused in vivo with hepatocytes in liver, Purkinje neurons in the brain, and
cardiac muscle in the heart, resulting in the formation of multinucleated
cells. No transdifferentiation was seen in the absence of fusion (Alvarez-
Dolado et al., 2003).
Fusion was again demonstrated to be the only mechanism of transdif-
ferentiation in a mouse infarct model. Unfractioned bone marrow (1×106)
or Lin-c-kit+ cells from mice constitutively expressing GFP were directly
injected into the infarcted mouse myocardium. No donor cells at either
day 9 or day 28 post MI expressed cardiac-specific markers, but did ex-
press the panhaematopoietic marker CD45. Thus, transplanted HSCs did
not transdifferentiate, but maintained their haematopoietic lineage. In a
further part of this study, chimeric mice (R26R strain having had their
bone marrow reconstituted with GFP bone marrow) were subjected to
myocardial infarction and stem cell mobilisation. Rare (approx 0.0065% of
all cardiomyocytes) GFP+ cardiomyocytes were seen at 28 days post MI.
However, all such events were shown to be secondary to fusion by dual
staining for GFP and LacZ (Nygren et al., 2004).
Other studies have also confirmed the presence of fusion within the
heart (Andrade et al., 2005; Zhang et al., 2004a). Additionally, cell fusion
has also been seen with cardiac progenitor cells (Oh et al., 2004), and in
vivo with mouse bone marrow having been shown to fuse with mouse ES
cells rather than demonstrating lineage plasticity (Terada et al., 2002).
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1.5.7.4 Fading Optimism for Haematopoietic Stem Cell use for Cardiac
Regeneration
The initial optimism for the use of HSCs for cardiac repair has now been
tempered by the raft of negative studies. But, there is still much to explain.
What is the cause of the different findings between research groups? Even
in the negative studies, bone marrow derived cells were seen to contribute
in small quantities to post natal cardiac cell turnover. Can this pathway
be fully understood, and thus optimised? HSC treatment has also been
shown to improve cardiac function, in the absence of transdifferentiation.
How is this caused and, again, can we improve this mechanism?
The negative studies have also had the effect of refocusing attention
on the other stem cell and progenitor constituents of bone marrow. Hence,
there has been an increase in research into the ability of MSCs and EPCs
to repair and ameliorate damage to the heart.
1.5.8 Mesenchymal Stem Cells
Mesenchymal stem cells (MSCs) can be found in bone marrow, muscle,
skin and adipose tissue. MSCs are characterised by the potential to dif-
ferentiate into muscle, fibroblasts, bone, tendon, ligament and adipose tis-
sue (Caplan, 1991). MSCs can be obtained from vigorous washing of cells
from bone marrow aspirates in culture since MSCs differentially adhere
to the plastic culture dish. This technique has been used to isolate MSCs
from humans, rats and mice (Barbash et al., 2003; Colter et al., 2000; Kreb-
sbach et al., 1997). Removing cells with HSC or EPC markers by FACS or
MACS prior to plating initial cultures further enhances the specificity of
this method.
MSCs that have been used in cardiac research are mainly from the het-
erogeneous population of cells derived from adherent bone marrow cul-
tures as described above. Several studies have demonstrated that these
cells can transdifferentiate into cardiomyocytes and vascular-like struc-
tures (Gojo et al., 2003; Makino et al., 1999; Min et al., 2002a; Planat-Benard
et al., 2004; Shake et al., 2002; Thompson et al., 2003; Toma et al., 2002). Un-
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like ES cells, MSCs do not spontaneously form cardiomyocytes in vitro,
but require stimulation to proceed along a cardiomyocytic lineage. Thus
far, treatment of MSCs with 5-azacytidine has successfully led to the de-
velopment of cells that express a cardiomyocytic phenotype. This phe-
notype not only displays ultrastructural characteristics of cardiomyocytes
but also the localisation of various cardiac-specific markers including, the
cytoplasmic proteins troponin, myosin, actin, and atrial naturetic factor as
well as transcriptional factors such as GATA4, MEF-2 and Nkx2.5. Spon-
taneous contraction and action potentials are observed, as are muscarinic
and adrenergic receptors. Adaptive functionality is suggested by the ap-
propriate response of these cells to agonists and antagonists with a cor-
responding rise in intracellular molecules and change in contraction rate
(Hakuno et al., 2002; Makino et al., 1999; Planat-Benard et al., 2004; Ran-
gappa et al., 2002).
MSCs have been shown to differentiate into cardiomyocytes and en-
dothelial cells in vivo when transplanted into the heart in both non-injury
and myocardial infarction models. The cells have been strictly charac-
terised by immunohistochemistry and positively stain for cardiac and en-
dothelial specific markers, as well as gap junction proteins. (Gojo et al.,
2003; Rangappa et al., 2002; Shake et al., 2002; Toma et al., 2002; Wang
et al., 2000). Myocardial function and capillary formation are significantly
increased in experimental groups treated with MSCs when compared to
controls (Abeel A. Mangi, 2002; Davani et al., 2003; Tomita et al., 2002).
The ability of MSCs to transdifferentiate into specialised cells that im-
prove function of the failing heart makes MSCs a realistic option for cel-
lular transplantation. This is further underlined by the relative ease by
which they can be maintained and expanded in culture. The ability to
grow MSCs in culture also makes them a promising target for gene trans-
duction. The value of combining gene therapy with cellular transplanta-
tion has already been demonstrated in a rat myocardial infarction model.
Rat MSCs were isolated, expanded ex-vivo and retrovirally transduced to
over express Akt1, a mediator of survival signals and glucose metabolism.
These cells were then transplanted into the heart of the recipient animal
82
Introduction 1.5 Stem Cells for Cardiac Repair
one-hour following myocardial infarction. When compared to transplan-
tation with standard MSCs, there was a significant decrease in collagen
formation and inflammation — processes that may well be detrimental
to recovery of cardiac function. Furthermore, 80–90% of lost myocardium
was regenerated and function was completely normalised (Mangi et al.,
2003). Such combination therapy has yet to be used in a clinical setting.
However, the use of bone marrow stem cells has already been tested
in the setting of human heart disease. Unlike animal studies, in which at-
tempts have been made to study specific cell lines, early clinical trials have
tended to use a mononuclear cell fraction isolated from bone marrow as-
pirates. This fraction contains HSCs, MSCs and EPCs, and this should be
kept in mind when considering the results of clinical studies. Mononuclear
cells have been delivered via several routes including intracoronary alone
or combined with angioplasty and stenting following acute MI. So far,
small numbers of patients have been studied with limited control groups.
However, the therapy appears to be safe and functional benefits have been
recorded, with reduction in wall motion abnormalities and improvements
in left ventricular ejection fraction and myocardial perfusion (Strauer et al.,
2002). Similar results have been generated by mononuclear cell adminis-
tration via direct endocardial injection concomitant with coronary artery
bypass (Hamano et al., 2001). A third technique — transendocardial in-
jection of bone marrow derived mononuclear cells — has been used to
treat patients with chronic severe CAD and heart failure. This method, has
also produced encouraging results with improved cardiac function and
patients experiencing less symptoms as well as being able to reduce their
cardiac medications (Perin et al., 2003; Tse et al., 2003). All trials published
to date have been open label and small in size. The promise of these initial
findings must be confirmed by larger randomised controlled trials before
routine use of adult stem cell therapy can begin.
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1.5.9 Endothelial Progenitor Cells
Successful cellular therapy for cardiac regeneration will require trans-
plantation of functioning cardiomyocytes and concomitant generation of
an adequate blood supply. Endothelial progenitors cells (EPCs) can con-
tribute to tissue revascularisation and can be isolated from adult bone mar-
row or from the peripheral circulation (termed circulating endothelial pro-
genitor cells — CEPs). Adult derived EPCs and CEPs can be distinguished
from mature endothelial cells by a functional in vitro assay due to their
high proliferation rate. Temporally, they form late-outgrowth colonies, in
which the cells are mainly EPCs and CEPs, and can form colony forming
unit-endothelial cells (Lin et al., 2000; Rafii & Lyden, 2003).
Mature endothelial cells, EPCs and CEPs share several endothelial spe-
cific markers. However, only EPCs and CEPs express AC133 (CD133) (Mi-
raglia et al., 1997; Yin et al., 1997). Cells expressing CD133+VEGFR2+ can
proliferate in vitro to form mature endothelial cells (Gehling et al., 2000;
Peichev et al., 2000). Human CEPs have also shown potential to differ-
entiate to cardiomyocytes. When co-cultured with neonatal rat cardiomy-
ocytes, human CEPs formed cells with a cardiomyocytic phenotype as de-
fined by positive staining for cardiac specific markers, such as troponin,
atrial naturetic peptide and MEF-2. Functional gap junctions were also
demonstrated with transfer of Lucifer yellow dye and calcein between the
cells (Badorff et al., 2003).
EPCs and CEPs play an important role in neovascularisation in vivo
(Asahara et al., 1999). Circulating EPCs are mobilised in response to organ
ischaemia, trauma and acute myocardial infarction (Gill et al., 2001; Shin-
tani et al., 2001; Takahashi et al., 1999). The increase in CEPs post-MI is
mirrored by a rise in the growth and migratory cytokine VEGF-A, and sug-
gests a role for this factor in the mobilisation of progenitor cells (Rabbany
et al., 2003). Also, 3-hydroxy-3-methylglutaryl co-enzyme A (HMG-CoA)
reductase inhibitors (statins) have been shown to augment mobilisation
of EPCs. This important observation may provide an alternative mecha-
nism by which statins decrease morbidity and mortality in patients with
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ischaemic heart disease (Dimmeler et al., 2001).
Transplantation of EPCs and CEPS has been shown to promote neovas-
cularisation of the ischaemic heart and improve function. Transdifferentia-
tion to endothelial cells, smooth muscle cells and cardiomyocytes has been
characterised by immunohistochemistry (Kawamoto et al., 2001; Kocher
et al., 2001; Yeh et al., 2003). In animal models of MI, transplantation of
EPCs or CEPs causes a significant increase in capillary density, regional
blood flow and collateral formation in the ischaemic heart. In addition,
cardiac function is also significantly improved following transplantation
(Kamihata et al., 2002; Kawamoto et al., 2001, 2003; Kocher et al., 2001).
Encouraging results such as these has led to human clinical studies of
EPC transplantation. Two studies have been completed to date; EPCs or
CEPs were transplanted either intracoronary following acute MI or en-
docardially at the time of coronary bypass surgery. There have been no
adverse outcomes as yet, and both studies were able to show an increase
in cardiac function with improved myocardial perfusion (Assmus et al.,
2002; Stamm et al., 2003).
1.5.10 Cardiac Stem Cells
1.5.10.1 Old Paradigm
The adult heart, until recently, was understood to be a post-mitotic organ,
i.e., it consists of a constant number of cells from birth to death unless
cells are lost to pathological insults. The only adaptive cellular response
was considered to be cardiomyocyte hypertrophy (Chien & Olson, 2002;
MacLellan & Schneider, 2000; Soonpaa & Field, 1998).
This view point is now being challenged. The first suggestions of a
new understanding of cardiac cellular homoeostasis was the discovery of
ongoing cell division in adult hearts as demonstrated with mitotic index
counting and BrdU and Ki-67 labelling studies. Cell division was seen un-
der normal physiological conditions, but appeared to be stimulated by car-
diac injury such as myocardial infarction, LVH and heart failure (Anversa
& Kajstura, 1998; Beltrami et al., 2001; Kajstura et al., 1998).
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Two elegant studies, using differing methods, have also suggested on-
going post-natal cardiomyocyte renewal. The first study used genetic-fate
mapping, and concluded that adult mammalian cardiomyocytes are re-
freshed after injury (Hsieh et al., 2007). Double-transgenic MerCreMer-
ZEG mice were used.
The mice were produced by crossbreeding transgenic B6129-Tg
(Myh6-cre/Esr1) 1Jmk/J (referred to as MerCreMer) mice, in which the
cardiomyocyte-specific α-myosin heavy chain (Myh6) promoter drives ex-
pression of a 4-OH-tamoxifen-inducible Cre recombinase fusion protein,
with B6.Cg-Tg (ACTB-Bgeo/GFP) 21Lbe/J (referred to as ZEG) reporter
mice, in which constitutive β-galactosidase expression is replaced by the
expression of GFP upon the removal of a loxP-flanked stop sequence.
The double-transgenic mice allowed fate tracking of adult cardiomy-
ocytes in a pulse-chase fashion. After a 4-OH-tamoxifen pulse, GFP ex-
pression was irreversibly induced, marking only cardiomyocytes. During
normal ageing or after experimental injury (the chase), the percentage of
GFP+ cardiomyocytes can either remain unchanged or decrease. A de-
crease in GFP labelled cells would indicate new myocyte formation, as
long as the new cells were shown to have a cardiomyocyte phenotype.
GFP labelled cells would also have to be shown not to have an abnormally
high attrition rate related to the transgene construct.
The fate tracking demonstrated that, in mice, up to a year in age, there
was no change in GFP+ cardiomyocytes, indicating that there was no sig-
nificant physiological cell turnover. However, in injury models, a signif-
icant decrease was seen. Both in myocardial infarction and in pressure
overload (by transverse aortic constriction), GFP labelling, at 3 months
post intervention, was reduced compared to sham operated mice (67.5%
P=0.0001, 75.7% P<0.05, and 82.8% respectively). Cell fusion was elimi-
nated as a significant cause by dual staining for GFP and β-galactosidase
and was seen to occur on average in 1.4% of cardiomyocytes, an order
of magnitude lower than the reduction in labelled cells seen. Using PCR
and immunohistochemistry c-kit labelling was seen to be up-regulated in
myocardial infarction compared to control mice (7.5 +ve cells/1000 nuclei
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compared to 1 cell in 25,554, respectively 3 days post intervention). These
results are compatible with the existence of cardiac progenitor cells that
are able to participate in de novo cardiomyocyte formation after cardiac
injury.
Further indirect evidence for the existence of post natal cardiomyocyte
renewal was documented in a novel paper measuring carbon-14 (C14)
within genomic DNA of human myocardial cells (Bergmann et al., 2009).
Atmospheric C14 levels were static until, above ground, nuclear bomb
tests caused a sudden increase in the 1950s. Following the Limited Nu-
clear Test Ban Treaty in 1963, C14 levels dropped exponentially, primarily
due to atmospheric diffusion (not radioactive decay as the half-life is 5730
years). Human C14 levels mirror atmospheric levels via incorporation into
the food chain. As DNA is relatively stable following a cell’s last division,
the quantity of C14 incorporated into a cells DNA can be used to ascertain
its inception date.
To determine the extent of post-natal DNA synthesis, flow cytome-
try and mass spectrometry were used to selectively carbon date human
cardiomyocytes. Concentrations of C14 in subjects born after the nuclear
bomb tests corresponded to atmospheric levels several years after their
birth, whilst in subjects born prior to the nuclear bomb tests, C14 levels
were higher than expected. This disparity suggests that DNA of myocar-
dial cells continues to be synthesised many years after birth. From the ob-
tained results, a mathematical model was used to estimate that approxi-
mately 1% of cardiomyocytes are renewed each year at the age of 25. The
renewal rate then decreases with age, e.g., 0.45% a year at 75 years old.
This means that at the age of 50 about 55% of cardiomyocytes remain from
birth and 45% have been replaced, and that on average a cardiomyocytes
age is six years younger than the individuals.
The discovery of myocardial chimeras5, increased the suspicion of the
existence of a cardiac stem cell (CSC).
Myocardial chimerism was demonstrated by testing for the presence
of Y chromosome in ex-planted hearts of male patients who had received
5Presence of two or more populations of genetically distinct cells.
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female donor hearts. Male derived myocytes and endothelial cells were re-
vealed within the female heart. This finding was interpreted as represent-
ing cardiac repair affected by circulating progenitor cells (Quaini et al.,
2002). A second similar study, in which the hearts of females who had
received male bone marrow were examined for presence of the Y chromo-
some, concluded that bone marrow progenitor cells were capable of transit
to the heart and its subsequent repair (Deb et al., 2003).
The chimera studies suggest the existence of a population of cardiac
progenitors recruited from a non-cardiac source such as bone marrow.
However, additionally, several independent investigators have now pre-
sented strong evidence for a resident population of cardiac progenitor cells
within the heart. The isolated cardiac progenitor cells have standard stem
cell defining characteristics and are capable of differentiating into multi-
ple cardiac cell lineages such as cardiomyocytes, endothelial and vascular
cells. Similar findings have been replicated in mice, rats, dogs and humans.
In animal models, the CSCs have been shown to repair and improve car-
diac function following myocardial ischaemia.
The presence of a cardiac progenitor cell is now broadly accepted, but
the true phenotype of the progenitor remains to be determined. Several
phenotypes with progenitor ability have been described within the heart:
the side-population, c-kit+, sca-1+, cardiosphere, and isl1+ phenotypes.
1.5.10.2 Side-population Cardiac Progenitor Cell Phenotype
The ability of stem cells or progenitor cells to preferentially efflux Hoechst
33342 dye compared to differentiated cells, due to the presence of mem-
brane pumps encoded by the multiple drug resistance genes, has allowed
their identification using flow cytometry. As stem cells efflux the Hoechst
dye, they appear close to, and almost parallel to, the y axis when analysed
using flow cytometry, which led to the label of side-population (SP) cells.
Cells with a SP phenotype have been isolated from mouse hearts. They
accounted for approximately 1% of the total cell population. In culture, the
SP cells were able to form colonies and to differentiate to a cardiomyocyte
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lineage in co-culture with primary cultures of cardiomyocytes (Hierlihy
et al., 2002).
The efflux of Hoechst dye is dependent on the expression of ABCG2,
a member of the ATP-binding cassette transporter family. ABCG2 is ex-
pressed within embryonic mouse hearts and down regulated towards ges-
tation. ABCG2-expressing cells were also demonstrated within the adult
mouse heart. They became more prevalent following MI and were able to
produce a muscle like phenotype, staining positive for α-actinin, when in
co-culture with cardiomyocytes.
The full extent of plasticity, and functional benefits of treatment with
cardiac SP cells remain to be investigated.
1.5.10.3 c-Kit+ Cardiac Progenitor Cells
Cardiac progenitor cells were isolated from adult rat hearts by selecting
cells positive for c-kit and negative for blood lineage markers (CD34,
CD45, CD20, CD45RO) (Beltrami et al., 2003). Such labelled cells were
infrequent, approximately 1 per 10,000 myocytes. In culture, the c-kit+
cells were clonogenic and multipotent, able to differentiate into endothe-
lial cells, smooth muscle cells and cardiac myocytes. Generated myocytes,
although identified as myocytes due to positive immunohistochemical
staining, did not function physiologically as myocytes — neither sarcom-
eres or spontaneous contractions were observed.
In a rat MI model, injected c-kit+ CSCs improved LV function and in-
creased blood vessel density. GFP tracking of injected cells demonstrated
plasticity with formation of both de novo cardiomyocytes and vascular
cells. A significant contribution from fusion was excluded by demonstrat-
ing that newly formed cells were diploid rather than tetraploid. C-kit+
cells were also seen to improve LV function in a rat ischaemia-reperfusion
model when injected intra-arterially within the aortic root.
Human adult heart tissue also contain c-kit+ CSCs at a low frequency
(1.8% of total population). As with rat CSCs, they are proliferative, clono-
genic and multipotent. Myocytes, vascular cells and endothelial cells were
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all obtained in vitro. Furthermore, human c-kit+ cells were able to regener-
ate myocardium and vasculature when used to treat immunodeficient rat
and mice following MI. Myocardial function was improved in the treated
animals (Bearzi et al., 2005, 2007).
An uneven distribution of c-kit+ cells within the heart was observed,
with a higher frequency of cells found in the atria and within the apex of
the left ventricle. Currently, there is no experimental evidence to explain
this finding, but it has been proposed that these segments of myocardium
are relatively protected from haemodynamic stresses and therefore pro-
vide a safer environment to harbour such important resources as cardiac
progenitor cells.
1.5.10.4 Sca-1+ Cardiac Progenitor Cells
Stem cell antigen 1 (Sca-1) was one of the first cell surface markers iden-
tified as marking HSCs (Spangrude et al., 1988). More recently, skeletal
muscle derived stem cells were found to highly express Sca-1, and 90% of
SP cells within skeletal muscle were found to express Sca-1 (Asakura et al.,
2002; Qu-Petersen et al., 2002). This suggested to some investigators that
if a cardiac progenitor cell was present within the heart that there was a
significant chance it would express Sca-1.
Subsequently, Sca-1+ has been shown to identify a population of car-
diac progenitor cells resident within the heart. Unlike their Sca-1+ HSC
counterparts, cardiac Sca-1+ progenitors are negative for CD34 and CD45.
Sca-1 positive cells were identified at a ratio of 1 in 10,000 cells, propor-
tionally 0.3% of the myocardial cellularity. In vitro, Sca-1+ cells were able
to spontaneously differentiate into beating cardiomyocytes with sarcom-
eres and express appropriate cardiac transcription factors when cultured
with oxytocin or 5-azacytidine (Matsuura et al., 2004; Oh et al., 2003).
In a mouse model of myocardial ischaemia-reperfusion, after Sca-1+
cells were injected intravenously, evidence that cells had homed to the
border zone of the infarct was seen. A Cre-Lox donor recipient pair was
used for lineage tracing and phenotype identification. Host mice were the
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R26R reporter line, bearing Cre-dependent LacZ behind a loxP-flanked
neomycin phosphotransferase stop signal. Donor mice contained a myosin
heavy chain-Cre recombinase sequence, thus Cre recombinase was only
expressed in cardiomyocytes. Donor cells were found to differentiate into
cardiomyocytes, with and without fusion to host cells in approximately
equal proportions. Fused cells were identified by expression of LacZ by
cardiomyocytes and de novo cardiopoiesis was observed by dual staining
for MHC-Cre and sarcomeric actin.
1.5.10.5 Cardiac Progenitor Cells Isolated Using Cardiosphere Culture
A pure tissue culture technique for isolating cardiac progenitor cells has
also been published. Using human myocardial biopsies and murine heart
samples, cardiac progenitor cells were isolated and clonogenicity demon-
strated.
Human myocardium from surgical or endomyocardial biopsies were
partially enzymatically digested and then cultured for 14–24 days. Small
round cells were seen to bud off from the primary ex-plant and divide
in suspension. The isolated cells were then grown in suspension culture,
in differentiation media, which induced formation of a ball of cells that
has been termed a cardiosphere (Messina et al., 2004). The cells from the
cardiosphere were shown to be clonogenic and highly proliferative. Im-
munostaining suggested that about 20% of cells were c-kit+, 90% CD105+,
and 40% CD90+.
When cardiospheres were grown in co-culture with rat neonatal car-
diomyocytes, approximately 20% of cardiospheres were seen to contract
spontaneously. Moreover, spontaneous calcium transients were seen in a
small percentage of these contracting cells.
Human cardiosphere derived cells, when injected into the border zone
of myocardial infarcts engrafted and migrated into the infarct zone. After
20 days, the percentage of viable myocardium within the infarct zone was
greater in the treated group than in the fibroblast treated control group;
likewise, echocardiography performed on day 20 post-infarct revealed a
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higher LVEF in the cardiosphere treated group (42.8±3.3%) than in either
the fibroblast-treated (25.0±2.0%, P<0.01) or the PBS-treated (26.0±1.8%,
P<0.01) group (Smith et al., 2007).
The cardiosphere model for obtaining cardiac progenitor cells may
present a useful clinical approach as the cells can be isolated from rou-
tine clinical biopsies, then expanded to clinically relevant numbers, and
have shown potential for cardiac repair in animal experiments.
1.5.10.6 Islet-1 Expressing Cardiac Progenitor Cells
A further distinct population of cells with cardiac progenitor activity is
marked by the presence of LIM homeodomain transcription factor islet-1
(isl1). The cell’s origin can be traced from the embryonic heart where the
cells contribute to formation mainly of the right ventricle, both atria, and
the outflow tract (Cai et al., 2003). Expression of isl1 is lost when the cells
mature and differentiate into cardiomyocytes.
Some isl1 cells remain in situ following birth in the atria, outflow tract,
and the right ventricle, corresponding to their sites of contribution to car-
diac development in the embryo. The cell surface markers c-kit, and Sca-
1, are absent from isl1 labelled cells. In vivo, isl1 cells, can be expanded,
and differentiated into cardiomyocytes when co-cultured with cardiac my-
ocytes in the absence of cell fusion and demonstrate terminal differentia-
tion markers and electrophysiological characteristics of fully differentiated
cardiomyocytes (Laugwitz et al., 2005).
Genetic fate-mapping studies have documented that isl1+ precursors
from the second heart field can generate diverse cardiovascular cell types,
including endothelial, cardiac, and smooth muscle cells, in vivo. The tran-
scriptional signature of isl1+/Nkx2.5+/flk1+ is able to define a multipotent
cardiovascular progenitor, which can give rise to cells of all three lineages
(Moretti et al., 2006). Thus a developmental paradigm for cardiogenesis is
envisaged, whereby muscle and endothelial lineage diversification arises
from a single cell-level decision of a multipotent isl1+ cardiovascular pro-
genitor cell. This suggests a strategy for cardiovascular tissue regeneration
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via isolation, renewal and directed differentiation of multipotent isl1+ cells
into specific mature cardiac, pacemaker, smooth muscle and endothelial
cell types (Moretti et al., 2006).
The capacity for isl1+ cardiac progenitors to engraft and repair the
damaged ventricle remains to be determined.
1.5.11 Clinical use of Cardiac Progenitor Cells
Adult and embryonic stem cells have shown potential for the treatment
of cardiovascular diseases in particular ischaemic heart disease and heart
failure. Results from animal studies and initial human trials are encourag-
ing and have prompted the development of larger clinical trials. However,
important aspects of stem cell biology and the transplantation process re-
main unresolved.
For therapeutic cellular transplantation to occur, many clinical prob-
lems remain to be resolved. We must define which patient groups are suit-
able for this therapy and which stem cell or cell types are the most effec-
tive, given the underlying pathology. The optimum timing and method of
delivery still remain to be determined and may have a significant bearing
on the beneficial outcome of cellular transplantation. Long-term side ef-
fects of treatment are unknown, since most of the clinical studies are very
recent.
Pressing scientific problems are also unresolved. The mechanism by
which transplanted stem cells improve cardiac function is not understood.
It was initially assumed that stem cells might improve cardiac function by
undergoing differentiation into replacement cardiomyocytes or vascular
cells to take on the role of non-functioning tissue. Stem cell derived car-
diomyocytes would therefore improve function by contributing mechan-
ically to contraction whilst stem cell derived endothelial cells would im-
prove blood supply by a process of neoangiogenesis. However, direct ev-
idence for these assumptions is poor and provides sufficient doubt to al-
low for alternative theories for the mechanism of functional benefit. These
include cell fusion and other mechanisms such as release of local fac-
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tors modulating cell division, apoptosis, extra cellular matrix homoeosta-
sis or metabolic efficiency. The cellular signals and mechanisms involved
in homing, engraftment and differentiation of stem cells are partly estab-
lished for ES cells, but on the whole remain undiscovered for adult stem
cells. Understanding of these processes will increase the potential bene-
fits of stem cell therapy. Finally, as mentioned earlier, immunomodulation
strategies and methods of removing xenoproducts from the culture and
isolation of stem cells are in their infancy and need more work.
In summary, in spite of the exponential growth of interest and initial
progress made in stem cell therapy for treatment of cardiovascular disease
there is much to be done and we are still some way from achieving the
ultimate goal of effective cellular regeneration.
Studies using human adult stem cells have shown that they can ame-
liorate loss of cardiac function following myocardial infarction in animal
models. Histological examination in these studies demonstrated that the
transplanted cells have in some cases formed new cardiomyocytes and
vascular structures. The positive animal and human studies, plus the need
for effective treatments, have quickly led to phase I trials of adult stem and
progenitor cells.
Early clinical trials have used the mononuclear cell fraction isolated
from bone marrow aspirates containing HSCs, MSCs and endothelial pro-
genitor cells. So far the studies have involved relatively small numbers of
patients and have demonstrated that adult stem cell therapy for heart dis-
ease appears to be safe and may improve cardiac function (see Tables 1.7
& 1.8). Large randomised control trials are undoubtedly needed before the
true value of this approach can be decided. The trials so far can be divided
into two categories: acute or chronic studies.
1.5.11.1 Acute Studies
Cells are injected shortly after an acute myocardial infarction once the
patient has received best medical treatment and primary angioplasty to
restore flow down the culprit coronary artery. Bone marrow is aspirated
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from the posterior iliac crest within 10 days of the infarct. Following sep-
aration of the mononuclear cellular fraction, and sometimes following
additional culture, the cells are injected down the culprit vessel in an
angioplasty-like procedure. Studies have used between 3–10 injections per
artery of 2–3 ml of cells through an over-the-wire PTCA balloon inflated
for up to 3 minutes at a time. The numbers treated per study range from
6 to 34 patients and the follow up of the patients has ranged from 3 to 16
months. Using echocardiography, LV angiography and MRI, the studies
have documented an improvement in a range of functional parameters, in-
cluding ejection fraction, wall motion scoring, infarct size, wall thickening
and LV dimensions (Abdel-Latif et al., 2007; Lipinski et al., 2007; Martin-
Rendon et al., 2008). In addition, thallium and PET results have shown
improved perfusion and viability in keeping with results of pressure wire
studies demonstrating improved coronary flow reserve. On a cautionary
note, one study was stopped due to a trend of in-stent stenosis, but the
study was too small for these numbers to reach statistical significance and
their findings could well be in the realms of normal outcomes as on av-
erage 20% of people will suffer in-stent stenosis following standard PCI
(Kang et al., 2004).
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1.5.11.2 Chronic Studies
Patients with chronic heart failure secondary to ischaemic heart disease
have been treated with cells directly injected into the myocardium or in-
tracoronary either at the time of cardiac bypass surgery or percutaneously.
Both methods of delivery have been used to inject cells, overcoming the
fact that diseased arteries may not be useful for efficient cell delivery
to the target area. Studies have enrolled between 4 and 21 patients with
follow-up between 3 and 12 months. Some studies have used as many as
16 intramyocardial injections of up to 0.2 ml of cell suspension per injec-
tion. The results have shown improved cardiac function and perfusion.
Patients at follow-up experience fewer symptoms and a reduction in car-
diac medications (Perin et al., 2003). It should be remembered that none of
the chronic studies so far have been sufficiently powered to detect signifi-
cant changes in function as they were solely designed to test safety.
Taken together, the acute and chronic studies are reassuring and all
have confirmed the safety and feasibility of cellular therapy with no signif-
icant rise in biochemical markers of myocardial damage, dysrrhythmias or
any other adverse event in the treated groups compared to controls. Most
have shown functional benefit, although only one phase II study was pow-
ered to detect this outcome (Wollert et al., 2004). Many questions remain
concerning the use of progenitor cell therapy in the treatment of heart dis-
ease (Lovell & Mathur, 2010): which patients will benefit; what cell type
is best; when is the best time to deliver the cells and what delivery tech-
nique should be used to do this? Such questions can only be answered by
well-designed randomised control trials targeting specific patient groups,
carried out using standardised reproducible techniques and adequately
powered to detect significant differences in robust outcome measures (Bar-
tunek et al., 2006). Should this approach be bypassed in a haphazard or
disjointed fashion, the true potential of this revolutionary approach to the
treatment of cardiovascular disease may never be realised.
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1.5.12 Mechanisms of Cellular Repair
At present, one area of debate is the role of cell fusion in adult stem cell
transdifferentiation and the part it plays in any functional benefits derived
from stem or progenitor cell transplantation.
The possibility of stem cells acquiring a new phenotype by fusion with
a differentiated cell type rather than by direct transdifferentiation and ac-
quisition of a new phenotype was first demonstrated by two in vitro stud-
ies, which both demonstrated that adult cells, in this instance mouse bone
marrow and adult neural cells could gain a new phenotype by fusion with
embryonic stem cells (Terada et al., 2002; Ying et al., 2002).
More recently, this phenomenon has been used to explain the develop-
ment of the hepatocyte phenotype from bone marrow derived progenitor
cells (Vassilopoulos et al., 2003; Wang et al., 2003). This finding begs the
question as to whether cell fusion is the process that explains progenitor-
derived cells expressing cardiomyocytic and endothelial cell phenotypes,
as discussed previously. The possibility of cell fusion has not been ad-
dressed in the majority of stem cell transplant studies and future publi-
cations must examine this with rigour if the mechanisms of cellular trans-
plantation are to be understood.
Recent studies have started to try and resolve the issues of cell fusion vs
differentiation using techniques such as a Cre-Lox recombination system
to detect cell fusion. This method has been used in a mouse model, in the
presence of ischaemia, where the overall engraftment of transplanted stem
cells to the heart was about 3%. Half of the engrafted cells were the result
of cell fusion events, the other half were felt to represent transdifferentia-
tion and expressed appropriate cardiomyocytic markers. In the absence of
ischaemia in this model, stem cell fusion with cardiomyocytes was seen at
a very low level (Alvarez-Dolado et al., 2003; Oh et al., 2003). However in
contrast to these findings, quantification of DNA failed to reveal cell fusion
in a rat myocardial infarction model, following stem cell transplantation
(Beltrami et al., 2003). Human heart sections from female patients, who
had received male bone marrow transplants, were found to contain cells
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Figure 1.7: Proposed mechanisms of action of adult stem Cells. Several mecha-
nistic pathways have been implicated in the process of cardiac repair following
experimental myocardial injury in animal models and are shown here. Initially
direct myogenesis and vasculogenesis driven by stem cell plasticity were con-
sidered to be the primary mechanisms of benefit. Subsequently, fusion has been
demonstrated to account for some instances of presumed de novo blood vessel
and muscle formation. Many now believe that a paracrine effect of transplanted
cells on the host organ is the major driver of benefit. It is unknown which of these,
either alone or in combination are relevant to man.
that carried the Y chromosome suggesting donor origin. These donor cells
displayed a cardiac phenotype which was shown to result form a process
of transdifferentiation rather than cell fusion (Deb et al., 2003). Interpreta-
tion of these conflicting results is difficult and it remains to be seen what
the true extent of cell fusion is and whether it is beneficial or detrimental.
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1.6 Hypothesis of Thesis
Hypothesis The unifying hypothesis of this thesis is that administration
of adult derived bone marrow progenitor cells leads to significant restora-
tion of cardiac function in both the acute and chronic infarct setting. Fur-
thermore, it is proposed that the mechanism of benefit will differ in the
acute setting compared to the chronic setting, in that the acute benefit will
be considered to be derived by an indirect action of paracrine factors and
chronic benefit is gained by direct differentiation of progenitor cells into
cardiac tissue.
In order to test the hypothesis of the thesis several aims were identified
to investigate bone marrow progenitor cell actions, both in the acute and
chronic setting:
Aims for Acute Studies
1. To Isolate and prepare bone marrow mononuclear cells.
2. To deliver the mononuclear cells into a cardiac ischaemia-
reperfusion injury model.
3. To identify and quantify the homing and engraftment of delivered
mononuclear cells.
4. To evaluate any improvement in cardiac function sustained follow-
ing delivery of bone marrow derived progenitor cells acutely in the
ischaemia-reperfusion injury model.
5. To use a tissue co-culture system to identify the acute indirect
(paracrine) effects of bone marrow derived cells.
6. To perform a proteomic analysis to identify important pathways
relevant to the acute benefits of bone marrow cell delivery in the
ischaemia-reperfusion injury model.
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Aims for Chronic Studies
1. To use in situ hybridisation in histological sections from human sex-
mismatch cardiac transplants to demonstrate evidence of chronic re-
pair of cardiac tissue via transdifferentiation.
2. To transdifferentiate, in vitro, the mesenchymal sub-population of
bone marrow into cardiomyocytes.
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Materials and Methods
The three core experimental elements of this thesis were: cell culture; a rat
ischaemia-reperfusion model; and, put broadly, cell characterisation.
Both primary cultures and cell lines were used in experiments. The
primary isolation of BMMNCs is described below. The primary culture of
neonatal rat cardiomyocytes is described in chapter §4.4.1.1. The culture
of the Huss human MSC lines and human umbilical vein endothelial cells
(HUVECS) are also described within their respective chapters in §5.2 and
§4.4.1.2.
The rat ischaemia-reperfusion model is common to two separate chap-
ters and is thus described below.
Cell characterisation involved immunohistochemistry and microscopy
for cell tracking and phenotyping. Other techniques were also used in cell
characterisation including flow cytometry for: cell surface markers; reac-
tive oxygen species quantification; cell cycle analysis; mitochondrial mem-
brane potential dyes, and apoptosis and necrosis. Methods applicable to
more than one chapter will be described below, otherwise they will be
found in their appropriate chapters. Additional less successful techniques
were also attempted including the oxygen electrode, live cell confocal mi-
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croscopy, and ATP quantification, that were all used in an attempt to assess
mitochondrial function.
2.1 Animal Husbandry
All animals received care in accordance with national guidelines and the
Animals (Scientific Procedures) Act of 1986. Experiments were performed
with the authority of the local area ethics committee under home office
project and personnel licenses.
2.2 Bone Marrow Harvesting
In summary, rats were killed, their femur and tibias excised and all extra-
neous tissue was discarded. The bone ends were removed and whole bone
marrow was flushed from tibias and femurs using a 22 G needle and Dul-
beco’s Modified Eagles Medium (DMEM) with 10% Foetal Bovine Serum
(FBS). The mononuclear cell fraction was separated using a Percoll gradi-
ent by centrifuging for 30 minutes at 500 × g (Histopaque 1.077g, Sigma,
U.K., Product No. 10771-500ml). The BMMNCs were decanted from the
formed distinct layer and washed, centrifuged and re-suspended three
times. The cells were then suspended in phosphate buffered saline (PBS)
or culture medium depending on their experimental destiny. Prior to use
of cells in any experiments viability was tested using the trypan blue ex-
clusion test (Life Technologies, U.K., Product No. 15250-61).
2.2.1 Rats for Bone Marrow Harvesting
Wistar rats, weighing 200–320 g, were used as cell donors for all transplan-
tation studies unless otherwise stated. All animals were purchased from
Harlan, U.K., and were kept within the William Harvey Research Insti-
tutes’, or University College London’s animal facility for at least twenty-
four hours before commencing experiments. Rats were fed a standard rat
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chow diet and allowed tap water ad libitum. Prior to cell collection all an-
imals were killed using the Schedule 1 listed techniques of concussion or
gas induced asphyxiation with cervical vertebrae dislocation.
2.2.2 Dissection Equipment
The day before dissection all instruments and glassware were sterilised
using an autoclave for 15 minutes at 121◦C with a pressure of 1.05 bar
(LTE Scientific, U.K., Osprey). For dissection a bone cutter, forceps and
dissection scissors (All VWR International, U.K., Product Nos 233-0010,
406/0070/00, SIS-310-060Y respectively) were used.
2.2.3 Rat Tibia and Femur Dissection
For dissection rats were placed in the supine position and doused in 70%
ethanol. An incision was made in the midline of the abdomen through
the skin but not extending into the abdominal muscles. This incision was
extended, by blunt dissection, in this plane laterally to expose the muscles
of the legs. This procedure was completed by removing the distal skin of
both legs by pulling the remaining skin back over the feet and then finally
off the leg.
The muscles of the leg were then removed with scissors. The foot was
fully flexed and the hip and knee extended to allow removal of the calf and
quad muscles. Following this the foot was extended and the knee flexed
to allow removal of the shin and thigh muscles.
The hip was then fully extended and the hip joint dislocated to allow
removal of the leg. The foot of the isolated leg was then removed by flex-
ing the foot and cutting through the ankle joint and supporting tendons.
The femur and tibia were then hyperextended dislocating the tibia-patella
joint and isolating the tibia. Then femur was subsequently dislocated from
the patella-femur joint. Both the isolated femur and tibia were placed in
PBS (Sigma, U.K., Product No. D8662) in a sterile Petri dish (BD Falcon,
U.K., Product No. 353003) on ice. This procedure was then repeated for
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the contralateral leg.
2.2.4 Bone Marrow Flushing from Tibia and Femurs
After the harvested tibia and femur bones were placed within a Petri dish
they were taken to a culture hood. Any remaining strands of muscle were
removed using sterile gauze (Safetec Vision, U.K., Product No. GSD3790)
by rubbing up and down the length of the bones. The ends of each of
the bones were then removed using bone cutters that allowed a clean cut
across the bones. Without bone cutters if scissors were used significant
amounts of bone marrow was lost due to extensive shattering and frag-
mentation of the bone ends.
Each bone in turn was then suspended over a 50 ml centrifuge tube
(Appleton Woods, U.K., Product No. BC028), using forceps. A 22 G “blue”
needle, attached to a 20 ml syringe (Both from B&D, Product Nos 305155
and 301625, respectively) containing culture media (DMEM with 10%
FCS, both from Invitrogen-Gibco, Product Nos respectively 11880-028, and
10082-147), was then inserted into the cavity of the bone and the bone mar-
row was vigorously flushed out into the centrifuge tube. Each bone usu-
ally required 5 ml of media to adequately flush the cavity, success was
indicated by the bone becoming pale suggesting that all the marrow has
been flushed out.
2.2.5 Bone Marrow Mononuclear Cell Isolation
Successful bone marrow flushing resulted in obtaining a whole bone mar-
row (WBM) suspension in culture media. The bone marrow mononuclear
cell (MNC) fraction can then be separated using a Percoll gradient.
To separate the MNCs the initial suspension of WBM is centrifuged for
5 minutes at 500 × g. The subsequent supernatant is discarded and the
cell pellet is resuspended in 5 ml of media. This is then layered carefully
and slowly on top of 5 ml of Histopaque 1.077 g (Sigma, U.K, Product No.
10771-500ml). The MNC layer is then separated out by centrifuging for 30
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minutes at 500 × g, with the centrifuge brake set to zero.
Following centrifugation, a cloudy cream layer of MNCs is formed be-
tween the top layer of culture media and the bottom layer of Histopaque.
The MNCs are selectively removed using a micropipette and placed in 5
ml of culture media. The cells are then washed by centrifuging at 500 ×
g for 5 minutes and the supernatant discarded and the cells resuspended
in 5 ml culture media (DMEM plus 10% FBS), this step is repeated for a
total of three repetitions. The cells are then counted using a haemocytome-
ter (VWR International, U.K., Product No. 403/0040/03) and viability as-
sessed using trypan blue (5 minutes incubation at 37◦C, from Invitrogen,
U.K., Product No. 15250-061). The cells are then washed and resuspended
in the appropriate solution and at the appropriate concentration according
to the combination that was required for the planned experiment.
2.3 Cell Culture
2.3.1 Cell Media
Several different types of cell were used in the experiments in this thesis
and accordingly several different types of cell culture media were used
depending on the cell type (see Table 2.1). For BMMNC isolation and cul-
ture DMEM mixed in a ratio of 60:40 parts with MCDB was used plus 10%
FBS, and the constituents of DMEM are shown below (Table 2.2). Further
details for making the media are found in §4.4.2.1 where additionally the
constituents of MCDB are also shown (Table 4.1). For the human MSC cell
lines Glasgow Minimum Essential Medium (GMEM) was used and fur-
ther details can be found in §5.2. HUVECS were maintained in culture us-
ing endothelial growth media 2 (EGM-2), and primary cultures of neonatal
rat cardiomyocytes were sustained with a mixture of DMEM and Medium
199. Additional information for both cell types can be found in §4.4.2.
Following DMEM purchase from the manufacturer further reagents
were added to the cell culture medium to optimise conditions for BMMNC
culture and isolation.
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2.3.2 Cell Passaging
Cell cultures were detached from culture vessels when required for cell
passaging or when needed for certain experiments. Cell detachment was
performed using Accutase (Sigma, U.K, A-6964). Unlike trypsin, Accutase
does not need to be removed in normal cell passaging and is simply in-
activated by addition of new media. Typically cell dissociation was per-
formed by aspirating old media from the culture vessel and then adding
enough Accutase to cover the surface of the plastic. Cells were then left
to stand for 5–10 minutes. Once free or semi-free floating cells were seen
the culture vessel was tapped against the palm of the hand, twice. Cells
were then collected into a centrifuge tube, with additional aspiration of
cells up and down the culture vessel to ensure maximum detachment of
cells. Cells would then be re-plated in fresh media or taken to be used in
an experiment as needed.
2.3.3 Storing Cells
Batches of cells were in some instances stored for practical reasons regard-
ing timing of experiments, or to provide a repository of cells to use for
future experiments, or to allow reinvestigation of the cells characteristics
in the light of any future new understanding or questions that may be
Table 2.1: Table of cell medias — different cell mediums were used as required
for the needs of individual cell types.
Cell type Cell Medium Used
Neonatal Cardiomyocytes Dulbeco’s Modified Eagles Medium (DMEM)
and Medium 199
BMMNCs Mix of Molecular, Cellular and Developmental
Biology Media (MCDB) and DMEM
Huss Human MSC cell lines Glasgow Minimum Essential Medium (GMEM)
HUVECS Endothelial Growth Medium 2 (EGM-2)
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Table 2.2: Constituents of Dulbeco’s modified eagle medium.
Component Mg/Litre
Inorganic Salts
CaCl2 · 2 H2O 265
Fe(NO3)3 0.1
KCl 400
MgSO4 · 7 H2O 200
NaCl 6400
NaH2PO4 · 2 H2O 140
Amino Acids
L-Arginine 84
L-Cystine 48
L-Histidine 42
L-Glutamine 584
Glycine 30
L-Isoleucine 104.8
L-Leucine 104.8
L-Lysine 146.2
L-Methionnine 30
L-Phenylalanine 66
L-Serine 42
L-Threonine 95.2
L-Tryptophan 16
L-Tyrosine 72.4
L-Valine 93.6
Inositol 7
Vitamins
Choline Chloride 4
Folic Acid 4
Nicotinamide 4
DL-pantothenic acid, Ca Salt 4
Pyridoxal HCl 4
Riboflavin 0.4
Thiamine HCl (aneurine) 4
Other Compounds
D-Glucose 4500
Phenol Red 15
NaHCO3 3700
Penicillin 100,000 units
Streptomycin Sulphate 100
Sodium Pyruvate 110
Antimycotic (Butyl-p-hydroxybenzoate) 0.2 109
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raised.
To store cells a freezing media was made consisting of 10% dimethyl
sulfoxide (DMSO, from Sigma, U.K., D5879) and 90% FBS. Firstly, the
DMSO was filter sterilised using a 0.2 µm filter (VWR International, U.K,
402/0800/11), and then mixed with the FBS. Cryotubes (VWR Interna-
tional, U.K, 479-6837) were then labelled with the current date, cell type
and passage number. These were then placed on ice. The culture flasks of
the cells to be stored were removed from the incubator and their cell media
was removed. Following this the flasks were rinsed with warm PBS and
6 ml of Accutase was added to each flask and incubated for 5 minutes at
37◦C. The flasks were then rapped on the bench to dislodge the cells and
then the cells were pooled into a 50 ml centrifuge tube and centrifuged for
5 minutes at 500 × g. The supernatant was removed and the cells were
resuspended and mixed thoroughly in the freezing media at a concentra-
tion of 1 × 106 cells/ml. One ml of cell suspension was aliquoted into
each cryotube on ice and then stored in cryoboxes (VWR International,
U.K., 215/0886/01), these were then left at −20◦C for 6 hours and subse-
quently moved to a −80◦C freezer overnight. The following morning the
cells were placed in liquid nitrogen for long term storage and were re-
moved as needed.
2.3.4 Thawing Cells
When frozen cells stored in liquid nitrogen were needed they were thawed
and prepared for culture in the following way: cell media were pre-
warmed to 37◦C and culture flasks were labelled appropriately.
When all preparations were complete, one cryotube of cells was re-
moved from the liquid nitrogen tank and the cap was given a 1/4 turn. The
tube was then placed in a water bath at 37◦C and gently swirled until the
cell suspension had completely thawed. The cryotube was removed from
the water bath and rinsed with 70% ethanol and then placed in the culture
hood. The cells were then gently resuspended using a 1000 µl pipette and
then added to the pre-warmed media. The cells were subsequently seeded
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at the required density and in the appropriate culture dish, for the planned
experiment.
2.3.5 Cell Counting and Viability
2.3.5.1 Cell Counting
Cells in suspension were quantified using a haemocytometer. The cell sus-
pension was vigorously mixed to insure a uniform distribution of the
cells through out the suspension media. The glass cover slip was then se-
cured on top of the haemocytometer by sharply exhaling on to the cov-
erslip, to produce a thin layer of condensation on the coverslip, which is
then quickly slid onto the haemocytometer. An adequate seal is accompa-
nied by the appearance of Newton’s rings1 between the coverslip and the
haemocytometer. Ten microlitres of the cell suspension to be counted is
then pipetted into the top and bottom of the chamber, under the coverslip.
The total number of cells within the four large corner squares was then
counted and an average value for a square was then calculated (see Fig-
ure 2.1; the haemocytometer is actually composed of nine large squares,
which are in turn further subdivided into sixteen smaller squares).
Results are more accurate when a square contains between 20–100 cells.
Cell suspensions were diluted to achieve this when required. To improve
accuracy a protocol was used to determine which square a cell would be
allocated to when a cell was found crossing the lines between two individ-
ual squares (see Figure 2.1).
The total volume of a square is equal to 0.1 mm3 (each square has sur-
face area of 1 mm2 and a depth of 0.1 mm). The total number of cells in any
given cell suspension can thus be calculated by multiplying this number
by 10,000, providing the number of cells that would be found in 1 ml of
such a cell suspension. The total number of cells is given by multiplying
this number by the actual number of ml of cell suspension that the original
1Named after Isaac Newton, the rings are a concentric circular pattern of rainbow
colours produced by the composite wavelengths of light refracting different amounts as
they pass through the coverslip.
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sample was taken from.
1
2
Figure 2.1: Quantifying cells in suspension using a haemocytometer. The haemo-
cytometer is split into nine large squares, which are further subdivided into 16
smaller squares. Typically, the number of cells within the four corner cells would
be counted and then an average count obtained. As the area of one large square
is 0.1 mm3 the number of cells in 1 ml can be obtained by multiplying the aver-
age count result by 10,000. To improve accuracy, a consistent system was used to
decide which square a cell would be allocated to when a cell was found crossing
the lines between two individual squares. Thus, any cell lying on the left hand or
top line of a square was allocated to that square. However, if the cell was lying on
the right hand or bottom line the cells were not added to the total cell count for
that square. E.g., as shown in the figure, the cell count of square 1 would be 1 and
the cell count of square 2 would be 3.
2.3.5.2 Cell Viability Through Trypan Blue Exclusion
Counting of cells in suspension was frequently combined with a trypan
blue test. This dye exclusion test determines the number of viable and
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dead cells within the cell suspension. Live cells with intact cell membranes
can exclude the trypan blue dye, whereas dead cells do not exclude the
dye and are stained blue. Thus, the percentage of viable cells can be found
by dividing the number of unstained cells by the total number of cells
counted (see Equation (2.1)).
viable cells(%) =
total number of viable cells per ml of aliquot
total number of cells per ml of aliquot
× 100 (2.1)
To perform the trypan blue exclusion test, an equal volume of trypan
blue (Invitrogen, U.K., 15250-61) and cell suspension was mixed together.
This mixture was then incubated for 5 minutes at room temperature. Then
10 µl of this mixture was added to the haemocytometer and the number of
unstained (viable) and stained (nonviable) cells were quantified. The total
number of viable cells is obtained by multiplying the number of viable
cells by 2. This corrects for the dilution of the cells by addition of the trypan
blue.
2.4 Flow Cytometry
Flow cytometry involves the scanning of single cells flowing past excita-
tion sources in a fluid medium. The information provided by this tech-
nique is rapidly obtained, quantitative, and allows multiparameter analy-
ses of single cells. Measurement of visible and fluorescent light emission
allows quantification of antigenic, biochemical and biophysical character-
istics of individual cells. Flow cytometry technology can also separate dis-
tinct subpopulations of cells on the basis of these measured characteristics,
usually by electrostatic deflection.
Flow cytometry was used for cell phenotyping of BMMNCs as de-
scribed in §3.3.6 and also for assessing cell apoptosis and necrosis, mito-
chondrial membrane potential, reactive oxygen species quantification and
cell cycle analysis as documented in §4.4. Protocol specifics are discussed
within these respective sections.
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Figure 2.2: CyAn ADP detector block and optical filter layout. SSC - side scatter.
2.4.1 CYAN ADP
For all flow cytometric analysis a bench-top CyAn™Advanced Digital
Processing (ADP) high-performance flow cytometer was used from Dako-
Cytomation, U.K.
The CyAn ADP has three excitation lasers (Laser 1 - 488 nm, Laser 2 -
405 nm, and Laser 3 - 635 nm). The independent and alignment-free focus-
ing optics allow 9 simultaneous colour and 2 scatter parameter detection
at rates of up to 50,000 events per second (as shown in Figure 2.2).
Alongside the CyAn ADP, the sister software package Summit® was
used for instrument control, data acquisition and analysis. The Summit®
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software instrument control panel provided access to laser control, event
rate settings, system maintenance functions such as clean and rinse, and
sheath management system functions. The sample parameters panel has
software controls for adjusting parameter settings such as threshold, PMT
(Photomultiplier tubes) voltage and gain. It also allowed full 9 × 9 inter-
laser compensation of fluorescence parameters. This information was re-
tained within the data storage format and could be re-examined and ad-
justed at any time post data acquisition.
2.4.2 Compensation
Compensation of fluorescent data acquired using flow cytometry is the
removal of cross-contamination error due to the spectral emissions over-
lap between fluorophores. Without compensation fluorescent intensities
measured tend to be higher than the actual true value. This can cause sig-
nificant error in data analysis unless handled correctly.
Compensation is needed as commonly flow experiments use two or
more fluorescent markers at a time and although emission spectra are in-
dividually characteristic they are not completely unique and many fluo-
rophores consequently have a degree of spectral overlap, e.g., FITC (Fluo-
rescein Isothiocyanate) and PE (Phycoerythrin) (see Figure 3.2).
The fluorescent overlap of emission spectra between fluorophores, in
this case between PE and FITC, leads to light from the PE fluorochrome
leaking in through the FITC detection channel and vice versa for the PE
channel. Thus, this overlap, of emission spectra means that each fluo-
rophore is contributing to the others measured fluorescent intensity. In
other words, the intensity of FITC fluorescence is not solely attributed to
FITC but a combination of the FITC signal and the portion of the PE emis-
sion spectra that overlaps into the FITC emission spectra. Similarly, the
measured PE fluorescent intensity also has a contribution from the por-
tion of the FITC emission spectra that overlaps into PE wavelength. Com-
pensation aims to remove this overlap and consequent exaggeration of the
fluorescent intensities measured by flow cytometry.
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2.4.2.1 Band-pass Filters
Appropriate band-pass filters, thresholding and gating are simple tech-
niques that can be used to reduce the need for compensation.
Band-pass filters can reduce ”noise” or cross contamination between
fluorophores by limiting the extent of the overlap that is measured by the
PMTs. In other words, they reduce the size of the contribution of the over-
lap to the measured intensity and thus bring the observed median fluores-
cence closer to the true median fluorescence.
2.4.2.2 Autofluorescence and Gating
Autofluorescence is non-specific fluorescence emitted from unstained and
stained cells not attributable to the fluorescence emitted by an antibody-
fluorophore conjugate applied to the sample. It is thought to be primarily
due to intracellular flavins. A high level of autofluorescence can make suc-
cessful compensation difficult to achieve. Hence, every attempt should be
made to reduce autofluorescence prior to applying compensation.
Many autofluorescence related problems can be eradicated by using a
well positioned gate in a plot of FSC (Forward Scatter) vs SSC (Side Scat-
ter). This gate defines the cells of interest, and removes debris — and the
autofluorescence it generates. This simple procedure was performed be-
fore adjusting compensation settings.
2.4.2.3 Compensation in Practise
To properly assess the extent of spectral overlap and subsequently apply
the appropriate amount of compensation between different fluorophores
it was necessary to prepare samples specifically for this purpose. Thus,
in addition to the samples needed for a particular experiment, separate
samples we prepared that were individually stained with each of the flu-
orophores being used. Unstained samples and isotype control samples
(each fluorophore is conjugated to a nonspecific antibody — this combi-
nation is the isotype control) were also prepared.
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For example, firstly, unstained cells were run through the flow cytome-
ter and an appropriate threshold set. Then the cells of interest were gated
using a bivariate histogram of FSC vs SSC, this gate was then applied to
all appropriate histograms.
Following this the unstained cells were used to adjust the PMT voltages
such that the peak of the fluorescent intensity for each fluorophore being
used was centred in the first log decade of the histogram. This adjusted for
autofluorescence and therefore should reduce any autofluorescent contri-
bution to positive event detection.
Typically, to compensate for the over estimation due to spectral overlap
between fluorophores the contribution due to the overlap was removed as
accurately as possible. For example to do this for FITC and PE, the ob-
served PE signal was compensated by subtracting out a percentage of the
observed FITC signal. Similarly, the observed FITC signal was compen-
sated by removal of a percentage of the observed PE signal.
The aim was to apply a correction factor to each fluorescent channel
such that the median fluorescent intensity in the cell population stained
with a fluorophore of a different type was equal to the median fluores-
cent intensity of the unstained population. In plainer terms, the median
fluorescence measured in the PE channel should be equal in both samples
stained with FITC and in unstained or isotype control labelled samples.
Practically, this was achieved by running the isotype control through
the cytometer and recording the median fluorescence for each fluorophore
used in the experiment. Then, single fluorophore labelled samples were
processed and compensation values adjusted. Thus, for an experiment in-
volving FITC and PE, a sample solely labelled with a FITC conjugated an-
tibody was acquired and using a bivariate plot of FITC vs PE the median
value for PE was compensated so that its median value becomes equal to
that of the unlabelled or isotype control sample’s median PE intensity. This
procedure was then repeated but with only a PE labelled sample and this
time the FITC intensity was compensated until equal to the median FITC
value of the unlabelled or isotype control cells.
Once the PMT voltages and compensation settings were configured as
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described above they were not changed throughout each individual ex-
periment.
2.5 Cell Labelling with CFDA SE Green Cell
Tracker Dye
For cell tracking experiments, on the day of cell injection BMMNCs were
isolated as previously described. They were then labelled with the cell
tracker dye carboxyfluorescein diacetate, succinimidyl ester (CFDA SE,
Molecular probes, V-12883) by incubating for 15 minutes at 37◦C in a 10
µM dye solution in PBS. The cells were serially washed and re-suspended
at 107 cells in 500 µl PBS ready for injection in the ischaemia-reperfusion
model.
Prior to use in any experiment, a small aliquot of each batch of CFDA
SE labelled cells were assessed, using flow cytometry, for effective stain-
ing by quantifying the percentage of cells successfully stained. Positively
stained cells were detected in the FL1-FITC channel, after appropriate gat-
ing and adjustment of gain, so unlabelled controls cells all fell within 100–
101 on the log-scale. Cells were regarded as positively labelled if they were
detected above 101 on the log-scale histogram plot. As before, a CyAn™
ADP High-Performance Flow Cytometer, using the 405 nm laser, in con-
junction with Summit™ version 4.3 software (both from DakoCytomation)
were used for analysis.
2.6 Ischaemia-reperfusion model
The in vivo ischaemia-reperfusion model (IR) used through out this the-
sis was implemented by transient ligation of the left anterior descending
artery (LAD) of male rats followed by a period of reperfusion that has been
previously described (Wayman et al., 2002).
Further detailed description of the methods used in the rat LAD liga-
tion ischaemia-reperfusion injury model can be found below.
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2.6.1 Anaesthesia and Ventilation
Rats were anaesthetised with the rapid-onset short-acting barbiturate gen-
eral anaesthetic sodium thiopental (Intraval™ from Merial, U.K., 120
mg/kg intra peritoneum) and maintained by supplementary injections
(≈10 mg/kg i.v.). Subsequently an endotracheal tube was inserted via a
tracheostomy and the animals were ventilated (Inspira ADV, Harvard Ap-
paratus Ltd, U.K., 55-7058). The breath rate was observed to determine
state of anaesthesia. Typically, general anaesthesia was achieved in under
5 minutes and breath rate was expected to be one per second.
2.6.2 Electrocardiogram Acquisition
A continuous electrocardiogram (ECG) recording was taken through-
out the duration of all experiments. This was accomplished by insert-
ing three needle electrodes (29 Gauge, 2 mm Pins, ADInstruments Ltd,
U.K., MLA1204) within the sub-cutaneous tissue of the rat. The needle
electrodes were inserted into an Animal Bio Amp (ADInstruments Ltd,
ML136) which in turn was connected to a T Type Pod (ADInstruments Ltd,
ML132). The signal was then sent to the PowerLab 8/30 (ADInstruments
Ltd, ML870) before finally connecting to a Dell PC (Windows XP®) where
the data was collected and analysed using Chart 5™ for Windows (ADIn-
struments Ltd). See Figure 2.3 for a schematic of the ischaemia-reperfusion
injury model apparatus set up including the equipment needed for ECG
monitoring.
2.6.3 Tracheostomy
A midline incision was made in the neck and the adipose tissue and fas-
cia were dissected using fine forceps. The sternohyoid muscle was identi-
fied by its central position between the sternocleidomastoid muscles. The
trachea was found directly posterior to this muscle. The sternohyoid was
then either cut or pulled aside to reveal the trachea. A 4/0 tie was passed
under and around the trachea ≈5 mm below the larynx. An incision was
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Figure 2.3: Schematic of physiological monitoring equipment set-up and inter-
connections for the rat ischaemia-reperfusion model. All equipment from ADIn-
struments Ltd, except for ventilator that was purchased from Harvard Apparatus
Ltd, and portex polythene tubing for cannulas from Scientific Laboratory Sup-
plies.
made just proximal to the larynx large enough to insert the endotracheal
tube. The endotracheal tube was inserted to a distance of ≈15 mm depth
into the trachea and secured by knotting the silk tie. The endotracheal tube
was then attached to the ventilator. Care was taken to avoid blood collect-
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ing around the tracheostomy, to reduce the risk of a leak into the trachea
and consequent aspiration into the ventilator through the endotracheal
tube.
2.6.4 Common Carotid Artery Cannulation
Following on from above, from the same incision, the sternocleidomas-
toid was again used as a landmark (the common carotid artery (CCA)
runs parallel to the striation of this muscle) and the CCA was then lo-
cated and separated from its surrounding fascia and the vagus nerve. The
curved forceps were then used to hook two 4/0 silk ties under and around
it from below. The two ties were positioned about 10–15 mm apart to al-
low adequate distance for the forthcoming arteriotomy. The distal thread
was tied off and a vascular clamp was placed proximal to the other thread.
At the distal end of the segment, micro-scissors were used to cut into the
CCA. A catheter (Portex Fine Bore Polythene Tubing, Scientific Laboratory
Supplies, 800/100/200) was introduced into the CCA towards the heart
and advanced ≈8–10 mm. The proximal tie was then used to secure the
catheter in the CCA. The vascular clamp was released and the patency of
the catheter checked by infusing small amounts of saline. Successful can-
nulation of the CCA was confirmed by observation of pulsatile blood in
the catheter. Finally, the catheter in the CCA was connected to the blood
pressure transducer (Physiological Pressure Transducer, ADInstruments
Ltd, MLT844).
2.6.5 External Jugular Vein Cannulation
The external jugular vein (EJV) was identified as superficial to the stern-
ocleidomastoid muscle and superior to the clavicle. Similar to CCA can-
nulation, two 4/0 ties were hooked around the EJV. The distal tie was tied
off to occlude the distal vein. A cannula was then inserted into the EJV and
secured with the proximal tie. The patency of the cannula was checked by
infusing with a small amount of saline.
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2.6.6 Measurement of Haemodynamics
The right CCA and EJV were cannulated as described in the previous sec-
tions. The CCA arterial line was connected to a pressure transducer for
monitoring of heart rate (HR), and mean arterial pressure (MAP) (MLT844
pressure transducer, ML221 bridge amp, ADInstruments Ltd). The pres-
sure rate index (PRI), a relative indicator of myocardial oxygen consump-
tion, was calculated as the product of MAP and HR, and expressed in
mmHg/min. Saline was administered immediately after and throughout
reperfusion at a rate of 1 ml/kg/h.
Rat’s body temperature was continuously recorded (Rectal probe
MLT1403, Bio Amp ML132, ADInstruments Ltd) and maintained at 37◦C
using a homeothermic controller unit (Morphy Richards). All physiolog-
ical data was interpreted using PowerLab Chart5™ software, running
on a Dell Latitude X300 (Intel M, 1200 MHz, 512 MB RAM, Dell Inc,
RoundRock, Texas) on Windows XP® Professional Service Pack 2 (Mi-
crosoft). See Figure 2.3 for a schematic of the equipment set-up and their
interconnections.
2.6.7 Thoracotomy
To start, the skin around the chest was lifted and dissected away to reveal
the underlying muscles. Enough skin and muscle was removed to allow all
ribs to be visualised. The tip of the fine curved forceps were then inserted
into the ninth intercostal space, avoiding puncture of the mediastinum.
Next, the forceps were hooked underneath and manoeuvred up 1–2 rib
spaces superior to the initial insertion point, then the point of the forceps
was brought back out through the intercostal space at this location.
Diathermy was then used to cut away the tissue isolated by the forceps
until only the ribs remained intact. The costal arteries and veins around the
ribs were cauterised to avoid excessive blood loss. The ribs, now exposed
and isolated, were cut through using scissors.
The size of the thoracotomy was expanded, if needed, in similar steps
as described above until the thoracotomy was sufficiently large enough to
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expose the whole of the heart. Finally, the apex of the thymus was fixed
with a large vascular clamp and then inverted superiorly to expose the
aorta and pulmonary trunk.
2.6.8 Left Anterior Descending Artery Occlusion
The origin of the LAD was routinely identified as characteristically lying
≈2 mm from the edge of the pulmonary trunk. A needle with 6/0 silk was
passed under then LAD at a mural depth of ≈3 mm to ensure the ligature
was passed consistently under the LAD. The ligature was the hooked back
out of the ventricle 4–5 mm away from the entry point.
Before further intervention in all experiments the animals were al-
lowed to stabilise for 15 minutes before LAD ligation. The coronary artery
was then occluded (designated as time 0 in all experiments) by tightening
of the occluder.
The loose ends of the ligature were fed into the snare. To occlude the
LAD the snare was tightened against the myocardium. Successful ligation
of the LAD was indicated by visible blanching and hypokinaesia of the
anterior wall of the left ventricle. For lengthy periods of ischaemia the
snare and ligature were clamped tight with a pair of needle holders. The
exposed mediastinum was then covered with gauze soaked in saline to
avoid excessive fluid loss through the thoracotomy.
The LAD was left occluded as long as required for each experimental
protocol. At the end of the period of acute myocardial ischaemia, the oc-
cluder was re-opened to allow the specified length of reperfusion before
the experiment was terminated. Throughout this series of experiments
reperfusion time was either two or six hours.
2.6.9 Cell Injection
When required placebo or cells were injected intravenously via the
catheter in the EJV. A total of 107 BMMNCs suspended in 0.5 ml PBS was
administered to each rat, using a 1 ml syringe. Controls, as discussed pre-
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viously, were the sham operated group (undergoing thoracotomy only)
that received 107 cells, and the placebo group (undergoing ischaemia-
reperfusion injury) that received only vehicle (0.5 ml PBS).
2.7 Echocardiography
Transthoracic echocardiography was performed, on required animals, at
up to three time points: before LAD ligation; immediately after reperfu-
sion following closure of the thoracotomy with surgical glue; and finally
at six hours following reperfusion.
Studies were performed by two senior echocardiography technicians
blinded to the control and experimental groups. Echocardiography was
performed on anaesthetised rats, in the supine position with shaved
chests, using a Phillips Sonos 5500 echo machine. A high frequency trans-
ducer (12–5 MHz) was used and an ECG was simultaneously recorded.
The heart was imaged in the 2-dimensional mode in short-axis view
of the left ventricle (LV) at the level of the papillary muscle. This view
was used to record M-mode tracings. Each measurement was taken three
times and the mean value calculated. Anterior and posterior end-diastolic
and end-systolic wall thickness and LV internal dimensions were mea-
sured according to the American Society of Echocardiography leading-
edge method from three consecutive cardiac cycles. The LV ejection frac-
tion (LVEF) and the LV percent fractional shortening (FS) were calculated
as follows:
FS% = [(LVd− LVs)/LVd]× 100 (2.2)
EF% = [(LVd3 − LVs3)/LVd3]× 100 (2.3)
Where LVd and LVs represent left ventricular diastolic and systolic di-
mensions respectively.
To improve the ability to detect subtle changes in left ventricular func-
tion, Tissue Doppler Imaging (TDI) was applied to both short- and long-
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axis views of the rat heart to measure myocardial velocity.
TDI is a novel use of ultrasound to image the motion of myocardial tis-
sue with Doppler echocardiography. Typically, Doppler echocardiography
is used to measure the blood flow velocity by ultrasound reflection from
erythrocytes. The normal velocity range of erythrocytes in blood ranges
from 10 cm/s to 150 cm/s. However, the velocities of myocardial tissue are
lower (1–20 cm/s) but the amplitude is much greater than that produced
by blood. Hence, by adjusting standard Doppler instruments to record low
velocity, high amplitude signals from myocardial tissue, and to exclude
high velocity, low amplitude signals from blood TDI of myocardial tissue
can be obtained.
TDI acquisition was performed at a frequency of 5 MHz. Frame rate
was set to maximum. The gain was lowered from the usual settings for
blood flow Doppler recordings and the velocity scale was adjusted to a
lower aliasing velocity (≈ 20–30 cm/s) to optimise the TDI signal.
Myocardial velocities measured using TDI are prone to error intro-
duced by detection of indirect movement of myocardium, e.g., movement
of the heart in respiration. Clearly, measurements containing such errors
would provide inaccurate assessment of the true state of myocardial con-
tractility.
Freeze-frame and cine loop images were therefore also acquired for the
TDI acquisitions and downloaded to a windows compatible computer for
off-line analysis using Phillips QLAB™ or AMID© advanced quantifica-
tion software. This allowed the processing of the TDI data and calculation
of myocardial velocity gradient2, myocardial strain rate3, and myocardial
strain4. All three measures are relative or dimensionless values that over-
come the problems of indirect myocardial movement.
2The difference in velocity of adjacent myocardial endocardial and epicardial seg-
ments.
3A measure of myocardial deformation, representing the relative displacement be-
tween two marked points within the myocardium.
4The change in myocardial strain over time.
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2.8 Animal Termination and Tissue Collection
At the end of all ischaemia-reperfusion injury experiments the rats were
killed with an overdose of anaesthetic (30 mg thiopentone i.v.) and exci-
sion of the heart. To aid regional analysis, each heart was cut in the short-
axis into three sections: the atria; ventricle; and apex, and then fixed sepa-
rately for 24 hours in neutral buffered formalin and subsequently paraffin
blocked.
2.9 Histology
All histological techniques encompassing tissue fixation, slide prepara-
tion, counterstains, immunohistochemistry, in situ hybridisation and mi-
croscopy were performed within the Histopathology department at Can-
cer Research UK (CRUK) at Lincoln’s Inn Fields, London.
2.9.1 Immunohistochemistry
The whole process from harvesting tissue to performing immunohisto-
chemistry on tissue sections may be broken down into the following logi-
cal and temporal steps: harvesting and fixing tissue, blocking, embedding
(blocking out), microtomy, dewaxing and blocking, counterstaining and
immunohistochemistry. These steps are now detailed below.
2.9.1.1 Tissue Fixation
After rats were killed, the excised heart was collected and placed in a 50 ml
sterile pot in Neutral Buffered Formalin (NBF). If the lungs were collected
they were injected via the trachea with NBF prior to being put in a sterile
pot. Additionally, the heart was cut into three short axis segments: atria,
ventricles, and apex. Each segment was placed in separate labelled pot.
Collected organs were then left in NBF for 24 hours at room temperature.
They were drained and placed in 70% ethanol and left for a minimum of
24 hrs prior to blocking.
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Table 2.3: Tissue blocking entailed using a vacuum infiltration process — auto-
mated using Tissue-Tek VIP.
Reagent Length of Incubation
70% ETOH 30 mins
80% ETOH 1 hr
95% ETOH 1 hr
95% ETOH 1 hr
100% ETOH 1 hr
100% ETOH 1 hr
100% ETOH 1 hr
Xylene 1 hr
Xylene 1 hr
Xylene 1 hr
Wax (Fibrowax-paraffin) 1 hr
Wax (Fibrowax-paraffin) 1 hr
Wax (Fibrowax-paraffin) 1 hr
Wax (Fibrowax-paraffin) 1 hr
2.9.1.2 Cell Culture Fixation
When fixing cells within culture plates a slight different method was
needed. First cell media was removed from the culture plates by aspi-
ration. The cells were washed in PBS and then fixed by incubation with
4% Paraformaldehyde (Sigma-Aldrich, U.K., P6148). The cells were then
washed with PBS, and then stored (covered in PBS) at 4◦C until required
for staining.
2.9.1.3 Tissue Blocking
After fixation, tissues were removed from the 70% ethanol and blocked,
i.e., embedded in paraffin and prepared for sectioning. For blocking a vac-
uum infiltration process was used and this was automated with a Tissue-
Tek VIP (see Table 2.3 for incubation steps and their lengths).
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2.9.1.4 Tissue Sectioning
Embedded tissue blocks were sectioned at 4 µm, using a Jung Biocut 2035
Microtome. As sections were cut they were dropped in distilled water,
warmed to 38–40 ◦C. These sections were picked up on frosted glass mi-
croscope slides, 3 by 1 inches, and 1 mm thickness (Thermoshandon color-
frost yellow-end charged microscope slides, 9991002), and then incubated
at 37◦C overnight. Slides were then stored in sealed slide boxes at room
temperature, out of direct sunlight, until required for use.
2.9.1.5 Dewaxing and Blocking of Endogenous Peroxidases and Alka-
line Phosphatases in Paraffin Embedded Tissue
Sections were dewaxed and blocked using a Sakura diversified stainer
(DRS-601). This procedure dewaxed sections by a 4 minute immersion in
sulphur-free xylene (BDH). Sections were then washed by immersion in
100% ethanol for 1 minute prior to blocking for endogenous peroxidases
by immersion in a solution of 30% hydrogen peroxide (BDH) in methanol
for 10 minutes. This was followed by rehydration by 1 minute immersions
in decreasing concentrations of ethanol (100%, 95%, 70%) before the sec-
tions were rinsed in tap water and washed in PBS.
If the final antigen detection step required an alkaline phosphatase
dependent method then sections were blocked for endogenous alkaline
phosphatase by immersion in 20% acetic acid in methanol at 4◦C for 2
minutes before being washed in PBS.
2.9.1.6 Immunohistochemical Staining Protocol for Paraffin Embed-
ded Tissue
When antigen retrieval was required this was either by microwave treat-
ment in preheated sodium citrate buffer at pH 6 for 10 minutes at 700 W,
or by incubation in bovine trypsin at 37 ◦C for 15 minutes, or by pressure
cooking in preheated sodium citrate buffer at pH 6 for 10 minutes.
Sections were then rinsed in tap water and washed in PBS for 10 min-
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utes prior to the application of normal serum (DAKO) from the donor
species of the secondary antibody at a dilution of 1:25 for 15 minutes. Ex-
cess serum was shaken off the slides and without washing the primary
antibody was applied for a period of 35 minutes at room temperature.
Sections were washed in PBS before a species-specific biotinylated sec-
ondary antibody was applied for a period of 35 minutes. The sections
were washed in PBS and the tertiary antibody applied; either streptavidin-
horseradish peroxidase (strep-HRP) at a dilution of 1:500 or streptavidin-
alkaline phosphatase (strep-AP) at a dilution of 1:50, whichever was used
was then incubated for 35 minutes at room temperature prior to washing
in PBS. Each PBS wash consisted of two 5 minute washes.
Strep-HRP was detected by DAB (Sigma) for 4–6 minutes. Sections
were then washed in PBS for 2 × 5 minutes prior to being rinsed in tap
water.
Strep-AP was detected using the Vector Red Alkaline Phosphatase Sub-
strate Kit 1 (Vector Laboratories). This was prepared according to the man-
ufacturers’ instructions and applied for 10–30 minutes or until a red colour
could be detected macroscopically. Sections were then washed in PBS for
2 × 5 minutes and rinsed in tap water.
Following this protocol sections were either stained lightly with
haematoxylin and eosin (section 2.9.1.8) or would proceed directly to an-
other protocol for a combined procedure such as in situ hybridisation for
DNA (section 2.10).
2.9.1.7 Immunofluorescence Staining Protocol for Paraffin Sections
When an antibody was detected with the Vector Red Alkaline Phosphatase
Substrate Kit 1 (Vector Laboratories), this could be detected fluorescently
in the Cy 3 channel (532 nm). Sections were prepared according to the
protocol above (section 2.9.1.6) but did not proceed to H&E counterstain.
Instead after the PBS wash, sections were mounted in Vectashield Hard Set
mountant with DAPI (Vector Laboratories) prior to visualisation (section
2.11.2).
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2.9.1.8 Haematoxylin and Eosin Counterstain
Sections were counterstained using a Sakura diversified stainer (DRS-601).
This automatically immersed sections in Shandon Harris’ haematoxylin
(Anatomical Pathology Intl.) for 3 min, followed by a rinse in flowing tap
water for 30 sec. Sections were then immersed in acid alcohol (1% v/v con-
centrated HCl in 70% ethanol) for 15 sec and washed for 30 sec in flowing
tap water prior to immersion in a saturated solution of lithium carbonate
(Sigma) in distilled water for 20 sec. Sections were washed in tap water,
placed in eosin for 2.5 min, then washed in tap water again. This was fol-
lowed by rapid dehydration through graded alcohols (70%, 95%, 100%) to
xylene.
2.9.1.9 Immunohistochemistry in Tissue Culture Wells
After cells in culture plates were fixed, as described in §2.9.1.2, immuno-
histochemical staining was performed as outlined here. Cells were first
washed in PBS. Blocking was then performed for endogenous peroxidases
by incubating in hydrogen peroxide (VWR International, U.K, BDH3690-
1) at 1 in 100 dilution in PBS. Then three washes were performed using
PBS. The cells were then permeabilised with 0.5% Triton X-100 (Tween
20, Sigma-Aldrich, U.K., P1379) in PBS for 15 minutes. Three further PBS
washes followed this. From this step onwards the method for immunohis-
tochemistry is the same as that as applied to paraffin embedded sections
as described in §2.9.1.6. The only difference is found in the final step for
counterstaining. For cells in culture wells haematoxylin is applied for 20
seconds, then washed away with water and a few drops of lithium car-
bonate (VWR International, U.K.) are introduced into each well and sub-
sequently washed off straight away in running water. Three or four drops
of Glycergel (Dako, U.K., C0563) were then placed on top of the cells and
then a coverslip placed on top of this. Once the cells had dried they were
ready to be imaged.
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2.10 In Situ Hybridisation for DNA
In situ hybridisation for the X and Y chromosomes and human pan-
centromere marker were performed either on dewaxed tissue or im-
munostained tissue prior to counterstaining. Some tissue was examined
fluorescently either for the Y chromosome or pan centromere maker alone
or for the X and Y chromosome together.
Full details of the X and Y chromosome in situ hybridisation method
can be found in chapter §6.2.3 and for human pan-centromere marker in
chapter §5.2.
2.11 Imaging
2.11.1 Bright Field Imaging
Conventional bright field images were taken using a Nikon Q imaging
micropublisher camera on a Nikon ME 600 microscope.
2.11.2 Fluorescence Imaging
Fluorescent images were taken using an Olympus BX41 microscope
equipped with SmartCapture software and integral camera (Digital Sci-
entific). This allowed acquisition of photographs in the DAPI, FITC, Cy3,
Cy5 and Aqua channels. In addition to this, acquisition could be paused
allowing settings to be modified to also allow the acquisition of bright field
monochromatic images allowing the capture of combined fluorescent and
non fluorescent images of the same tissue.
2.12 Statistical Analysis
Data were analysed using GraphPad Prism version 4.0–5.0 (GraphPad
software, USA) or using R: A language and environment for statistical
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computing (Team, 2010). Both packages were used for statistical analysis
and for production of graphs.
For descriptive statistics values have been displayed as the mean± the
standard error of the mean (SEM) in most cases. An exception to this was
the fluorescent intensities obtained from flow cytometry, such intensity
data is usually significantly skewed and as such it is common practise, as
used here, to use the median value as a better summary statistic.
For parametric data with a normal distribution the Student’s t-test
was used to compare populations. In the instance of normalised data a
one-sample t test was used against a hypothetical value of one. For non-
parametric data samples were compared with the Mann-Whitney tests.
Statistical tests of significance were always performed as two-tailed tests
and considered statistically significant if P was<0.05.
2.13 Buffers and Solutions
Unless otherwise stated, distilled water refers to ’Milli-Q Plus’ water pro-
duced by the reverse osmosis ’ultra pure water system’ (Millipore).
Neutral Buffered Formalin (NBF)
Formalin, full strength (37–40% formaldehyde) 100ml
Na2HPO4 (BDH) 6.5 g
NaH2PO4 (BDH) 4.0 g
Distilled water 900 ml
ADS Buffer
500 ml buffer was made and stored at 4◦C for < 2 weeks.
To 500 ml of sterile distilled H2O the following were added:
3.4 g NaCl 116 mM
2.38 g HEPES 19.9 mM
0.06 g NaH2PO4 0.76 mM
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0.5 g Glucose 5.5 mM
0.2 g KClC 5.4 mM
0.05 g MgSO4 0.4 mM
The pH was then adjusted to 7.35 with 1 M NaOH
Buffer was then filtered into a 500 ml flask with a 0.22µm filter.
Tris Buffer
Tris base 12.1 g
Deionised water 950 ml
pH to 7.4 with 1N HCl then adjust to 1L with deionised water.
4% Paraformaldehyde (PFA)
16g Paraformaldehyde (Sigma) 16 g
PBS (CRUK) 400 ml
PFA was dissolved in PBS at 70◦C and cooled to room temperature.
Phosphate Buffered Saline (PBS)
NaCl (Sigma) 8 g
PBS (CRUK) 400 ml
KCl (BDH) 0.35 g
Na2HPO4 1.43 g
KH2PO4 (BDH) 0.25 g
Distilled water 1L
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Diaminobenzidine (DAB)
DAB (Sigma) 0.05%
PBS (CRUK) 9 ml
Hydrogen peroxide (VWR) 0.001%
10 x salt solution
NaCl (Sigma) 176.2 g
Na2HPO4 14.2 g
1M Tris-HCl (Sigma) 100 ml
0.2M EDTA (Sigma 250 ml
The di-sodiumhydrogenphosphate was dissolved in water and adjusted
to pH 6.8. The sodium chloride, Tris-HCl and EDTA were then added in
order, and the volume was made up to 1 L with water and stored at room
temperature.
20 x SSC (pH 7.5) (CRUK)
Na citrate (Sigma) 88 g
Distilled water to 1 L
1M Tris-HCl (Sigma) 100 ml
0.2 M EDTA (Sigma) 250 ml
Formamide Buffer
10 x salt solution 250 ml
Formamide (non-deionised) (Sigma) 1.25 L
Distilled water to 2.5 L total
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Sodium Citrate Buffer
Tri-sodium citrate (Sigma) 2.94 g
Distilled water 1 L
pH to 6.0 with HCl.
Trypsin
Distilled water at 37◦C 200 ml
Bovine trypsin 200 µg
CaCl 200 µg
pH to 7.8 with NaOH.
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CHAPTER 3
Bone Marrow Mononuclear Cells Significantly
Reduce Infarct Size in a Rat Myocardial
Ischaemia-Reperfusion Model
3.1 Introduction
Bone marrow mononuclear cells (BMMNCs) are emerging as a new thera-
peutic modality for the treatment of ischaemic heart disease. Evidence for
an intrinsic myocardial homoeostatic repair mechanism first came to light
from sex-mismatch studies of human heart and bone-marrow transplants
(Deb et al., 2003; Mller et al., 2002; Quaini et al., 2002). It was clear from
these novel studies that the intrinsic response, although present, is too
small to adequately replace the cells lost from an acute myocardial infarc-
tion. However, such studies did intensify the investigation of the intrigu-
ing concept of cell therapy, a treatment that would for the first time, in con-
trast to other contemporary therapies, address the fundamental pathology
of myocardial ischaemia and heart failure — myocyte loss through necro-
sis and apoptosis.
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Animal and human studies have demonstrated extrinsic cell delivery
or augmentation of the native progenitor cell homoeostatic mechanism
can reduce scar burden and symptoms, improve cardiac function and
remodelling, and reduce stress defects (Assmus et al., 2002; Orlic et al.,
2001a,b; Perin et al., 2003; Strauer et al., 2002; Tse et al., 2003). The mecha-
nism behind the beneficial effects of these cells remains unclear. Multiple
competing hypotheses are currently being explored. Initially, transdiffer-
entiation was thought to be the main mechanism driving the beneficial ef-
fects. However, there are now several articles refuting transdifferentiation
as the key mechanism responsible for the beneficial results (Balsam et al.,
2004; Murry et al., 2004; Nygren et al., 2004). Others have reported that
the paracrine effect produced by injected cells was significant in produc-
ing the positive effects of cellular therapy (Gnecchi et al., 2006; Takahashi
et al., 2006; Uemura et al., 2006).
If the main mechanism of action of the injected cells is paracrine, rather
than transdifferentiation, it would be likely that any intervention to re-
duce myocardial necrosis and apoptosis would have the most chance to
impact at the time of the greatest loss of myocytes, i.e., in the immediate
reperfusion phase of myocardial ischaemia. It could be argued that if the
cells were given too late after reperfusion, and transdifferentiation was
not a significant effect, then any anti-apoptotic and pro-survival effects
would be diminished as the majority of salvageable cells would already
have been lost in the early phases of reperfusion.
No study, to my knowledge, has examined the effects of administering
BMMNCs cells at the time of reperfusion and looked at outcome in the first
few hours after ischaemia-reperfusion injury. Most studies have adminis-
tered cells some considerable length of time after reperfusion either due
to practical reasons or as it was felt that the hypoxia, acidosis, free radical
generation, inflammation, and calcium influx at the time of reperfusion
would not be optimal for cell survival and engraftment. If cell therapy can
modulate reperfusion injury studies that apply cells after the immediate
reperfusion period will miss the window of opportunity that exists for de-
livering reperfusion modulating therapy and the consequent infarct size
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reduction. These late cell delivery studies have also tended to use out-
come measures at longer time points as they were typically designed to
detect transdifferentiation. The long term outcome measures are unable to
directly measure any impact on reperfusion injury. Thus, the combination
of late cell delivery and longer outcome measures will have minimised the
detection of any effects on reperfusion injury.
Hence, a novel experiment was designed to look at the effects of
BMMNC injection at the immediate on set of reperfusion to expose the
maximum number of salvageable cells to any beneficial paracrine effects.
Furthermore, outcome would be assessed at six hours following reperfu-
sion to clarify early benefits of BMMNC therapy on reperfusion injury.
The primary null hypothesis was that the mean infarct size in control and
BMMNC treated animals would not be significantly different.
3.2 Aims and Hypotheses
Hypotheses
1. BMMNCs will home to the acutely ischaemic rat myocardium when
injected intravenously.
2. BMMNCs will not have a detrimental effect on infarct size or LV
function despite the inflammatory phenotype of many of the con-
stituent cells.
3. BMMNCs will reduce infarct size when administered in acute MI.
4. BMMNCs will improve LV function when administered in acute MI.
5. Prolonged tissue culture will reduce BMMNCs homing to the acutely
ischaemic rat myocardium.
6. Prolonged tissue culture will reduce BMMNCs induced improve-
ment of LV function in the acutely ischaemic rat myocardium.
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Aims
1. To establish a rat myocardial infarction model.
2. To measure LV function of the rat heart using echocardiography.
3. To measure infarct size in the rat heart.
4. To isolate BMMNCs from the rat.
5. To assess the quantity, viability and phenotype of isolated BMMNCs.
6. To stain BMMNCs with a cell tracker dye.
7. To track and quantify homed cells to the rat myocardium using the
fluorescent properties of the cell tracker dye.
8. To assess differences in cell homing and LV function between ani-
mals receiving cells in ischaemia or on reperfusion.
9. To assess differences in cell homing and LV function between ani-
mals receiving cells cultured for 24 or 72 hours.
3.3 Methods and Materials
3.3.1 Overview of Experiments
This study required performing two experiments in parallel. The experi-
ment was designed in this way due to the mutually exclusive nature of the
outcome measures used in the study (See Figure 3.1). Thus, experiment
A‘s aim was to assess cell homing, LV function, and biochemical changes
after BMMNC injection either during ischaemia or after reperfusion. Ex-
periment B was designed to assess the effect on infarct size. A dose of
107 BMMNCs was chosen as the therapeutic dose as several studies have
shown this dose can produce functional benefits (Hamano et al., 2002; Tse
et al., 2003), in addition other studies have shown a dose-response effect,
thus it was hoped the dose-effect could be capitalised on by using a higher
dose of cells (Meluzin et al., 2006; Schuster et al., 2004).
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Figure 3.1: Experiment outline: Flow chart of the two parallel experiments in-
cluded in this study. The main outcome measures for each parallel stream were
mutually exclusive as they each necessitated complete destruction of the assayed
myocardial tissue; these being cell homing counts from histological sections (Expt
A), and infarct size assessment (Expt B). Experiment A assessed cell homing,
LV function, and biochemical changes after BMMNC injection either during is-
chaemia or after reperfusion. Experiment B assessed area at risk and infarct size
following BMMNC injection.
3.3.2 Animals
All animals received care in accordance with national guidelines. Experi-
ments were performed with the authority of the local area ethics commit-
tee under home office project and personnel licences. Both recipient and
donor rats were Male Wistar rats weighing 250–320 g (Harlan, UK).
3.3.3 Whole Bone Marrow and Bone Marrow Mononuclear
Cell Collection and Culture
Whole bone marrow (WBM) was flushed from tibias and femurs using a
22 G needle and DMEM + 10% FCS. The mononuclear cell fraction was
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then separated using a Percoll gradient by centrifuging for 30 minutes at
500 × g (Histopaque 1.077 g, Sigma). Cells were then cultured in DMEM
+ 10% FCS, at 106 cells/ml, the media was changed every 48 hours. See
§2.2 in the methods chapter for a more complete description.
3.3.4 Cell Counting and Viability
Following cell collection, the WBM and BMMNC harvest was quantified
by counting the number of cells collected and their viability was assessed
using the trypan blue exclusion test see §2.3.5 for further details.
3.3.5 Histology of Collected Whole Bone Marrow and
Bone Marrow Mononuclear Cells
In addition, to cell counting and cell viability as a measure of quality, the
harvested cells were also used to produce histology sections. Cell pellets
of harvested cells were prepared, fixed and paraffin blocked as described
previously §2.9.1.1. Sections were cut and eosin-haematoxylin stained.
Then the cells of haematological lineage were identified and quantified
by their unique appearance and characteristic nuclear staining.
3.3.6 Flow Cytometry Cell Surface Antibody Phenotyping
of Whole Bone Marrow and Bone Marrow Mononu-
clear Cells
3.3.6.1 Staining Protocol
After harvesting of WBM and BMMNCs the cell surface phenotype was
assessed using flow cytometry.
WBM and BMMNCs were harvested as previously described (see §2.2),
then rinsed in wash buffer (cold PBS 0.1% NaN3, 1.0% FBS). A cell count
was performed, and subsequently the cells were pelleted by centrifugation
at 500 × g for 5 minutes. Following this the cells were re-suspended at
2×107 cells/ml.
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Antibodies were added to flow cytometry tubes (DakoCytomation,
U.K., 996052) in the following ways. CD45-FITC, CD45RA-PE-Cy5 and
CD3-APC were used simultaneously, to triple stain cells, for each sam-
ple 1 µg of each antibody was added to a 50 µl of wash buffer in a FACS
tube. The unique excitation and absorption spectra of FITC, PE-Cy5 and
APC allowed co-staining using the above antibodies will maintaining the
ability to identify and quantify the fluorescent intensities generated by the
individual antibody-fluorophores conjugates (see Figure 3.2).
Similarly, the unique spectra of FITC and PerCP made it possible to
perform dual staining with CD34-FITC and CD90-PerCP. As with the
other antibodies, 1 µg of each antibody was used in a total volume of 50 µl
of wash buffer.
The isotype control was prepared at a similar concentration of 1 µg of
antibody in a total volume of 50 µl wash buffer (See Table 3.1 for further
details of all antibodies).
Once the antibodies had been prepared, 1 × 106 cells in 50 µl of wash
buffer were added to each antibody tube. The tubes were then mixed by
vortexing and then incubated for 20 minutes at 4◦C in the dark. The cells
were then washed twice by pelleting at 350 × g for 5 minutes and re-
suspended in wash buffer. Finally, the cells were re-suspended in 0.5 ml
of wash buffer and taken to the flow cytometer for analysis on ice, pro-
tected from light.
3.3.6.2 Antibodies Used for Cell Surface Phenotyping
Allophycocyanin (APC)-conjugated mouse monoclonal anti-rat CD3 was
used to identify T-lymphocytes (BD, 557030). PE-Cy5-conjugated to mouse
anti-rat CD45RA monoclonal was used for B-lymphocyte (BD, 557015).
Peridinin Chlorophyll-a Protein (PerCP)-Conjugated to mouse mono-
clonal anti-rat CD90 (Thy1.1) was used to identify HSCs and MSCs (BD,
557266). Fluorescein Isothiocyanate (FITC)-conjugated Mouse Anti-Rat
CD45 monoclonal antibody was used as a pan-leukocyte marker (BD,
554877). FITC-conjugated mouse anti-CD34 monoclonal antibody was
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used as a marker for HSCs and EPCs (Santa Cruz Biotech, sc-7324). For
isotype controls Ig Isotype control cocktail-A was used containing mIgM-
APC, mIgG1-PE and mIgG1-FITC (BD, 558509). For further details of the
antibodies see Table 3.1.
(a)
(b)
Figure 3.2: Excitation and emission spectra for the three fluorophores used in
combination to simultaneously stain for CD45, CD45RA, and CD3.
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3.3.6.3 Data Collection with CyAn ADP
A CyAn™ ADP High-Performance Flow Cytometer, with 405, 488, and
635 nm lasers, in conjunction with Summit™ version 4.3 software (both
from DakoCytomation) was used for processing all flow cytometry sam-
ples, subsequent data acquisition, and post-processing analysis. After op-
timising, thresholding and gates, to eliminate collection of debris, 10,000
events were collected for each sample. SSC and FSC data were collected.
In addition, FITC conjugated antibodies were detected in FL1 (530/40), PE
conjugated antibodies in FL2 (575/25), PE-Cy5 and PerCP in FL4 (680/30)
and APC conjugated antibodies in FL8 (665/20).
Compensation was applied as follows, firstly, unstained cells, then iso-
type control samples were used to set the PMT voltages for each fluores-
cence channel so that the cell population fell in the first decade log scale.
A univariate plot (Log scale) histogram for each channel was generated
and the PMT voltage adjusted until the peak intensity appeared centred
in the first log decade of the histogram. Once the PMT voltage was set
and compensation optimised it was not adjusted for the rest of the data
collection.
3.3.7 Cell Labelling with CFDA SE Green Cell Tracker Dye
For cell tracking experiments, on the day of cell injection BMMNCs were
isolated as previously described. They were then labelled with the cell
tracker dye carboxyfluorescein diacetate, also previously described in §2.5.
3.3.8 Ischaemia-Reperfusion Model
The in vivo ischaemia-reperfusion model used through out this thesis was
implemented by transient ligation of the left anterior descending artery
(LAD) of male rats followed by a period of reperfusion that has been pre-
viously described (Wayman et al., 2002) and is described in depth in §2.6.
In summary, all animals were anaesthetised with intraperitoneal
thiopentone. The rats, subsequently, were intubated and ventilated. The
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right common carotid artery (CCA) and external jugular veins (EJV) were
cannulated. The rats temperature, heart rate, and mean arterial pressure
were collected throughout. An electrocardiogram (ECG) was also, con-
tinuously, recorded. A parasternal thoracotomy was performed and the
LAD coronary artery was isolated. A snare occluder was then positioned
around the LAD. The animal was allowed to stabilise for 15 minutes before
proceeding with further interventions.
The snare occluder was then tightened inducing ischaemia of the LV
in the LAD territory (designated as time 0). Thus, rats were subjected to
30 minutes of myocardial ischaemia by occlusion of the LAD followed
by 6 hours of reperfusion. The experimental intervention, injection of 107
BMMNCS, via the EJV, was given during ischaemia or at a later time point
after reperfusion had commenced.
Two different controls were used, one, a sham procedure in which a
thoracotomy was undertaken but the LAD was not occluded and, two,
ischaemia-reperfusion injury but no intervention other than injection of
placebo — PBS was used as this was the vehicle for cell delivery in the
experimental arm.
3.3.9 Cell Injection
When required placebo or cells were injected intravenously via the
catheter in the EJV. A total of 107 BMMNCs suspended in 0.5 ml PBS
was administered to each rat, using a 1 ml syringe. Controls as dis-
cussed previously, were the sham operated group undergoing thora-
cotomy that received 107 cells, whilst the placebo group undergoing
ischaemia-reperfusion injury received only vehicle (0.5 ml PBS).
3.3.10 Blood Sampling and Analysis
At the end of ischaemia-reperfusion injury, before animal sacrifice, blood
was removed from the abdominal aorta using a 22 G needle. All sam-
ples, were frozen, and sent to an external laboratory in Spain for analysis.
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Troponin, liver function tests, urea and electrolytes, full blood count, and
CKMB levels were quantified.
3.3.11 Functional Assessment with Echocardiography
Transthoracic echocardiography was performed on all animals at up to
three time points: before LAD ligation, immediately after reperfusion fol-
lowing closure of the thoracotomy with surgical glue, and finally at six
hours following reperfusion. In depth methods can be found in §2.7.
3.3.12 Determination of Area At Risk and Infarct Size
When required, the area at risk (AAR) and infarct size were determined at
the end of the reperfusion period coincident with termination of the rat.
Firstly, the LAD was re-occluded, and non-perfused myocardium was
identified using retrograde myocardial perfusion by injecting 1 ml of
Evans blue dye (2% wt/vol, Sigma, E2129) into the rat via the right CCA
cannula. All animals were then killed by an overdose of anaesthetic and
the heart excised. The heart was then rinsed and cut into 4–5 mm sections,
the right ventricle was removed and the AAR, taken as the non-stained
myocardium, was separated from the perfused blue-stained myocardium.
The ischaemic and non-ischaemic tissue was weighed, and the AAR ex-
pressed as a percentage of the left ventricle (LV).
The AAR tissue was then finely diced and incubated in nitrotetra-
zolium blue chloride (NBC) (0.5 mg/ml, Sigma-Aldrich, N6876-500) for
30 minutes at 37◦C. The NBC reacts with dehydrogenases present in the
non-ischaemic myocardium to produce formazan which forms a dark blue
stain. The non-perfused ischaemic myocardium is dehydrogenase deplete
and thus fails to stain. The stained and non-stained tissue are weighed and
provide a measure of infarct size as a percentage of the AAR.
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3.3.13 Animal Termination and Tissue Collection
At the end of all, ischaemia-reperfusion injury, experiments the animals
were killed with an overdose of anaesthetic (30 mg thiopentone i.v.) and
excision of the heart. To aid regional analysis, each heart was cut in the
short-axis into three sections the atria, ventricle, and apex and fixed sepa-
rately for 24 hours in neutral buffered formalin and then paraffin blocked.
3.3.14 Histological Analysis
For histological examination, 4 µM sections were cut and stained with
haematoxylin-eosin. For quantification of BMMNCs found in the heart,
10 sections of 4 µM thickness were cut per heart from each of three regions
- atria, ventricle and apex. These were de-waxed and stained with DAPI
(Vector Labs, H-1200) and mounted. The total numbers of cells labelled
with cell tracker dye (seen in the FITC channel) were counted for each
entire section from fluorescent micrographs captured using a Zeiss fluo-
rescent microscope with SmartCapture 2 (Digital Scientific, U.K.) imaging
software using a Power Mac G5 Dual 1.8 GHz (Apple Inc., Cupertino, Cal-
ifornia). The mean count of 10 sections from each region was calculated
and expressed as cells/mm2.
The number of cells counted was expressed with respect to area to cor-
rect for cell counting bias that could be produced by the variable surface
area of the heart sections examined. First, an absolute count was obtained
by counting every CFDA SE positive cell found in the entire section.
To generate the area adjusted cell count the surface area of each sec-
tion was determined by scanning each slide at 1200 DPI and then count-
ing the number of pixels, with Adobe® Photoshop® again using a Power
Mac G5 Dual 1.8 GHz (Apple Inc., Cupertino, California), that made up
each section. The number of pixels for each section was then transformed
to mm2 by translating the pixel count into mm by using a scale bar that
had been scanned, alongside each slide, and measured in Adobe® Photo-
shop®. Mean value was then calculated for each batch of ten sections from
the atria, ventricle and apex for each rat in the study and these values were
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then collated and averaged for each experimental group.
3.3.15 Quantifying Apoptosis and Necrosis in Rat
Myocardium
3.3.15.1 Ischaemia-Reperfusion Protocol
The ischaemia-reperfusion injury, for the experiments quantifying apopto-
sis and necrosis, was performed as previously described in section §3.3.8.
There was, however, a change in the total time of reperfusion. The LAD
occluding snare, as before, was tightened at time 0, and after 30 minutes
of LAD-occlusion, the occluder was released to allow 2 hours of reperfu-
sion of the myocardium compared to six hours as used in the other in vivo
ischaemia-reperfusion experiments.
3.3.16 Statistical Analysis
General statistical methods are discussed in §2.12, further to this, differ-
ences in cardiac function and cell engraftment were studied using a two-
way repeated-measures analysis of variance (ANOVA). If a significant F
ratio was obtained, a Bonferroni post hoc test was used to specify pair-
wise differences. A value of p<0.05 was considered statistically significant.
All summary values are expressed as the mean ± SEM.
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3.4 Results
3.4.1 Quantification, Viability and Histological Character-
istics of Rat Bone Marrow Isolates
3.4.1.1 Quantity and Viability of Collected Cells
The total number of cells flushed from the rat bone marrow, designated
as WBM, was counted prior to density separation. From a representative
series, n=10, 525.60±31.84×106 WBM cells were collected on average. The
WBM cells were simultaneously assessed for viability, this was found to
be consistently high, with 96.12±0.44% WBM cells found to be viable by
trypan blue exclusion.
Following density separation, the remaining cells designated BMM-
NCs were counted and assessed for viability. A mean of 52.72± 10.07×106
BMMNCs were counted of which 97.05±0.30% were viable.
A clear and strong relationship between rat weight and number of
WBM and BMMNCs collected can be seen in Figure 3.3. This constant re-
lationship allows prediction of the number of donor rats needed to sup-
ply recipients for any given number of experiments as long as the num-
ber of donor cells to be injected and the total number of injections re-
quired are known. With the aim of refining and reducing animal use in
cell donor experiments, this number was calculated as follows. The aver-
age number of BMMNCs obtained was divided by the average weight of
the rats used to obtain the cells. Thus, per 1 g of total body weight, for
male Wistar rats 151,016 BMMNCs can be harvested on average. This in
turn can be used to calculate the minimum body weight that will give the
required number of cells for a particular experiment. For example 107 cells
are needed to inject each rat in the donor cell studies in this thesis, typ-
ically each experiment requires n=6. Therefore, we need a rat weighing:
(6× 107)/151, 016 = 397.3 g to donate enough cells to complete the experi-
ment (without allowing any room for error or below average return of cell
collection numbers).
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(a)
(b)
(c)
Figure 3.3: Graphs showing the correlation between (a) animal weight and quan-
tity of whole bone marrow (WBM) collected, (b) animal weight and quantity
of bone marrow mononuclear cells (BMMNCs) collected, and (c) the amount of
WBM collected and the subsequent amount of BMMNCs collected.
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Table 3.2: Descriptive statistics of animal weights and subsequent cell number
and viability of whole bone marrow (WBM) and bone marrow mononuclear cells
(BMMNCs) obtained from rat bone marrow.
Parameter Value
Sample Number 10
Weight (g) 349.1 ± 18.83
WBM Total Cells (×106) 525.6 ± 31.84
WBM Viability (%) 96.12 ± 0.44
MNC Total Cells (×106) 52.72 ± 10.07
MNC Viability (%) 97.05 ± 0.30
3.4.1.2 Histological Assessment
Bone marrow was processed using the Histopaque centrifugation tech-
nique with the aim of collecting a purified population of BMMNCs. The
success of this procedure was assessed by cell counting of H&E stained
sections to quantifying the percentage of neutrophils remaining within
the mononuclear fraction after separation, for a representative sample,
n=6, 2.6±0.9% of the total cell population were neutrophils rather than
mononuclear cells after the separation stage, from a different perspective
this number tells us that the sample had 97.4±0.9% “purity”, see Fig-
ures 3.4 (a) and (b).
3.4.2 Cell Surface Phenotype of Rat WBM and BMMNCs
Cell surface phenotyping was performed on whole bone marrow (WBM)
and the subsequently separated mononuclear cell fraction (MNC). After
appropriate gating (see Figure 3.5), flow cytometry fluorescent analysis
(bone marrow from, n=12, rats) of MNCs after separation from WBM
indicated that 84.21±2.34% expressed the pan-leukocyte marker CD45
(See Table 3.3), significantly more than that expressed in the WBM frac-
tion (45.21±1.3%,P=0.0005). Lymphocyte markers were also found on
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(a)
(b)
Figure 3.4: Haematoxylin and Eosin staining of (a) whole bone marrow show-
ing numerous neutrophils and debris and (b) histopaque separated mononuclear
cells.
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the mononuclear cells, 2.53±0.22% were CD3 positive, a T-lymphocyte
marker, and 15.68±0.7% expressed CD45RA, a B-lymphocyte marker (See
Tables 3.3 and 3.4). A recognised marker of haematopoietic and mesenchy-
mal stem cells, CD90.1, was expressed in 50.47±3.22% of the mononuclear
cell fraction (See Table 3.3). Results for WBM are included in all of the
above tables with tests of significance for comparisons of staining percent-
ages compared to the mononuclear fraction.
Dual staining revealed that 75.94±2.23% of the MNC fraction were pos-
itive for both CD45 and CD45RA, 2.67±0.22% were positive for CD45 and
CD3, while 3.36±0.24% were dually positive for CD3 and CD45RA sug-
gesting that the majority of the MNC fraction expressed a B-cell phenotype
(See Tables 3.5, 3.6, and 3.7).
Example histograms obtained from the flow analysis of mononuclear
cells for CD45 (Figure 3.6), CD45RA (Figure 3.7), CD3 (Figure 3.8), and
CD90/1 (Figure 3.9) are also shown.
(a)
Figure 3.5: Plot of forward scatter (FSC) and side scatter (SSC) characteristics of
rat mononuclear cells, (a) with a linear scale and (b) with a log scale. Region R1
was used to gate on cells that were to be further quantified for cell surface markers
CD45, CD3, CD45RA, and CD90.1
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Table 3.3: Percentage of whole bone marrow (WBM) and mononuclear cells
(MNC) staining positive for CD45, CD3, and CD90.1 cell surface markers. As as-
sessed using flow cytometry with mouse monoclonal antibodies conjugated to
FITC, APC and PE-Cy-5, respectively.
CD45 CD3 CD90.1
WBM MNC WBM MNC WBM MNC
Sample No. 12.00 12.00 12.00 12.00 12.00 12.00
Mean 45.20 84.21 1.28 2.53 18.15 50.47
SEM 1.30 2.34 0.10 0.22 0.75 3.22
P Value 0.0005 P<0.0001 P<0.0001
Table 3.4: Percentage of whole bone marrow (WBM) and mononuclear cells
(MNC) positive for CD45RA low and high staining. Assessed with flow cytome-
try.
CD45RA Low CD45RA High
WBM MNC WBM MNC
Sample No. 12.00 12.00 12.00 12.00
Mean 73.48 81.12 12.52 15.68
SEM 1.26 0.89 0.72 0.70
P Value 0.0005 0.0001
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Table 3.5: Descriptive statistics (Mean±SEM) and p values for percentage of
whole bone marrow (WBM) and mononuclear cells (MNC) staining dually or
singly positive (+) and negative (-) for CD45 and CD45RA.
WBM (n=12) MNCs (n=12) p value
CD45-CD45RA+ 53.91±0.42 22.93±2.08 <0.0001
CD45+CD45RA+ 43.56±0.47 75.94±2.23 <0.0001
CD45-CD45RA- 2.44±0.11 0.89±0.12 <0.0001
CD45+CD45RA- 0.10±0.010 0.24±0.04 <0.005
Table 3.6: Descriptive statistics (Mean±SEM) and p values for percentage of
whole bone marrow (WBM) and mononuclear cells (MNC) staining dually or
singly positive (+) and negative (-) for CD45 and CD3.
WBM (n=12) MNC (n=12) P value
CD45-CD3+ 1.32±0.07 1.33±0.078 0.92
CD45+CD3+ 1.38±0.12 2.67±0.22 <0.0001
CD45-CD3- 57.77±1.36 17.30±2.45 <0.0001
CD45+CD3- 39.53±1.31 78.70±2.67 <0.0001
Table 3.7: Descriptive statistics (Mean±SEM) and p values for percentage of
whole bone marrow (WBM) and mononuclear cells (MNC) staining dually or
singly positive (+) and negative (-) for CD45RA and CD3.
WBM (n=12) MNC (n=12) P value
CD3+CD45RA- 0±0 0.01±0 0.191
CD3+CD45RA+ 2.08±0.14 3.36±0.24 <0.0001
CD3-CD45RA- 3.88±0.47 0.94±0.15 <0.0001
CD3-CD45RA+ 94.03±0.42 95.7±0.37 0.007
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Figure 3.6: Histograms showing plots of cell count vs fluorescent intensity for
mononuclear cells (MNC) stained with isotype control or CD45 antibody conju-
gated to FITC.
Figure 3.7: Histograms showing plots of cell count vs fluorescent intensity for
mononuclear cells (MNC) stained with isotype control or CD45RA antibody con-
jugated to PE-Cy-5.
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Figure 3.8: Histograms showing plots of cell count vs fluorescent intensity for
mononuclear cells (MNC) stained with isotype control or CD3 antibody conju-
gated to APC.
Figure 3.9: Histograms showing plots of cell count vs fluorescent intensity for
mononuclear cells (MNC) stained with isotype control or CD90.1 antibody con-
jugated to PE-Cy-5.
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3.4.3 Ischaemia-Reperfusion Model
Before beginning the formal experiments in which BMMNCs were injected
into a rat IR model a period of time was spent becoming familiar with the
Rat IR model. For this, n=62, Wistar rats (weight 324±66 g) were used.
An attrition rate of 16.1% was noted, of these premature deaths prior to
successful completion of an experiment 9.6% were attributed to vascular
injury and 6.5% to anaesthetic complications.
3.4.4 Quantification of Donor BMMNCs in Host My-
ocardium
Donor BMMNCs were incubated with, the green fluorescent dye, CFDA
SE (Molecular Probes) prior to injection into host animals. The aim was
to use the emitted fluorescence of the cell dye to differentiate the injected
donor cells from host tissue.
As shown in Figure 3.10 (a) and (b), donor BMMNCs could be clearly
differentiated from native cells due to the presence of the green fluorescent
cell tracker dye. Subsequently, this property was used to quantify donor
cells with the host animal’s hearts as explained in the methods section (see
Section 3.3.14).
Tissue sections of host rats were counted as set out in the methods,
but in summary each rat heart was separated into 3 separate segments,
the atria, left ventricle and the apex. The total number of donor cells, as
identified by the presence of the cell tracker dye, was counted for ten entire
sections for each of the three segments.
3.4.4.1 Quantification of Cells in Control Ischaemia-Reperfused Donor
Hearts
Animals that underwent ischaemia-reperfusion injury and did not receive
cells, but only 500 µl of the delivery agent, PBS, acted as controls in all
experiments (labelled Control IR group). This group was used to test the
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(a)
(b)
Figure 3.10: Donor cells, as indicated by white arrows, within the donor ischaemic
myocardium were identified due to the fluorescent properties of the cell tracker
dye CFDA SE, in both (a) and (b). Cell nuclei were stained with DAPI, seen here
as a blue, and cardiomyocytes and red blood cells can be seen in red due to their
autofluorescent properties in the far red spectrum.
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specificity of the method for identifying labelled donor cells within the
donor myocardium.
No positively cell tracker dye labelled cells were seen within the host
myocardium of any control IR group rats. This suggests that CFDA SE
method of labelling donor cells for subsequent quantification in host
hearts is 100% specific.
3.4.5 Longer Culture of BMMNCs Reduces Homing in
Myocardial Ischaemia-Reperfusion Injury
Initially the pre-treatment of BMMNCs prior to injection into a rat model
of IR injury was examined.
The effects of time spent in culture on BMMNCs ability to migrate and
engraft into the ischaemia-reperfusion injured rat heart were investigated
by comparing the number of cells engrafted in hearts after treatment with
BMMNCs that had been cultured for 24 hours or for 72 hours prior to their
use (n=4 rats for both groups). All other culture conditions were kept the
same, length in culture was defined as time from cell harvest to time of cell
injection in IR model.
3.4.5.1 Whole Heart Cell Count Comparisons
There was a more than threefold significant increase in the number of
donor cells found within host hearts when BMMNCs cultured for only
24 hours, prior to injection into the ischaemia-reperfusion model, when
compared to those cultured for 72 hours, 3.02±0.17 cells/unit area in con-
trast to 0.74±0.07 cells/unit area, P<0.0001 (see Table 3.8 on page 163 and
Figure 3.11 on page 166).
These results show a significant increase in the number of cells homing
to the IR injured rat hearts when BMMNCs were only cultured for 24 hours
compared to 72 hours. Thus, all further experiments were performed using
BMMNCs either freshly isolated or cultured for a maximum of 24 hours.
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3.4.5.2 Segmental Cell Count Comparisons: Atria, Ventricle, and Apex
The increase in donor cells found in the whole hearts of the 24 hour cell
culture group compared to the 72 hour cell culture group was also seen at
a segmental level.
The mean number of cells observed within the atria for 24 hour cul-
tured cells was 1.36±0.07 cells/unit, over twice the number found in the
atria when cells cultured for 72 hours were used, 0.56±0.08 cells/unit,
P=0.0002 (see Table 3.8 on page 163 and Figure 3.11 on page 166).
The same findings were repeated for the ventricles, although the dif-
ferences were larger, the mean for 24 hour cultured cells being 3.50±0.28
cells/unit, over four times the mean for 72 hour cultured cells, 0.81±0.11
cells/unit, P<0.0001.
The disparity in the number of donor cells, from the two experimental
groups found in the host hearts, was found to be at its widest in the apical
segments. The mean area adjusted number of donor cells for the 24 hour
group was 4.19±0.24 cells/unit, nearly five fold larger than the mean for
the 72 hour group, 0.84±0.16 cells/unit, this divergence was found to be
highly significant P<0.0001.
3.4.5.3 Intra Group Comparison of Cell Counts
There were significant differences between the number of donor cells
found within the three heart segments for the 24 hour group. More cells
were found in the ventricle and apex segments than the atria, P<0.001 in
both cases, and the apex contained a greater number of donor cells than
the ventricle, P<0.05. In contrast to the 24 hour group no significant dif-
ferences were seen between the heart segments in the 72 hour group.
These results suggest that BMMNC pre-treatment, in this case time
spent in culture, can significantly effect cell homing. As the 24 hour time
point was significantly better than the 72 hour time point all further ex-
periments we carried out with freshly isolated BMMNCs (i.e., used on the
day of their harvest) or after a maximum of 24 hours spent in tissue cul-
ture. Next the effect of timing of cell delivery was investigated.
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3.4.6 BMMNC Homing Is Influenced by Whether Cell
Delivery Occurred During The Ischaemic or Reper-
fusion Phase of the IR Model
The number of cells that homed to rat hearts in a IR model was quantified
for two different timings of delivery of 107 BMMNCs. The two alternate
cell injection times were: 1) during ischaemia (after ischaemia had been
established for 15 minutes and while the LAD ligature was still clamped
in place), and 2) during the reperfusion phase (cell delivery immediately,
i.e, less than 60 seconds, after LAD ligature removal).
Thus, this experiment involved four groups:
• The sham group — open thoracotomy only, and cell treatment,
• The control group — ischaemia-reperfusion injury, but vehicle treat-
ment only
• The ischaemic group — cardiac ischaemia-reperfusion injured rats
receiving BMMNCs during the ischaemic period
• The reperfusion group — cardiac ischaemia-reperfusion injured rats
receiving BMMNCs at the start of the reperfusion period.
3.4.6.1 Whole Heart Cell Count Comparisons
In the control group not even a single homed cell was found within the rat
hearts as identified using the green cell tracker dye (n=2 rats, 60 sections).
The mean whole heart cell count for the sham group was 0.34±0.06
cells/unit area, this was significantly lower than the whole heart cell count
for the ischaemic group, 1.58±0.13 cells/unit area, and for the reperfusion
group, 2.18±0.20 cells/unit area, P<0.001 for both comparisons (see Fig-
ure 3.12). Although, the cell count for donor cells found in the reperfusion
group was numerically superior to that of the ischaemia group it was not
found to be statistically significant. For tabulated data for all three groups
see Table 3.9.
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3.4.6.2 Segmental Cell Count Comparisons: Atria, Ventricle and Apex
The mean, area adjusted, number of cells counted in the atria of the sham
group was 0.27±0.06 cells/unit area, this was significantly lower than
the number of cells found in the ischaemic group, 0.92±0.14 cells/unit
area, and in the reperfusion group, 0.98±0.16 cells/unit area, P<0.001 and
P=0.008 respectively.
The cell count, by area, was also significantly lower in the sham groups
ventricular portion, 0.34±0.05 cells/unit area, than both the ischaemic and
reperfusion groups ventricular segments, 1.69±0.27 cells/unit area and
2.63±0.35 cells/unit area, P<0.001 for both cases.
The apex segments of the sham controls was also found to contain less
donor cells, 0.42±0.15 cells/unit area, than the ischaemic group, 2.12±0.27
cells/unit area or the reperfusion group, 2.91±0.38 cells/unit area, both
means differed significantly from the sham mean with P<0.001.
3.4.6.3 Intra Group Comparisons of Heart Segments
No significant differences were seen in the number of cells found within
the three segments examined for the sham group’s hearts (See Table 3.9
and Figure 3.12).
For the ischaemic group there were significantly more cells observed
in the ventricle and apex than in the atria, P<0.05 and P<0.001. Also, there
was a trend towards counting more cells within the apex segment com-
pared to the ventricular segment but this was not found to be significant.
Analysis of the reperfusion group showed similar findings to the is-
chaemic group. There were significantly fewer cells in the atria when com-
pared to the ventricle or the apex, both with P<0.01. A non-significant
trend for finding more cells in the apex than the ventricle was noted.
Finally, a trend to counting more cells in hearts from the reperfusion
cell delivery group was seen compared to the ischaemia group. This trend
was not significant. But in the hope of optimising all adjustable parameters
all future experiments were performed by administering 107 BMMNCs at
the on set of the reperfusion phase.
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(a)
(b)
Figure 3.11: Mean cell counts adjusted by area of section from ischaemia-
reperfusion injured hearts injected with bone marrow mononuclear cells (BMM-
NCs) cultured for either 24 or 72 hours prior to injection. Figure (a) shows the
means for the entire heart and (b) shows the regional means for the atrial, ven-
tricular and apex segments. == indicates P value<0.001.
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(a)
(b)
Figure 3.12: Mean cell counts, adjusted for area, in hearts of sham controls treated
with bone marrow mononuclear cells (BMMNCs) and for ischaemia-reperfusion
injured hearts, treated with BMMNCs during ischaemia or upon reperfusion. Dif-
ferences in cell counts for the whole heart are shown in (a) and by region in (b).
FF Indicates P<0.01, == indicates P<0.001. 167
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3.4.6.4 The Effect of BMMNC Delivery In Ischaemia or During
Reperfusion on Echocardiographic Measurements of the Left
Ventricle in a Rat Ischaemia-Reperfusion Model
Parasternal short axis views were used to obtain all echocardiographic
data. An example of the M-Mode tracing obtained using this method is
shown in Figure 3.13. The operators were blinded to the specific treatment
group and all readings were repeated 3 times.
Fractional shortening (FS) demonstrated no significant changes be-
fore and after thoracotomy (no IR injury induced in the sham group) in
sham operated animals, results respectively 50.2±5.3% to 49.6±4.7% (n=4,
P=0.9), See Figure 3.14.
In control animals following 30 minutes of LAD occlusion and 6
hours of reperfusion a decrease in FS% was observed from 49.6±0.9% to
23.8±0.9%, (n=3, P=0.007) demonstrating a significant functional decrease
in cardiac function. This decrease in FS was similar after either of the cell
treatments.
There was no significant difference in the FS% when cells were in-
jected during the ischaemic period compared to control animals (control
23.8±0.9%, vs. ischaemia 27.8±3.0%, n=6, P=0.3) or if injected at the be-
ginning of reperfusion (control 23.78±0.93% vs reperfusion 31.77±2.96%,
n=6, P=0.06).
However, it is noted that an improvement in FS approached signifi-
cance in the reperfusion group versus the control group and thus may
indicate a trend towards improvement. These data suggest that cell ther-
apy administered either during the ischaemic period or reperfusion was
not associated with a decrease in cardiac function compared to control an-
imals treated with PBS.
Tabulated data for all other LV dimensions can be found in Table 3.10
and graphs of the same data can be found in Figure 3.15. Several signif-
icant differences were seen between dimensions measured in the control
group compared to the two cell treated groups but no overall pattern of
benefit or harm is revealed.
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Figure 3.14: Echocardiographic measurement of left ventricular fractional short-
ening percentage, a marker of LV function. The four experimental groups are
shown: Sham (No injury), No cells (Control group with injury but no cell treat-
ment), On ischaemia (Injury and cell treatment during ischaemia) and on reper-
fusion (Injury and cell treatment during reperfusion). No significant difference
was measured in fractional shortening percentage between the Control group or
either of the cell treated groups.
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3.4.7 Quantification of Myocardial Infarct Size in a Rat
Ischaemia-Reperfusion Model Following BMMNC
Injection
The length of cell culture and timing of cell delivery experiments sug-
gested that cell homing and thus possibly outcome may be optimised by
delivering freshly isolated cells immediately on reperfusion in the rat IR
model. This “optimum” combination was therefore tested to elucidate any
effects on infarct size.
For this experiment n=6 for both controls and cell treated rats. There
was no significant difference in baseline demographics for body weight
(Controls 308±16.8 g, cell group 314±17.2 g, P=0.79) or in LV weight (Con-
trols 550.8±21.3 mg, cell group 522.8±32.7 mg, P=0.49) as shown in Fig-
ure 3.16.
However, although the LV area at risk (AAR) weights were not sig-
nificantly different between the control group (279.7±16.5 mg) and the
cell treated group (257±20.1, P=0.404) the infarct weight was significantly
less in the cell treated group (85.5±14.8) compared to the control group
(147.5±7.41, P=0.0066) as seen in Figure 3.17.
Thus, the model of IR injury used in these experiments lead to an aver-
age infarct size (Infarct weight/AAR weight) of 54.4±2.2% with an aver-
age area at risk (AAR weight/LV weight) of 50.9±2.5% in control animals.
Injection of 1 × 107 BMMNCs, as characterised previously, immediately
following reperfusion resulted in an infarct size of 32.1±3.5%, with aver-
age area of risk of 49.65±1.3% which equates to a 41% reduction in infarct
size compared to control animals in which PBS was injected (P<0.001) as
seen in Figure 3.18. There was no significant difference of the area at risk
between the control and BMMNC treatment group.
No significant differences were measured in physiological parameters
of the rats between the control group and the cell treated group. Changes
in the physiological readings during the experiment are shown for blood
pressure (see Figure 3.19), heart rate (see Figure 3.20) and for temperature
(see Figure 3.21).
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(a) (b)
(c) (d)
(e) (f)
Figure 3.15: Wall thickness of anterior and posterior walls and left ventricular in-
ternal dimensions (LVID) in systole and diastole. (a) Anterior wall in diastole, (b)
Anterior wall in systole, (c) LVID in diastole, (d) LVID in systole, (e) Posterior wall
in diastole, and (f) Posterior wall in systole. Echocardiography was performed
pre and 6 hours post ischaemia-reperfusion injury (IR) for the control group, cells
on ischaemia and cells on reperfusion groups. F Indicates P<0.05, FF indicates
P<0.01, == indicates P<0.001.
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(a) Total body weight of rats.
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(b) Total weight of left ventricular portion of ex-
cised rat hearts
Figure 3.16: Total weight in grams of (a) whole body and (b) left ventricles of rats
undergoing myocardial ischaemia-reperfusion injury and subsequent injection of
phosphate buffered saline, the control group, or 107 bone marrow mononuclear
cells, the BMMNCs group. No significant differences were demonstrated between
the two group’s mean values, for either body weight or left ventricular weight.
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(a) Total weight of area at risk.
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(b) Weight of infarcted myocardium.
Figure 3.17: Weight of (a) area at risk of left ventricle and (b) infarcted portion of
area at risk. Tissue taken from rats undergoing myocardial ischaemia-reperfusion
injury and subsequent injection of control vehicle (PBS) or 107 bone marrow
mononuclear cells (BMMNCs), respectively labelled as the control and BMMNCs
group. There was no significant difference in the area at risk for the two groups.
However, the weight of the infarcted portion of the area at risk was significantly
lower in the BMMNC treated group, P=0.007.
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(a) Percentage of area at risk of whole left ventricle.
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(b) Infarcted myocardium as a percent of area at
risk
Figure 3.18: Percentage of (a) area at risk of the total left ventricle and (b) the
area at risk characterised as infarct. All rats underwent myocardial ischaemia-
reperfusion injury and subsequent injection of vehicle (PBS), i.e., the control
group, or 107 bone marrow mononuclear cells the BMMNCs group. There was no
significant difference in the percentage of left ventricle at risk for the two groups.
In contrast to this, the percentage of the infarcted portion of the area at risk was
significantly lower in the BMMNC treated group, P=0.0007.
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3.5 Discussion
The isolation of BMMNCs from rats was successfully achieved using a
centrifugation separation technique. Harvested cells were highly viable
(97%) and histological examination suggested that the technique was spe-
cific for isolating mononuclear cells (<3% of isolated cells were neu-
trophils).
BMMNCs were subsequently successfully labelled with the green flu-
orescent cell tracker dye CFDA SE (labelling success >95%). Using the cell
tracker dye injected donor cells were able to be tracked in host organs.
Flow cytometry was used to phenotype the harvested BMMNCs. Thus,
the isolated cells were found to be comprised of a mix of B and T-cells
as well as a high proportion of cells expressing haematopoietic stem cell
markers. This combination of cells is in keeping with previous reports in
which BMMNCs were injected in acute MI models or clinical trials.
A rat ischaemia-reperfusion model was established and this was sub-
sequently combined with the ability to track injected donor cells to inves-
tigate the interaction of BMMNCs in the IR model.
Several variables have been considered likely to exert significant in-
fluence on the efficacy of BMMNC treatment for cardiovascular diseases.
These are: cell type delivered, dose of cells, timing of cell delivery with
respect to the index injury, route of cell delivery, and the nature of the un-
derlying cardiovascular disease. One of the most significant parts of the
process of cell therapy, but often overlooked, are the biological changes
brought about during the isolation and subsequent cell culture of the col-
lected cells. As a demonstration of such effects, homing of BMMNCs that
had been cultured for 24 hours compared to 72 hours prior to injection in a
rat IR model was compared. Cells cultured for only 24 hours homed to the
myocardium significantly more than cells cultured for 72 hours. The biol-
ogy responsible for this result has not been explored further to date, but it
raises an important issue around the appropriate testing of different isola-
tion and culture techniques to optimise cell performance for treating car-
diovascular diseases. This finding influenced the later studies, in that all
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future experiments were performed with freshly isolated BMMNCs (i.e.,
used on the day of isolation) to minimise detrimental effects brought about
by prolonged tissue culture.
As mentioned above, two of the important variables that need to be
defined with respect to cell therapy are what is the best route for cell deliv-
ery and what is the best time for cell delivery? Some information was shed
on these questions by comparing cell homing and cardiac function in rats
treated with 107 BMMNCs either during ischaemia or immediately dur-
ing reperfusion. The first observation of note was that significantly more
BMMNCs homed to the IR injured hearts compared to the Sham control
hearts. This suggests that BMMNC homing is increased to ischaemic my-
ocardium over non-ischaemic myocardium. This is likely to be brought
about by the up-regulation of a cell surface receptor such as CXCR4 in
ischaemic tissues.
When the number of cells homed to the hearts were compared to cell
delivery in ischaemia or on reperfusion a non-significant trend was seen
to more frequent homing in the reperfusion group. When the same groups
cardiac function was assessed using echocardiography to measure FS%
again no significant differences were found. In comparison to the control
group (IR injury but no cells) both the ischaemia and reperfusion groups
tended to have better function but no significant differences were demon-
strated. This result fails to find evidence for the theoretical possibility
that injection of BMMNCs early during myocardial infarction may have
a detrimental effect on the myocardium or on the cells themselves.
As cells cultured for 24 hours or less and cells given on reperfusion
were documented to produce the highest frequency of injected BMMNCs
within the host myocardium this combination of methods was used in all
further experiments.
A novel finding was demonstrated using this combination of meth-
ods when infarct size in the IR injury model was compared between cell
treated rats (107 BMMNCs) and controls. Thus, infarct size was seen to
significantly decrease by 41% in cell treated animals over controls.
The majority of reports that exist regarding the beneficial effects of
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bone marrow derived cells on cardiac function following myocardial in-
farction have injected cells several days after the ischaemic event. One re-
port has compared the effects on cardiac function and infarct size on cells
injected from 1 hour to 1 week after myocardial infarction in the rat (Hu
et al., 2007). Although the cell type was different (bone marrow derived
mesenchymal stem cells), injection at 1 hour lead to a smaller reduction in
infarct size (approximately 20%) than we have shown here but translated
into a significant improvement in cardiac function at 4 weeks. Although
the authors conclude that the level of inflammation seen acutely following
the ischaemic insult may impair the response to cell therapy our data sug-
gests that injection of cells before the 1 hour time point leads to a greater
reduction in infarct size with no detrimental effect on cardiac function.
Several different mechanisms that may contribute to cardiac repair
based around the concept of transdifferentiation have been proposed. One
of the first reports on this subject demonstrated that a significant recov-
ery of cardiac function was accompanied with transdifferentiation of the
transplanted bone marrow derived cells into a cardiomyocyte phenotype
(Orlic et al., 2001a). Subsequent reports have suggested that bone mar-
row derived cells can also transdifferentiate into other cell types that may
improve cardiac function by other mechanisms, e.g., promotion of angio-
genesis (Kamihata et al., 2001) or may facilitate other cell survival mecha-
nisms, e.g., Akt expression (Mangi et al., 2003).
Due to the short time scale needed to induce an effect in the work de-
scribed here it is highly unlikely that cellular differentiation accounts for
the dramatic decrease in infarct size seen given that it has previously been
shown that relatively limited differentiation takes place over a period of 7
days (Gallo et al., 2007). It seems more likely that given the size and timing
of the protective effect seen here, in rats treated with BMMNCs, that the
benefit is due to direct effects on ischaemia-reperfusion injury.
It has been shown in animal models that reperfusion injury may ac-
count for up to 50% of the final infarct size and strategies such as ischaemic
preconditioning further half infarct size beyond the benefits seen by early
reperfusion (Yellon & Hausenloy, 2007). The identification of several po-
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tential mediators of this injury pathway has lead to the possibility of phar-
macological and mechanical interventions. Indeed, the various mediators
of reperfusion injury — oxidative stress, changes in pH, inflammation, in-
tracellular calcium levels and mitochondrial membrane potential change
— are all possible targets for interaction with bone marrow derived cells
injected at the time of reperfusion.
BM derived cells have been shown to exhibit properties such as release
of paracrine factors and expression of cardioprotective genes (Dai et al.,
2007, 2008; Xu et al., 2007; Zhang et al., 2004b) that may be beneficial.
Thus, there seems to be a coherent argument that BMMNCs may have
reduced infarct size as seen in the experiments documented here by modu-
lating reperfusion-injury. As things stand, this premise is based on circum-
stantial evidence that BMMNCs release cardioprotective factors known to
modulate reperfusion-injury, and that the speed and the size of the in-
farct size reduction shown here have only ever previously been achieved
through pre- or post-conditioning experiments that reduce reperfusion-
injury.
The results of clinical trials suggest that there may be a beneficial effect
on cardiac function when cells are administered 5 days after successful
reperfusion for myocardial infarction (Schachinger et al., 2006). However,
in another study when cells were injected at a time closer to the point of
successful reperfusion (24 hours) no beneficial effect was seen (Janssens
et al., 2006). This has led some experts to advocate a later time-point of cell
delivery. They have postulated that the myocardial tissue is intrinsically
hostile around the time of infarction and a less then ideal environment in
which to engraft transplanted cells.
However, the data presented in this chapter suggests that there may
be a very early window of opportunity (i.e., less than 24 hours following
reperfusion) that exists for bone marrow derived cell therapy to prevent
myocardial necrosis and that this time point should be considered when
designing future clinical trials.
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CHAPTER 4
Bone Marrow Mononuclear Cells Reduce
Myocardial Reperfusion Injury By Activating The
PI3K/Akt Survival Pathway
4.1 Introduction
In the previous chapter and as described in the peer-reviewed publica-
tion of this work, (Lovell et al., 2010), a novel finding was demonstrated
with respect to infarct size. The new observation was that myocardial in-
farct size was seen to decrease significantly by 41% in BMMNC treated
animals over controls in an acute rat IR model. This reduction in infarct
size was statistically significant and the magnitude of change also sug-
gests that if maintained in humans such a reduction in infarct size would
be clinically important. Therefore, it would seem worthwhile in pursuing
further knowledge of this process. The experiments set out in chapter 3
document a beneficial outcome but no firm indication of the mechanism
producing the benefit had been sought. Thus, this chapter describes a se-
ries of experiments designed to further understand how BMMNCs reduce
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myocardial infarct size in an acute IR setting.
As research budgets and time are not limitless, a focused approach to
investigation was taken. A hypothesis was built based on observations
taken from chapter 3 and also from contemporary work in this field. The
hypothesis was that infarct size reduction was brought about by paracrine
actions of the injected cells modulating ischaemia-reperfusion injury. The
observations that this hypothesis is drawn from are detailed in the follow-
ing paragraphs.
An unusual feature of the effects documented in chapter 3 is that a large
reduction in infarct size was seen over a short period of time (at most six
hours). During this time it is unlikely that previously presumed mecha-
nisms of benefit such as cell transdifferentiation or plasticity have enough
time to influence events through direct formation of cardiomyocytes and
vasculature. This would suggest that infarct size reduction seen in ani-
mals treated with BMMNCs, in the experiments described here, are due to
a more rapid process, e.g., a paracrine effect.
In addition, the small number of the cells/mm2 found within the is-
chaemic myocardium compared to the size of the effect seen leads to fur-
ther consideration that the effect is most likely attributable to a paracrine
action rather than direct BMMNC transdifferentiation, as the transdiffer-
entiation of such a few cells into cardiomyocytes would not produce the
size of infarct reduction observed here.
Multiple independent research groups have also published extensive
studies that have failed to find evidence of transdifferentiation of BMM-
NCs into cardiomyocytes or vascular cells in animal infarct models (Bal-
sam et al., 2004; Mollmann et al., 2006; Murry et al., 2004; Ziegelhoef-
fer et al., 2004). This provides further incentive to look elsewhere for the
mechanism of the infarct size reduction seen with injection of BMMNCs
in the IR model in chapter 3.
When the timing and magnitude of the BMMNC effect are consid-
ered there are few comparable interventions that can achieve the same
outcome. One increasingly well researched effect that has a similar time
course of action and size of effect is amelioration of IR injury either
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through pre- or post-conditioning. In animal models, reperfusion injury
can account for up to 50% of the final infarct size and strategies such as
ischaemic pre-conditioning can further halve infarct size beyond the ben-
efits seen by early reperfusion (Yellon & Hausenloy, 2007). Both pre- and
post-conditioning reduce IR injury via activation of a final common route
the reperfusion injury salvage kinase (RISK) pathway (Hausenloy et al.,
2005b).
There are several published studies in this area that provide support
for the hypothesis that infarct size reduction may be brought about by
paracrine actions of injected BMMNCs cells modulating IR injury.
In an in vitro model of acute ischaemia BMMNCs have demonstrated
a potent anti-ischaemic effect (Kubal et al., 2006). Human cardiac tissue
from the right atrium underwent IR injury with and without co-culture
with BMMNCs. Myocardial injury and myocyte apoptosis was quanti-
fied. BMMNC co-culture significantly reduced both myocardial injury and
apoptosis. This effect was ameliorated by the use of inhibitors of compo-
nents of the RISK pathway, namely PKC and p38 MAP kinase.
Others have demonstrated that BMMNCs are able to release cytokines
that can activate the RISK pathway. The same groups were able to replicate
the finding of decreased apoptosis in cardiomyocytes when co-cultured
with BMMNCs. This effect was enhanced if BMMNCs were primed by a
period of hypoxia prior to the co-culture. Furthermore, evidence for the
mechanism of this benefit being a paracrine mechanism was found as
conditioned media was able to produce the same effects in the physical
absence of the BMMNCs. When used in vivo, in a rat myocardial infarc-
tion model, conditioned media was able to improve microvessel density,
decrease fibrosis and improve LV function within the infarcted rat hearts
(Takahashi, 2006; Uemura et al., 2006).
The reduction in myocardial injury with reduced CK release and apop-
tosis in myocytes from human right atrial tissue has also been shown to be
comparable to the size of effect generated by ischaemic pre-conditioning
(which is know to act via the RISK pathway) (Lai et al., 2009b), with either
co-culture with BMMNCs or with BMMNC conditioned media. The bene-
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fit was also found not to be additive, a finding that could suggest that they
are both acting via the same pathways. All positive effects were abolished
with an inhibitor of insulin like growth factor-1 receptor.
Others have concurred that the action of conditioned media is strong
evidence for a paracrine effect. And they agree, that the documented re-
lease of proteins, such as VEGF, FGF, HGF, IGF-1, thymosin beta-4, that
are known to activate the RISK pathway is further evidence of a paracrine
effect and suggests that myocardial protection via the RISK pathway may
be one of the primary mechanisms by which benefit is derived (Gnecchi
et al., 2008). The ability to block benefit by inhibitors of this pathway is
another supportive finding that points to activation of the RISK pathway
as a major mechanism of benefit (Kubal et al., 2006; Lai et al., 2009b).
Given the positive findings of BMMNCs ability to reduce myocardial
injury. One of the most prominent groups working in this area proceeded
to examine the action of these cells in the human heart in patients un-
dergoing cardiac surgery. Two studies were performed by this group. In
the first study, BMMNCs were administered intramuscularly or via intra-
coronary infusion during CABG in patients documented to have myocar-
dial scarring as defined by akinetic or dyskinetic segments by dobutamine
stress echocardiography. No differences in myocardial injury or function
were seen between the control group and the BMMNC treated group. This
would be the predicted result if the main mechanism of acute benefit from
BMMNCs is to reduce myocardial injury invoked via IR injury (Ang et al.,
2008).
The second study, from the same group, went further in investigating
the possibility of a paracrine effect of BMMNCs on IR injury, and was the
first clinical study designed to address possible anti-ischaemic actions of
BMMNCs. In this trial, forty-four patients undergoing CABG were ran-
domised to either control group or BMMNC infusion during each dose of
cardioplegia (Lai et al., 2009a). No difference in myocardial injury or in
cardiac function was seen between the two groups. This result was un-
expected as the hypothesis was that the BMMNCs would ameliorate IR
injury induced at the time of CABG surgery.
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In vitro studies were performed to help understand this result. Co-
culture of BMMNCs with myocytes from the same patients undergoing
CABG significantly reduced myocardial injury and necrosis and apop-
tosis after provocation with IR injury compared to controls. The size of
the effect was comparable to that seen in the myocytes after ischaemic
pre-conditioning, and combining the two treatments did not produce ad-
ditional benefit. Furthermore, when myocytes were harvested after pa-
tients had undergone initiation of cardiopulmonary bypass (a process that
would expose the myocytes to ischaemic pre-conditioning) no effect was
seen when cells were co-cultured with BMMNCs and underwent IR injury.
Thus, the in vivo results suggest no clinical benefit was seen with
BMMNC treatment in this setting as the action of BMMNCs is likely to
be reduction of myocardial injury induced by IR injury and this pathway
had already been fully activated by a period of ischaemic pre-conditioning
when the patients were placed on cardiopulmonary bypass. This is further
in-direct evidence that one of the acute benefits of BMMNC treatment is
the modulation of IR injury, this is likely to be brought about by activation
of the RISK pathway. As ischaemic pre-conditioning ultimately works via
the same pathway, this could explain why the two interventions cannot be
combined for additional benefit.
Therefore given the published evidence thus far, it is possible that
given the timing and size of the protective effect seen in the rats
treated with BMMNCs in chapter 3, and its similarity to pre and post-
conditioning, that the benefit is due to direct effects on IR injury possi-
bly via activation of the RISK pathway. Specific growth factors released
by BMMNCs that have already been shown separately to be cardioprotec-
tive include vascular endothelial growth factor (VEGF) (Hiasa et al., 2004),
hepatocyte growth factor (HGF) (Wang et al., 2004), fibroblast growth fac-
tor (FGF) (Tang et al., 2005), insulin-like growth factor 1 (IGF-1) (Otani
et al., 2000), and transforming growth factor (TGF) (Baxter et al., 2001a).
Mediators of reperfusion injury — oxidative stress, changes in pH, in-
flammation, intracellular calcium flux and the mitochondrial permeability
transition pore are all possible targets for interaction with BMMNCs in-
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jected at the time of reperfusion. As BMMNCs have already been shown to
exhibit release of paracrine factors and express cardioprotective genes that
may act beneficially on the RISK pathway, one logical line of enquiry is
investigation of this possibility preferentially over other hypotheses (Kin-
naird et al., 2004a,b,c; Xu et al., 2007; Zhang et al., 2004b). With this premise
in mind a series of hypotheses, aims, and experiments were formulated in
an attempt to begin to answer the question of whether paracrine effects
produced by BMMNCs are responsible for infarct size reduction in IR in-
jury.
4.2 Aims and Hypothesis
Hypothesis
1. BMMNCs ameliorate myocardial infarct size through the release of
locally acting factors that activate the reperfusion injury salvage ki-
nase pathway reducing reperfusion injury. Beneficial changes will be
observed in cardiomyocyte mitochondrial function, reactive oxygen
species generation, cell division, and apoptosis and necrosis.
Aims
1. To isolate and culture cardiomyocytes.
2. To use cell tracker dye to identify one population of cells within a
mixed co-culture population.
3. To establish a flow cytometry protocol and gating system that allows
the subtraction of data generated by cells stained with the cell tracker
dye.
4. To establish techniques to quantify cellular mitochondrial function,
reactive oxygen species generation, cell division, and apoptosis and
necrosis.
5. To establish techniques to quantify cellular oxygen consumption.
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6. To assess in vivo, activation of the RISK pathway in the rat I-R injury
model.
7. To perform proteomic analysis of cardiomyocytes and BMMNCs
with a view to identifying candidates that may beneficially influence
cellular mitochondrial function, reactive oxygen species generation,
cell division and, apoptosis and necrosis.
4.3 Experiment Design
Three separate groups of experiments are encompassed within this chap-
ter: firstly, in vitro co-culture experiments; secondly, an in vivo proteomic
study; and thirdly, an in vivo assessment of survival pathways activated
and chronic functional changes following BMMNC injection in I-R injury
(see Figure 4.1).
4.3.1 Co-culture Experiments
Co-culture experiments were performed by incubating neonatal rat car-
diomyocytes or HUVECs with either 4 × 104 BMMNCs or WBM for 24
hours, or in the case of controls neither but with the addition of an extra
4 × 104 HUVECS or cardiomyocytes to control for any effects extra cell
numbers may induce. It was hoped that a co-culture system would have
several advantages, these including, a more controlled environment with
the ability to focus on one factor at a time, the close proximity of the cells to
each other, and the ability to control and magnify the dose of cells. Hope-
fully these advantages would magnify effects compared to those found in
vivo and therefore be easier to detect.
To optimise the proximity of the cells and to avoid losing any bene-
fits induced by cell to cell contact, a novel method for co-culture was de-
veloped. A typical co-culture system involves the culture of two different
populations of cells in the same culture well. One population is separated
from the other by it being cultured not in the well but on a plastic insert
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Figure 4.1: Overview of experiment design of studies included in this chapter.
Study A: Co-culture experiments. Study B: Proteomic Experiments performed by
Kate Lee in the Centre of Clinical Pharmacology, William Harvey Research Insti-
tute (WHRI). Studies C and D: Experiments performed by Prof. Suzuki’s group
in the Centre for Translational Medicine and Therapeutics within WHRI. WBM
- Whole Bone Marrow, BMMNCs - Bone Marrow Mononuclear cells, HUVECs -
Human Umbilical Vein Endothelial Cells, ROS - Reactive Oxygen Species, I/R -
Ischaemia-Reperfusion, LY294002 - phosphatidylinositol 3-kinase inhibitor.
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that hangs down into the well and is in communication with the other
cells through micropores in the plastic insert. The pores do not allow cell
migration but do allow small molecule passage.
However, in this thesis a new technique that has not previously been
used anywhere else was attempted. As the majority of outcome measures
in the in vitro experiments were based on flow cytometry techniques this
allowed the simultaneous use of flow cytometry separation of the cells in
co-culture at the point of analysis rather than using a plastic insert. Thus,
the two cell populations in co-culture were not separated physically but by
prior labelling of one of the cell populations before initiation of cell culture.
The green fluorescent cell tracker dye CFDA SE (Molecular probes, U.K.)
was used to label one population of cells. Subsequently the cells could be
identified by flow cytometry and the two populations could be analysed
separately by the use of appropriate gating. Further details regarding this
approach can be seen in §4.4.3.
4.3.2 Proteomic Studies
As well as a focused, co-culture based, investigation of the mechanisms in-
volved in the infarct size reduction, a research strategy with a wider scope
was also needed. This was implemented by performing a proteomic anal-
ysis of the rat in vivo ischaemia-reperfusion model. Rat hearts from three
groups were investigated — control hearts with IR injury but not cell treat-
ment, hearts treated with 107 BMMNCs at the onset of reperfusion and
hearts treated with the cell vehicle (PBS) only at the onset of reperfusion.
All of the proteomic analysis of the hearts in the three groups was per-
formed by Kate Lee a PhD student in the Centre of Clinical Pharmacology
within the William Harvey Research Institute (WHRI). She was supervised
by Patricia Munroe, Professor of Molecular Medicine, and Dr Kit-Yi Leung
a Lecturer in Proteomic Medicine both at the WHRI.
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4.3.3 Functional Assessment and Survival Pathway
Investigation
A third group of experiments were performed using the I-R model and the
premise of infarct size reduction by introduction of 107 BMMNCs at the
point of reperfusion. This set of experiments were performed by Prof Ken
Suzuki’s group (Professor of Translational Cardiovascular Therapeutics)
in the Centre for Translational Medicine and Therapeutics within WHRI.
These experiments included in vivo assessment of apoptosis and necro-
sis, determination of cardiac function and cardiac fibrosis at 7 days post I-
R injury and cell treatment. Activation of the PI3K/Akt survival pathway
was also assessed using Western blot analysis.
4.4 Methods
4.4.1 Cell Culture
4.4.1.1 Cardiomyocytes
Cardiomyocytes were prepared as primary cultures from one day old
Sprague-Dawley rat pups (Harlan, U.K.).
Preparation Prior to cell collection, all reagents and equipment were pre-
pared. Initially, 30 mg of collagenase (Lorne Laboratories, U.K., LS04176)
and 600 µl pancreatin (Gibco, U.K., 45720-018) were added to 100 ml of
ADS buffer (described in §4.4.9). This mixture was placed on ice and bub-
bled with 95%O2/5%CO2. Then, 50 ml of ADS (without collagenase or
pancreatin) was placed on ice and bubbled with 95%O2/5%CO2.
Plating media and FBS (50 ml) were placed into a water bath at 37◦C.
Sterilised ADS (without collagenase or pancreatin) was placed into a Petri
dish that was used to collect the hearts.
In addition, 25 ml of FBS was filter sterilised and prepared, also, 100 ml
of enzyme digest (ADS + collagenase + pancreatin) was filter sterilised into
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two 50 ml centrifuge tubes. Finally, 12ml of sterilised FBS was aliquoted
into 6 falcon tubes (2 ml in each tube).
Heart Preparation In theory, each pup provides approximately 1 × 106
cells. Given cells are plated at 1 × 106 cells per well, a litter of pups (20)
will seed approximately 10–12 wells.
All dissecting instruments (large and small scissors, curved forceps)
were placed in a beaker containing 70% ETOH. Each pup was washed
in water and then 70% ETOH immediately before killing. Pups were
killed via cervical dislocation and decapitation. The chest cavity was then
opened with fine scissors and the hearts removed with curved forceps.
Each heart was then placed in a Petri dish with sterile ADS buffer and cut
into 4–5 pieces. Once all the hearts had been collected and minced, they
were taken to the culture hood for further preparation.
Enzyme Digestion The enzyme digestion stage of the cardiomyocyte
preparation involves multiple stages of digestion, washing, and centrifu-
gation which are repeated in a cycle until six loops have been completed.
Detailed instructions are given below and the method for enzyme diges-
tion is also shown in Figure 4.2 and in Figure 4.3.
Firstly, the “digestion flask” was prepared by washing with 10 mls of
enzyme digest (as shown in Table 4.6) and then aspirating and discarding
the digest. A 25 ml pipette was then used to aspirate the hearts and ADS
from the dissection dish and then used again to pipette the mixture into
the digestion flask.
The ADS in the digestion flask was then aspirated and exchanged for
7 ml of fresh ADS, and then repeated once more. Then, the ADS was once
more aspirated but on the third occasion was exchanged for 7 ml of en-
zyme digest and placed on a magnetic stirrer at 37◦C.
Thus starts digestion 1. The mixture was incubated for 15 mins and
then the supernatant aspirated and discarded. Following this 7 ml of en-
zyme digest was again added to the digestion flask and incubated at 37◦C
for 15 mins to start digestion 2.
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Next, the supernatant (which should now start to contain cardiomy-
ocytes) was removed once again but this time was added to 2 ml of FBS
in a 15 ml centrifuge tube. Seven ml of enzyme digest was then added to
the digestion flask and incubated for approximately 8–10 mins (the super-
natant becomes cloudy when adequate digestion has occurred) which is
digestion 3.
Simultaneously the 15 ml centrifuge tube was centrifuged at 500 × g
for 4 mins. The supernatant was discarded and the cells re-suspended in 4
ml FBS. Following this, 6 ml of FBS was added to a T-25 culture flask in a
water bath at 37◦C which became the “collection flask” the cells from the
centrifuge tube were subsequently added to this flask. After 8–10 mins di-
gestion the supernatant was removed from the digestion flask and added
to 2 ml FCS in a 15 ml centrifuge tube. The supernatant was then spun and
the cells re-suspended in 4 ml of FCS taken from the collection flask. The
cells were added to the collection flask and the pattern continued as above
until 6 digests had been pooled.
Plating Cells After all the digestion steps had been completed the
pooled cells were filtered through fine mesh into a 15 ml centrifuge tube.
The suspension was then centrifuged at 500 ×g for 4 minutes. The su-
pernatant was removed and then plating media was added to the cells
(approximately 1 ml per pup). Small aliquots were then removed from
the suspension and a cell count performed using a haemocytometer as
described in §2.3.5. The cell density was adjusted, if required, by adding
more plating media to achieve 1–1.5 × 106 cells/ml. Cells were then pre-
plated to remove fibroblasts, 5 ml of cell suspension was placed on each
10 cm Petri dish and placed in an incubator for 60 mins.
The cells were then aspirated from the plates and pooled together
in a 50 ml centrifuge tube. A cell count was performed and, if needed,
extra plating media was added to achieve a concentration of 0.5 × 106
cells/ml. Then bromo-deoxy-uridine (BrdU) (0.1 mM, Sigma, U.K., B9285)
was added to the cells (i.e., 100µl BrdU (5 ×10−2M stock) per 100 ml me-
dia).
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For each well in a 6 well plate, 2 ml of cell suspension at 0.5 × 106
cells/ml was added. The cells were left overnight in the incubator and the
media was changed the following day. The plating media was replaced
with maintenance media (shown in Table 4.3) at this juncture with the ad-
dition of 0.1 mM BrdU. All following media changes used maintenance
media.
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Figure 4.2: Neonatal Cardiomyocyte Preparation Technique using Multiple En-
zyme Digestion Steps.
Enzyme Digestion
1. Wash 100ml glass bottle containing stirrer with 10ml of enzyme digest and aspirate2. Use 25ml pipette to suck up hearts and ADS from dish and place in bottle3. Aspirate ADS and add 7ml fresh ADS, and repeat once more
STEP -1 Aspirate ADS and add 7ml enyzme digest to cells.
Incubate for 15min,37˚C, and stir
Aspirate and discard suvpernatant
STEP -2Add 7ml enzyme digest
Incubate for 15min,37˚C, and stir
Remove supernatant place in 50ml Falcon tube then and add to 2ml of FCSCentrifuge supernatant at 700rpm for 4 min
STEP -3Add 7ml enzyme digest
Incubate for 8-10 min,37˚C, and stir
Discard supernatantand resuspend cells in 4ml FCS
Add 6ml FCS to small flask and add cells to flask
Remove supernatant place in 50ml Falcon tube then and add to 2ml of FCSCentrifuge supernatant at 700rpm for 4 min
STEP -4Add 7ml enzyme digest
Incubate for 8-10 min,37˚C, and stir
Discard supernatantand resuspend cells in 4ml FCS
Add cells to flask. Placein incubator
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Figure 4.3: Cardiomyocyte preparation continued. . .
Remove supernatant place in 50ml Falcon tube then and add to 2ml of FCSCentrifuge supernatant at 700rpm for 4 min
STEP -5Add 7ml enzyme digest
Incubate for 8-10 min,37˚C, and stir
Discard supernatantand resuspend cells in 4ml FCS
Add cells to flaskPlace in incubator
Remove supernatant place in 50ml Falcon tube then and add to 2ml of FCSCentrifuge supernatant at 700rpm for 4 min
STEP -6Add 7ml enzyme digest
Incubate for 8-10 min,37˚C, and stir
Discard supernatantand resuspend cells in 4ml FCS
Add cells to flaskPlace in incubator
Remove supernatant place in 50ml Falcon tube then and add to 2ml of FCSCentrifuge supernatant at 700rpm for 4 min
STEP -7Add 7ml enzyme digest
Incubate for 8-12 min,37˚C, and stir
Discard supernatantand resuspend cells in 4ml FCS
Add cells to flaskPlace in incubator
Remove supernatant place in 50ml Falcon tube then and add to 2ml of FCSCentrifuge supernatant at 700rpm for 4 min
Discard supernatantand resuspend cells in 4ml FCS
Add cells to flaskPlace in incubator
STEP -4ContinuedAfter digestion
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4.4.1.2 Human Umbilical Vein Endothelial Cells
Primary cultures of human umbilical vein endothelial cells (HUVECs)
were purchased externally, as pooled, cryopreserved ampules with
>500,000 cells/amp, in EGM (CC-2519, Cambrex, U.K.).
When needed, cells were thawed as described in §2.3.4. Thawed cells
were seeded in culture wells at the manufacturers recommended density,
e.g., for a six well culture plate the recommended seeding density is 10,000
cells/cm2, each well has an area of 9.6 cm2, therefore, each well was seeded
with a total of 96,000 cells per well.
All HUVECs were cultured in endothelial growth media (EGM, CC-
3024 from Cambrex, U.K) plus additional supplements using the EGM-2
bulletkit (CC-3162, Cambrex, U.K.). Constituents of the EGM-2 bulletkit
are shown in §4.4.2.2.
4.4.1.3 Whole Bone Marrow and Bone Marrow Mononuclear Cell
Collection
Whole bone marrow and bone marrow mononuclear cells were collected
and cultured as set out in §2.2.
4.4.1.4 Human Whole Bone Marrow and Bone Marrow Mononuclear
Cell Collection
Human bone marrow and mononuclear cells were taken from research
samples made available from the REGENERATE trials by Prof. Anthony
Mathur (Yeo & Mathur, 2009).
For bone marrow collection, patients were placed in the right lateral
position. Under sterile conditions, the skin over the iliac crest of the pelvis
was anaesthetised with lignocaine. All syringes and the bone marrow tro-
car were pre-coated with saline containing Heparin at 1000 units/ml. At
a point mid-way between the anterior superior iliac spine (ASIS) and the
posterior iliac spine. The bone trocar was pushed through a prior skin in-
cision and subcutaneous tissues aiming towards the ASIS. Once within
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the bone marrow cavity aspiration of bone marrow was performed with
a total collection of 100 ml being made. On completion, a thick dressing
was applied with firm pressure to the wound site. The patient was then
advised to lie on their back for at least 30 minutes before mobilising to
ensure that adequate pressure had been maintained on the wound to min-
imise bleeding.
The bone marrow was then transferred immediately to the Stem Cell
Laboratory at St. Bartholomew’s Hospital in a polystyrene box with the
bone marrow kept at room temperature.
Small samples of the bone marrow were taken from the bone marrow
harvest for basic science research purposes. Samples were either stored
as whole bone marrow or further processed using the Ficoll-Paque den-
sity centrifugation separation technique to isolate the MNC population.
For storage, both samples were washed in 0.9% saline to give a cell pel-
let which was then reconstituted in 10 ml autologous serum and frozen
in an equal volume of freezing media consisting of 20% DMSO in 4.5%
HAS/autologous serum. This was then frozen down in a control rate
Thermo freezer using pumped liquid nitrogen and stored in a Dewar at
-170◦C in liquid nitrogen vapour.
4.4.2 Cell Medias
4.4.2.1 DMEM and MCDB Medias
A mixture of DMEM and MCDB was used as the media for culture of
WBM and BMMNCs. Using MCDB 201 powder (Sigma, U.K., M6770 ) 1.77
g was weighed out and added to 100 ml of distilled water (see Table 4.1
for composition of MCDB). Initially, the solution was made up to 90 ml,
and then the pH was adjusted to 7.4 with concentrated NaOH, and finally
was made up to 100 ml. This solution was then filtered through a 0.2 µ fil-
ter. DMEM-Low Glucose (DMEM-LG), from Gibco, was then mixed with
the MCDB solution in the following ratio 40 parts MCDB 201 to 60 parts
DMEM-LG. FBS was then added to produce a final concentration of 20%
FBS.
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Table 4.1: Composition of MCDB
COMPONENT g/L
INORGANIC SALTS
NH4VO3 0.000000006
CaCl2•2H2O 0.294
CuSO4•5H2O 0.00000025
FeSO4•7H2O 0.001668
MgSO4 (anhyd) 0.18057
MnSO4 0.000000075
(NH4)2MO4•4H2O 0.000000618
NiCl2•6H2O 0.0000000012
KCl 0.22365
NaCl 7.597
NaSiO3•9H2O 0.000142
Na2HPO4 (anhyd) 0.07099
Na2SeO3 0.000000865
ZnSO4•7H2O 0.000028744
AMINO ACIDS
L-Alanine 0.00891
L-Arginine•HCl 0.0632
L-Asparagine•H2O 0.150
L-Aspartic Acid 0.01331
L-Cysteine•HCl•H2O 0.03513
L-Glutamic Acid 0.01471
L-Glutamine 0.14615
Glycine 0.00751
L-Histidine•HCl•H2O 0.02097
L-Isoleucine 0.01312
L-Leucine 0.03935
L-Lysine•HCl 0.03654
L-Methionine 0.00448
L-Phenylalanine 0.00496
L-Proline 0.00576
L-Serine 0.03153
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Table 4.2: Reagents added to EGM using the EGM-2 bulletkit.
Reagent Volume (ml)
Foetal Bovine Serum 10
Vascular Endothelial Growth Factor 0.5
Heparin 0.5
Hydrocortisone 0.2
Epidermal Growth Factor 0.5
Gentamicine Sulphate & Amphotericin-B 0.5
Ascorbic Acid 0.5
Long R Insulin-Like Growth Factor-1 0.5
4.4.2.2 EGM-2
EGM media was mixed with the EGM-2 bulletkit for the culture of HU-
VECS, the constituents of which are shown in Table 4.2.
4.4.2.3 Plating and Maintenance Media for Cardiomyocytes
For plating and maintenance media, Dulbeco’s Modified Eagle Medium
(Gibco, U.K., 11880-028), Medium 199 with Hank’s Salts (Invitrogen,
22350-029), and foetal bovine serum (FBS) (Gibco, U.K., 10091-148), were
mixed in the amounts as shown in Table 4.3.
Table 4.3: Constituents of plating and maintenance media for neonatal rat car-
diomyocyte culture.
Media DMEM (ml) Medium 199 (ml) Horse serum (ml) FBS (ml)
Plating 340 85 50 25
Maintenance 400 100 0 5
203
BMMNCs activate the PI3K/Akt Pathway 4.4 Methods
4.4.3 Cell Tracker Dye Labelling
Cells were labelled with the cell tracker dye carboxyfluorescein diacetate,
succinimidyl ester (CFDA SE, Molecular probes, V-12883) as described in
§2.5.
The initial method for assessing the effects of BMMNC co-cultured
cells using several flow cytometry based end-points was to label the BMM-
NCs with the cell tracker dye and subsequently use the presence of the dye
to identify the cells, these cells were then subtracted from further analy-
ses using an exclusion gate during flow cytometry analysis. Therefore, al-
though the cells would be mixed in suspension, the presence of the cell
tracker dye would allow assessment of characteristics of one individual
cell population at a time.
However, in practise as BMMNCs or WBM were added to established
cultures for only 24 hours, flow cytometry demonstrated that one PBS
wash prior to cell detachment was enough to remove more than 98%
of the cell tracker labelled BMMNCs. Hence, PBS washing of cell co-
cultures prior to cell detachment significantly reduced “contamination” of
detached cell suspension samples resulting in <2% of the assessed pop-
ulation being identified as BMMNCs labelled with the cell tracker dye
(For n=12 experiments after washing, mean ± SEM for labelled cells =
1.8 ± 0.35 %). Figure 4.4 demonstrates significant difference in number of
cell tracker labelled cells in samples prepared without washing and with
washing).
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Figure 4.4: Histogram of green fluorescent FL1 intensity of HUVECS co-cultured
with BMMNCs labelled with cell tracker dye (CFDA SE), green line, and his-
togram of HUVECS co-cultured with BMMNCs labelled with cell tracker dye but
with washing step to remove BMMNCs prior to HUVEC cell detachment and
flow cytometry assessment.
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4.4.4 Apoptosis and Necrosis Quantification
A well known flow cytometry method was used to quantify apoptosis
and necrosis of cultured cells. Cells to be tested were dual stained with
propidium iodide (PI) which is only taken up by necrotic cells and with
Annexin-V conjugated to FITC which specifically binds to cells undergo-
ing apoptosis. Thus, staining cells simultaneously with FITC-Annexin V
(green fluorescence) and PI (red fluorescence) allows (bivariate analysis)
the discrimination of intact cells (FITC-PI-), early apoptotic (FITC+PI-) and
late apoptotic or necrotic cells (FITC+PI+).
Initially, the PI was prepared. The stock solution of PI (Molecular
Probes, U.K, P3566) was diluted in HEPES buffer (see Table 4.5) as per
the manufacturers guidelines.
Cells to be tested were detached from their culture dishes by washing
with PBS (which first removes any added WBM or BMMNCs) and then in-
cubating with Accutase for 5 mins. Cells were then aspirated and pipetted
into a centrifuge tube that was then spun at 500 × g for 5 minutes. Cells
were re-suspended in cell media. For controls, either 20% FCS was added
to FACS tubes or 1 mM Staurosporine (Sigma, U.K, S4400) that induced
apoptosis and was used as a positive control (Kabir et al., 2002). The cells
were then left to incubate for three hours.
The cells were then pelleted by a 500 × g spin and then washed in cold
PBS. A cell count was then performed. The cells were pelleted once more
and then re-suspended in HEPES buffer at 1×106 cells/ml.
Then, 100 µl aliquots of the HEPES buffer cell suspension were added
to each FACS tube. Following this, 5 µl of Annexin-V-FITC (Molecular
probes, U.K., A13199) was introduced into each tube. The cells were then
incubated in a dark box for a total of 15 minutes and PI was added to each
for the last 5 mins of the incubation. To finish, 400 µl of HEPES buffer was
added to each sample. Samples were then taken for analysis on the CyAn
ADP flow cytometer (see §2.4.1 for further information).
For analysis, the SSC and FSC were collected. Annexin V-FITC was
detected in the FL1 green channel (520 nm) and PI in FL3 the deep red
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channel (650 nm).
A bivariate dot plot was used to analyse the collected data, with FL1-
FITC on the x axis and FL3-PI on the Y axis. Four quadrants were then
drawn within the dot plot. The four quadrants were then quantified for
percentage of the total cells contained within each quadrant. Thus normal
or “alive” cells were found in the lower left quadrant (FITC-lo, PI-lo), in
the lower right quadrant apoptotic cells were found (FITC-hi, PI-lo), and in
the right upper quadrant late apoptotic or “dead” cells were found (FITC-
hi, PI-high).
4.4.5 Reactive Oxygen Species Quantification
Reactive oxygen species (ROS) within cultured cells was quantified
with flow cytometry and the use of a green fluorescent dye 5-
(and-6)-chloromethyl-2,7-dichlorodihydrofluorescein diacetate, acetyl es-
ter (CM−H2DCFDA) (Invitrogen, U.K., C6827). ROS can be detected by
the redox-sensitive fluorescent dye CM−H2DCFDA as the dye is resis-
tant to oxidation and non-fluorescent in reduced form but is membrane-
permeable. Once within a cell, esterases cleave acetate groups from the
dye. Reactive chloromethyl groups in the dye then bind to cellular thi-
ols trapping the dye inside the cell where oxidation causes conversion to
the more hydrophilic non-fluorescent reduced dye 2,7-dichlorfluorescein
(DCFH), which is then rapidly oxidised to form a two-electron oxidation
product, the highly fluorescent 2,7-dichlorfluorescein (DCF) in a reaction
with the oxidising species H2O2 (Shanker et al., 2004). The dye now in its
green fluorescent form can be excited at 502 nm and subsequently emits at
523 nm.
CM−H2DCFDA is oxidised by cellular hydrogen peroxide, hydroxyl
radicals, and various free radical products lying downstream from hy-
drogen peroxide. It is relatively insensitive to oxidation by superox-
ide (Royall & Ischiropoulos, 1993). However, hydrogen peroxide is pro-
duced by dismutation of superoxide (Halliwell & Gutteridge, 1999). Thus,
CM−H2DCFDA serves as an indirect marker of superoxide production.
207
BMMNCs activate the PI3K/Akt Pathway 4.4 Methods
Hence, ROS quantification using this dye represents mostly hydrogen per-
oxide, hydroxyl radicals, or their downstream free radical products.
Extensive and successful use of CM−H2DCFDA for measuring cel-
lular ROS is well documented (Liu et al., 2001; Madhavan et al., 2006;
O’Donovan et al., 2005; Ohashi et al., 2002; Shanker et al., 2004). Fur-
thermore, compared to other DCF dyes, the chloromethyl group in
CM−H2DCFDA gives it better cell retention and a more reliable fluores-
cent signal in live cells. This made it a good candidate for use here (Liu
et al., 2001).
To quantify ROS in cultured cells, CM−H2DCFDA was added to cul-
ture media to a final concentration of 10 µM. The old culture media was
then removed and the new media containing the ROS dye was added to
the cells which were then incubated for 20 mins in the dark at 37◦C. The
cells were then washed with PBS and subsequently detached by 5 mins in-
cubation with Accutase. The cells were then aspirated with a pipette and
placed directly in FACS tubes and taken to the flow cytometry room in a
box for light protection. The negative controls were cells without dye and
positive controls were cells incubated with dye and H2O2 (Sigma, U.K,
H-6520) at a concentration of 100 µM.
All samples were analysed on the CyAn ADP flow cytometer using 488
nm excitation and a 530/40 nm bandpass emission filter (see §2.4.1). For
analysis, the median of fluorescence intensity from the FL1 channel was
taken as ROS generation. Quantitative assessment of ROS generation was
performed by normalisation to the control group.
4.4.6 Mitochondrial Membrane Potential Assessment
Mitochondrial membrane potential (∆Ψm) was assessed with the tetram-
ethylrhodamine ethyl ester, percholate (TMRE) (Invitrogen, U.K., T-669).
TMRE is a derivative of rhodamine 123 and has been used to quantify
∆Ψmby fluorescence imaging (Ehrenberg et al., 1988; Loew et al., 1993).
Much like rhodamine it is a cell-permanent lipophilic cation and it emits
red-orange fluorescence at 574 nm and absorbs at 549 nm. TMRE accumu-
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lates proportionally, rapidly and reversibly in the mitochondria of living
cells due to the negative ∆Ψm of the mitochondria with respect to the cy-
tosol. Therefore, it serves as a “Nernstian” indicator of ∆Ψm, as mitochon-
drial depolarisation results in a loss of dye from the mitochondria and
a decrease in mitochondrial fluorescence intensity (Budinger et al., 1998;
Chen, 1988; Ehrenberg et al., 1988; Levraut et al., 2003; Loew et al., 1993;
O’Reilly et al., 2003).
It is of interest that the when TMRE and other rhodamine derivatives
are used at higher concentrations, e.g., at micromolar concentrations, rho-
damines can accumulate to levels inside mitochondria at which fluores-
cence self-quenching is obtained. This is caused by the enhanced dissipa-
tion of excitation energy by the high probability of molecular collisions
and the formation of dye aggregates with altered fluorescence properties.
Under these circumstances, paradoxically, mitochondrial depolarisation
(causing movement of dye into the cytosol) can produce an increase of flu-
orescence as the intramitochondrial dye levels decrease to levels at which
self-quenching is reduced. Although there are useful measurements that
can be made using this dequenching approach, this may not be the case
if the phenomenon is unwittingly induced. Therefore, unless purposeful
dequenching is being sought, using the lowest feasible dye concentration
possible is likely to produce the most robust experiments (Zorov et al.,
2004).
For assessment of mitochondrial membrane potential, TMRE was
made up in cell culture media at a final concentration of 40 nm. There-
fore, initially the old media was removed and discarded. Fresh media with
TMRE was then added to each culture well and incubated for 30 mins at
37◦C. The wells were then washed with warm PBS and then 1 ml of Accu-
tase was added to each well and incubated until the cells were seen to de-
tach and float freely in the cell media. The subsequent cell suspension was
removed and transferred into FACS tubes for analysis on the flow cytome-
ter. Again, the CyAN ADP flow cytometer was used. The 488 nm laser was
used for excitation and fluorescent intensity of the TMRE was recorded
in the FL2 channel using a 575/25 nm bandpass filter. For negative con-
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trols the uncoupling agent carbonyl cyanide m-chlorophenylhydrazone
(mClCCPC) was also added to cells at 50 µM final concentration and incu-
bated for 30 minutes.
4.4.7 Cell Cycle Quantification
4.4.7.1 Propidium Iodide Characteristics
Propidium iodide (PI) staining with subsequent flow cytometry was used
to assess the cell cycle. The foundation of this technique is that the stained
material incorporates an amount of dye proportional to the amount of
DNA. The stained material is then measured in the flow cytometer and the
emitted fluorescent signal yields an electronic pulse with a height (ampli-
tude, often termed intensity) proportional to the total fluorescence emis-
sion from the cell. Thereafter, such fluorescence data are considered a mea-
surement of the cellular DNA content.
Thus, the key feature of DNA probes is that they are stoichiometric,
whereby the number of molecules of the probe bound is equivalent to the
number of molecules of DNA found. In fact, PI binds to DNA by interca-
lating between bases with a stoichiometry of one dye per 4–5 base pairs
of DNA. Hence, when PI binds to DNA bases, the intensity of the fluo-
rescence emitted will reflect the DNA content in such PI-labelled nuclei.
Other important properties of PI include binding to RNA, necessitating
treatment with nucleases to distinguish between RNA and DNA staining.
PI is membrane impermanent and generally excluded from viable cells,
therefore, cell lysis for DNA staining is required. Once PI is bound to nu-
cleic acids, its fluorescence is enhanced 20- to 30-fold, and the excitation
maximum is 535 nm and emission maximum is 617 nm. PI may be excited
by a 488 nm argon-ion laser, and is usually detected in FL2 or FL3 channel
depending on the flow cytometer set up.
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4.4.7.2 Propidium Iodide and Flow Cytometry for Cell Cycle Analysis
The use of flow cytometry with PI enables the identification of the cell
distribution during the various phases of the cell cycle. The emitted flu-
orescent light of PI generates an electronic signal that can be recorded
for its intensity (FL3) but can also be measured for pulse-area (FL3A) and
pulse-width (FL3W) of the samples. By plotting the FL3W versus FL3A in
a dot plot graph, a discrimination of a G1 doublet from a G2/M single can
be made. This discrimination is important, as if a sample contains many
doublets this could mistakenly increase the relative number of cells in the
G2/M-phase of the cell cycle, yielding an overestimation of G2/M popu-
lation. Since the FL3W increases with the diameter of the doublet particle
while both the G1 doublet and the G2/M single produce a same FL3A sig-
nal is likely to discriminate the doublet from the single cell. Therefore, in
the dot plot graph of area vs width a gate should be set around the sin-
gle population. The histogram graph of the gated population should then
show the four distinct phases that can be recognised in a proliferating cell
population the G0/G1-, S- (DNA synthesis phase), G2- and M-phases (mi-
tosis). The percentage of cells in G1, S phase and G2/M can then either be
estimated subjectively with applied region markers or by using a program
that will mathematically deconvolute the DNA histogram and thus give a
more accurate measurement of the percentage of cells in each phase.
Aside from excluding doublets from cell cycle analysis, there are two
instrument settings that are important to consider. The first is the adjust-
ment of acquisition to exclude debris which allows the flow cytometer
more time for the particles of interest, i.e, optimises acquisition speed.The
second, is the acquisition speed, for high accuracy measurements a low
speed of around 50 events per second is advisable. If the speed is increased
too much, peaks in the histograms may become wider as a result of de-
creasing accuracy. On the contrary, if the speed is too low, particle sedi-
mentation effects can influence a counting result. Acquisition speed can
be varied by direct manipulation of acquisition parameters on the flow cy-
tometer or by changing the density of the cells suspension being analysed.
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Figure 4.5: Example of FL3 intensity Histogram obtained during assessment of
the cell cycle with propidium iodide
4.4.7.3 PI Staining Method
For the experiments describe here, cell cycle analysis was performed by
first removing the old culture media from the plates. Each well was
washed with PBS at 37◦C and then cells were incubated with Accutase for
5 mins. Each plate was knocked sharply to loosen the cells, detachment
was checked under an inverted microscope. Cells were subsequently col-
lected into centrifuge tubes and pelleted at 500 × g for 5 mins. Cells were
then resuspended in culture media at 106 cells/ml which was checked by
performing a cell count. Cells were then pelleted again and resuspended
in 200µl of cold PBS (approx 4◦C) and vortexed. Two mls of ice cold 70%
ETOH was added to the samples and left for at least 30 mins on ice. Cells
were then pelleted with 5 min of centrifugation at 300 × g and resus-
pended in 400µl of PBS, cells were checked for clumping and if found
were passed through a 25 G needle. Following this 50 µl of RNase at 1
mg/ml (Sigma, U.K., Ribonuclease A, R5000), and 50 µl of PI at 400 µg/ml
(Invitrogen, U.K., P3566) were added to the cells and incubated for 30 min
at 37◦C.
Samples were processed on the Dako CyAN ADP flow cytometer us-
ing the 488 nm excitation laser. The flow rate was adjusted to a slow rate,
aiming for 50 events per second. PI fluorescence was detected in FL3, us-
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ing the PE-Texas Red/PI bandpass filter of 613/20 nm. A Plot of PI Area
vs PI Lin was constructed and then used to exclude doublets by drawing
the appropriate gate. A histogram plot of PI fluorescence was then formed
and three regions were added to this R1, R2, and R3. Thus, G0/G1 was
calculated as 2 × R2, G2 as 2 × R3, and S phase as R1 - (2 ×R2) - (2×R3).
4.4.8 Cardiomyocyte Immunohistochemistry
Isolated and cultured cardiomyocytes were stained with a cardiomy-
ocyte specific antibody to assess the quality of the cultures obtained. The
cells were fixed and prepared for immunohistochemistry as described in
§2.9.1.9.
When ready, the cardiomyocyte cultures were permeabilised for 15
minutes in 0.5% Triton-X-100 in PBS at room temperature. The cultures
were washed in PBS twice for 5 minutes. The primary antibody (Troponin
I, Mouse IgG anti-human Troponin I1, Chemicon, USA, MAB3150) was
then added and incubated with the cells for 45 mins at 1:1000 dilution in
PBS at room temperature. Following three 5 minute PBS washes, the sec-
ond layer (Biotinylated rabbit anti-mouse IgG, Dako, E0354) was added
for 35 minutes at 1:300 dilution. A further three five minute PBS washes
were then performed. The tertiary layer Streptavidin-HRP (Dako, P0397)
was then incubated for 35 minutes at 1:500 dilution. A final three washes
with PBS were then performed prior to addition of the chromagen 3,3’-
diaminobenzidine (DAB, Sigma, D6815, 5 mg in 10 ml PBS plus 20 µl of
30% H2O2) for 2 minutes. Finally, the cells were washed in tap water and
counterstained.
4.4.9 Reagents and Materials
ADS Buffer
A 500 ml bottle of sterilised water was used to make the ADS buffer by
adding the salts, glucose, and HEPES in the quantities as shown in Ta-
1Also reacts with other species including rats and mice.
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ble 4.4. The buffer was filtered through a 0.22µm filter, and stored at 4◦C.
ADS buffer was freshly prepared for each new batch of cardiomyocytes.
Table 4.4: Ingredients for ADS buffer.
Weight (g) Ingredient Final Concentration (mM)
3.4 NaCl 116
2.38 HEPES 19.9
0.06 NaH2PO4 0.76
0.5 Glucose 5.5
0.2 KCl 5.4
0.05 MgSO4 0.4
To Finish adjust pH to 7.35 with 1M NaOH
HEPES Buffer
Table 4.5: Constituents of HEPES Buffer.
In 500 mls of distilled water, the following were added:
Weight (g) Ingredient
1.19 HEPES
4.09 NaCl
0.1387 CaCl2
pH = adjusted to 7.4
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Antibiotics
Penicillin and streptomycin (Sigma, U.K., P0781) were added to a final
concentration of 1% to all culture media used.
Enzyme Digestion Mix
To digest the neonatal pup hearts, an enzyme mix, filtered through a 0.2µm
filter, of pancreatin (Gibco, 45720-018), collagenase (Lorne Laboratories,
LS004176), and ADS buffer was used in the quantities shown in Table 4.6.
Upon receipt of pancreatin, it was filter sterilised, aliquoted into 700 µl
batches and stored in eppendorf tubes in a 20◦C freezer.
Table 4.6: Enzyme digestion mix for neonatal rat cardiomyocyte harvest.
Component Quantity
Pancreatin 0.6 g
Collagenase 0.03 g
ADS Buffer 100 ml
All filtered through 0.2µm filter
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4.4.9.1 Reagents
Table 4.7: Table of all other reagents, equipment, and materials used in cardiomy-
ocyte culture
Item Supplier Product Code
5-bromo-2-deoxyuridine (BrdU) Sigma B9285
Small scraper BDH 402/0378/04
Collagenase Type 2 Lorne Laboratories LS04176
Pancreatin 4X N.F. (10X) Liquid Gibco 45720-018
Dulbeco’ss MEM without Phenol red Gibco 11880-028
Medium 199 Gibco 21151-030
Glass Pasteur pipettes BDH 241/2559/00
Filter Disc, 0.22 25mm Millipore SLGPR25LS
Filter Disc, 0.45 25mm Millipore SLHA025BS
Horse Serum Gibco 16050-098
Foetal Bovine Serum (NZ) Gibco 10091-148
Trypsin 0.025%/EDTA 0.01% BioWhittaker BW-5012
Trypsin Neutralising solution BioWhittaker BW5002
HEPES buffer solution, 1M liquid Gibco 15630-056
Cover glasses, circular BDH 406/0189/76
Collagen type IV Sigma C0543
Hydrogen cyanamide Sigma C1920
Acetic acid, glacial Sigma A6283
Primaria 6-well tissue culture plate Falcon (Becton Dick) 3846
Primaria 90x20mm cell culture Petri dish Falcon F3803
T/C Dish 100mm Marathon F3003
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4.5 HUVEC Results
4.5.1 Reactive Oxygen Species
4.5.1.1 Reactive Oxygen Species Measurement in HUVECS Co-
cultured with Human Whole Bone Marrow and Bone Marrow
Mononuclear Cells
Human Whole Bone Marrow Quantification of reactive oxygen species
(ROS) demonstrated no differences between the mean fluorescent inten-
sity of control HUVECs (153.7±19.05) compared to HUVECS co-cultured
for 24 hours with hWBM (152±19.3). Normalised data generated by di-
viding the mean fluorescent intensity of each experimental result by its
corresponding control result showed, on average, a non-significant drop
of 0.01% in ROS generation in the co-cultured cells (See Figure 4.6).
The experiment was repeated with the addition of 100 µM H2O2 to both
the control HUVEC group and to the HUVECS co-cultured with hWBM
for 24 hours. This resulted in an increase in ROS in the control group
(520.1±67.35) and in the co-culture group (292.7±28.44) compared to the
control HUVECS cultured without H2O2. The normalised data show a sig-
nificant 3.4 fold increase in the mean for the controls (p<0.0001) and a 1.9
fold increase in the mean for the hWBM treated cells (p=0.0001, see Fig-
ure 4.6).
The difference of the normalised means between controls treated with
H2O2 (3.39±0.44) and the H2O2 treated HUVECS co-cultured with hWBM
(1.91±0.19) is significant (p<0.0001). This represents a ≈44% drop in ROS
detection when HUVECS, subjected to 100 µM H2O2, are co-cultured with
hWBM for 24 hours.
Human Mononuclear Cells A significant difference (p=0.0152) was seen
between the mean intensity of the fluorescent dye measured in control
HUVECS (162.5±11.23) and the HUVECS co-cultured for 24 hours with
hMNCs (155.1±11.42). When the data was normalised the difference be-
tween the groups remained significant (p=0.01) and it was noted that the
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Figure 4.6: Normalised mean fluorescence intensity of reactive oxygen species. In
HUVECS co-cultured with human whole bone marrow (hWBM) with and with-
out 100 µM H2O2. All data were normalised against results from control HUVECS
receiving no treatments.F Indicates significant differences in sample means of
p=0.0001 over the mean of the controls.= Indicates a significant difference of the
sample mean of p<0.0001 against control samples treated with 100 µM H2O2.
mean normalised intensity of HUVECS co-cultured for 24 hours with hM-
NCs was ≈5% lower than the control value (see Figure 4.7).
In the H2O2 addition experiments, no significant difference was seen
between the means of the control and hMNC added groups (197.30±11.57
and 189.10±10.42 respectively, Table 4.9).
After normalisation, there remained no significant difference between
the H2O2 control and hMNC added groups. However, there was a signifi-
cant difference between the HUVEC control groups with and without in-
cubation with 100 µM H2O2 (p=0.0299, see and Figure 4.7). This difference
was reduced, not significantly, after 24 hours co-culture with hMNCs.
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Figure 4.7: Normalised mean fluorescence intensity of reactive oxygen species. In
HUVECS co-cultured with human mononuclear cells (hMNCs) with and without
100 µM H2O2. All data were normalised against results from control HUVECS
receiving no treatments. The symbols indicate significant differences in sample
means of Fp=0.01 and =p=0.0299 over the mean of the control HUVECS not incu-
bated with H2O2.
Table 4.8: Descriptive statistics of the mean fluorescence intensity of reactive oxy-
gen species dye (CM-H2DCFDA) measured in the FL1 channel. In HUVECS co-
cultured with human whole bone marrow with and without 100 µM H2O2.
HUVECS HUVECS & 100 µM H2O2
Control Plus hWBM Control Plus hWBM
n 6 6 18 18
Mean 153.70 152.00 520.10 292.70
SEM 19.05 19.30 67.35 28.44︸ ︷︷ ︸ ︸ ︷︷ ︸
P value Not significant 0.0002
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Table 4.9: Descriptive statistics of the mean fluorescence intensity of reactive
oxygen species dye (CM-H2DCFDA) measured in the FL1 channel. In HUVECS
co-cultured with human mononuclear cells (hMNCs) with and without 100 µM
H2O2.
HUVECS HUVECS & 100 µM H2O2
Control Plus hMNCs Control Plus hMNCs
n 6 6 6 6
Mean 162.50 155.10 197.3 189.10
SEM 11.23 11.42 11.57 10.42︸ ︷︷ ︸ ︸ ︷︷ ︸
P value 0.0152 Not significant
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4.5.1.2 Reactive Oxygen Species Measurement in HUVECS Co-
cultured with Rat Whole Bone Marrow and Bone Marrow
Mononuclear Cells
The effects of co-culturing HUVECS with rat whole bone marrow (rWBM)
and rat bone marrow mononuclear cells (rMNCs) on production of ROS
within the HUVECS was also investigated.
Rat Whole Bone Marrow The mean fluorescent intensity of the ROS dye
was exactly the same in control HUVECS and in HUVECS co-cultured
for 24 hours with rWBM (124.5±4.52 and 124.5±4.22, see Table 4.10). After
normalisation of the data, the mean of the co-cultured cells remained equal
to that of the control data (1±0.01, see Figure 4.8).
Reproducing the experiment in the presence of 100 µM H2O2 revealed
a non-significant reduction between the control group (349.40±29.61) and
the rWBM treated group (288.5±11.6, see Table 4.10). Normalisation of
this data concurred that the H2O2 treated rWBM group’s mean was nu-
merically lower than the mean of the H2O2 control group but this was
not found to be significant. However, both the H2O2 treated groups
mean values, controls (2.8±0.24, p=0.0006) and rWBM treated (2.32±0.09,
p<0.0001), significantly increased compared to the control HUVECS not
treated with H2O2 (see Figure 4.8).
Rat Mononuclear Cells No significant difference was observed between
the mean intensities measured in the control HUVEC group (94.8±1.46)
and the rMNCs HUVEC co-culture group (93.14±1.71, see Table 4.11).
Likewise, the normalised data demonstrated no significant difference be-
tween the control and treatment group means (see Figure 4.9).
Following treatment with 100 µM H2O2 a significant increase in the
means of the control H2O2 and rMNC co-culture H2O2 groups were seen
above that of the control HUVEC group. Normalisation of the data (as
shown in Figure 4.9) demonstrated that this was a 1.4 fold increase for the
H2O2 control group (p=0.0003) and a 1.3 fold increase for the H2O2 rMNC
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Figure 4.8: Normalised mean fluorescence intensity of reactive oxygen species
dye. In HUVECS co-cultures with rat whole bone marrow (rWBM) with and with-
out 100 µM H2O2.
Table 4.10: Descriptive statistics of the mean fluorescence intensity of reactive
oxygen species dye (CM-H2DCFDA) measured in the FL1 channel. In HUVECS
co-cultured with rat whole bone marrow (rWBM) with and without 100 µM
H2O2.
HUVECS HUVECS & 100 µM H2O2
Control Plus rWBM Control Plus rWBM
n 6 6 6 6
Mean 124.50 124.50 349.40 288.50
SEM 4.52 4.22 29.61 11.60︸ ︷︷ ︸ ︸ ︷︷ ︸
P value Not significant Not significant
treatment group (p=0.0007) over the non-hydrogen peroxide treated HU-
VEC control. As seen with the cell types hMNCs and rWBM there was
also a numerically lower mean found in the rMNC treated H2O2 group
compared to the HUVECs alone H2O2 group, which was not statistically
significant unlike the significant decrease seen with hWBM.
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Figure 4.9: Normalised mean fluorescence intensity of reactive oxygen species
dye. In HUVECS co-cultures with rat mononuclear cells (rMNCs) with and with-
out 100 µM H2O2.
Table 4.11: Descriptive statistics of the mean fluorescence intensity of reactive
oxygen species dye (CM-H2DCFDA) measured in the FL1 channel. In HUVECS
co-cultured with rat mononuclear cells (rMNCs) with and without 100 µM H2O2.
HUVECS HUVECS & 100 µM H2O2
Control Plus rMNCs Control Plus rMNCs
n 6 6 6 6
Mean 94.80 93.14 133.70 123.70
SEM 1.46 1.71 4.33 3.89︸ ︷︷ ︸ ︸ ︷︷ ︸
P value Not significant Not significant
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4.5.2 Mitochondrial Membrane Potential
The red fluorescent dye, TMRE, was used to assess mitochondrial mem-
brane potential (∆Ψm). The effects of co-culturing HUVECS for twenty-
four hours with hWBM, hMNCs, rWBM, and rMNCs on HUVECs ∆Ψm
was investigated. In each case HUVECS cultured under the same condi-
tions accept addition of the human or rat bone marrow cells acted as con-
trols.
4.5.2.1 Mitochondrial Membrane Potential Quantification in HUVECS
Co-cultured with Human Whole Bone Marrow or Human Bone
Marrow Mononuclear Cells
Human Whole Bone Marrow Control HUVECs, grown under stan-
dard culture conditions, were found to have a significantly higher mean
∆Ψm when compared to the mean ∆Ψm of HUVECs cultured under the
same conditions except for co-culture with hWBM for 24 hours prior
to the mitochondrial membrane potential assessment (n=12, normalised
mean=0.98±0.01, p=0.0156, see Figure 4.10). All data was normalised
against the paired control value. Although the result is statistically signifi-
cant, the magnitude of difference is small and thus may not be biologically
important.
Human Mononuclear Cells In contrast to the results obtained with
hWBM, no significant difference was noted between the mean ∆Ψm of
control HUVECs or that of HUVECs co-cultured for 24 hours with hM-
NCs (n=12, normalised mean=1±0.01, see Figure 4.10), as before all data
was normalised against paired controls.
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4.5.2.2 Mitochondrial Membrane Potential Quantification in HUVECS
Co-cultured with Rat Whole Bone Marrow or Rat Bone Marrow
Mononuclear Cells
Rat Whole Bone Marrow The mean normalised ∆Ψm of HUVECs co-
cultured with rWBM was found to be significantly greater than that of the
HUVEC controls (n=12, normalised mean=1.03±0.01, p=0.0002, see Fig-
ure 4.11), all data was normalised with respect to controls. The finding of
a significant increase of the ∆Ψm is in direct contrast to the significant de-
crease in ∆Ψm seen with addition of the hWBM cells. As with hWBM, the
magnitude of change is slight and therefore difficult to evaluate its biolog-
ical significance.
Rat Mononuclear Cells Unlike the rWBM cells, the rMNCs produced
no significant increase or decrease in the mean normalised ∆Ψm (n=12,
normalised mean=1.01±0.01, see Figure 4.11). As before, all data was nor-
malised against the paired control sample. This result concurs with that
found with 24 hour co-culture with hMNCs which also did not produce
any significant changes in the mean normalised ∆Ψm of the HUVECS.
4.5.3 Apoptosis and Necrosis
A combination of either Annexin-V, conjugated to FITC, and PI, or
Annexin-V, conjugated to R-PE, with To-Pro-3 was used to assess the
amount of apoptosis and necrosis among co-cultures of HUVECs. The
HUVECS were cultured alone or together for 24 hours with one of the
following cells: hWBM, hMNCs, rWBM, or rMNCs.
4.5.3.1 Quantification of Apoptosis and Necrosis in HUVECS Co-
cultured with Human Whole Bone Marrow or Human Bone
Marrow Mononuclear Cells.
Human Whole Bone Marrow When HUVECS were co-cultured with
hWBM for 24 hours, necrosis was seen to decrease significantly compared
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Figure 4.10: Graph showing the mean normalised fluorescence intensity of TMRE
dye measured in the FL2 channel. HUVECS were co-cultured with either human
whole bone marrow (hWBM) cells or human mononuclear cells (hMNCs). F Sig-
nifies significant difference compared to control sample mean, p value<0.005.
Figure 4.11: Graph showing the mean normalised fluorescence intensity of TMRE
dye measured in the FL2 channel. In HUVECS co-cultured with either rat whole
bone marrow (rWBM) cells or rat mononuclear cells (rMNCs). FF Signifies sig-
nificant difference from the control sample mean, p value<0.001
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to the control samples (n=12, 0.8±0.08% vs 1.14±0.09%, P=0.0003).
No differences were seen in late apoptotic events between the
hWBM group (n=12, 17.22±0.86%) and the control group (17.49±1.09%,
P=0.7466).
However, early apoptotic events were significantly lowered by 24 hour
culture with hWBM (n=12, 3.62±0.14%) compared to the control HUVEC
group (4.29±0.12%, P=0.0012).
The number of cells defined as alive was numerically higher in the
hWBM group with respect to the control group, but this was not found
to be statistically significant (n=12, 78.35±0.89% vs Controls 77.08±1.16%,
P=0.1649).
The raw data for apoptosis and necrosis in HUVECS co-cultured with
hWBM can be seen in Table 4.12 and data normalised against the paired
control can be reviewed in Figure 4.12.
Human Mononuclear Cells As found with hWBM a significantly higher
percentage of necrotic cells were found in controls (1.18±0.1%) in com-
parison to HUVECs cultured with hMNCs for twenty-four hours (n=12,
0.91±0.08%, P=0.0214).
However, no differences were seen in late apoptosis, which was ob-
served as frequently in controls (18.61±0.71%) as it was in hMNC co-
cultured HUVECS (n=12, 17.67±0.66%, P=0.1792).
In contrast, early apoptosis was significantly reduced in hMNC
co-cultured HUVECS (n=12, 4.05±0.15%) when tested against controls
(5.07±0.13%, P=<0.0001).
The proportion of cells identified as alive was significantly greater in
the hMNC co-cultured HUVECS (n=12, 77.37±0.76%) with respect to the
control HUVECS (75.14±0.77%, P=0.0198).
The raw data for quantification of apoptosis and necrosis in HUVECS
co-cultured with hMNCs can be found in Table 4.13 and normalised data
can be seen in Figure 4.13.
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Table 4.12: Descriptive statistics for percentage of necrotic, early and late apop-
totic, and alive cells in human umbilical vein endothelial cells co-cultured for
twenty four hours with human whole bone marrow (hWBM) and without (Con-
trols), n=12 for both groups.
Necrosis Late Apoptosis Early Apoptosis Alive
Control hWBM Control hWBM Control hWBM Control hWBM
Mean 1.14 0.80 17.49 17.22 4.29 3.62 77.08 78.35
SEM 0.09 0.08 1.09 0.86 0.12 0.14 1.16 0.89︸ ︷︷ ︸ ︸ ︷︷ ︸ ︸ ︷︷ ︸ ︸ ︷︷ ︸
P-value 0.0003 0.7466 0.0012 0.1649
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Figure 4.12: Graph showing the normalised mean percentage of necrotic, apop-
totic, and alive HUVEC cells co-cultured with human whole bone marrow. Re-
sults were normalised against control HUVECs cultured alone. FF Signifies sig-
nificant difference from the control sample mean, p value<0.001.
4.5.3.2 Quantification of Apoptosis and Necrosis in HUVECS Co-
cultured with Rat Whole Bone Marrow or Rat Bone Marrow
Mononuclear Cells.
Rat Whole Bone Marrow Assessment of necrosis revealed no differences
in the amount of necrosis in HUVECs cultured in isolation (3.13±0.22%)
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Table 4.13: Descriptive statistics for percentage of necrotic, early and late apop-
totic, and alive cells in human umbilical vein endothelial cells co-cultured for
twenty four hours with human mononuclear cells (hMNC) and without (Con-
trols), n=12 for both groups.
Necrosis Late Apoptosis Early Apoptosis Alive
Control hMNC Control hMNC Control hMNC Control hMNC
Mean 1.18 0.91 18.61 17.67 5.07 4.05 75.14 77.37
SEM 0.10 0.08 0.71 0.66 0.13 0.15 0.77 0.76︸ ︷︷ ︸ ︸ ︷︷ ︸ ︸ ︷︷ ︸ ︸ ︷︷ ︸
P-value 0.0214 0.1792 <0.0001 0.0198
Necrosis Late Apoptosis Early Apoptosis Alive
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Figure 4.13: Graph showing the normalised mean percentage of necrotic, apop-
totic, and alive HUVEC cells co-cultured with human mononuclear cells. Results
were normalised against control HUVECs cultured alone. F Signifies a significant
difference from the control mean with p value<0.05, and = indicates a significant
difference from the control mean with p<0.0001.
compared to HUVECs co-cultured for twenty-four hours with rWBM
(n=12, 3.13±0.43%, P=0.9697).
Also, no difference was seen in late apoptosis (6.87±0.31% vs
6.63±0.38%, P=0.4099) between controls and the co-cultured group re-
spectively. As was the case in early apoptosis (6.24±0.49% vs 6.15±0.46%,
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Table 4.14: Descriptive statistics for percentage of necrotic, early and late apop-
totic, and alive cells in human umbilical vein endothelial cells co-cultured for
twenty four hours with rat whole bone marrow (rWBM) and without (Controls),
n=12 for both groups.
Necrosis Late Apoptosis Early Apoptosis Alive
Control rWBM Control rWBM Control rWBM Control rWBM
Mean 3.13 3.13 6.87 6.63 6.24 6.15 83.77 84.09
SEM 0.22 0.43 0.31 0.38 0.49 0.46 0.68 0.98︸ ︷︷ ︸ ︸ ︷︷ ︸ ︸ ︷︷ ︸ ︸ ︷︷ ︸
P-value 0.9697 0.4099 0.8445 0.6513
P=0.8445), and in the proportion of cells measured as alive (83.77±0.68%
vs 84.09±0.98%, P=0.6513).
The raw data for apoptosis and necrosis measurement in HUVECs co-
cultured with rWBM can be viewed in Table 4.14 and data normalised to
the paired control sample can be seen in Figure 4.14.
Rat Mononuclear Cells No differences were seen in the amount of
necrosis in controls (6.81±0.53) versus HUVECS co-cultured with rMNCs
(n=12, 6.72±0.50, P=1.03).
In fact, no significant differences were seen in any of the measurements
of apoptosis and necrosis in controls compared to the co-cultured HU-
VECS; late apoptosis (6.84±0.45 vs 6.79±0.56, n=12, P=0.89), early apop-
tosis (8.53±0.41 vs 8.53±0.47, n=12, P=0.96), and proportion of alive cells
(77.82±0.91 vs 77.96±1.04, n=12, P=0.9658).
The raw data for apoptosis and necrosis for controls and for HUVECs
co-cultured with rMNCs can be found in Table 4.15 and data normalised
against controls can be seen in Figure 4.15.
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Figure 4.14: Graph showing the normalised mean percentage of necrotic, apop-
totic, and alive HUVEC cells co-cultured with rat whole bone marrow. Results
were normalised against control HUVECs cultured alone. No significant differ-
ences between co-cultured HUVECS and controls was observed.
Table 4.15: Descriptive statistics for percentage of necrotic, early and late apop-
totic, and alive cells in human umbilical vein endothelial cells co-cultured for
twenty four hours with rat mononuclear cells (rMNC) and without (Controls),
n=12 for both groups.
Necrosis Late Apoptosis Early Apoptosis Alive
Control rMNC Control rMNC Control rMNC Control rMNC
Mean 6.81 6.72 6.84 6.79 8.53 8.53 77.82 77.96
SEM 0.53 0.50 0.45 0.56 0.41 0.47 0.91 1.04︸ ︷︷ ︸ ︸ ︷︷ ︸ ︸ ︷︷ ︸ ︸ ︷︷ ︸
P-value 1.0342 0.8984 <0.9658 0.9658
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Figure 4.15: Graph showing the normalised mean percentage of necrotic, apop-
totic, and alive HUVEC cells co-cultured with rat bone marrow mononuclear
cells. Results were normalised against control HUVECs cultured alone. No sig-
nificant differences between co-cultured HUVECS and controls was observed.
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4.5.4 Cell Cycle
4.5.4.1 Cell Cycle Analysis in HUVECS Co-cultured with Human
Whole Bone Marrow or Human Bone Marrow Mononuclear
Cells
Human Whole Bone Marrow Cell cycle analysis using flow cytometry
and PI staining revealed that in control HUVECS 65.86±2.11% of cells
were in the G0/G1 phase of the cell cycle, 12.37±1.28% were in S phase
and 23.85±0.55% were found to be in G2 (See Table 4.16). When HUVECS
were co-cultured for 24 hours with hWBM no significant differences were
found in the proportion of cells in the corresponding phases of the cell
cycle. Thus in HUVECS co-cultured with hWBM 64.43±1.47% were in
G0/G1, 12.12±1.3% were in S phase, and 24.09±0.67% in G2 phase (P val-
ues respectively, 0.62, 0.87, and 0.72).
Human Mononuclear Cells As with hWBM, no statistical differences in
the phases of the cell cycle were seen between control HUVECS and the
HUVECS co-cultured with hMNCs for twenty-four hours. As such for con-
trols and co-cultured HUVECS respectively 66.24±1.92% vs 66.59±1.67%
cells were found in G0/G1, 12.39±1.64% vs 10.76±1.82% were in S phase,
and 21.80±0.78% vs 23.67±0.82% were observed in G2. P-values were all
non-significant, but may be seen in Table 4.16.
4.5.4.2 Cell Cycle Analysis in HUVECS Co-cultured with Rat Whole
Bone Marrow or Rat Bone Marrow Mononuclear Cells
Rat Whole Bone Marrow No differences in the proportion of cells
in G0/G1, S, or in G2 were seen between control HUVECs and HU-
VECs co-cultured with rWBM for 24 hours. For controls 66.57±1.77%,
11.13±1.82%, and 22.31±0.7% of cells were found in G0/G1, S, and G2
phases respectively. For the co-cultured group 63.34±2.14%, 13.49±2.01%,
and 23.17±0.78% of cells were identified within the G0/G1, S, and G2 cell
cycle phases. All P-values were non-significant, see Table 4.16.
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Table 4.16: Results of cell cycle analysis of HUVECS cultured alone (Controls) or
for 24 hours with one of the four following cell types, human whole bone marrow,
human mononuclear cells, rat whole bone marrow, or rat mononuclear cells. No
significant differences were found between any of the controls and their paired
experimental group.
G0/G1 S phase G2
Controls Plus Cells Controls Plus Cells Controls Plus Cells
Human whole bone marrow
Mean 65.86 64.43 12.37 12.12 23.85 24.09
SEM 2.11 1.47 1.28 1.30 0.55 0.67︸ ︷︷ ︸ ︸ ︷︷ ︸ ︸ ︷︷ ︸
P-value 0.6177 0.8668 0.7158
Human mononuclear cells
Mean 66.24 66.59 12.39 10.76 21.80 23.67
SEM 1.92 1.67 1.64 1.82 0.78 0.82︸ ︷︷ ︸ ︸ ︷︷ ︸ ︸ ︷︷ ︸
P-value 0.8982 0.5507 0.155
Rat whole bone marrow
Mean 66.57 63.34 11.13 13.49 22.31 23.17
SEM 1.77 2.14 1.82 2.01 0.70 0.78︸ ︷︷ ︸ ︸ ︷︷ ︸ ︸ ︷︷ ︸
P-value 0.2127 0.2215 0.6447
Rat mononuclear cells
Mean 67.72 65.31 9.46 11.94 23.34 22.75
SEM 1.76 1.55 1.58 1.74 0.96 0.89︸ ︷︷ ︸ ︸ ︷︷ ︸ ︸ ︷︷ ︸
P-value 0.3552 0.1587 0.0555
Rat Mononuclear Cells As with all of the other co-culture experiments
no differences were seen in any of the phases of the cell cycle between the
control HUVECs or the HUVECs co-cultured for 24 hours with rMNCs.
For controls G0/G1 constituted 67.72±1.76% of cells, S phase 9.46±1.58%
of cells, and G2 23.34±0.96% of cells. In comparison for co-cultured cells
G0/G1 was 65.31±1.55%, S phase 11.94±1.74%, and G2 22.75±0.89% of
cells. No P-values were significant as shown in Table 4.16.
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4.6 Cardiomyocyte Results
4.6.1 Cardiomyocyte Histology
The success of cardiomyocyte primary cell culture was assessed by observ-
ing the “purity” of the cells within the cardiomyocyte cultures. True car-
diomyocytes were identified with a specific antibody (Troponin I, Chemi-
con, MAB3150). Examples of cardiomyocyte cell cultures, stained with the
Troponin antibody and visualised with DAB staining, demonstrating high
levels of cardiomyocyte purity can be seen in Figure 4.16.
4.6.2 ROS Quantification in Cardiomyocytes Co-cultured
with Human Whole Bone Marrow or Bone Marrow
Mononuclear Cells
ROS generation was quantified in primary cultures of rat cardiomyocytes
with and without either human WBM or human BMMNCs.
4.6.2.1 Whole Human Bone Marrow
The mean fluorescent intensity of the ROS dye was not significantly dif-
ferent between the control group consisting only of cardiomyocytes when
tested against the group to which hWBM had been added (n=6, 92.8±10.7
compared to 94.5±11.1 respectively, P=0.8, see Table 4.17). When H2O2
was added to both groups the mean fluorescent intensity increased sig-
nificantly in both groups, but there was no difference in the means be-
tween the two H2O2 plus groups (Controls 123.2±5.2 vs hWBM 120.4±6.2,
P=0.66). Normalisation of the data (see Figure 4.17) with respect to the
control group without added H2O2 reiterated the findings that no signifi-
cant differences were seen between the experimental groups except for the
expected rise in ROS in both groups with the addition of H2O2.
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(a)
(b)
Figure 4.16: Photomicrograph of cultured cardiomyocytes stained with Troponin
antibody and visualised with DAB staining (brown). (a) - low power ×20 mag-
nification and (b) ×60 magnification. In both photos the majority of cells can be
seen to stain positive for Troponin suggesting a high level of selection for car-
diomyocytes within the cultures. Black arrows highlight negatively stained cells,
i.e., cells not identified as cardiomyocytes that are likely to represent endothelial
cells or fibroblasts.
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Figure 4.17: Reactive oxygen species (ROS) quantification in cardiomyocytes cul-
tured alone - controls, or with 104 human whole bone marrow cells (hWBM) for
twenty-four hours. Also shown, ROS assessment in cardiomyocytes with and
without hWBM after incubation with 100 µM H2O2. Results were normalised
against the paired control value.
Table 4.17: ROS quantification in cardiomyocytes cultured with and without hu-
man whole bone marrow, in the presence or absence of 100µM H2O2.
Cardiomyocytes Cardiomyocytes & 100 µM H2O2
Control Plus hWBM Control Plus hWBM
n 6 6 6 6
Mean 92.79 94.46 123.2 120.4
SEM 10.69 11.12 5.198 6.153︸ ︷︷ ︸ ︸ ︷︷ ︸
P value 0.798 0.6564
4.6.2.2 Human Mononuclear Cells
As with human WBM, no differences were seen with respect to the mean
ROS values in controls (81.9±8.8) compared to the intervention groups
with added hMNCs (71.5±12.2, n=6, P=0.48, see Table 4.18). Repeat exper-
iments with the addition of H2O2 to both groups demonstrated an increase
in ROS. There was no difference between the control or hMNC groups
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Figure 4.18: Reactive oxygen species (ROS) quantification in cardiomyocytes cul-
tured alone - controls, or with 104 human whole bone marrow mononuclear cells
cells (hMNCs) for twenty-four hours. Also shown, ROS assessment in cardiomy-
ocytes with and without hMNCs after incubation with 100µM H2O2. Results were
normalised against the paired control value.
Table 4.18: ROS quantification in cardiomyocytes cultured with and without hu-
man bone marrow mononuclear cells, in the presence or absence of 100µM H2O2.
Cardiomyocytes Cardiomyocytes & 100 µM H2O2
Control Plus hMNCs Control Plus hMNCs
n 6 6 6 6
Mean 81.93 71.53 107.1 109.9
SEM 8.849 12.29 7.309 8.828︸ ︷︷ ︸ ︸ ︷︷ ︸
P value 0.482 0.7853
(107.1±7.3 vs 109.9±8.8, n=6, P=0.79)
Normalisation of the data (see Figure 4.18) by dividing paired values
with the ROS values gained from the control group confirmed that there
were no significant differences between controls and the hMNC group
with or without H2O2 addition.
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Figure 4.19: Mitochondrial membrane potential assessment in cardiomyocytes
co-cultured with hWBM or hMNCs.
4.6.3 Mitochondrial Membrane Potential Quantification
in Cardiomyocytes Co-Cultured with Human Whole
Bone Marrow or Mononuclear Cells
Mitochondrial membrane potential was assessed in cardiomyocytes co-
cultured in isolation or with the addition of hWBM or hMNCs for twenty-
four hours.
Results were normalised using the paired control values and are shown
in Figure 4.19. No significant differences were noted in ∆Ψm between the
control groups and cardiomyocytes when co-cultured with either hWBM
(normalised mean 0.99±0.018, n=12, P=0.69) or with hMNCs (normalised
mean 1.09±0.88, n=12, P=0.33).
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4.6.4 Confocal Microscopy for Assessment of Mitochon-
drial Membrane Potential
Several experiments (n=24) were attempted to assess ∆Ψm, using a sec-
ond method, live cell culture confocal microscopy with the red fluorescent
mitochondrial dye TMRE. The main benefit of this technique was the po-
tential added ability to dynamically alter the conditions of cell culture, by
adding stem cells or pharmacological compounds or altering oxygenation,
and assessing real-time changes in ∆Ψm.
Using this technique, it was possible and reassuring to directly visu-
alise mitochondrial staining with TMRE (including 3D reconstructions)
and to obtain fluorescence intensity measurements even from single cells,
but experimental results varied widely and were not reproducible (see Fig-
ure 4.20).
Initially, this was felt to be due to difficulties in maintaining a stable
working environment with appropriate temperature, oxygenation, and
humidity. However, further work suggested that the combination of the
mercury lamp used for the phase contrast microscopy, the confocal laser,
combined with the requirement for multiple scans when setting up the
study area or when used for serial assessment before and after an interven-
tion caused marked and significant photobleaching of the TMRE dye (see
Figure 4.20). This resulted in a large and artefactual lowering in the mean
fluorescent intensity completely obscuring real changes in ∆Ψm brought
about by any of the experimental interventions. For this reason this exper-
imental approach was abandoned.
4.6.5 Oxygen Electrode
A second experimental approach that was abandoned was the use of an
oxygen electrode to assess the rate of oxygen consumption of cells in sus-
pension culture as a surrogate marker of mitochondrial function.
Unfortunately, despite multiple repeated attempts stable readings
could not be produced using this apparatus. This prohibited accurate and
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Figure 4.20: Confocal microscopy assessment of mitochondrial membrane poten-
tial, (a) - confocal microscope image of cells labelled with TMRE red fluorescent
dye (b) - Typical time course of mean red fluorescent intensity measurement for
a single cell demonstrating significant drop in fluorescent intensity that is likely
to be explained by photo bleaching induced by multiple scans with repeated ex-
posure to the confocal laser and the mercury lamp. This precipitant drop in mean
fluorescence just from repeated scans
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reliable measurements of oxygen consumption. For example, as shown
in Figure 4.21, when calibrating the equipment, prior to cell addition, a
steady baseline reading of 100% should be recorded but this could not be
obtained. Both constant negative or positive drift away from the expected
plateau reading of 100% oxygen saturation were seen before and after cal-
ibration as well as after cell addition and subsequent washing steps.
Multiple measures were taken in an attempt to solve these issues in-
cluding exclusion of contaminating bacteria, checking of integrity of seals
within the oxygen chamber and assessing for excessive oxidation of the
electrode. No cause for the problems were found and the use of the oxy-
gen electrode was abandoned due to lack of accuracy or reproducibility
in the experiments, due to the uncontrollable problem of the wandering
baseline.
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Figure 4.21: Recordings demonstrating why use of the oxygen electrode was
abandoned. (a) - negative baseline drift in the absence of cells before and after cal-
ibration - constant plateau of 100% saturation should be obtained prior to adding
cells. (b) - both positive and negative baseline drift with subsequent failure to
return to 100% following zero point calibration. (c) - recording of saturations fol-
lowing cell addition demonstrating steep decline in oxygenation, but following
washing to remove cells baseline returns to greater than maximum 100% satura-
tion and then continues to drift artificially higher.
243
BMMNCs activate the PI3K/Akt Pathway 4.7 Collaboration
4.7 Collaboration
As discussed in §4.3.2 and in §4.3.3 further collaborative studies looking at
potential mechanisms of the reduction of infarct size seen with BMMNCs
were performed. These studies were planned and initiated by myself and
my supervisors. In addition, the majority of the cells used in these studies
were provided by myself to the collaborators or derived following meth-
ods set out in this thesis. These collaborations are now described in further
detail.
4.7.1 Functional Investigations and PI3K/Akt Pathway
Assessment
Several experiments were performed in conjugation with Mohammed
Yasin a PhD student with Prof. Thiemermann and with Prof. Suzuki’s
group both at the WHRI in the Centre for Translational Medicine and
Therapeutics. These studies were designed to assess changes on apopto-
sis and necrosis, evaluate cardiac function and myocardial fibrosis after
seven days reperfusion, and to evaluate activation of the PI3K/Akt sur-
vival pathway including downstream mediators.
4.7.1.1 Methods
Infarct Model The same method as set out in §2.6 was used to induce
reperfusion-ischaemia injury in rats throughout this group of experiments.
Thus, rats were anaesthetised with thiopentone, tracheotomised and ven-
tilated, and subjected to LAD-occlusion (25 min) and reperfusion (for 30
min, 2 h or 7 days). Area at risk (AAR) of the left ventricle was demarcated
by perfusion with Evans Blue and infarct size was measured by staining
the AAR with nitro blue tetrazolium, as previously described (Thiemer-
mann et al., 1997).
In Vivo Quantification of Apoptosis Cardiomyocytes (CMCs) from the
AAR of hearts previously rendered ischaemic and then reperfused (2h)
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were isolated and analysed for CMC apoptosis and necrosis by flow cy-
tometry as previously described (Sivarajah et al., 2009). Gating of the
CMC population was determined by the degree of binding of troponin-
T monoclonal antibody (SC-20025, Santa Cruz, USA). Troponin-T binding
in the gated population was 70±6% (n=5). Annexin 5-FITC/propidium io-
dide apoptosis detection kit (556570, BD Biosciences Pharmingen, UK) was
used to dual stain live AAR CMC isolates. All stained AAR CMC isolate
samples were analysed within 1 hour using a flow cytometer (FACScan,
Becton Dickinson, UK) with Cell-Quest software (BD, UK). Cardiomy-
ocyte apoptosis was also confirmed using a caspase-9 FLICA assay kit
(CS0300, SigmaAldrich, UK).
Determination of Cardiac Function Cardiac function was analysed us-
ing echocardiography (Vevo-770 imaging system and 23.5 MHz probe, Vi-
sual Sonics, USA) under anaesthetic (1.5% isoflurane) on the day before
and 7 days post IR injury. The percentage fractional area of contraction
(%FAC) was assessed with 2D images at the papillary muscle level. Left
ventricle ejection fraction (LVEF) was measured by M-mode.
Haemodynamic catheter analysis of LV function was performed (on
the same days as echocardiography) by inserting a 2 Fr micro-tipped
pressure transducer (Millar Instruments, USA, SPR-320) through the right
carotid artery and advanced into the LV for measurement of ventricular
pressure. Left ventricular peak systolic pressure (LVPSP), end diastolic
pressure (LVEDP), maximal slope of systolic pressure increment (+dP/dt),
diastolic decrement (-dP/dt), the relaxation time constant (tau), and heart
rate were all analysed using LabChart Pro software (ADInstruments, UK).
Determination of LV Fibrosis Excised hearts were immediately fixed by
perfusion (via aortic cannulation) with 4% paraformaldehyde, followed
by immersion in 4% paraformaldehyde, on ice for 30 minutes. The hearts
were then washed with PBS and incubated in PBS containing 30% sucrose
(w/v) at 4◦Covernight. The fixed hearts were then cut transversely into
three pieces, each of which was embedded in OCT compound (VWR, UK,
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361603E), frozen in liquid nitrogen-cooled isopentane and stored at -80◦C.
Subsequently, cryosections were stained with 0.1% Sirius red (VWR, UK,
720-1194) for 10 minutes at room temperature. The sections were rinsed
5 times in deionised water and then rinsed for 1 min in picric alcohol (20
ml absolute alcohol; 70 ml H2O; 10 ml saturated aqueous picric acid). The
sections were then dehydrated through a methanol series and mounted
in DPX (VWR, UK, 360292F). The degree of sirius red staining was visu-
alised by an all-in-one microscope (Keyence, BZ-8000, USA). Planimetry
was used for quantification.
Determination of PI3K/Akt Pathway Activation Wistar rats were sub-
jected to 25 minutes ischaemia followed by 2 hours reperfusion. On com-
pletion of the experiment the hearts were excised and frozen in liquid ni-
trogen. Cytosolic and nuclear protein homogenates were prepared from
the frozen myocardium (AAR only) as described (Meldrum et al., 1997).
Protein extracts from the cytosol were analysed for phosphorylation of
Akt, GSK-3β, and p38 MAPK by western blots as previously described
(Collino et al., 2006). Protein extracts from both the cytosol and nu-
cleus were analysed for nuclear translocation of p65 NF-κB, as described
(Collino et al., 2006).
Immunodetection was performed using primary antibodies against
mouse anti-phosphorylated AktSer473, mouse anti-phosphorylated p38
MAPK (587F11, and 28B10, both from Cell Signaling Technology, USA),
rabbit anti-total Akt, rabbit anti-total GSK-3β, goat anti-phosphorylated
GSK-3β Ser9, and mouse anti-NF-κB p65 (sc-8312, sc-8257, sc-11757, sc-
8008, all from Santa Cruz, USA).
Blots were incubated with specific secondary antibodies conjugated
with horseradish peroxidase and developed with an ECL detection sys-
tem (RPN2135, GE Healthcare Life Sciences, UK). Immunoreactive bands
were visualised by autoradiography and band density was evaluated us-
ing the Gel Pro Analyzer 4.5, 2000 software (Media Cybernetics, USA). The
proportion of phosphorylated to total protein was normalised to the vehi-
cle treated group. Membranes were then stripped and incubated with α4-
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actin monoclonal antibody and subsequently with anti-mouse antibody to
assess gel loading homogeneity.
4.7.1.2 Results
In Vivo Quantification of Necrosis A significant decrease in the number
of necrotic myocytes was seen when BMMNCs were injected immediately
upon reperfusion. For all groups n=5, thus, 6.1±1.1% of cells were found to
be necrotic in shams vs 16.3±1.3% myocyte necrosis in controls vs 4.9±1%
myocyte necrosis in BMMNC treated animals, P<0.01 (see Figure 4.22).
In Vivo Quantification of Apoptosis Similarly, injection of BMMNCs
immediately after ischaemia and upon reperfusion significantly reduced
the proportion of cells undergoing apoptosis (n=5 all groups, 7.8±0.5% in
shams, 27.7±3.2% in vehicle controls, and 13.9±3.4% in BMMNC group, P
<0.05, see Figure 4.22).
In Vivo Quantification of Caspase 9 Activation The observation of re-
duced apoptosis with BMMNC treatment as detected using flow cytome-
try and Annexin V-FITC with PI was confirmed by measurement of cas-
pase 9 expression. The percentage of cells isolated from the area at risk
expressing caspase 9 was measured and found to be significantly reduced
in cell treated compared to vehicle treated animals (BMMNCs 12.7±2.6%
vs PBS 30.6±4.2%, n=5, P<0.01, see Figure 4.22).
Effects of Timing of Cell Injection In addition to measuring the effects
of injecting 107 BMMNCs after 2 hours ischaemia and on the commence-
ment of reperfusion (designated as time 0). Additional studies were per-
formed to assess the percentage of cardiomyocytes undergoing necrosis,
apoptosis, and caspase 9 activation when 107 BMMNCs injection was de-
layed to after commencement of reperfusion. The chosen timings of in-
jection were thus, after 0, 15, 30, 60, and 90 minutes of reperfusion (see
Figure 4.22).
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It is notable that a similar pattern was seen, across all three measure-
ments, for the time course of injections for the percentage of cardiomy-
ocytes undergoing necrosis, apoptosis, and caspase 9 activation. Thus,
there was a trend to reduced necrosis, apoptosis, and caspase 9 activation
at all time points. However, the reduction was greatest at the earlier time
points and was seen to lessen at the longer time points. In fact, the reduc-
tion in necrosis, apoptosis, and caspase 9 activation was only significant
across all three measurements when 107 BMMNCs were injected at 0, 15,
or 30 minutes after reperfusion had commenced, becoming non-significant
when cells were injected at 60 or 90 minutes.
Cardiac Function When assessed 7 days after IR injury, administration
of BMMNCs reduced IR-induced infarct size and fibrosis, i.e., cardiac scar
formation. These findings were associated with prevention of impairment
in systolic and diastolic LV function measured by echocardiography and
haemodynamic catheterisation.
Improvements in systolic function by BMMNC therapy were demon-
strated by significantly higher values for LVEF (BMMNC 71±3% vs PBS
48±4%, n=11, P<0.0001, see Figure 4.23).
Other measures of systolic function were also improved after cell treat-
ment, FAC (BMMNC 47±2% vs PBS 36±3%, n=11, P<0.01); dP/dtmax
(BMMNC 10×103 mmHgs-1 ±0.4% vs PBS 8×103 mmHgs-1 ±1%, n=7,
P<0.05); and Contractility Index (BMMNC 162±10 vs PBS 113±3, n=7, P
<0.001).
Similarly, improvements in diastolic function by BMMNC therapy
were demonstrated by lower values for LVEDP (BMMNC 4±1 mmHg vs
PBS 16±3 mmHg, n=7, P<0.01); dP/dtmin (BMMNC -9×103 ±0.5 mmHgs-1
vs PBS -7×103 ±1 mmHgs-1, n=7, P<0.01) ; and Tau (BMMNC 12×10-3 ±0.5
vs PBS 10×10-3 ±1, n=7, P=0.075).
Activation of PI3K/Akt Pathway All infarct size reduction benefits of
administration of BMMNCS on IRI was abolished by the administration
of LY294002 (a PI3K inhibitor), see Figure 4.24.
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(a) (b)
(c)
Figure 4.22: In Vivo Quantification of Cardiomyocyte Apoptosis, Necrosis, and
Caspase 9. Apoptosis and necrosis was assessed using flow cytometry and extent
of PI and Annexin V-FITC staining. White columns: V - Vehicle (PBS) adminis-
tered at the onset of reperfusion (0 mins), black columns: represent a time series
for points of administration of 107 bone marrow mononuclear cells (BMMNCs)
after two hours ischaemia and following 0, 15, 30, 60, or 90 minutes reperfusion.
Thus, (a) - is time series for percent myocyte necrosis, (b) - percent myocyte apop-
tosis, and (c) - percent myocyte caspase 9 expression. CMC - cardiomyocyte. F
Signifies significant difference from vehicle group with P<0.05, and FF signifies
difference with P<0.01.
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Figure 4.23: Assessment of left ventricular function using echocardiography
seven days after ischaemia-reperfusion injury. Three groups are shown, sham -
thoracotomy only, PBS - ischaemia reperfusion injury (IRI) but receiving vehi-
cle (PBS) only, and BMMNC - IRI and received 107 bone marrow mononuclear
cells on reperfusion. BMMNC injection ameliorated loss of LV function compared
to the PBS group. == Signifies a significant difference from the BMMNC treated
group compared to the PBS group, P<0.0001. (LVEF) was calculated from mea-
surements using M-mode in the short axis at the level of the papillary muscles.
The LVEF is calculated by taking the cube of the LV internal dimensions in sys-
tole away from the cube of the LV internal dimensions in diastole and dividing
the result by the LV internal dimensions in diastole.
The cardioprotective effect of BMMNCs was associated with the in-
creased expression of the pro-survival PI3K/Akt signalling pathway.
BMMNCs resulted in a significant increase, in phosphorylation of serine-
473Akt and serine-9GSK-3β (see Figures 4.24 and 4.25) which was abol-
ished by the pre-treatment of animals with the PI3K inhibitor LY294002
(0.3 mg/kg i.v.), indicating that the activation of Akt (and the subsequent
inhibition of GSK3β) were secondary to the activation of PI3K.
Furthermore, BMMNCs resulted in a significant reduction in the phos-
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(a) (b)
Figure 4.24: (a) Infarct size was measured in animals subjected to 25 min my-
ocardial ischaemia followed by 2 h reperfusion or sham animals. The area at
risk (AAR) was expressed as a % of the left ventricle (LV) and the infarct size
was expressed as a % of the AAR. When compared with PBS, pre-treatment with
the LY294002 (0.3 mg/kg i.v.) abolished the attenuation of infarct size caused by
the systemic intravenous injection of 10 million bone marrow mononuclear cells
(BMMNCs) upon reperfusion. (b) Western blot demonstrating that systemic in-
travenous injection of 10 million BMMNCs upon reperfusion significantly aug-
mented the phosphorylation of Aktserine-473. FF Signifies statistical difference
against PBS with P<0.01. The PI3K inhibitor LY294002 abolished all BMMNC in-
duced effects in both (a) and (b).
phorylation of p38-MAPK and nuclear translocation of NF-κB, and both
effects were attenuated by the PI3K inhibitor (0.3 mg/kg i.v.). See Fig-
ures 4.25 and 4.26.
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(a) (b)
Figure 4.25: Western blots demonstrating that systemic intravenous injection of
10 million bone marrow mononuclear cells (BMMNC) upon reperfusion - (a) sig-
nificantly augmented the phosphorylation of GSK-3βserine-9, - and (b) signifi-
cantly reduced the nuclear translocation of NF-κB. The PI3K inhibitor LY294002
abolished all significant BMMNC induced effects in both (a) and (b). F Signifies
statistical difference against PBS with P<0.05.
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Figure 4.26: Western blot demonstrating that systemic intravenous injection of 10
million bone marrow mononuclear cells (BMMNCs) upon reperfusion reduced
the phosphorylation of p38-mitogen activated protein kinase (MAPK). LY294002
abolished all significant BMMNC induced effects. F Signifies statistical difference
against PBS with P<0.05.
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4.7.2 Proteomics
The wider changes within the myocardium following IR injury, together
with possible mechanisms of infarct reduction after BMMNC injection,
were investigated with a proteomic study. The study was set up as shown
in Figure 4.1 and as described in §4.3.2, this work was the result of a col-
laboration with Kate Lee a PhD student supervised by Prof. P. Munroe and
Dr. K. Leung.
4.7.2.1 Methods
Analysis of the cardiac proteome was performed after 25 minutes of LAD-
occlusion followed by reperfusion for six hours prior to harvesting the rat
hearts. Interventions were performed at the onset of reperfusion and con-
sisted of vehicle (PBS) or 107 BMMNCS. There was a third experimental
group which consisted of sham operated animals, i.e., animals that under-
went thoracotomy but were not rendered ischaemic via LAD occlusion.
Changes in the cardiac proteome were investigated by two-
dimensional gel electrophoresis (2-DE) coupled with electro-spray ionisa-
tion (ESI) mass spectrometry (MS) that was used to identify differentially
expressed protein spots in myocardial samples from sham operated ani-
mals plus PBS, ischaemia/reperfusion (25 min/6 h) plus PBS, and from
ischaemia/reperfusion (25 min/6 h) plus BMMNC (n=3, for all groups).
Protein homogenates were individually prepared for each rat from 80
to 140 mg of ground frozen myocardium (AAR only) using 1 ml lysis
buffer per 100 µg tissue. Protein concentration of homogenates was quanti-
fied by Bio-Rad protein assay (Bio-Rad). Duplicate 2D gels were produced
for each sample using 200 µg total protein separated on 18 cm non-linear
(NL) pH4–7 immobilised pH gradient (IPG) strips (GE-Healthcare Life-
sciences, UK).
Large format, homogeneous, 12% SDS PAGE gels were used for second
dimension separation and then stained using the plus one silver staining
kit (GE-Healthcare Lifesciences, UK). Images were scanned and analysed
using PDQuest software (BioRad, UK). Spot intensity values were nor-
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malised using total density in gel method.
Fold changes and unpaired MannWhitney P-values were calculated for
SHAM vs PBS and PBS vs BMMNC comparisons. Over a hundred spots
had significant>2.5-fold differences (P<0.05) in either or both of the com-
parisons, and were selected for trypsin digestion, peptide extraction, and
protein identification using LCMS/MS, Q-Tof Micro (Micromass, UK). The
resultant peak list data (PKL file) was then used to search the SwissProt
database using the MASCOT (Matrix Science) online server for a match.
Only peptides with scores over 45 were considered to be significant, the
MASCOT scores were calculated from these.
Twenty µg of protein homogenate was electrophoresed in duplicate
on 10% Bis-tris gels (Invitrogen, UK) and transferred to PVDF mem-
branes (GE-Healthcare Lifesciences, UK), and subsequently blocked in
Tris buffered saline containing 0.05% Tween-20 (TBS-Tween) with 3% non-
fat dry milk at 4◦C overnight. Blots were probed with either anti-14-3-3
or anti-SDHA antibodies (Abcam, UK). Loading was verified by probing
the duplicate gel with anti-GAPDH antibodies (Abcam, UK) for each ex-
periment. Blots were incubated with the appropriate secondary antibody
(Santa Cruz Biotechnology, USA). Chemiluminescence was detected us-
ing ECL reagents (GE-Healthcare Lifesciences, UK). Bands were detected
and quantified using TotalLab v1.1 (Phoretix, UK), and volumes were nor-
malised to the GAPDH volumes for the duplicate gels.
4.7.2.2 Results
The tabulated proteomic results are shown in Tables 4.19 and 4.20. The
general trend observed from all of the proteomic data is that the cardiopro-
tection afforded by BMMNCs is associated with a reversal in the metabolic
and mitochondrial protein disturbances associated with IR injury.
When assessing protein difference between the experimental groups
initially the Sham operated group was compared to the vehicle (PBS)
group, and then the proteomic alterations attributable to BMMNC ap-
plication were elucidated by comparing the PBS group to the BMMNC
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group. From these comparisons approximately 1100 different proteins
were matched across across 18 different 2D gels.
The proteins identified from spots found to be significantly altered are
detailed in Table 4.19. Fold changes and P-values of these proteins are
shown in Table 4.20 along with the observed and theoretical Mr and pI.
The proteins identified as being altered by IR injury can be categorised
as being involved with mitochondrial respiration, stress response, cel-
lular energy metabolism, and sarcomeric/cytoskeletal structure or func-
tion. Disturbances in mitochondrial oxidative phosphorylation compo-
nents (complex I and complex III and ATP synthase) were observed in IRI
suggesting mitochondrial dysfunction. Several stress responsive proteins
were also altered in IR injury: stress-70 protein (Hspa9), and the cytoplas-
mic antioxidant Peroxiredoxin-6 were both affected by IRI. The expression
levels of several energy metabolism enzymes were also disturbed, possi-
bly reflecting a switch in substrate preference (Stanley & Sabbah, 2005).
Galectin-5, a beta-galactoside-binding lectin, was up-regulated from un-
detectable levels in the PBS myocardial samples compared to Sham.
Many of the protein alterations were reversed when the BMMNC
group was compared to PBS, such that levels were similar to that seen in
the Sham group. For example, the spots identified as NADH-ubiquinone
oxidoreductase 75kDa subunit, and cytochrome b-c1 subunit 6 that had
10- and 6-fold changes respectively in the Sham vs PBS comparison were
seen to have 7- and 10-fold changes respectively in PBS vs BMMNC. Frag-
ments of ATP synthase subunit beta, identified in 16 different spots, all
showed down-regulation in Sham vs PBS, possibly reflecting enhanced
protein degradation in IR injury, and up-regulation in PBS vs BMMNC.
Four of these had significant alteration in both comparisons showing sim-
ilar degree of expression change (13-, 6-, 3- and 2-fold decrease in Sham vs
PBS; 13-, 9-, 3- and 3-fold increase in PBS vs BMMNC). IR injury related
expression changes were also corrected for Enoyl CoA hydratase and lac-
tate dehydrogenase, hinting at a reversal of the IR injury related substrate
switch. A 12-fold up-regulation in the chaperon protein 14-3-3 epsilon in
the BMMNC group compared to PBS was also seen.
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Table 4.19: Spots with significant fold changes for which a single protein ID was
found. SSP are spot identification numbers assigned by PDQuest software. Mas-
cot details are as follows; mascot score (the sum of the peptide scores), the number
of peptides found and the sequence coverage of these peptides (only including
peptides with individual scores over 35). Theoretical Mr and PI values for the
protein identified are shown as well as the observed Mr and PI of the spot as
estimated from its position in the gel.
Observed in Gel Theoretical Mascot
SSP Mr Pl Mr Pl Protein name UniProtKB
/Swiss-Prot
Accession
Score Pep’s % sc
1430 34500 4.40 29155 4.63 14-3-3 protein epsilon P62260 164 3 20
2616 47500 4.80 32803 4.80 40S ribosomal protein SA P38983 50 1 4
2546 45000 4.80 51556 7.16 Adenylyl cyclase-associated
protein 1
Q08163 55 1 4
3209 20000 5.00 56318 5.19 ATP synthase subunit beta P10719 144 2 5
1225 21000 4.50 56318 5.19 ATP synthase subunit beta P10719 192 2 7
3208 22000 5.00 56318 5.19 ATP synthase subunit beta P10719 51 1 4
4235 24000 5.40 56318 5.19 ATP synthase subunit beta P10719 110 2 4
4329 29000 5.40 56318 5.19 ATP synthase subunit beta P10719 69 1 2
1424 34000 4.60 56318 5.19 ATP synthase subunit beta P10719 131 2 8
3433 34000 5.00 56318 5.19 ATP synthase subunit beta P10719 436 6 18
2443 35000 4.80 56318 3.00 ATP synthase subunit beta P10719 91 1 3
3523 40000 5.20 56318 5.19 ATP synthase subunit beta P10719 280 4 14
3632 47000 5.20 56318 5.19 ATP synthase subunit beta P10719 314 5 16
2609 47500 4.80 56318 5.19 ATP synthase subunit beta P10719 457 6 12
2626 52500 4.90 56318 5.19 ATP synthase subunit beta P10719 167 3 8
3626 54500 5.20 56318 5.19 ATP synthase subunit beta P10719 711 9 29
3636 57000 5.10 56318 5.19 ATP synthase subunit beta P10719 226 5 15
3706 57000 5.10 56318 5.19 ATP synthase subunit beta P10719 215 3 9
2712 57500 4.90 56318 5.19 ATP synthase subunit beta P10719 707 8 26
2119 14500 4.80 10417 4.90 Cytochrome b-c1 complex sub-
unit 6
Q5M9I5 131 1 20
3627 57000 5.20 53424 5.21 Desmin P48675 463 7 20
7722 62000 6.60 67123 8.76 Dihydrolipoyllysine-residue
acetyltransferase component
of pyruvate dehydrogenase
complex
P08461 228 4 9
7323 31500 6.60 31496 8.39 Enoyl-CoA hydratase P14604 71 1 3
7110 16000 6.30 16186 6.17 Galectin-5 P47967 157 3 21
7702 70000 6.40 58307 5.85 Hydroxysteroid
dehydrogenase-like protein
2
Q4V8F9 75 2 4
6425 37000 6.20 36589 5.70 L-lactate dehydrogenase B chain P42123 77 1 6
4521 37000 5.40 36589 5.70 L-lactate dehydrogenase B chain
(or LDHA)
P42123 72 1 3
8853 67500 6.70 79293 7.70 Methylcrotonoyl-CoA carboxy-
lase subunit alpha, mitochon-
drial (mouse)
Q5I0C3 166 3 6
3305 25000 5.00 22142 5.03 Myosin light chain 3 P16409 334 5 33
1206 17500 4.40 18868 4.86 Myosin regulatory light chain 2 P08733 57 1 8
1213 17500 4.40 18868 4.86 Myosin regulatory light chain 2 P08733 108 2 16
3228 15000 5.20 18868 4.86 Myosin regulatory light chain 2 P08733 135 3 20
4207 19000 5.40 223370 5.59 Myosin-6 P02563 279 4 3
1207 19000 4.40 113780 8.4 NAD(P) transhydrogenase Q61941 58 1 2
7112 17000 6.50 79362 5.65 NADH-ubiquinone oxidoreduc-
tase 75 kDa subunit
Q66HF1 102 2 2
5408 32000 5.80 24803 5.64 Peroxiredoxin-6 O35244 388 7 44
3518 42500 5.10 73812 5.97 Stress-70 protein (aka HSPA9) P48721 85 1 2
4702 60000 5.20 73812 5.97 Stress-70 protein (aka HSPA9) P48721 739 10 21
7723 67500 6.60 71570 6.75 Succinate dehydrogenase
[ubiquinone] flavoprotein
subunit, mitochondrial
Q920L2 73 1 2
1320 29000 4.50 32661 4.69 Tropomyosin alpha-1 chain (or
Tropomyosin beta chain)
P04692 58 1 4
1248 25000 4.50 35709 4.95 Troponin T, cardiac muscle P50753 59 1 3
4523 43000 5.60 49892 4.95 Tubulin alpha-4A chain Q5XIF6 191 3 11
8710 67000 6.60 66140 6.15 WD repeat-containing protein 1 Q5RKI0 157 4 11
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4.8 Discussion
The mechanism of action of bone marrow derived cells in repairing car-
diac tissue is currently under debate. In the previous chapter a significant
reduction in infarct size was found with early administration of BMMNCs
in an IR injury model. This observation was associated with the demon-
stration of a limited number of BMMNCs within the myocardium, sug-
gesting that the benefit was unlikely to be due to transdifferentiation. Fur-
thermore, the speed of onset and magnitude of the effect seen was com-
parable to that seen in modulation of IR injury. Thus, the hypothesis that
BMMNCs produce benefit in IR by release of locally acting paracrine fac-
tors was investigated in this chapter. The hypothesis was tested with both
in vitro and in vivo techniques, and with a proteomic study.
4.8.1 In Vitro
The in vitro studies involved the use of flow cytometry to observe the ef-
fects of both human and rat whole bone marrow and their corresponding
mononuclear cell fractions on apoptosis and necrosis, mitochondrial po-
tential, ROS generation, and the cell cycle of HUVECS and neonatal rat
cardiomyocytes.
Tissue culture of HUVECs and neonatal rat cardiomyocytes was per-
formed, as was isolation of rat and human bone marrow derived cells. This
process was very successful, with only one infected culture plate in three
years. Cardiomyocyte cultures were found to be relatively pure using im-
munohistochemistry for the cardiomyocyte specific antibody Troponin I.
Despite the success of tissue culture, it should be noted that the culture
of the rat neonatal cardiomyocytes was a costly and prolonged procedure,
and required the use of 20 pups for each experiment performed. In future,
consideration should be given to the use of a cardiomyocyte cell line in the
early phases of the investigation as this could reduce costs and animal use
during the optimisation of experimental protocols.
The bone marrow derived cells were co-cultured with the cells un-
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der investigation using a novel method whereby the bone marrow de-
rived cells were stained with a green cell tracker dye (CFDA SE) prior
to insertion into the co-culture system. This approach was taken as it was
hoped to maximise any benefits seen by increasing the proximity of the
bone marrow derived cells to the HUVECs and cardiomyocytes. At the
time of flow cytometric analysis the cell tracker dye allowed separation
of the bone marrow derived cells from the other cells of interest, namely
the HUVECS and neonatal cardiomyocytes. As it transpired although this
technique proved to be highly successful its use was not required as the
bone marrow derived cells were easily separated from the cells to be in-
vestigated by simple aspiration and washing of the cultures prior to their
detachment.
Flow cytometry was used to analyse several parameters of the co-
cultured cells. Initially, no results could be produced using the CyAn ADP
flow cytometer. After prolonged consultation, several site visits, and mul-
tiple sample tests it was discovered with the help of Dako, the company re-
sponsible for the CyAn ADP, that there was an internal fault with the flow
cytometer. The entire machine was replaced and following this all sub-
sequent experiments progressed with minimal problems. Thus, apoptosis
and necrosis, ROS generation, the cell cycle and mitochondrial membrane
potential were all successfully quantified in HUVECs and cardiomyocytes.
Two experimental techniques were abandoned during investigation of
the in vivo effects of bone marrow derived cells on the HUVECs and car-
diomyocytes. Both the assessment of mitochondrial membrane potential
with confocal microscopy and assessment of oxygen usage with an oxy-
gen electrode were abandoned due to a lack of stable readings and repro-
ducible results.
Regarding results, taking first the studies with HUVECs, human WBM
did not change ROS generation with respect to control cells at rest. When
ROS production was stimulated by the addition of H2O2, a significant 44%
reduction in ROS generation was seen in the hWBM treated HUVECs over
the control cells. It should be noted that the control group had an equiv-
alent number of HUVECS added to the culture wells at the same time as
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the hWBM. This was performed in all control wells for all the in vitro ex-
periments, the cells were added to control for any differences that changes
in cell numbers may have induced such as a dilution of the added H2O2.
Human MNCs showed a significant 5% reduction in ROS at rest and a
non-significant drop of 4% when stressed with the addition of H2O2. Both
rat WBM and rat MNCs demonstrated no differences compared to controls
when ROS was assessed “unstressed”. The addition of H2O2 resulted in a
trend for lower ROS production in the cell treated cultures, with a non-
significant 17% and 7% reduction in ROS production seen in rat WBM and
MNCs respectively.
It is of note that addition of H2O2 always produced a significant in-
crease in ROS generation compared to the untreated cells. However, in the
hWBM experiments the addition of H2O2 produced a much larger increase
in ROS generation than seen with the other experiments. It was only this
experiment that showed a significant benefit. It is possible that the lack of
significance found in the ROS reduction with the other cell types was due
to a failure to stress the cells enough. In other words, it may be difficult to
demonstrate any difference in ROS generation when the cells are in a low
ROS environment. This may be because no benefit can be demonstrated
with the addition of cells as there is no benefit to be gained when ROS
production is already low. This could be clarified in future by perform-
ing a dose response study by adding increasing amounts of H2O2 to the
cultures and monitoring benefits gained with higher ROS stimulus.
Mitochondrial membrane potential did not change in HUVECs co-
cultured with either rat or human MNCS. Divergent results were seen
with WBM, a 3% significant decrease with rat WBM treatment was seen
compared to a significant 2% increase with human WBM. These results
are difficult to interpret due to their conflicting nature and the biological
significance of such small changes may also be questioned.
The extent of apoptosis and necrosis was not seen to alter with co-
culture with either rat WBM or rat MNCs. Both human WBM and human
MNCs demonstrated reduced apoptosis and necrosis, with consequently a
1.3% non-significant increase in alive cells with human WBM, and a signif-
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icant 2.2% increase in live cells with human MNCs. Again, the size of the
changes seen are unlikely to be biologically significant. Also of note, the
beneficial effects were only seen with the human cells and could suggest a
species specific effect.
Quantification of the cell cycle demonstrated no changes in the cell cy-
cle of HUVECs cultured with either rat or human bone marrow derived
cells in comparison to controls.
Neonatal rat cardiomyocytes were co-cultured with human WBM and
MNCs. As with HUVECs changes in ROS, and mitochondrial membrane
potential were assessed. However, the cell cycle was not assessed, as there
was no effect seen in HUVECs, a highly proliferative cell line, it was felt
that any effect on cardiomyocytes was very unlikely to be seen. Further-
more, apoptosis and necrosis was not investigated in vitro in favour for
assessment in vivo under IR injury conditions.
No differences were seen in ROS generation with or without H2O2,
or in mitochondrial membrane potential in the neonatal cardiomyocytes
when co-cultured with either human WBM or human MNCs.
Taken together the results demonstrate a trend for reduced ROS pro-
duction when ROS generation was stimulated by addition of H2O2, al-
though only hWBM produced a significant decrease in HUVECs. No
changes in ROS were seen in cardiomyocytes. Mitochondrial potential
was also unchanged in cardiomyocytes and small significant conflicting
changes were seen with rat and human WBM in HUVECs. As for apopto-
sis and necrosis, small benefits were seen with human WBM and MNCs in
HUVECs. Finally, no changes in the cell cycle were seen.
These findings provide weak support for the hypothesis that bone mar-
row derived cells reduce infarct size through release of local factors that
act by modulating ROS, mitochondrial membrane potential, and apopto-
sis and necrosis. No evidence for an effect on the cell cycle was seen.
The strength of this study could have been improved in several ways.
Firstly, the majority of the studies were carried out under optimal culture
conditions. In this situation the cells are unlikely to be suffering stress and
it is difficult to demonstrate benefit with co-culture with bone marrow de-
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rived cells as the conditions are already optimal and benefit beyond this
is difficult to demonstrate. It would be better to test the ability of bone
marrow derived cells to change outcomes under conditions of stress such
as hypoxia when the ability to detect change would be greater as the size
of potential differences in ROS generation, mitochondrial potential, and
apoptosis and necrosis would be greater. With this in mind, it was planned
to repeat the tissue culture experiments under conditions of IR injury. A
modular hypoxic chamber was purchased (Wolf Labs, UK, MC-101) to
perform these experiments but it did not arrive in time to allow the ex-
periments to be included in this thesis.
Secondly, the case for bone marrow derived cells, releasing locally act-
ing factors that influence pro-survival mechanisms, could be have been
improved by assaying the culture media to define what factors were re-
leased by the bone marrow cells. Additionally, the effects of co-culture
with bone marrow cell conditioned medium, instead of directly with the
cells, would further the paracrine factor hypothesis. Furthermore, if the
locally released factors had been identified, then the effects of adding or
blocking the individual factors in culture could have been sought. It is also
of interest to repeat the co-culture experiments with a non-bone marrow
derived cell type. In preparation for this a rat cardiac fibroblast cell line
was established, however, the experiments have not be completed yet. In
retrospect, it would probably have been more beneficial performing these
experiments than duplicating the co-culture experiments with both hu-
man and rat WBM and MNCs with both HUVECs and cardiomyocytes.
In the setting of acute myocardial infarction, ROS have been reported to
play a significant role in tissue necrosis and IR injury (Asimakis et al., 2002;
Yoshida et al., 2000). As such it is of note that some evidence for reduced
ROS production was shown here with bone marrow derived cell treat-
ment. Thus, ROS reduction is one possible mechanism for the observed
beneficial action of BMMNCs in IR injury. Further evidence for this is pro-
vided by the demonstration that bone marrow derived cells, in particu-
lar MSCs, can ameliorate ROS. MSCs have been shown to constitutively
express the enzymes required to manage ROS. In particular high levels
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of glutathione peroxidase (Valle-Prieto & Conget, 2010) and MSCs have
been shown to to produce superoxide dismutase (SOD) (Kemp et al., 2010)
and also to induce the upregulation of SOD in endothelial cells through a
paracrine effect via STAT3 activation (Liu et al., 2010).
Several cellular mechanisms counterbalance the production of ROS.
The best characterised are the enzyme pathways involving catalase and
glutathione peroxidase that help convert H2O2 to water, and the SODs
that coordinate the formation of H2O2 from the superoxide radical O2 · –
(Giordano, 2005). Thus, glutathione peroxidase and SODs are a major part
of the antioxidant defence that protects cells from the rigours of oxidative
damage from ROS, which can directly interact with lipids, proteins, DNA,
causing cell damage and death if left unchecked (Davies, 1995; Hensley
et al., 2000). The potential of SOD to modulate IR injury is underlined by
its ability to reduce infarct size in transgenic mice that overexpress SOD
(Chen et al., 1996).
4.8.2 In Vivo
Further to the observations found in chapter 3, reassuringly the results
were able to be replicated here with the confirmation that administration
of BMMNCs at the beginning of reperfusion, in a myocardial IR injury
model (25 min ischaemia, 2 h reperfusion) results in a significant reduction
in myocardial infarct size.
Working towards the aim of elucidating the mechanism behind the
infarct size reduction additional experiments were performed. Thus,
BMMNC injection was found to reduce the number of cardiomyocytes
undergoing apoptosis within the area subjected to IR injury. In addition,
caspase-9 activation was reduced, another indication of reduced apopto-
sis. It is not surprising to find that the decrease in infarct size is seen to-
gether with a reduction in apoptosis. What remains to be determined is
what is the mechanism behind the reduction in apoptosis?
A time series was also constructed in which the administration of
BMMNCs was performed at 0, 15, 30, 60, or 90 minutes after commenc-
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ing reperfusion following ischaemia. Apoptosis, necrosis, and caspase-9
activation where then assessed in the digested rat hearts. The time series
demonstrated that the earlier the BMMNCs were injected after commenc-
ing reperfusion the greater the benefit with respect to reduced apopto-
sis, necrosis, and caspase-9 activation. Loss of significant benefit was seen
when BMMNCs where administered at greater than 30 minutes after com-
mencing reperfusion.
The IR injury model was extended here from six hours as performed
in chapter 3 up to 7 days. This longer model demonstrated that the car-
dioprotection induced by BMMNCs was not transient, in fact there was
evidence for a functional benefit at this time point. BMMNC treatment
prevented the development of a significant systolic and diastolic cardiac
dysfunction, which was seen in control animals, when measured with
echocardiography or LV pressures. Additionally at this time point BMM-
NCs were seen to reduce the development of scar tissue (reduction of in-
tramural fibrosis assessed by histology). Again both of these findings, of
improved function, and reduced fibrosis at seven days are not surpris-
ing given the acute reduction in infarct size seen along with the reduction
in apoptosis also demonstrated. These findings help substantiate the find-
ings of reduced infarct size, and it is important to demonstrate a functional
benefit, however, the findings still provide little insight into the mecha-
nism involved other than at least one final end-point — that being reduc-
tion in apoptosis.
Turning to consideration of the mechanism of action of the infarct size
reduction, it was observed that the cardioprotection afforded by BMMNCs
was similar to that afforded by ischaemic pre-conditioning, a known gold
standard for the experimental reduction of myocardial infarct size (Murry
et al., 1986). The cardioprotective effect of preconditioning is induced by
pro-survival kinases such as PI3K-Akt and MEK1/Erk1/2, these protec-
tive kinases are collectively termed the reperfusion injury salvage kinase
pathway (RISK).
Activation of the RISK pathway at the time of myocardial reperfu-
sion can confer powerful infarct size reduction. A diverse range of acti-
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vating mechanisms have been demonstrated, these include growth factors
(Hausenloy & Yellon, 2007), many of which have been shown to be re-
leased by stem cells, for example VEGF and FGF (Kinnaird et al., 2004a).
The cardioprotective actions of RISK pathway activation remain to
be completely resolved, but leading suggestions with experimental evi-
dence include inhibition of the mitochondrial permeability transition pore
(mPTP), activation of anti-apoptotic mechanisms including inhibition of
pro-apoptotic factors, e.g., BAD and BAX, and facilitation of calcium up-
take into the sarcoplasmic reticulum ameliorating calcium triggered mPTP
opening (Hausenloy & Yellon, 2009).
The small quantity of cell engraftment 2 hours after injection (esti-
mated as <1% of the total injectate), combined with the speed of the car-
dioprotective effect of BMMNC administration, coupled to the finding that
BMMNCs can secrete mediators of the RISK pathway suggests that the ob-
served cardioprotective effects could be due to activation of the RISK path-
way. Various mediators of reperfusion injury — oxidative stress, changes
in pH, inflammation, intracellular calcium levels, and the mitochondrial
permeability transition pore are all possible targets for interaction with
BMMNCs injected at the time of reperfusion.
Specific growth factors released by BMMNCs that have been shown
to be cardioprotective include vascular endothelial growth factor (VEGF),
hepatocyte growth factor (HGF), fibroblast growth factor (FGF), insulin-
like growth factor1 (IGF-1), and transforming growth factor (TGF) (Kin-
naird et al., 2004a).
A number of the observations documented here support the hypothe-
sis that paracrine growth factors secreted by BMMNCs contribute to the
cardioprotective effects of BMMNCs. This hypothesis is supported by the
following findings, administration of BMMNCs upon reperfusion was as-
sociated with activation of the PI3K/Akt phosphorylation survival kinase
pathway, and when PI3K activity was inhibited, with LY294002, the car-
dioprotective effect seen with injection of BMMNCs was negated, high-
lighting the key importance of the activation of the PI3K/Akt pro-survival
pathway in the observed beneficial effects. The increase in Ser-473Akt
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phosphorylation also resulted in the inhibition of GSK3β, suppression
of which has been documented to reduce infarct size and to cause pro-
nounced anti-inflammatory effects (Tong et al., 2002), which are, at least in
part, due to prevention of the activation of NF-κB24. The findings that the
inhibition of activation of PI3K with LY294002 abolished all of the above
effects of BMMNCs on cell signalling as well as their cardioprotective ef-
fects supports the view that the cardioprotective effects of BMMNC may
be secondary to activation of the PI3K/Akt survival pathway.
4.8.3 Proteomics
In order to further investigate the down stream molecular mechanisms as-
sociated with PI3K/Akt-signalling we analysed changes in the global pro-
teome of hearts subjected to IRI and treated upon reperfusion with BMM-
NCs. Within the proteomic data set, many of the protein alterations mea-
sured in the BMMNC group compared to PBS control seem likely to be
secondary to the reduced cell death associated with treatment, however,
several proteins with a possible mechanistic role in cardioprotection were
identified in the BMMNC treated group. Two significant proteins were the
heat shock protein stress-70 protein (aka HSPA9 or HSP70), which has also
been shown to be up-regulated in cardioprotection as afforded by hydro-
gen sulphide (Calvert et al., 2009), and the chaperon protein 14-3-3 epsilon
which is known to have pro-survival functions including its ability to bind
and inhibit the Bcl-2 related protein Bad in its phosphorylated conforma-
tion (Masters et al., 2001). Bad phosphorylation is thought to be one of the
many downstream actions of the PI3K/Akt pathway (Datta et al., 1997).
4.8.4 Conclusion
In conclusion, a single dose of systemic intravenous BMMNCs upon reper-
fusion reduces infarct size and cardiac dysfunction caused by regional my-
ocardial ischaemia and reperfusion. This reduction in infarct size was as-
sociated with activation of the PI3K/Akt survival pathway. Furthermore,
267
BMMNCs activate the PI3K/Akt Pathway 4.8 Discussion
BMMNC treatment induced alterations in protein expression consistent
with known cardioprotective pathways. Results from clinical BMMNC tri-
als suggest positive effects on cardiac function when cells are administered
5 days after successful reperfusion of myocardial infarction (Schachinger
et al., 2006). However, in another study when cells were injected at a time
closer to the point of successful reperfusion (24 h) no beneficial effect was
seen (Janssens et al., 2006).
The data presented here suggests that there may be a very early win-
dow of opportunity (i.e., less than 24 h following reperfusion) that exists
for bone marrow derived cell therapy to prevent myocardial necrosis, and
that this time point should be considered when designing future clinical
trials. In addition, it appears that the cardioprotective benefit shown here
is too rapid to be related to stem cell plasticity and may be attributable to
activation of the RISK pathway. This raises the possibility of unearthing
one or more molecules that could be administered in lieu of BMMNCs to
achieve similar protection, thus avoiding the need for cell collection and
any potential harmful effects that may manifest as a consequence of cell
injection.
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Immortalised Human Mesenchymal Stem Cells
Fail to Show Potential for Cardiomyogenic
Differentiation In Vitro or for Homing to Infarcted
Myocardium In Vivo.
5.1 Introduction
One of the main arguments of this thesis is that there are likely to be two
mechanisms by which bone-marrow derived cells produce benefit in the
“damaged” myocardium, and that these mechanisms differ depending
on whether cells are delivered during acute IR injury, when paracrine ef-
fects are predicted to predominate, or whether they are delivered at some
time distant to the acute event in the setting of chronic LV dysfunction,
when transdifferentiation with direct myogenesis and vasculogenesis is
predicted to predominate.
The results from the previous chapter and the work by others consid-
ered in the discussion there §6.4 provides strong evidence for a new under-
standing of cardiac homoeostasis, one in which the heart, and its vessels,
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are able to undergo continual repair and replacement throughout adult
life. Evidence for the source of this cell replacement has pointed at both
bone marrow origin (again, as discussed in §6.4) and for a role for the
emerging cardiac stem cells (as discussed in §1.5.10).
Whatever the origin of the repair mechanism is, one thing that is clear
is that the magnitude of the repair process is inadequate to regenerate
the amount of myocardium that is lost during a myocardial infarction. In
chronic heart failure due to significant cardiomyocyte loss, with prolonged
LV dysfunction, substantial amounts of cells will need to be replaced to
make any impact on the clinical course. Therefore, there is a need to facil-
itate the repair process. Two divergent strategies that could be considered
to bolster the intrinsic repair response are: enhancing the intrinsic response
through pharmaceutical agents; or, secondly, supplementing the intrinsic
response through the use of exogenously transplanted cells.
Mesenchymal stem cells (MSCs) are a well investigated subpopula-
tion of BMMNCs (as discussed in §1.5.8). Here the potential of MSCs to
form cardiomyocytes is investigated. If proven, this would make them
suitable candidates for exogenous transplantation in chronic heart fail-
ure, with the hope that they could reverse the disease process through
de novo myogenesis. Two compounds with potential to induce cardiomy-
ocyte differentiation were chosen to be tested in vitro. These compounds
were 5-azacytidine and ascorbic acid (vitamin C). 5-azacytidine was cho-
sen as it has previously been shown to successfully cause transdifferen-
tiation of MSCs into cardiomyocytes (Antonitsis et al., 2008; Choi et al.,
2004; Fukuda, 2003; Kadivar et al., 2006; Makino et al., 1999; Xu et al., 2004;
Zhang et al., 2005). Ascorbic acid was selected as it was the only one of 880
compounds that enhanced differentiation of embryonic stem cells into car-
diomyocytes. All compounds were used at 10 µM (Takahashi et al., 2003).
The role of MSCs in an acute rat cardiac IR model was also investigated
here.
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5.1.1 Hypothesis
1. Human MSCs can be transdifferentiated into cardiomyocytes, in
vitro, using 5-Azacytidine or Ascorbic Acid.
2. Human MSCs can home to the ischaemic myocardium in rats.
5.1.2 Aims
1. To culture human MSCs.
2. To transdifferentiate human MSCs into a cardiomyocyte phenotype
with either 5-Azacytidine or Ascorbic acid.
3. To immunohistochemically phenotype transdifferentiated cells.
4. To inject human MSCs into a rat ischaemia-reperfusion model.
5. To track injected MSCs using in situ hybridisation for human Y-
chromosome.
6. To quantify homed cells within the myocardium.
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5.2 Methods
5.2.1 Human Mesenchymal Stem Cell Culture
Four immortalised human MSC lines were used for the in vitro experi-
ments. Two cell lines were derived from human bone marrow and were
labelled as L87/4 and L88/5, while the other two MSC cell lines were de-
rived from peripheral blood and were termed V54.1 and V54.2. All four
cell lines were a gift from Prof. Ralf Huss (Institute of Pathology, Univer-
sity of Munich, Germany) to the Department of Histopathology within
CRUK at 44 Lincoln’s Inn Fields, London. As such the cell lines are some-
times collectively referred to as Huss cell lines. All four cell lines were
immortalised using the simian vacuolating virus 40 (SV40) large T antigen
and cellular cloning.
The four cell lines have previously been immunophenotyped and
found to stain negative for CD45, CD68, CD133 and HLA-DR, whilst they
stained positive for the presence of CD105, CD10 and CD117 (Conrad
et al., 2008).
In vivo, the two bone-marrow derived MSC lines L87/4 and L88/5
have been shown able to contribute to a wide range of mesenchymal tis-
sues in NOD/SCID mice (Thalmeier et al., 2001).
All cell lines were cultured with Glasgow Minimum Essential Medium
(GMEM) supplemented with 20% FBS and penicillin (100 µg/ml), strepto-
mycin (250 ng/ml), and amphotericin B (85 µg/ml). The cell lines were all
cryopreserved and were thawed when needed, as described in §2.3.4.
Cells were passaged when the majority of wells in a culture plate had
reached 70–80% confluence, as described in §2.3.2.
5.2.2 In Vitro Transdifferentiation Method
In an attempt to differentiate the four MSC lines into cardiomyocytes, first
passaged MSCs were exposed to different concentrations (0.6125, 1.25, 2.5,
5 and 10 µM) of 5-azacytidine (Sigma-Aldrich, A2385) or ascorbic acid
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(used at the same concentrations, Sigma-Aldrich, A4403) for 24 hours on
day 3 of culture.
Cells were grown in twenty-four well plates, with the different concen-
trations of 5-azacytidine or ascorbic acid taking up the first five columns
of the culture plate. The final column was used for control MSCs that were
treated with vehicle only (DMSO).
In total, eight plates were grown for the testing of each cell line and
for testing each of 5-azacytidine and ascorbic acid. Thus, for each cell line
and for each individual concentration of the compounds tested n=32, in
other words 32 wells were assessed for cardiomyocyte formation in total
for each experimental variable.
Changes in morphology were compared with the untreated cell cul-
tures on a daily basis for up to 14 days following exposure to 5-azacytidine
or ascorbic acid. Successful differentiation to a cardiomyocyte phenotype
was acknowledged if spontaneous contraction of cells was noted and if
the same cells subsequently stained positive for cardiomyocyte specific
marker (Troponin-I) using immunohistochemistry. Staining for Troponin-I
was performed, as described in §4.4.8.
5.2.3 Rat Ischaemia-Reperfusion Model
The rat IR model was used as described in §2.6. In contrast to the in vitro
studies only one cell line was examined in the in vivo model. This was the
L88/5 human bone marrow derived MSC line, which has already shown
in vivo potential (Thalmeier et al., 2001). The cells, at a dose of 1×107 in 500
µl PBS, were administered via the right internal jugular vein immediately
upon reperfusion. Animals were terminated six hours following IR injury
and tissue was collected and prepared for blocking, as described in §2.8.
In total, four rats received the MSC cell treatment and two rats received
vehicle only (PBS).
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5.2.4 In Situ Hybridisation
The human MSC line L88/5 used in the in vivo study was derived from
a human male subject. Therefore, in situ hybridisation for the human Y-
chromosome was used to identify and quantify cells homed to the IR in-
jured rat hearts. This was performed as previously discussed in §6.2.3.
In addition to the Y-chromosome labelling, to confirm the findings
from the Y-chromosome probe, in situ hybridisation on the heart sec-
tions was also performed using human pan-centromere probe (Cam-
bio, PAHC0001-G), aside from substitution of the Y-probe for the pan-
centromere probe no other changes were needed to the in situ hybridis-
ation method used for the Y-chromosome.
In total, 10 sections from each ventricle from the MSC treated rats was
examined with in situ hybridisation for each of the Y and pan-centromere
in situ probes. Additionally, 10 sections from each of the two control rats
were also examined.
5.3 Results
5.3.1 In Vitro Transdifferentiation
The results presented here are conclusively negative. Both 5-azacytidine
and ascorbic acid failed to induce myogenic differentiation of any of the
four MSC lines examined here at any of the concentrations tested. On the
whole, there were no obvious morphological changes seen between con-
trol cells or cells treated with either 5-azacytidine or ascorbic acid (see Fig-
ure 5.1).
Infrequently, some cells, usually on an individual cell basis, were seen
to form a more myocyte-like morphology becoming longer, broader and
flatter (see Figure 5.2). However, no evidence for spontaneous contraction,
one of the hallmarks of a cardiomyocyte phenotype, was ever found in any
of the culture cells. Furthermore, when tested immunohistochemically,
the few interesting cells that had taken on a more myocyte-like morphol-
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ogy were never found to stain positively for the cardiac specific marker
Troponin-I.
Therefore, no evidence for differentiation towards a cardiomyocyte-
like phenotype was found using any of the four MSC lines with either
ascorbic acid or 5-azacytidine.
5.3.2 Mesenchymal Stem Cell Injection in a Rat Ischaemia-
Reperfusion Model
In situ hybridisation for the human Y-chromosome was used to identify
any injected human male MSCs cells that may have homed to the IR in-
jured rat hearts. Using this approach only one cell was found to be posi-
tively labelled with the Y-chromosome probe amongst the 40 sections re-
viewed, these being 10 sections from the LV of each rat (see Figure 5.3).
As this result was not expected, to provide further confirmation, an-
other 40 sections from the same rat hearts were examined using in situ hy-
bridisation for human pancentromere DNA. As this probe produces mul-
tiple signals within a positively labelled nuclei, it produces a better signal
to noise ratio and thus helps spot rare events. It also reduces false positive
results. The results using the pancentromere probe confirmed the results
found using the Y-chromosome probe — only one cell in 40 sections was
identified, as one of the injected MSCs, due its positive labelling with the
human pancentromere marker. The results from the in situ hybridisation
tracking studies show an almost complete failure of MSC homing and en-
graftment to the IR injured rat hearts, six hours after intravenous delivery.
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(a)
(b)
Figure 5.1: Photomicrographs of MSC cell line V54.1 four days after exposure to
(a) vehicle only and (b) µM 5-azacytidine. No significant difference in cell mor-
phology is seen between the two groups. Visual inspection did not reveal any
evidence for spontaneous contraction in either group
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(a) (b)
(c) (d)
Figure 5.2: Cells, in this case the L88/5 human mesenchymal stem cell line 5 days
after exposure to 5 µM 5-azacytidine, were rarely found to take on myocyte like
morphology, this was sometimes seen in small groups of cells as shown in (a), but
more frequently it was seen in one or two cells at a time, for example as shown
by the white arrows in (b) and more obviously in the centre of photos (c) and (d).
Despite the promising morphological changes no cells at anytime were seen to
spontaneously contract.
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(a) (b)
(c) (d)
Figure 5.3: In situ hybridisation for human Y-chromosome seen as green dots
(FITC), against blue nuclei (DAPI). (a) Negative control for Y-chromosome in the
male Huss cell line L88/5 and (b) the positive control, showing multiple cells
positive for the Y-chromosome. (c) is the negative control for Y-chromosome in
the rat heart treated with 107 L88/5-mesenchymal stem cells following IR injury
(d) is a positively labelled section from the same model, the white arrow marks
the presence of one cell possibly positive for Y-probe within the rat heart, and thus
may represent a cell that homed and engrafted into the reperfused myocardium.
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(a) (b)
(c) (d)
Figure 5.4: In situ hybridisation with human pancentromere probe. Pancen-
tromere marker is seen has multiple green dots (FITC) within the blue nuclei
(DAPI) of the cells. (a) and (b) show the negative and positive controls for the
pancentromere marker in sections of the human mesenchymal stem cell (MSC)
line L88/5, all cells within the positive control were seen to test positive with
multiple signals seen in each nuclei — providing a much better signal to noise
ratio compared to the results of the Y-chromosome probe. (c) shows the negative
control in rat heart, while (d) represents the only cell found to be positive for pan-
centromere marker within all sections tested from the rat hearts treated with 107
L88/5-MSCs following ischaemia-reperfusion injury.
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5.4 Discussion
Mesenchymal stem cells, are a heterogeneous population of cells that pro-
liferate in vitro and form colonies. They have a fibroblast-like morphol-
ogy, and can differentiate into bone, cartilage, and fat cells (Horwitz et al.,
2005). Further to this well described tri-lineage potential, MSCs have been
shown to transdifferentiate in vitro towards cardiomyocyte and vascular
cell phenotypes.
In vivo pre-clinical studies have demonstrated that MSCs have the ca-
pacity to instigate both myocardial repair and neovascularisation in mod-
els of cardiac injury. MSC transplantation in MI (Amado et al., 2005; Toma
et al., 2002; Valina et al., 2007) and ischaemic cardiomyopathy (Silva et al.,
2005) have reported functional benefits that include reduced scar forma-
tion and infarct size, improved regional and global ventricular function,
and increased vascular density and myocardial perfusion. There has also
been evidence of benefit in models of non-ischaemic models such as di-
lated cardiomyopathy (Nagaya et al., 2005; Ohnishi et al., 2007).
This emerging potential of MSCs both in vivo and in vitro suggests a
role for their use in a wider clinical context. Their potential clinical use is
encouraged by other beneficial characteristics, which include ease of col-
lection, storage and subsequent tissue culture that allows dose escalation if
required. MSCs also appear to be relatively immunoprivileged and there-
fore a possible candidate for allogeneic treatment, a wider emerging ben-
eficial immunoregulatory role for MSCs is also emerging that is reviewed
in (Uccelli et al., 2008).
The above observations of the regenerative potential of MSCs in vitro
and in vivo suggest that they are an ideal candidate for potential use in
chronic heart failure, with the aim of de novo myogenesis and vasculoge-
nesis. That is why, the potential of four immortalised human MSC lines to
differentiate into cardiomyocytes in vivo was explored here. Moreover, the
capacity for one of the cells lines, L88/5, to impact positively in an acute
rat IR model was also investigated.
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5.5 In Vitro Model
Transdifferentiation of any of the four human MSC lines used here to-
wards a cardiomyocyte phenotype was not achieved with either the use
of 5-azacytidine or ascorbic acid. Lack of cardiomyocyte differentiation
was shown by failure of any observation of spontaneous contraction, and
also by lack of any cells staining positive with the cardiomyocyte-specific
marker troponin-I. In the experiment described here, cells were exposed to
5-azacytidine for 24 hours on day three of culture and were then observed
for up to 14 days following this for signs of myogenic differentiation.
In contrast to the results documented, here others have successfully
transdifferentiated MSCs into cardiomyocytes. The original description of
MSCs differentiating into cardiomyocytes was performed in immortalised
cells by repeated dosing with 5-azacytidine (Makino et al., 1999). The exact
cause of the failure in the experiments here is yet to be fully elucidated. All
four cell lines were immortalised and this may have changed the biology
of the MSCs and resulted in their failure to transdifferentiate. However,
this did not impede the transdifferentiation of MSCs to myocytes in the
work by Makino (Makino et al., 1999). In contrast to that work, MSCs were
only exposed once for 24 hours in the experiments described here, but
other studies have had success with transdifferentiation with the same 24
hour protocol (Tomita et al., 1999).
With respect to culture conditions, MSCs were cultured in a well recog-
nised standard media with the usual additions, and under the usual con-
ditions. The MSCs have previously been phenotyped and express a typical
pattern of markers both negative and positive expected for MSCs (Conrad
et al., 2008). For differentiation, five concentrations of 5-azacytidine were
used encompassing the range of doses described in the literature. It would
therefore appear that culture conditions cannot explain the failure of dif-
ferentiation observed. Ascorbic acid also failed to differentiate MSCs into
cardiomyocytes at any of the doses tested, but this finding was not com-
pletely unexpected as ascorbic acid had only previously been shown to
work in embryonic stem cell differentiation (Passier et al., 2005; Takahashi
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et al., 2003).
5-azacytidine, a cytosine analogue, can cause phenotypic changes in
multiple cell types by activating novel gene expressions both in vitro
and in vivo (Fukuda, 2002). The complete mechanism for the action of 5-
azacytidine remains undefined, but it has been suggested it may activate
silent genes by inhibiting DNA methylation (Chiu & Blau, 1985; Creusot
et al., 1982; Jones & Taylor, 1980) or modulate genes to alter their responses
to exogenous triggers (Chiu & Blau, 1985; Clough et al., 1982) — a process
that may be entirely stochastic. In a worst case scenario, 5-azacytidine in-
duced differentiation could be due to a random reprogramming of gene
expression induced by the drug, rather than to MSC potential for car-
diomyogenic differentiation. This unpredictable differentiation of MSCs
may explain the negative results obtained here. Alternatively, the negative
results could be due to some negative effect of the immortalisation process
that remains unidentified as yet.
In summary, four human MSC lines failed to differentiate into car-
diomyocytes with exposure to either 5-azacytidine or ascorbic acid. This
failure has not been fully explained, but may represent an insight into the
stochastic nature of the mechanism of action of 5-azacytidine, or it may be
due to a side-effect of the immortalisation process that is yet to be defined.
This experiment could be repeated with freshly isolated MSCs, to resolve
the possibility of the immortalisation process being a factor in the failure
of transdifferentiation seen here.
5.6 In Vivo Model
Human MSCs did not home to the rat heart following IR injury. In a rat
cardiac IR model, 1×107 human MSCs, from the L88/5 cell line, were in-
travenously injected immediately upon reperfusion. Six hours later the
rat hearts were removed and subsequently examined using in situ hy-
bridisation for both human Y-chromosome and human pancentromere
marker. Using both techniques, human Y-chromosome and pancentromere
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labelling were clearly demonstrated in purified sections of the human
MSC line L88/5. When these techniques were applied to the rat hearts,
a method allowing identification of any homed cells within the heart, only
one cell labelled with Y-chromosome was found after reviewing 40 ven-
tricular sections from MSC treated rats. This finding was confirmed with
the use of the pancentromere probe, which again showed only one posi-
tively labelled cell out of the 40 sections reviewed. These results show an
almost complete lack of homing of the human L88/5 MSC line towards the
ischaemic rat heart. As homing was not assessed at any earlier time points
it cannot be ruled out that there was initially good cell homing but subse-
quently poor cell retention within the ischaemic myocardium as demon-
strated at six hours following reperfusion.
The lack of cell homing here may have been due to the cross-species
nature of the transplant, as human MSCs were injected into fully immuno-
competent rats. These possibilities could be examined by repeating the ex-
periment with the same human MSC line, but using a immunodeficient
host animal such as the NOD/SCID mouse. Notably, the same human
MSC line as used here has been shown to engraft in a diverse range of
organs when injected into the NOD/SCID recipient mice (Thalmeier et al.,
2001). An alternative approach would be to inject freshly isolated rat MSCs
into the rat IR model. The effects of immortalisation of the cell line on its
homing ability is unknown. The use of fresh cells would also address this
concern.
There is mounting evidence that MSC homing to ischaemic tissues is a
very inefficient process. In other words, there may be no deficiencies in the
model used here, simply provision of further evidence of the poor homing
and engraftment ability of MSCs within the ischaemic heart. Additionally,
the cell delivery method significantly effects the efficiency of MSC hom-
ing and engraftment — intramuscular injection being better than intra-
coronary, and both being better than intravenous delivery (Freyman et al.,
2006; Li et al., 2009).
Several studies have compared MSC homing and engraftment ability.
In a rat MI model, in which injected MSCs were tracked using whole body
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bioluminescence, 80% of intravenously injected cells were removed by the
host within 24 hours and only 5% survived to 48 hours at which time the
remaining cells were almost entirely located in the lung. In the same study,
10% of cells injected intra-aortically survived at 48 hours. The cells were
distributed throughout the heart, lungs, and kidney. Whilst intramyocar-
dial injection resulted in 25% cell survival at 48 hours and the majority of
cells appeared to be located in the heart (Li et al., 2009). A similar study
of intravenous injection of MSCs demonstrated initial localisation in the
lungs with a subsequent redistribution to non-target organs such as liver,
kidney, and spleen. Cardiac localisation was only detectable by SPECT
and not by MRI, indicating that the concentration of incorporated cells
in the heart was below the detection level of MRI and thus cardiac en-
graftment could be considered minimal (Kraitchman et al., 2005). These
results were confirmed by a third study demonstrating that the majority
of MSCs were entrapped within the lungs after intravenous delivery (Bar-
bash et al., 2003). It has been speculated that the trapping of MSCs within
the pulmonary tissues is related to their relatively large cell size. However,
a complete explanation remains to be determined.
Others have sought alternative explanations for poor MSC cell homing.
For example, ROS are generated during both ischaemia and reperfusion
and have been shown to inhibit cellular adhesion of engrafted MSCs — an
effect that could be reversed by a free radical scavenger (Song et al., 2010).
It is hoped that with further research, the complete homing and engraft-
ment mechanism will be unravelled, providing opportunities to optimise
therapeutic delivery of MSCs into the ischaemic heart.
In conclusion, cell homing after intravenous injection of MSCs in a rat
IR model was found to be insignificant. The low frequency of cells found
within the rat hearts resembles the findings of other studies that have
demonstrated that MSC retention after intravenous injection is minimal,
with the majority of cells becoming trapped within the lungs. Intramuscu-
lar and intra-arterial delivery of MSCs have been shown to avoid this pit-
fall. It is also possible that the use of human MSCs in fully immunocom-
petent rats contributed to the poor MSC homing that was evident here.
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Further work in this area could be optimised with respect to MSC reten-
tion in ischaemic tissues by intramyocardial injection of rat MSCs into rat
hearts, or some other alternative same-species donor and host model.
5.7 Conclusion
Mesenchymal stem cells are an attractive option for clinical cardiovascu-
lar therapy because of their ability to facilitate myocardial and vascular
repair. In addition there is potential for their use in allogeneic transplanta-
tion. Finally, they are easy to collect, manipulate and expand once in tissue
culture. However, as was demonstrated here, many aspects of the biology
of their therapeutic use remain to be fully understood and optimised. Con-
tinued research into the basic physiology of MSCs, especially with respect
to their therapeutic uses, is needed if we are to fully realise their clinical
potential.
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CHAPTER 6
Evidence for Cellular Regeneration by
Extra-cardiac Progenitors in Transplanted Human
Hearts
6.1 Introduction
The adult heart has long been considered to have no post-natal repair
mechanism. Adaptive cellular mechanisms to injury or stress have been
felt to encompass either cardiomyocyte hypertrophy or cardiomyocyte
death and subsequent fibrosis.
However, evidence for a cellular repair process within the adult heart
that is capable of generating new cardiomyocytes and vascular cells, rather
than resorting to a fibrotic process is now emerging. The new evidence is
mainly arising from two sources. Firstly, from human sex-mismatch trans-
plant studies — transplant cases where male patients have been given
a female heart or female patients have been given a male bone marrow
transplant — this scenario results in chimerism, a term that describes an
organism formed from at least two genetically distinct populations of cells
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(in these cases a mix of cells with either a XY or XX sex chromosome phe-
notype). Of note, the term chimerism was appropriated from the ancient
Greek legend of the Chimera, a mythical animal that was composed of
three genetically different origins — part lion, part goat, and part snake
(Bolli, 2002). The second strand of evidence comes from detailed examina-
tions of both animal and human myocardial tissue (also often from trans-
planted hearts) and its cellular constituents with respect to stem cell phe-
notype and kinetic studies examining cell turnover and replication.
Through a collaboration with Prof. Marlene Rose, Professor in trans-
plant immunology at the Royal Brompton and Harefield NHS Trust, sec-
tions from ex-planted female hearts originally transplanted into male pa-
tients were made available for research studies.
Due to the unique properties of the sex-mismatch heart transplant sam-
ples supplied, which allow cell lineage tracing, evidence for human post
natal cardiac repair was looked for. A method that combined both im-
munohistochemistry for cell phenotyping with in situ hybridisation for
human X and Y chromosomes for cell tracking was used to characterise
the supplied tissue.
6.1.1 Sex-mismatch Transplantation
Human organ transplantation, although based on clinical need, can pro-
vide opportunities to further understand the processes involved in the
post-natal repair and restoration of adult tissues. In particular, this oppor-
tunity is provided when the donor transplant organ is sex-mismatched
with the recipient, i.e., transplanting a female organ into a male patient or
vice-versa. This situation can be capitalised on by using in situ hybridi-
sation, a technique that allows identification of individual chromosomes
within individual cells, on a cell by cell basis. For example, cells can be
identified as male, i.e., containing X and Y chromosomes, or as female,
i.e., containing two X chromosomes. This method is one of several tech-
niques that have been used to track or trace a cell’s lineage in stem cell
experiments. The combined use of a method of cell lineage tracking with
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a method for identifying a cell’s phenotype has proved to be one of the
core techniques applied in stem cell biology over the last decade. In ani-
mal models, cell fate and lineage are normally tracked using analogous but
different methods, such as the injection of cells from a transgenic model,
in which all cells carry a reporter gene such as GFP or LacZ, into another
animal whose cells lack the reporter gene. The two very commonly used
reporter genes of GFP and LacZ are dependent on genetic transfection of
cells and this is therefore an undesirable technique for human research.
A “naturally” occurring side-effect of human sex mismatch transplants is
thus to provide a unique and important opportunity by which cell lineage
may be tracked in humans due to sex chromosome differences, without
the need to resort to the use of gene transfection of human cells with other
report genes.
In the case of human heart sex-mismatch transplantation, the scenario
in which a male recipient receives a female heart has proved most useful
for lineage tracking. This allows investigation of post-natal cardiac repair.
The concept is based on the premise that all cells within the female trans-
planted heart when examined for the presence of sex chromosomes using
in situ hybridisation should be seen to have an XX phenotype. If any cells
are found to have an XY sex chromosome phenotype, these cells must have
originated from the host and migrated to the donor heart at some point af-
ter the transplantation. This finding can be further enhanced if the “new”
cell’s phenotype can also be identified, this is usually achieved by the use
of an immunohistochemical based method.
The technique of in situ hybridisation to identify the sex of cells within
female hearts transplanted into male donors was used here to identify the
cells’ origin, i.e., whether the cells were host or donor derived and thus
whether they could represent post-natal cardiac repair. Cells were also
phenotypically defined using immunohistochemistry.
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6.1.2 Hypothesis
Cells originating from the bone marrow contribute to post-natal cardiac
repair.
Aims
1. To use in situ hybridisation to visualise the ‘X’ chromosome to iden-
tify human female cells.
2. To use in situ hybridisation to visualise the ‘Y’ chromosome to iden-
tify human male cells, and to quantify the number of chimeric cells.
3. To apply dual ‘X’ and ‘Y’ probes on the same histological section,
thus labelling both sex chromosomes. This will identify the “sex”
of the cell without ambiguity and detect any occurrences of donor
and recipient cell fusion in sections obtained from patients who have
received a sex-mismatch transplant.
4. To use immunohistochemistry to characterise the phenotype of any
identified chimeric cells
5. To develop a technique of triple labelling — the combination of X
and Y in situ probes plus one immunohistochemical marker such as
CD45 — on the same coronary artery section, unequivocally iden-
tifying the origin and phenotype of cells within the sex-mismatch
heart transplant sections.
6.2 Methods
6.2.1 Sample Collection and Preparation
Biopsies were taken from female hearts that had been transplanted into
male patients, but that had subsequently been ex-planted due to trans-
plant rejection. Following biopsy collection, tissue was prepared for his-
tology by fixing, blocking and cutting, as set out in §2.9.
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In total, 10 paraffin sections were available for histological staining
from 10 different patients. Unfortunately, no clinical details were available
for the patients involved, such as age, duration of transplant and grade of
rejection, that may have provided further insight into the process of car-
diac chimerism.
The fixation of the collected tissues had not been standardised and had
been performed for variable lengths of time. This produced problems dur-
ing the digestion steps for both immunohistochemistry and in situ hy-
bridisation as the optimum timing of digestion had to be reviewed and
worked out with a time series for each individual block of tissue, rather
than just once for the whole collection. This meant that valuable tissue
from the small collection was lost while optimising the method for each
individual block. This clearly underlines the benefits of standardising all
methods on experiment reproducibility.
6.2.2 Immunohistochemistry
When required, immunohistochemistry was performed prior to the in
situ hybridisation step. Detailed methods for immunohistochemistry can
be found in §2.9. To help phenotype cells within the human myocardial
sections, the following antibodies were used: CD45 (Leukocyte common
antigen - for WBCs, Dako, M0701); CD31 (Endothelial cell marker, Dako,
M0823); and α-smooth muscle actin (Sigma, A-2547).
When performing combined immunohistochemistry and in situ hy-
bridisation, slides were dewaxed and taken down to 100% alcohol. They
were subsequently washed in running tap water. Antigen retrieval was
then performed. The optimum method for each antibody was determined
by comparing the results of multiple methods with multiple time points
used for each method. Usually one of no retrieval, trypsin digestion, mi-
crowave retrieval, or pressure cooker retrieval was used.
For example, for human CD31, following washing in tap water, mi-
crowave retrieval was performed by “cooking” slides in NaCitrate for 10
minutes in the microwave. After cooling, the slides were washed twice
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with PBS for 5 minutes each. Depending on the tertiary step used, en-
dogenous peroxidases or alkaline phosphatases were blocked. Slides were
then incubated in the primary antibody. Again, the optimum dilution and
length of incubation had to be determined by comparing a series of dilu-
tion strengths and incubation times. For CD31, the primary antibody was
used at a dilution of 1:50 and incubated for 35 minutes. For α-smooth mus-
cle actin, incubation was again 35 minutes and dilution was 1:4000. CD45
was used as 1:400 and incubated for 35 minutes.
After washing twice with PBS for 5 minutes, an appropriate biotiny-
lated second layer was used, such as biotinylated rabbit-anti mouse anti-
body (Dako, E354) at a dilution of 1:300 for 35 minutes.
After two PBS washes for 5 minutes the tertiary layer was added,
Streptavidin-Alkaline phosphatase (Dako, D396) at 1:50 for 30 minutes.
Slides were then washed twice with PBS for 5 minutes. Finally, the chro-
magen was added. This was often Vector red kit that was incubated for
10–30 minutes. Length of incubation was determined by visual inspection
and observation of chromagen deposition. If the samples were undergo-
ing in situ hybridisation, they would be washed in water and then the in
situ method as outlined before would be followed, otherwise the samples
would be washed in water, counterstained, and mounted.
6.2.3 In Situ Hybridisation Methods
Chimeric cells were visualised using in situ hybridisation for human X
and Y chromosomes with fluorescent probes. Cell phenotype was iden-
tified using fluorescent immunohistochemistry. The two techniques were
combined to produce a method for simultaneous cell lineage and pheno-
type tracking.
The in situ hybridisation method was a two day process.
Day One Firstly slides, if not done already, were dewaxed and then in-
cubated in 1M Sodium Thiocynate for 12 minutes at 80◦C. Slides were then
washed twice in PBS for 5 minutes.
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Digestion was then performed with 0.4% w/v pepsin in 0.1 M HCL at
37◦C. The length of this step was dependent on any prior digestion need
for combined immunohistochemistry. The optimum length of digestion
was determined by a time series and review of results. On digestion com-
pletion, proteases were quenched with 0.2% glycine in double concentra-
tion PBS for two minutes at room temperature. The slides were then rinsed
twice in PBS for 5 minutes.
Post-fixation was performed by incubating in 4% para-formaldehyde
in PBS for two minutes at room temperature. Then the samples were
washed twice in PBS for 5 minutes.
All slides were then dehydrated through graded alcohols and air dried.
Once dry the probe mixture (5–15 µl per slide) was added. Either human
X, Y or both was added to sections (Cambio or Qbiogene). The probe and
tissue section were then covered under a coverslip and the edges sealed
with rubber cement. The whole slide was then heated to 80◦C for 10 min-
utes. All slides were then placed in a humid chamber (an oven with beaker
of PBS inside) at 37◦C and incubated overnight.
Day Two The following day all slides were removed from the humid
chamber and washed three times for 5 minutes with SSC at 37◦C and
washed again a further three times but with PBS for 5 minutes.
To finish, slides were counterstained and mounted with Vectashield
Hard Set containing DAPI (Vector Laboratories, UK, H-1500).
Fluorescent images were acquired with an Olympus BX41 microscope
with integrated camera and SmartCapture software (Digital Scientific,
UK), see §2.11.2 for further information.
6.2.4 Novel Immunohistochemical and In Situ Hybridisa-
tion Triple Labelling Method
Most laboratories do not combine in situ hybridisation and immunohis-
tochemical techniques. When they are combined they are usually done so
in a dual fashion - one in situ probe plus one immunohistochemical anti-
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body and chromagen. The dual approach was helpful in initial studies of
chimerism offering the possibility of tracking a cell’s lineage and identify-
ing its phenotype.
However, after the observation that host and donor cell fusion can be
the mechanism by which chimerism is brought about, it has become im-
portant to find methods that can ascertain a cell’s lineage, its phenotype
and to simultaneously visualise donor and host cell fusion. In the con-
text of animal experiments, this triumvirate of aims can be accomplished
using sophisticated combinations of promoter and reporter genes in com-
bination with the Cre-Lox system. In humans, where chimerism can only
be studied under conditions in which a sex-mismatch transplant has oc-
curred, the only way to image fusion, while identifying a cell’s lineage and
phenotype, is by using a triple staining technique that uses in situ hybridi-
sation to identify X and Y chromosomes with a third stain for immuno-
histochemistry. Imaging both X and Y chromosomes plus an immunohis-
tochemical antibody, plus the use of a nuclear counterstain, is technically
challenging as four different chromagens, or alternatively four different
fluorophores, must be found that can be visualised independently with-
out impacting on the results of the other stains.
A novel technique was developed here that overcomes the problems
with spectral overlap using the ‘old’ or usual triple staining method —
X chromosome conjugated to FITC, Y to Cy3 and a marker of phenotype
stained for with Vector Red. Cy3 and Vector Red are difficult to distinguish
and can lead to false positive results for chimerism.
The new technique described here relies on the fact that all of the flu-
orophores used have distinct emission spectre and hence will not inter-
fere with the detection of each other. The new method utilises the same X
and Y probe as previously (FITC for X, Cy3 for Y), but ELF97 (Molecular
probes, E6578) is used for the marker of phenotype with TO-PRO 3 used
for the nuclear counterstain (Far red-Cy5, Molecular Probes). The ELF97
fluoresces in the blue-wavelength and as such is distinct from the green
and red wavelengths of the X and Y chromosomes or the far-red nuclear
counterstain. This gave interpretable images with less background artifact.
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To perform triple labelling using ELF97 as the chromagen for the im-
munohistochemistry and in situ hybridisation for X and Y chromosomes,
the following method was used.
Slides were first dewaxed and blocked. An additional blocking step
with the ELF97 blocking buffer followed for 30 minutes. Sections were
then incubated in rabbit serum at 1:25 dilution for 15 minutes. The appro-
priate primary antibody was then added to the slides for 35 minutes at
a dilution ten-fold greater than used with other chromagens. After each
incubation step, three washes with ELF97 wash buffer were always per-
formed for 5 minutes each. After a suitable secondary layer had been in-
cubated and rinsed off, Component A-Streptavidin was added to sections
for 30 minutes at a dilution of 1:250 in wash buffer. Then Component B-
Biotin-Alkaline Phosphatase was incubated with the sections for 30 min-
utes at 1:250 in wash buffer. Following this step, the sections were washed
three times in ELF97 pre-reaction buffer. Then sections were then coated
with Component C diluted 1:20 in Component D and incubated for 10
minutes. Sections were then rapidly rinsed in ELF97 stop buffer and then
incubated in a fresh batch of stop buffer for 10 minutes.
Following this step, slides were taken through the in situ hybridisation
protocol, unchanged apart from altering the counterstain to To-pro 3 (10
µl of To-pro 3 [Molecular probes, T3605] added to 1000 µl Prolong Gold
[Molecular Probes, P-7481] then approximately 50 µl added to each slide
prior to coverslipping).
6.2.5 Cell Counting
For cell counting, twenty visual fields were analysed on each slide. Fol-
lowing acquisition of each visual field as a saved jpeg image, the images
were loaded into ImageJ (Abramoff et al., 2004) and the number of cell
nuclei counted.
As described in the ImageJ manual, all images were imported into Im-
ageJ and then converted to grayscale using the Image Menu convert to
8-bit option. The images were then made binary using the Process menu
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selecting the make binary option. Finally, the cells were counted using the
analyse particles option (see Figure 6.1).
The cell count produced by ImageJ was taken as the total number
of cells for that visual field. All cells were then classified according to
morphology and expression of antibodies (CD45, CD31 and SMACT). In
addition, the cells were classified as either Y-chromosome-positive or Y-
chromosome-negative. Cells were considered positive if the Y signal was
contained in the nucleus and completely surrounded by cytoplasm for
each cell type. The percent of each cell type that was Y positive was calcu-
lated by dividing the total number of Y-positive cells counted by the total
number of nuclei counted for each specimen and for each cell type.
Furthermore, the position of the cells within the heart was classified
as myocardial or if within a vascular structure as intimal, medial or ad-
ventitial. Cells seen within the lumen of vessels were not counted. Also
of note, as other studies have shown the sensitivity for detection of Y-
chromosomes using the in situ hybridisation assay is less than 100%, the
real numbers of Y-chromosome-positive cells are usually about 1.5–1.75
times higher than detected. The percentages documented in the results
section here have not been corrected by this factor.
6.3 Results
6.3.1 Y Chromosome In Situ Probe
The Y chromosome in situ probe was successfully used to visualise human
male cells in control tissues — liver, skeletal muscle, penis, MSC line L88/5
— and the experimental tissue of human coronary artery (see Figure 6.2).
6.3.2 X Chromosome In Situ Probe
The X chromosome in situ probe was also successfully applied to con-
trol tissues and the experimental coronary artery tissue (see Figure 6.3 on
page 298).
295
Human Cardiac Chimerism 6.3 Results
(a)
(b)
Figure 6.1: Cell counting was assisted with the use of ImageJ Software (Ras-
band, W.S., ImageJ, U. S. National Institutes of Health, Bethesda, Maryland, USA,
http://rsb.info.nih.gov/ij/, 1997–2009.). For example, in (a) - for clarity, only cell
nuclei are shown, seen as blue, stained with DAPI shown from a section of human
myocardium, (b) - Using ImageJ software’s automatic particle analysis function,
individual cell nuclei can be counted and labelled for any photomicrograph im-
ages loaded into the software, a process that takes only a few seconds. This can be
done for fluorescent or light microscope derived images. This automation reduces
errors in cell counting but is also faster than the usual methods, especially when
counting the percentage of cells labelled with a rare but specific marker such as
the Y chromosome in chimeric studies — in which case the total cell count can
quickly be generated and then the few cells labelled with the rare marker can be
counted by hand prior to calculating the percentage of labelled cells.
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Figure 6.2: Positive control for human Y chromosome in situ probe — with Y chro-
mosome labelling visualised with FITC seen as green dots (white arrow) within
the DAPI labelled cell nuclei that appear blue. Cells shown here are human male
mesenchymal stem cell line L88/5.
6.3.3 Combined X and Y Chromosome In Situ Probe
Following the successful single application of the in situ sex chromosome
probes, double labelling was attempted and successfully achieved in posi-
tive controls including human male liver, skeletal muscle, penis and coro-
nary artery sections. In single labelling experiments FITC was used to vi-
sualise in situ labelling, however, in double labelling experiments, FITC
was used for X chromosome visualisation and Cy3 for the Y chromosome
labelling (see Figure 6.4).
6.3.4 Detection of Cardiac Chimerism
Evidence for cardiac chimerism (i.e., the presence of male Y-positive cells
within the female ex-planted hearts) was seen in all sections tested with
in situ hybridisation for human X and Y chromosomes. Episodes of fusion
were found very infrequently (only two instances in total) compared to
the extent of chimerism seen.
Cells labelled with the Y chromosome in situ probe were found
throughout the three distinct histological zones, of which human arter-
ies consist, these being the intima or neointima, media and adventitia. The
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Figure 6.3: Positive control for human X chromosome in situ probe — X chromo-
somes labelled with FITC are seen as green dots within the blue appearing cell
nuclei labelled with DAPI. Note in contrast to the previous figure several cells are
seen to contain two green dots as would be expected in human female cells where
cells contain two X chromosomes (white arrows). Cells seen here are taken from
a tissue section of human female coronary artery.
three layers can be distinguished due to their position in relation to the
lumen of the artery and the internal elastic membrane. The intima is the
inner most layer and, as such, forms the inner luminal surface. It usually
consists of a single layer of endothelial cells. The outer boundary of the
intima is formed by the internal elastic membrane, which also demarcates
the beginning of the media that consists almost entirely of smooth muscle
cells. The final outer layer is the adventitia that consists mainly of collagen
fibres secreted by fibroblasts. Macrophages are also frequently found here.
Intima and Neointima Male recipient cells were consistently found
within the neointima of arteries from the female donor hearts. Cells within
the neointimal layer labelled with the Y chromosome, seen as a red dot,
can be seen in Figures 6.5, 6.6, and 6.7. Such chimeric cells were found
more frequently in the neointima than within the media or adventitia.
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Figure 6.4: Combined X and Y chromosome in situ probe, X chromosome is visu-
alised using FITC shown in green and Y chromosome is marked with Cy3 seen
as red within the DAPI blue stained cell nuclei. Both chromosomes can be seen to
be positively labelled in this section of an arteriole from a male human heart.
Media Male recipient cells were also found within the medial portion of
the coronary arteries from the female ex-planted hearts (see Figure 6.8).
However, this was a much rarer finding than within the neointimal layer
of the arteries. This observation may be related to the increased distance
of the media from the vasculature when compared to the intima.
Adventitia In addition to finding Y-positive cells within the neointima
and medial layers, evidence of chimeric cells were also seen in the adven-
titial layer. Typically, much fewer Y-positive cells were seen in the adven-
titia than in the neointimal layer of the arteries examined, although some
sections of adventitia were sporadically found to have a much higher fre-
quency of Y labelled cells, for example, see Figure 6.9.
Thus, just as found in the medial layer, there was a much lower density
of chimeric cells in the adventitia compared to the neointima, but unlike
the medial layer rare pockets of high Y chromosome labelling were found
within the adventitia, whereas, the medial layer was seen to have consis-
tently low Y chromosome labelling.
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(a)
(b)
Figure 6.5: Photomicrograph of male recipient cells seen within the neointima
of a female donor coronary artery. X chromosome is seen as green (FITC) and Y
chromosome is seen as red (Cy3), cell nuclei are stained blue (DAPI). White box
in (a) is expanded in (b) to clarify dual staining for both X and Y chromosomes in
a single cell within the neointima.
6.3.5 Quantification of Y-chromosome Labelled Cells
In total, 6 sections from each of the ex-planted heart transplants were used
for quantification of Y labelled cells and for each section twenty visual
fields were assessed. The number of Y-positive cells are expressed as a
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Figure 6.6: Male recipient cells, as shown by dual staining for X chromosome
(FITC) and the Y chromosome (Cy3), within the neointima of the female donor
coronary artery. Cell nuclei appear blue (DAPI).
percentage of the total nuclei counted.
On average 4.81±0.67% of cells were found to be Y chromosome posi-
tive. This result excludes two outliers, in which the number of Y positive
cells (21.7 and 22.0% positive labelling) found in two separate visual fields
were found to be four standard deviations greater than the mean of the
rest of the sample.
With respect to the three histological compartments of the arteries
investigated, the neointima was seen to have consistently higher fre-
quency of Y labelled cells 4.84±1.38% compared to either that of the media
0.90±0.33%, or the adventitia 1.39±0.22%.
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Figure 6.7: Some sections of neointima, as shown here, contained a high density
of male recipient derived cells within the neointima of female donor coronary
arteries. X chromosome is seen as green (FITC) and the Y chromosome as red
(Cy3), cell nuclei are blue (DAPI).
Figure 6.8: Rarely, much rarer than finding male host derived cells in the neoin-
tima, male recipient cell were seen within the media of the female donor coronary
arteries. X chromosome is seen as green (FITC), the Y chromosome is seen as red
(Cy3) and cell nuclei are blue (DAPI).
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Figure 6.9: Male recipient cells were also seen in the adventitial layer of female
donor hearts. They were seen less often in the adventitia than seen in the neoin-
tima, but were found more frequently here than in the medial layer. Here at least
three male host derived cells (white arrows) can be seen within the adventitia of
the female donor coronary artery, as shown by their dual staining for X chromo-
some in green (FITC) and Y chromosome in red (Cy3), cell nuclei are blue (DAPI).
303
Human Cardiac Chimerism 6.3 Results
6.3.6 Immunohistochemical Markers
Inflammatory and Haematopoietic Markers Any of the Y positive male
cells that were demonstrated within the neointima, media and adventitia
of the coronary artery sections, could simply be circulating white cells.
To investigate whether this was the case, a triple labelling system was
utilised, in which the X chromosome was labelled with FITC (Green), the
Y chromosome with Cy3 (Red) and a marker of cell phenotype with Vec-
tor Red (Also red). In this case CD45, a pan-leukocyte cell surface marker,
was used to identify cells with an inflammatory or haematological iden-
tity. Figure 6.10 shows the positive and negative controls for the CD45
antibody.
The triple technique of FITC and Cy3 for sex chromosomes and Vec-
tor Red for CD45 staining was successfully applied to the human tissue
sections. However, the interpretation of the images was sometimes chal-
lenging with regard to identifying a true positive signal for the Y chro-
mosome due to the overlapping spectra of Cy3 and Vector Red, which are
both visualised on the same fluorescent wavelength. Despite this, CD45
positive cells were only ever seen on the endothelial surface on the lumi-
nal side of the arteries. Furthermore, when sections were triple labelled, all
of the Y positive cells observed within the neointima, media and adven-
titia were seen to be negative for CD45 staining. For example, Figure 6.11
demonstrates cells within the neointimal region that are positive for X and
Y chromosome but negative for CD45.
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Figure 6.10: Control sections from immunohistochemical staining of human
spleen with CD45 (a pan-leukocyte marker) are (a) positive control, positive stain-
ing seen as red (Vector Red) and (b) negative control, primary antibody not ap-
plied.
Figure 6.11: Triple labelling technique of female donor coronary artery ex-planted
from male recipients, with immunohistochemistry for CD45 (seen in red - Vec-
tor Red) and in situ hybridisation for human X and Y chromosomes, seen as
green and red dots respectively within the cell nuclei (FITC and Cy3). Red ar-
row demonstrates cell staining positively for CD45. White arrows indicate cells
positive for both X and Y chromosomes but negative for CD45, suggesting a host
derived cell with a non-leukocyte phenotype. Cell nuclei seen as blue.
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Endothelial Markers To further define the phenotype of male cells
found within the coronary arteries, sections were examined for the pres-
ence of X and Y chromosomes, and for the presence of CD31 (a marker of
endothelial cell phenotype).
Evidence for the presence of chimeric endothelial cells staining positive
for CD31 and containing both the X and Y chromosomes was seen (Fig-
ure 6.12), although due to problems with the method used, as discussed
below, the images are open to different interpretations.
The aforementioned problems of the triple labelling technique were
again a significant problem. The Y chromosome in situ probe is conjugated
to Cy3 and consequently fluoresces in the red channel, as does Vector Red,
used for the fluorescent marker of phenotype. Vector Red has useful qual-
ities, such as the production of a fluorescent precipitate that isn’t washed
off or destroyed by the subsequent in situ hybridisation steps following its
formation during immunohistochemistry. The issue, as discussed briefly
before, is that both the Cy3 used for the Y chromosome and the Vector
Red for phenotyping fluoresce in the red channel. Although their emis-
sion spectra are not identical, they possess significant portions of overlap.
Hence, a very intense signal in one channel can hide or cover a weak sig-
nal in the other channel. This is due to the limited dynamic range of the
photodetectors within the fluorescent microscope. The microscope adapts
to the strongest signal and detection of the weak signal is no longer within
its range. Unfortunately, the Vector Red stain gave a very intense signal
and obscured the signal from the Cy3 marker for the Y chromosome. This
coupled with the fact that they both appeared as red made it very difficult
to distinguish true Y positive cells from background noise and artifact.
Of all the sections stained and examined, the ‘best’ of these are shown in
Figure 6.12. As shown in the figure, the above described problems led to
images with major limitations. Although all the antibodies we used suf-
fered with the limitations described above, some were better than others,
for example CD45. This may be related to the extent of the antibody epi-
tope affinity. The better the antibody, the more Vector Red is precipitated
and the greater the contrast between Vector Red and the Cy3 of the Y chro-
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mosome probe.
Vascular Smooth Muscle The female artery sections were also stained
with smooth muscle actin (SMACT). Any cells staining positively for X
and Y chromosomes and SMACT would represent vascular smooth mus-
cle formed by the recipient after the transplant.
As discussed above, there were technical issues with the triple labelling
technique, in that the sections stained so strongly with Vector Red for
SMACT that any Y probe was difficult to detect amongst the intense signal
from the SMACT stain (see Figure 6.13).
Despite these shortcomings, some cells appeared to stain positive for
both the Y chromosome and SMACT. Such chimeric SMACT positive cells
were found within the media and neointima of the arteries examined.
6.3.7 Results of Novel Triple Staining Technique
After observing the difficulties of interpreting images produced with the
triple labelling technique of FITC for X chromosome and Cy3 for the Y
chromosome plus the use of Vector Red for labelling of a marker of cell
phenotype, it was clear that this technique could be improved by using
an alternative fluorophore for the marker of cell phenotype that would
not overlap with the Cy3 signal for the Y chromosome. A literature search
revealed the possibility of using ELF 97 (Molecular Probes, UK).
The ELF 97 immunohistochemistry kit contains an alkaline phos-
phatase substrate that yields a fluorescent precipitate — a process referred
to as enzyme-labelled fluorescence (ELF). This soluble ELF substrate fluo-
resces only weakly in the blue range. However, once its phosphate is enzy-
matically removed, an intensely fluorescent yellow-green precipitate ap-
pears at the site of enzymatic activity. The ELF precipitant can be excited at
345 nm and emits at 530 nm and can be visualised using a Hoechst/DAPI
long-pass filter, which is fitted as standard to most fluorescent microscope
units.
With ELF 97 used as the marker for cell phenotype, X and Y labelling
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remained the same using FITC and Cy3, but the nuclear stain was changed
to To-Pro-3 that emits in far red (Excitation 661 nm). Theoretically, these
four fluorophores would not overlap in the same way as the ’old’ triple
labelling technique and provide more precise images for interpretation.
The use of the new technique was limited due to the lack of remaining
tissue available for staining. However, once the optimum digestion and in-
cubation times had been defined by working through a matrix of digestion
and incubation times, the technique was found to provide clearer results
than the previous triple labelling technique. For example, in Figures 6.14
and 6.15, clear evidence of chimeric cells is seen with X and Y chromo-
some labelling and a marker of cell phenotype is visualised (in this case
SMACT - suggesting a smooth muscle phenotype). These images lack the
ambiguity of the old triple labelling technique and provide a more con-
vincing picture of chimerism with a definition of the cells phenotype and
its lineage. Ideally, this technique would have been used to repeat the ear-
lier studies using in situ hybridisation, plus a marker of cell phenotype,
including CD45, CD31 and more with SMACT, but there was no tissue left
for further experiments.
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(a)
(b)
Figure 6.12: Triple labelling of CD31 (endothelial cell marker) and X and Y chro-
mosomes in female donor coronary artery ex-planted from a male recipient. CD31
is shown as a red stain (Vector Red), X and Y chromosomes are shown as green
and red dots (FITC and Cy3), and cell nuclei are seen as blue (DAPI). Male host
derived endothelial cells were seen (white arrow) as demonstrated by presence
of staining for CD31 plus both X and Y chromosomes within the same cell.
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Figure 6.13: Female donor coronary artery ex-planted from male recipient is
shown. The section was stained with X and Y chromosome in situ probes seen
as green and red dots respectively (FITC and Cy3), also stained and smooth mus-
cle actin (SMACT) seen as a red stain (Vector Red). Extensive staining for SMACT
is seen in the medial layer of the coronary artery as this layer consists almost
entirely of vascular smooth muscle. White arrows point to cells that are Y chro-
mosome positive and SMACT positive — demonstrating a host derived vascular
smooth muscle cell within the donor coronary artery.
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Figure 6.14: New triple labelling technique combining immunohistochemistry for
smooth muscle actin (SMACT) seen as purple (ELF 97), with in situ hybridisa-
tion for human X and Y chromosome seen as green and red dots (FITC and Cy3)
within the cell nuclei, which are seen as blue (ToPro3). Unlike the previous triple
labelling technique (that used Vector red, FITC, Cy3) the fluorophores used with
this method have no spectral overlap and therefore produce a more defined im-
age with less chance of obtaining cells falsely identified as Y chromosome posi-
tive. This photomicrograph shows the new triple technique applied to a section
of female donor coronary artery ex-planted following transplantation into male
recipients. White arrows demonstrate cells positive for SMACT and both X and Y
chromosomes — suggesting male recipient derived vascular smooth muscle cells.
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Figure 6.15: Digitally enlarged example of new triple labelling technique, taken
from the previous figure 6.14, smooth muscle actin (SMACT) is shown as purple
(ELF 97), X and Y chromosomes are shown as green and red dots respectively,
within the cell nuclei seen as blue (ToPro3). White arrow demonstrates a cell pos-
itive for SMACT and both X and Y chromosomes — suggesting it is a male recip-
ient derived vascular smooth muscle cell.
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6.4 Discussion
The increasing burden of cardiovascular disease, coupled with its mor-
bidity and mortality despite best modern therapy, has led to an extensive
research effort focused on the development of better treatments.
One area that has received significant attention is the prospect of us-
ing stem cell derived techniques to improve outcomes in cardiovascular
diseases. Much of the hope for such new treatments is based around the
observation of chimerism within the post-natal myocardium. Opportuni-
ties to observe chimerism are best afforded in the human heart in the con-
text of sex-mismatched cardiac transplantation, in which a male patient
receives a female donor heart. Such circumstances offer an exceptional op-
portunity to identify newly derived cells within the donor heart, due to
the ability to detect the Y-chromosome that clearly identifies cells of host
origin (that must be “new” and formed post-natally) compared to cells of
donor origin.
Until recently, the adult heart was understood to be a post-mitotic or-
gan. The only adaptive cellular response was considered to be cardiomy-
ocyte hypertrophy. This view is now being challenged. The first sugges-
tion of a new understanding of cardiac cellular homoeostasis was the dis-
covery of continuing cell division in adult hearts, which appeared to be
stimulated by cardiac injury such as myocardial infarction, left ventricular
hypertrophy and heart failure (Beltrami et al., 2001).
The results obtained here further the base of evidence demonstrat-
ing the ability of cardiac tissues to undergo repair via contributions from
cells derived de novo during the adult heart‘s life span. Chimeric cells, as
demonstrated by the presence of Y chromosome positive cells within the
female hearts, were observed in the majority of sections reviewed. As all
cells within the donor hearts should be female with an XX phenotype, this
confirms that new cells have been added to the cardiac tissue mass, subse-
quent to the heart transplant taking place, that must be derived from the
host (in which all cells should have an XY phenotype). This is clear evi-
dence for a post-natal cardiac repair mechanism and refutes the previous
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model of the heart, in which no tissue repair was understood to occur and
the only mechanisms of change were either cell death and fibrosis or car-
diomyocyte hypertrophy. Now a third pathway has been revealed, of cell
replacement and renewal.
The demonstration of new host derived cells within donor my-
ocardium is an important one. However, the presence of the cells within
the cardiac tissue does not conclusively prove a process of cardiac repair
is occurring. To this end it is ideal to aim to prove the cells presence plus
its function. Thus, a triple labelling technique was used to identify the
cells’ lineage (X and Y chromosome in situ hybridisation labelling) plus
a marker for the cells’ phenotype (CD45, CD31, or SMACT). Using this
approach, none of the chimeric cells out with the arterial lumen were pos-
itive for CD45, suggesting that the newly formed Y-positive cells did not
have a leukocyte-like phenotype. Furthermore, evidence of chimeric cells
functioning as endothelial cells and smooth muscle cells was found, as
demonstrated by positive staining with CD31 and SMACT respectively.
The results from the triple staining technique were often difficult to inter-
pret due to the overlap in the fluorescent emissions of Cy3 (used for the
Y chromosome) with Vector Red (used to identify cell phenotype). Thus, a
new method for triple labelling was investigated with the aim of avoiding
fluorescent emission overlap — using FITC for the X chromosome, Cy3
for the Y chromosome, and ELF 97 for cell phenotype. This technique was
successfully developed for the first time, and as hoped, did provide clearer
images of a less ambiguous nature to allow better interpretation of the re-
sults. The new technique was not extensively applied due to the limited
number of remaining tissue sections available, but the few sections that
the technique was applied to gave clear results demonstrating chimeric
Y-positive cells with smooth muscle cell phenotype.
As all the histological specimens investigated here were obtained from
ex-planted female hearts suffering transplant rejection (after transplanta-
tion into male patients) and as the tissue was originally collected with
a focus towards investigating changes within the coronary arteries, an
opportunity was provided here to investigate the role of donor derived
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cells in the development of vascular chimerism. Documentation of repair
within the vascular system of the adult heart is as important as demon-
stration of myogenesis. As newly formed myocytes will have to be ade-
quately perfused for continued survival and optimum functioning. How-
ever, the focus on coronary arteries did limit simultaneous investigation of
changes within the cardiac muscle, i.e, the observation of cardiomyocyte
chimerism.
The frequency of Y chromosome labelled cells in the media and ad-
ventitia was less than that found in the neointimal layer. Both layers were
found to have approximately 1% of their total cellularity labelled with the
Y chromosome.
Y-positive chimeric cells were found in all three layers of the arterial
structure and examples of cells staining positive for CD31 and SMACT
were found. This suggests that donor derived cells are able to contribute
new cells with all three layers of the recipient arteries, with specific evi-
dence for smooth muscle and endothelial cell formation.
Several aspects of this study could be improved upon. Ideally, more
tissue would have been available for research but only a small finite collec-
tion of tissue was available and this could not be added to. The collection
of the tissue and its fixation had not been standardised and this probably
contributed to the wide variation in digestion times between tissue blocks
needed for optimum visualisation of the X and Y in situ probe in combina-
tion with the phenotypic markers. This meant that a lot of time, effort and
tissue was expended on optimising the method for each individual tissue
block, rather than once for the whole collection.
At the time that the human tissue was collected, this was done with a
view to examining transplant associated atherosclerosis in transplanted
hearts. Hence, the tissue found in the histological blocks consisted al-
most entirely of arterial sections. This provided an opportunity to examine
chimerism within the vasculature of the transplanted hearts, but there was
not enough myocardial tissue in the blocks to appropriately examine the
possibility of chimerism within the ventricular myocytes.
When counting cells, twenty visual fields were assessed from each sec-
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tion by capturing digital images that were then processed in ImageJ. In
retrospect, there was an unintentional bias towards capturing images of
visual fields containing neointima that contained the highest density of Y-
positive cells. Areas with lower levels of Y positive cells (the media and ad-
ventitia) were imaged less often, thus, the average percentage of Y-labelled
cells is likely to have been positively skewed away from the true mean. In
future, such skewing could be overcome by using some form of randomi-
sation with regards to collection of the visual field images used for the cell
counting.
Y chromosome labelling with in situ hybridisation is far from 100%
sensitive. The mean value for Y positive cells given here is therefore an
underestimation of the true mean. No corrective factor has been applied
here as in some other studies. Only the absolute values are provided here.
For example, within the literature correction factors ranging between 35–
50% have been used (Glaser et al., 2002; Laflamme et al., 2002; Quaini et al.,
2002).
Normal thickness tissue sections, 4 µ, were used throughout this study.
As the typical nucleus is thicker than this, there is a possibility that fusion
events or chimeric cells were missed, as the whole of a cell’s nucleus was
not imaged simultaneously. This issue could be addressed in future by the
use of confocal microscopy, a technique able to image up to 60µ of tissue
at a time.
As discussed above, the initial triple labelling technique produced im-
ages that were often difficult to interpret and this was addressed by the
development of a new triple labelling technique using ELF 97.
The use of the X and Y chromosome in situ hybridisation probe was
able to successfully identify new host derived cells within the donor
hearts. However, a failing of this method due to its nature is that the origin,
within the donor, of the cells could not be derived. All that can be stated
for certain is that new cells were found in the recipient hearts that were
donor derived and must have originated from an extra-transplant source.
Whether this source is from donor bone marrow, donor derived circulat-
ing progenitor cells or from a local progenitor cell source from the residual
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cardiac tissue left after the transplant remains to be determined.
6.4.1 Chimeric Cardiomyocytes Overview
Others have also shown the importance of studying solid organ or bone
marrow transplants and the insights they provide into the ability of circu-
lating cells to repopulate adult tissues. The majority of studies, as here,
have harnessed cases of transgender or sex-mismatch transplants, e.g.,
male patients who receive female hearts. As such, any cells identified
as containing the Y chromosome must be extra-transplant and therefore
also extra-cardiac in origin. The addition of immunostaining with specific
markers may then also identify the cells’ phenotype.
For example, in one prominent study (Quaini et al., 2002), when trans-
planted hearts were examined, Y-positive cells were found in the following
percentage: myocytes (9±4%), arterioles (10±3% percent) and capillaries
(7±1% percent). Of note, unlike the sections examined here, this group ac-
tively avoided assessing areas with neointimal formation in order to avoid
making measurements at sites of injury or of active inflammation that
may contain immunoreactive cells. They also used the absence of CD45
on chimeric cells to additionally indicate a non-inflammatory phenotype.
Additional studies of a similar ilk have confirmed that host-derived
progenitor cells can regenerate cardiomyocytes. However, very different
levels of host-derived cardiomyocytes in sex-mismatched transplanted pa-
tients have been described. For example, two studies were unable to find
any host-derived cardiomyocytes (Glaser et al., 2002; Hruban et al., 1993).
A third study only found very rare host derived single myocytes in one
out of four subjects tested (Fogt et al., 2003), whilst others found low lev-
els of cardiomyocyte chimerism, 0.04% (Laflamme et al., 2002), and 0.16%
(Mller et al., 2002). A higher frequency of mature cardiomyocytes, 1–2%,
were found in five myocardial biopsies 4 months after transplant (Bayes-
Genis et al., 2002), still much less than as claimed above, where a mean of
9% of myocytes were found to be Y-chromosome positive. In fact, in some
cases up to 15% of myocytes were found to be positively labelled (Quaini
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et al., 2002).
In a complementary study, in which the hearts of females who had
undergone sex-mismatched bone marrow transplantation were assessed
after autopsy for the presence of Y-chromosome positive cardiomyocytes,
the mean percentage of myocytes found to be positive was 0.23% (Deb
et al., 2003). This correlates with the majority of studies, which demon-
strate low levels of cardiomyocyte chimerism, usually <1%. This study
also suggests that, at minimum, the initial point of origin for the chimeric
cells found within the myocardium must be the bone marrow. It follows
that a circulating progenitor cells is likely to be an intermediary step in
this process.
The differences in the extent of Y-chromosome positive cells between
different studies has tried to be explained. There appears to be no cor-
relation between the degree of cardiac rejection and the length of time
since cardiac transplant, as several studies have given conflicting reports
with some suggesting higher rates with shorter transplant length and oth-
ers finding the opposite. The same is found with the extent of rejection,
which has shown to be both positively and negatively associated with an
increased percentage of Y-chromosome labelling (Bayes-Genis et al., 2004,
2002; Glaser et al., 2002; Hcht-Zeisberg et al., 2004; Quaini et al., 2002).
Some have suggested that the discrepancy in the percentage of cells
labelled with Y-chromosome, in the studies of cardiac chimerism, is due
to differences in the rigour of the methods applied to assess the pres-
ence of chimerism. It is suggested that the application of a multi-step ap-
proach to assessing Y-chromosome labelling will provide the true extent
of chimerism. In the first published application of this approach, 0.02% of
cells were found to be positively labelled after application of the technique
(Hcht-Zeisberg et al., 2004). The multi-step approach they used was first
to exclude any cells from the analysis that stained positive for either CD45
or CD68. Subsequently, any cells seen to be Y-positive were examined to
ascertain if they were true cardiomyocytes. Such cells were only passed as
cardiomyocytes if cells were large in size, with a centrally located nucleus
and typical striated cytoplasmic structure. In addition, immunofluorescent
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staining with antibodies against cardiac-specific proteins titin and calse-
questrin was also performed to confirm their identity. Additionally, single
band pass filters were used to ensure the Y-chromosome signal was not
due to autofluorescence of lipofuscin. Finally, any Y-positive cells that had
passed the above steps then had their nuclei studied by three-dimensional
confocal microscopy to confirm the exact location of the Y-chromosome
with respect to the cell’s nucleus. Using this multi-step approach, 80% of
cells that were initially defined as donor derived cardiomyocytes due to
the presence of the Y-chromosome were shown to be false positive results.
Alternative methods have been used to confirm the findings of
cardiac chimerism seen with the use of in situ hybridisation for the
Y-chromosome. One study investigated cardiac chimerism after sex-
mismatch peripheral-blood and bone marrow stem cell transplantation by
means of PCR of highly polymorphic short tandem repeat (STR) markers
(Bayes-Genis et al., 2004). Following PCR amplification of DNA extracted
from the LV free wall, 3 out of 6 patients were identified as having cardiac
chimerism, compared to none in the three patients who were all at an early
stage post-transplant. The number of chimeric cells was unable to be quan-
tified using this technique and the cells’ phenotype was also not assessed.
A further and older method that has also been used to observe chimerism,
within the transplanted heart, is the use of immunohistochemical staining
for donor specific MHC class II molecules. In this manner, endothelial cells
lining vessels of acutely rejecting allografts in rodents have been shown to
be donor derived (Hasegawa et al., 1998).
Host and donor cell fusion has been proposed as one of the possible
mechanisms for the development of chimeric cells. On examination of all
of the nuclei included in this study, only two isolated cells were found that
may have represented fusion events, both cells appearing to have three sex
chromosomes with an XXY arrangement. This finding may have been due
to two overlapping nuclei. This could have been clarified with the use of
confocal microscopy. Relatively few chimeric studies utilising human gen-
der mis-match transplants have investigated the possibility of fusion, but
those that have did not uncover any cases of fusion. Two studies using
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dual X and Y in situ hybridisation labelling of the sex chromosomes did
not report any fusion events (Bayes-Genis et al., 2002; Fogt et al., 2003). A
third study utilising laminin co-staining and chromosome 18 in situ hy-
bridisation again did not find evidence of fusion (Deb et al., 2003).
The role of chimeric cardiomyocytes observed in donor hearts is pre-
sumed to be beneficial with the expectation that they are integrated into
the myocardium and contribute to its normal function. However, there is
little evidence to back up this presumption. Histology has demonstrated
that the chimeric myocytes have normal appearance and immunohisto-
chemistry has shown that they express cardiomyocyte specific antibodies
(Bayes-Genis et al., 2002; Deb et al., 2003; Glaser et al., 2002; Hruban et al.,
1993; Hcht-Zeisberg et al., 2004; Minami et al., 2005; Mller et al., 2002). Ad-
ditionally, cardiomyocytes have been seen to form intercellular connec-
tions with the surrounding myocardium, as shown by immunostaining
with connexin43 antibody (Mller et al., 2002).
With respect to overall cardiac function, only one study has evaluated
this in a very small cohort. Echocardiographic evaluation of 3 out of 8
patients with >10% chimeric recipient cells showed no improvement in
LV function (Bayes-Genis et al., 2002).
The studies discussed above so far were focused on identifying
chimeric cardiomyocytes. Despite this, evidence for chimeric endothelial
cells (Minami et al., 2005; Quaini et al., 2002) and chimeric smooth muscle
cells (Fogt et al., 2003; Glaser et al., 2002; Quaini et al., 2002) were also seen
in these studies. Further evidence for vascular chimerism has also been
demonstrated in studies that have focused solely on this subject.
Examination of artificial grafts has proved a rich source of positive ev-
idence for donor derived formation of endothelial and vascular smooth
muscle (VSM) cells. As such grafts are entirely synthetic. Any cells demon-
strated on the graft after implantation must be donor derived (van der Lei
et al., 1986, 1985).
Studies of human sex-mismatch transplants using in situ probes for X
and Y chromosomes have also found evidence for chimerism of VSM cells.
One study demonstrated a range of 0.8% to 5.6% host-derived smooth
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muscle cells in coronary arteries (Glaser et al., 2002). A second study,
in female subjects who received a male bone marrow transplant, found
the mean percentage of male smooth muscle cells within the intima, me-
dia and adventitial microvessels of diseased coronary artery segments
was 9.4±2.8%, 2.2±0.9%, and 6.5±2.9%, respectively (Caplice et al., 2003).
These results are of a similar magnitude to that found in the study de-
scribed here.
6.4.2 Conclusion
In conclusion, there is strong evidence from animal and human transplant
studies that bone marrow is able to contribute to de novo formation of
both cardiac muscle and vasculature. The endogenous (or host) circulating
progenitor cell is able to contribute significantly to VSM and endothelial
cell formation, and to a smaller degree to cardiomyocyte formation. The
true role and functional consequences for cardiomyocyte chimerism are
unknown as yet, but they are likely to be beneficial at some small scale.
Two thoughts follow from these findings. Firstly, when utilising progeni-
tor cells, it will probably be easier to induce therapeutic neovascularisation
rather than myogenesis. Secondly, given the low level of intrinsic muscle
formation by the endogenous progenitor cells, any therapeutic functional
benefit will only be brought about by magnifying this effect either through
exogenous supplementation with other progenitor cells or by enhancing
production of the endogenous progenitor cells, e.g., by use of G-CSF.
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Discussion
Coronary artery disease is an increasing global problem resulting from
the interaction of several key elements. These are the increased number
of survivors of acute cardiac events, the rise and spread of cardiovascu-
lar risk factors, and the increasing age of the world’s population. Each of
these factors will lead to more cardiac events, but more people will sur-
vive and suffer the disability of impaired cardiac function. Thus, heart
failure, a condition with significant mortality and morbidity, will become
more common. Current pharmacological therapies fail to address the fun-
damental pathology of heart failure — the death or dysfunction of car-
diomyocytes. However, advances in stem cell biology have suggested a
mechanism of re-populating the heart muscle with functioning myocytes,
both with adult and embryonic stem cells (Behfar et al., 2005; Orlic et al.,
2001a), thereby addressing the underlying pathohistology of heart failure
for the first time. In contrast to such high hopes some have found limited
evidence for such a direct contribution to infarct healing via myogene-
sis with the use of adult derived cells (Balsam et al., 2004; Murry et al.,
2004). This has led to the continued exploration of the optimum way to
harness the unique characteristics of adult derived progenitor cells to im-
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prove impaired cardiac function. The experimental work in this thesis was
designed to further elucidate the mechanisms by which stem cells improve
damaged myocardium, both in the acute and chronic setting.
7.1 Were the Aims Achieved?
Several experimental aims were established in the introduction to this
thesis that would need to be accomplished in order to address the main
hypothesis of the thesis. Broadly speaking all of these aims were accom-
plished.
A prerequisite to all the experiments was the isolation and preparation
of bone marrow mononuclear cells (BMMNCs); this technique was suc-
cessfully developed and was routinely used in both rats and humans. Two
minor refinements in the technique significantly improved the collection
of bone marrow from rats: this was the use of a dedicated bone cutter to
remove the bone ends, without excessive shattering of the bone, and the
use of sterile gauze to remove any vestiges of muscle from the bone that
had previously inadvertently contaminated samples, disrupting the cen-
trifugation separation stage. Isolated rat cells were also characterised with
respect to basic histology demonstrating high efficiency in separation of
the mononuclear cell fraction, and with flow cytometry for further cell
phenotyping, which demonstrated that isolated cells were a mix of B and
T-cells and a high proportion of cells expressed haematopoietic stem cell
markers. In rats, the bone marrow derived cells could not be phenotyped
with respect to CD34 expression; despite following the manufacturers in-
structions and the use of multiple antibody dilutions and incubation times,
no antibody could be detected under any conditions.
A rat ischaemia-reperfusion (IR) injury model was used that in-
volved transient ligation of the left-anterior descending artery, induc-
ing ischaemia, subsequently followed by release of the ligature initiating
the reperfusion phase. This model was used in collaboration with Prof.
Thiemermann at the William Harvey Research Institute, Centre for Trans-
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lational Medicine and Therapeutics, where it had been in regular use for
several years (Sivarajah et al., 2009; Wayman et al., 2003). Additionally,
the model was newly developed at the Centre for Advanced Biomedical
Imaging at the Institute of Child Health under the guidance of Dr Lythgoe
and Prof. Martin, where the model was used to independently replicate
several important findings in the IR model.
With the establishment of the IR model, the next aim that needed to
be achieved was the administration and tracking of dispensed cells. As an
integral part of the IR model was cannulation of the right jugular vein,
it was decided to administer the cells via this route. For tracking of rat
BMMNCs, the original intention was to inject male cells into female rats
and use in situ hybridisation to track the male donor cells by detecting the
Y-chromosome. However, no commercially available rat Y-chromosome
probe existed, so an alternative solution had to be used. No transgenic
rats were available either, excluding the possibility of using a transgenic
GFP rat as the donor, although they are in use by others (Mothe et al.,
2005). Therefore a green cell tracker dye, CFDA SE, was used that allows
cells to be tracked and identified within tissues of interest after adminis-
tration due to the dye’s emission in the green fluorescent wavelength. This
technique was simple to perform and worked well in practise, others have
also had success with this technique in tracking injected cells under sim-
ilar conditions (Lutz et al., 2008). Injected cells that had homed to the IR
injured rat hearts were then simply quantified by the use of fluorescent
microscopy.
To evaluate changes in cardiac function sustained following adminis-
tration of BMMNCs in the IR model, three techniques were successfully
employed. Two longstanding techniques plus one new technique were
used: firstly, two dyes were used to assess the area at risk (AAR) of the
left ventricle (Evans’ blue) and to assess infarct size (tetrazolium blue)
(Thiemermann et al., 1997); secondly, haemodynamic catheters was used
for pressure transduction of the LV; thirdly, 2-D cardiac echocardiography
was used to assess LV function, although initially challenging compared to
the same procedure in humans, reproducible results were soon produced
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as experience of the technique was gained. The last technique, was devel-
oped for the first time within the institute, but has been used by others
previously (Gao et al., 2000; Sjaastad et al., 2000).
An important achievement to further understanding of the possible
paracrine actions of BMMNCs was the establishment of tissue cultures of
cardiomyocytes and endothelial cells (the likely end effectors of paracrine
factors) in co-culture with BMMNCs. Thus, both rat cardiomyocytes and
HUVECs were routinely cultured without problem. The typical co-culture
set up involves the use of a plastic insert that separates one set of cells from
the other. This technique was not used here. A novel technique was devel-
oped that harnessed the properties of the green cell tracker dye, CFDA SE.
Thus, the effector cells, i.e., BMMNCs were stained with the cell tracker
dye and then added for 24 hours to the cells to be examined (for example,
cardiomyocytes). Subsequently, using flow cytometry, the effector cells
were removed from any analysis by gating out any cells that were identi-
fied as stained with the green cell tracker dye due to its green fluorescence.
This method was only applicable here, as all of the outcome measures cho-
sen to evaluate changes in the co-culture system were measured by flow
cytometry. The flow cytometry outcome measures used to assess changes
induced in HUVECS or cardiomyocytes by co-culture with bone marrow
derived cells were quantification of ROS generation, mitochondrial mem-
brane potential assessment, quantification of apoptosis and necrosis and
assessment of the cell cycle. Aside from an initial problem due to an inter-
nal fault with the flow cytometer, all of these techniques were successfully
performed. However, two additional techniques were abandoned due to
lack of success: the oxygen electrode and the use of confocal microscopy
to dynamically measure mitochondrial membrane potential.
The final aim for the acute model was to establish a proteomic study;
this was accomplished by a major collaboration with Kate Lee, a PhD stu-
dent supervised by Prof. P. Munroe and Dr K. Leung at the WHRI, at the
Centre for Clinical Pharmacology. Additionally, an opportunity for a fur-
ther collaboration arose with Profs Thiemermann and Suzuki both at the
WHRI, Centre for Translational Medicine and Therapeutics. Through this
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collaboration several studies were designed to assess changes in the rat
IR model on cardiomyocyte apoptosis and necrosis, evaluate cardiac func-
tion and myocardial fibrosis after seven days’ reperfusion and to evaluate
activation of the PI3K/Akt survival pathway including downstream me-
diators following treatment with BMMNCs.
Two aims were outlined for the investigation of possible chronic mech-
anisms of bone marrow derived progenitor cell repair of cardiac tissue.
The first aim, that of using in situ hybridisation to visualise X- and Y-
chromosomes within human cardiac sex-mismatch transplants, was per-
formed successfully. The second aim, the additional use of immunohis-
tochemistry using a third fluorochrome for phenotyping of cells was ap-
plied with some limitation: the main issue was decreasing clarity of the
Y-chromosome probe. A novel method, using ELF 97 for combining three
fluorophores, one for each of the sex chromosomes and one for the marker
of phenotype, in the context of immunohistochemistry and in situ hybridi-
sation, was subsequently developed and produced far clearer results than
the usual technique.
7.2 Hypothesis
Through achieving many of the aims of the thesis, some evidence has been
found to support the main hypothesis that administration of adult derived
bone marrow progenitor cells leads to significant restoration of cardiac
function in both the acute and chronic infarct setting. It was also proposed
that the mechanism of benefit would differ in the acute setting compared
to the chronic setting and for this, evidence has also been found.
To expand on this point, the mechanism of acute repair from a logical
perspective could be considered more likely to be related to the release of
local factors that act on cells within the myocardium reducing IR injury.
Apart from very early reperfusion (Nallamothu et al., 2007) the only other
consistently observed mechanism of reducing infarct size, with subse-
quent preservation of cardiac function, is prevention of reperfusion injury
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(Yellon & Hausenloy, 2007). The possibility of injected BMMNCs transd-
ifferentiating into cardiomyocytes and endothelial cells within a matter of
hours following myocardial infarction, seems an unlikely prospect next to
the extensively documented interventions that can ameliorate reperfusion
injury (Gross & Gross, 2006). Thus, using the acute IR injury model and tis-
sue culture techniques evidence for a paracrine mechanism that could re-
duce reperfusion injury was sought, and evidence for this case was found
as discussed below.
In chronic cardiac dysfunction situations, such as in chronic heart fail-
ure a scenario, where the acute insult may have occurred weeks or months
previously there is no acute IR injury and thus no benefit would be gained
from reduction of reperfusion injury. As predicted, there are no studies
that demonstrate benefit of reperfusion injury modulation in this chronic
scenario. However, there are multiple sex-mismatch cardiac transplant
studies in humans, and one novel study that carbon dated human car-
diomyocyte DNA that demonstrates de novo generation of myocardium
and endothelial cells in the chronic setting (Bergmann et al., 2009; Deb
et al., 2003; Fogt et al., 2003; Glaser et al., 2002; Hcht-Zeisberg et al., 2004;
Laflamme et al., 2002; Mller et al., 2002; Quaini et al., 2002). Several stud-
ies have even suggested that the new cell formation is increased in patho-
logical conditions such as heart failure, in a hitherto undocumented ho-
moeostatic response (Beltrami et al., 2001; Kajstura et al., 1998; Urbanek
et al., 2003). Hence, in chronic cardiac conditions it appears as if a dif-
ferent mechanism of action must be used to explain the observations of
many independent researchers, that mechanism appears to be the produc-
tion of new myocytes and endothelial cells. Evidence for such activity was
sought in human sex-mismatch transplants. Furthermore, mesenchymal
stem cells (MSCs) were investigated to ascertain their ability to transdiffer-
entiate into cardiomyocytes in vitro and in vivo in the rat IR injury model.
If the MSCs did demonstrate such capabilities, this would highlight their
potential for use in chronic conditions that require myocyte replacement
rather than reduction of reperfusion injury.
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7.3 Acute Studies
The first finding in the acute model was the observation that the ability
of cells to home to the myocardium was reduced in cells cultured for 72
hours compared to cells cultured for 24 hours. To maximise the benefits
of cell treatment, every step of the process must be tested and optimised.
The handling of cells prior to their use is an under-investigated area. No
publications to date have reviewed optimisation of culture conditions with
respect to impact of cell homing. Much more work has been done to inves-
tigate the role of chemokines and growth factors in progenitor cell homing
to the myocardium. Stromal cell-derived factor-1 (SDF-1) has been identi-
fied as a significant factor in homing. It is up-regulated during ischaemia
(Ceradini et al., 2004; De Falco et al., 2004), and blocking of SDF-1 and
its receptor CXCR4 inhibits progenitor cell homing to the ischaemic my-
ocardium (Abbott et al., 2004). Further to this, over expression of SDF-1 en-
hances homing of progenitor cells to ischaemic tissues (Askari et al., 2003;
Yamaguchi et al., 2003). Thus, there is strong evidence for a prominent role
for SDF-1 in progenitor cell homing. Other candidates have also been iden-
tified to play a role in homing to the ischaemic myocardium: they include
IL-8, CXCR1/2, and β1- and β2-Integrin (Ip et al., 2007; Kocher et al., 2006;
Wu et al., 2006).
It would seem reasonable to suggest that the reduction in homing wit-
nessed with prolonged cell culture, prior to cell injection, may be related
to down regulation of one of the important stem cell homing receptors
such as CXCR4. To overcome this issue the effects of tissue culture on
the expression of CXCR4 on progenitor cells should be investigated. Re-
duced homing could be avoided either by rectifying the factors associated
with the down regulation of important receptors, or as others have already
done by inducing over expression of stem cell homing factors in the heart
or overexpressing their corresponding receptors on the cells to be injected
prior to their administration.
The next, noteworthy observation, from the acute model was the low
frequency of injected cells that were identified in the IR injured hearts
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at six hours following administration. Given that 107 BMMNCs were in-
jected, it can be estimated that <1% of the injected cells remained within
the myocardium six hours post injection. This provides some credence to
the hypothesis that acute benefits are related to paracrine action, as it can
also be roughly estimated that this number of cells, if they did undergo
transdifferentiation, would only replace the equivalent of 1 in every 3,500
cardiomyocytes (average 300 g rat has 500 myocytes per mm2, at most
0.14 homed cells were found per mm2). Such a small ratio of replacement
could not account for the infarct size reduction seen if the mechanism was
direct transdifferentiation. The small quantity of cell retention observed
here is in keeping with previously published work, for example, after in-
travenous infusion of ex vivo cultured endothelial progenitor cells in rats,
following myocardial infarction, after 24 hours only 2% of infusion was
found within the heart (Aicher et al., 2003). In a second study 3.2±1% cell
engraftment was seen at 1 hour after cell delivery (retrograde coronary
sinus injection in pigs), (Hou et al., 2005). In humans only background
activity was demonstrated from radiolabelled cells at approximately one
hour after intravenous cell injection, suggesting minimal retention of cells
(Hofmann et al., 2005).
The most striking finding in the acute model was the significant and
large reduction in infarct size seen with BMMNC treatment. No other
study has administered BMMNCs immediately upon reperfusion and
then assessed infarct size within a few hours. The closest study in compar-
ison to the work reported here, used a mouse infarct model with ligation of
the left coronary artery; however the ligature was never released removing
reperfusion injury from the model, but 108 BMMNCs were injected intra-
venously immediately at the onset of ischaemia. When assessed two days
later, infarct size was 17% less in treated animals (Hiasa et al., 2004). In
another similarity to the work described here, they estimated that homed
BMMNCs represented 1% of total nuclei counted. They also demonstrated
that BMMNCs can secrete VEGF in tissue culture and within ischaemic
myocardium; when VEGF was blocked, infarct size reduction by BMM-
NCs was attenuated. All of these findings are in concurrence with the hy-
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pothesis that the acute actions of BMMNCs in MI are related to paracrine
effects.
The only other work with BMMNCs that has come close to the same
time point of administration used a rabbit IR injury model, in which is-
chaemia lasted 30 minutes, following 5 hours of reperfusion 108 BMM-
NCs were injected intravenously. Infarct size was assessed 7 days later and
found to be on average 10% less in the treated group. Evidence of myoge-
nesis was seen using electron microscopy, but it was felt that the number
of regenerated cardiomyocytes within infarcted areas was too small to ex-
plain the 10% decrease in infarct size and the majority of benefit was due
to BMMNC induced expression of repair-related cytokines that facilitated
cardiac repair (Misao et al., 2006).
It is of interest that the work here administered BMMNCs at a time
point that is optimum to reduce reperfusion injury, consistent with this
the largest reduction in infarct size was seen at this time point. When cells
were administered either while the ligature remained in situ around the
coronary artery (Hiasa et al., 2004), or 5 hours after reperfusion (Misao
et al., 2006), both scenarios that would reduce impact on reperfusion in-
jury, infarct size reduction was still seen but lower than that see with the
work discussed here. Moreover, when BMMNCs were administered in a
swine model 4 days following infarction, a time point when no effect on
reperfusion injury would be expected, no infarct size reduction was seen
using cardiac MRI (de Silva et al., 2008).
However, infarct size reduction has been demonstrated at later time
points of injection in human studies. In the case of acute myocardial in-
farction (AMI), delivery of circulating progenitor cells or bone marrow
derived cells on average 5 days following infarction resulted in a signifi-
cant 11% infarct size reduction (Britten et al., 2003). This benefit was main-
tained at one year follow up (Schachinger et al., 2004). When bone mar-
row derived cells were given earlier, on average one day after successfully
primary angioplasty for AMI, MRI demonstrated a relative infarct size re-
duction of 28% in the treated group over control patients (Janssens et al.,
2006). These results in humans still offer support for the hypothesis of a
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paracrine effect of BMMNCs in the acute scenario due to the observation
that the earlier time point of injection after AMI produced the largest re-
duction in infarct size.
The results of one human study cannot be explained by this theory, as
it suggested infarct size reduction in the setting of chronic myocardial in-
farction, BMMNCs were administered intracoronary to patients between
5 months up to 8.5 years following the primary event SPECT and PET
were then used 3 months later to demonstrate a 30% infarct size reduction
(Strauer et al., 2005). Presumably, the infarct size amelioration seen in this
chronic study was due to myogenesis and vasculogenesis, but there is no
evidence to support or refute this from this study to date.
Investigation of infarct size reduction has also been performed exten-
sively in the MSC subpopulation of BMMNCs. MSCs have been admin-
istered by a variety of routes, at time points including 1 hour, 2 hours, 1
week and 2 weeks following induction of ischaemia. All studies appear to
have shown varying degrees of infarct size reduction, which can be aug-
mented by using MSCs transfected to overexpress VEGF (Hu et al., 2007;
Jiang et al., 2006; Matsumoto et al., 2005; Nagaya et al., 2004; Shyu et al.,
2006; Tang et al., 2006; Yang et al., 2007). The mechanism of benefit has
been suggested to be myogenesis and angiogenesis by several investiga-
tors, while others have considered a paracrine effect.
There are two MSC studies of note that support the hypothesis for an
acute paracrine effect. In a rat MI model, both MSCs transfected with Akt
and Akt-MSC conditioned media significantly limited infarct size when
administered into the infarct border zone one hour after ischaemia was es-
tablished (Gnecchi et al., 2006). The genes for VEGF, FGF-2, HGF, IGF-1,
and TB4 were all found to be up-regulated within the Akt-MSCs, espe-
cially in the setting of hypoxia. These data strongly support a paracrine
mediated mechanism for myocardial protection in AMI. The second sup-
portive study used cardiac cryoinjury in rats; immediately following in-
jury MSCs were injected into the border zone (Jaquet et al., 2005). Infarct
size was assessed 10 weeks later and found to be significantly reduced, but
no evidence of myogenesis or vasculogenesis could be found — indirect
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evidence for a paracrine effect over transdifferentiation.
7.3.1 Mechanism
Having observed a significant reduction in infarct size with BMMNC treat-
ment at the onset of reperfusion, evidence for a paracrine effect on IR in-
jury was sought, as this appeared to be the most likely mechanism given
the size and speed of the effect seen in the context of the limited number
of cells found within the myocardium. Other infarct size studies as de-
scribed above also contributed to the consideration of a paracrine effect as
the responsible mechanism.
To examine paracrine effects, co-culture experiments were performed
using rat and human BMMNCs in culture with either cardiomyocytes or
endothelial cells. The co-culture experiments demonstrated that BMMNCs
in some instances reduced the levels of reactive oxygen species, and apop-
tosis and necrosis, within the other co-cultured cell populations. No effects
on the cell-cycle were seen. An examination of in vivo paracrine effects
was then performed in the same rat IR model as used previously. Apopto-
sis and necrosis, and caspase-9 activation, within cardiomyocytes isolated
from the area at risk after IR injury, was assessed with flow cytometry and
found to be significantly reduced in the BMMNC treated group. No func-
tional improvement was seen at three hours post injection, but at 7 days
the BMMNC treated group had improved cardiac function, and reduced
burden of fibrosis versus controls. Western blot studies demonstrated ac-
tivation of the reperfusion injury salvage kinase (RISK) pathway within
hearts treated with BMMNCs, analogous to that seen in ischaemic pre- and
post-conditioning. Blocking the RISK pathway abolished the reduced in-
farct size produced by BMMNC treatment. Finally, global proteomic anal-
ysis confirmed BMMNC treatment induced alterations in protein expres-
sion consistent with known cardioprotective pathways.
Taken together these results support the hypothesis that in acute car-
diac IR injury, BMMNCs reduce infarct size by modulating reperfusion
injury with subsequent reduction of sequelae of reperfusion injury includ-
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ing apoptosis and necrosis, and reactive oxygen species (ROS) generation.
These changes had positive functional consequences as demonstrated by
improved cardiac function when assessed 7 days post IR injury. The small
numbers of injected cells retained in the heart did not correspond to the
level of infarct size reduction or to the functional benefit gained, thus it
appeared that a process other than de novo myogenesis or angiogenesis
accounted for the observed effects. However, evidence for a paracrine ef-
fect was found, as BMMNC treatment activated the RISK pathway, one of
the major mechanisms by which pre- and post-conditioning reduce IR in-
jury. Underlining this point, when the RISK pathway was blocked with a
specific inhibitor, all significant beneficial effects of the BMMNC treatment
were abolished. To comprehend the interaction of BMMNCs with the RISK
pathway and reperfusion injury it is first necessary to discuss reperfusion
injury, the RISK pathway, and the mechanisms entailed in greater depth.
7.3.2 Ischaemia-Reperfusion Injury
After an acute myocardial infarction, early and successful myocardial
reperfusion with primary percutaneous coronary intervention (PCI) is the
most effective strategy for reducing the size of infarction and improv-
ing outcome. The process of restoring blood flow to the ischaemic my-
ocardium, however, can induce injury that is termed reperfusion injury,
and can be defined as myocardial injury caused by the restoration of coro-
nary blood flow after an ischaemic episode. Such injury increases car-
diomyocyte death beyond that which was present at the start of reperfu-
sion (Piper et al., 1998). Animal models of AMI suggest that lethal reper-
fusion injury can account for up to 50% of infarct size, and in these models
a number of strategies have been shown to ameliorate reperfusion injury.
Several mediators of reperfusion injury have been identified. In broad
outline, reperfusion injury is caused by the restoration of blood flow that
induces a cascade of events that results in generation of ROS, intracellu-
lar Ca2+ overload, rapid restoration of physiological pH and mitochon-
drial re-energisation, and inflammation. These processes can culminate in
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cardiomyocyte death through opening of the mitochondrial permeability
transition pore (mPTP) and cardiomyocyte hypercontracture.
As the re-establishment of blood flow bringing oxygen and fuel would
normally be expected to be beneficial, the adverse consequences of restora-
tion of the blood supply are often thought of as a series of paradoxes.
Oxidative stress, in the shape of ROS, is part of the oxygen paradox, in
which the reoxygenation of ischaemic myocardium generates myocardial
injury that exceeds the injury induced by ischaemia alone (Hearse et al.,
1973).
The calcium paradox describes the rapid increase in intracellular Ca2+
and the subsequent deleterious effects this causes. Normal cellular Ca2+
homoeostasis is impaired due to sarcolemmal-membrane damage and
ROS-induced dysfunction of the sarcoplasmic reticulum. This results in
cellular and mitochondrial Ca2+ overload inducing cardiomyocyte death
by hypercontracture and by mitochondrial PTP opening (Piper et al.,
1998).
The last of the trio of paradoxes is the pH paradox, in which the sudden
restoration of physiologic pH during reperfusion contributes to reperfu-
sion injury (Lemasters et al., 1996). The return of blood flow rectifies cellu-
lar pH by washing away accumulated lactic acid and also allows restora-
tion of the action of energy-dependent ion pumps such as the sodium-
hydrogen exchanger and the sodium-bicarbonate symporter that are im-
portant in controlling cellular pH.
Although not considered one of the paradoxes of reperfusion injury,
inflammation has a significant role, especially neutrophils that cause vas-
cular plugging and release of harmful enzymes and ROS.
These four processes, the three paradoxes and inflammation, act in con-
cert in the following way to cause reperfusion injury. ROS are generated
by xanthine oxidase and the re-energised electron transport chain in the
cardiomyocyte mitochondria. A further source of ROS is NADPH oxidase
(mainly from neutrophils). ROS mediate myocardial injury by inducing
mPTP opening, acting as neutrophil chemoattractants, mediating dysfunc-
tion of the sarcoplasmic reticulum and contributing to intracellular Ca2+
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overload, damaging the cell membrane by lipid peroxidation, inducing
enzyme denaturation, and causing direct oxidative damage to DNA (Yel-
lon & Hausenloy, 2007).
ATP generation from re-energised mitochondria in the context of intra-
cellular Ca2+ overload induces cardiomyocyte death by hypercontracture,
a process contributed to by restoration of physiologic pH during reperfu-
sion. Moreover, the restoration of the mitochondrial membrane potential
drives the entry of Ca2+ into mitochondria that, in tandem with the loss of
the inhibitory effect of the acidic pH on the mPTP and the generation of
ROS, act in concert to mediate the opening of the mPTP (Yellon & Hausen-
loy, 2007).
The mitochondrial PTP is a non-selective channel of the inner mi-
tochondrial membrane. Opening of the channel collapses mitochondrial
membrane potential and uncouples oxidative phosphorylation, resulting
in ATP depletion and cell death (Hausenloy & Yellon, 2003). During is-
chaemia, the mPTP remains closed, only to open after myocardial reperfu-
sion in response to mitochondrial Ca2+ overload, oxidative stress, restora-
tion of a physiologic pH, and ATP depletion (Griffiths & Halestrap, 1995;
Kim et al., 2006). Opening of the mPTP induces cardiomyocyte death
by uncoupling oxidative phosphorylation and inducing mitochondrial
swelling. Therefore the mPTP is a critical determinant of lethal reperfu-
sion injury.
Finally, after reperfusion has been established for some hours, neu-
trophils accumulate in the infarcted tissue in response to the release of
the chemoattractants (ROS, cytokines, and activated complement). The
up-regulated cell-adhesion molecules P-selectin, CD18 and CD11, and in-
tracellular adhesion molecule 1 (ICAM-1) then facilitate the migration of
neutrophils into the myocardial tissue, where they mediate cardiomyocyte
death by causing vascular plugging, releasing degradative enzymes, and
generating ROS (Yellon & Hausenloy, 2007).
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7.3.3 Reperfusion Injury Interventions
It has been consistently shown that interventions, which address the
pathophysiology of reperfusion injury, can reduce myocardial infarct size.
A common connection in amelioration of reperfusion injury appears to
be activation of the RISK pathway (Hausenloy et al., 2005b). The RISK
pathway refers to a group of protein kinases that, when specifically acti-
vated during myocardial reperfusion, invoke cardioprotection by prevent-
ing lethal reperfusion injury. The RISK pathway is thus a mediator of cell
survival (Davidson et al., 2006; Hausenloy & Yellon, 2006, 2007).
The best described components of the RISK pathway are protein ki-
nases Akt and Erk1/2. Multiple signal transduction pathways triggered
by a diverse range of interventions that reduce reperfusion injury appear
to converge at the point of RISK pathway activation. Activation and sub-
sequent cardioprotection at the time of myocardial reperfusion in many
cases appears to be due to ligand binding at specific G-protein coupled re-
ceptors resulting in the transactivation of receptor tyrosine kinases which
in turn activate the PI3K-Akt and Ras-MEK1-2-Erk1/2 signalling cascades.
The mechanisms by which RISK pathway activation reduces reperfu-
sion injury — and consequently reduces infarct size — appears to be due
to anti-apoptotic signalling and inhibition of mPTP opening. RISK path-
way activation is associated with the recruitment of anti-apoptotic sig-
nalling systems such as the phosphorylation and inhibition of the pro-
apoptotic proteins BAX and BAD, the inhibition of caspase 3 activation,
and the phosphorylation and activation of p70s6K, which acts to inhibit
BAD (Harada et al., 2001), and the phosphorylation and activation of the
anti-apoptotic protein Bcl-2 (Hausenloy & Yellon, 2004). The second pro-
survival mechanism appears to be inhibition of mPTP opening (Bopassa
et al., 2006; Davidson et al., 2006; Juhaszova et al., 2004), an inner mem-
brane channel that can, as discussed above, mediate cell necrosis dur-
ing reperfusion (Crompton, 1999). The mechanism of mPTP inhibition re-
mains to be determined at this time.
The best known methods for inducing activation of the RISK path-
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way are pre- and post-conditioning (da Silva et al., 2004; Fryer et al.,
2001; Fujita et al., 2007; Hausenloy et al., 2005a; Manintveld et al., 2007;
Solenkova et al., 2006). Ischaemic preconditioning is a phenomenon in
which the size of a myocardial infarct is reduced by initiating episodes
of transient myocardial ischaemia and reperfusion before the sustained is-
chaemic episode. Ischaemic post-conditioning, on the other hand, which
also limits infarct size involves transient episodes of ischaemia and reper-
fusion immediately subsequent to re-establishing reperfusion (Kloner &
Rezkalla, 2006; Tsang et al., 2005; Yellon & Downey, 2003; Zhao & Vinten-
Johansen, 2006). Besides these mechanical methods of activating the RISK
pathway, and reducing reperfusion injury, a diverse range of cytokines,
growth factors and pharmaceuticals have also been shown to activate the
RISK pathway. These include TGFβ-1 (Baxter et al., 2001b), IGF-1 (Otani
et al., 2000; Yamashita et al., 2001), FGF-2 (Jiang et al., 2002), G-CSF (Ueda
et al., 2006), and Erythropoietin (Bullard et al., 2005; Hanlon et al., 2005).
The list of potential trigger agents is more extensive than described here
and a review of such agents can be found in Hausenloy & Yellon (2007).
7.3.4 Interaction of BMMNCs and Reperfusion Injury
Having now discussed reperfusion injury and the RISK pathway in greater
detail, the findings demonstrated here can be put in context. The infarct
size reduction shown here with injection of BMMNCs was associated
with activation of the RISK pathway, specifically the PI3K-Akt pathway,
and blocking this pathway ameliorated all significant benefits of BMMNC
treatment. Presumably activation of the RISK pathway by BMMNCs here
culminated in activation of the anti-apoptotic pathways discussed above
and inhibition of opening of the mPTP. There is no direct evidence for
this as no assessment of the mediators of the anti-apoptotic pathways was
made; likewise no investigation of the state of mPTP was made. However,
indirect evidence was seen, that of reduced apoptosis and necrosis and
caspase-9 activation. Further evidence was found in the proteomic analy-
sis, which indicated that BMMNC treatment resulted in the up-regulation
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of the chaperone protein 14-3-3 epsilon that is known to have pro-survival
functions including its ability to bind and inhibit the Bcl-2 related pro-
tein Bad in its phosphorylated conformation (Masters et al., 2001). As dis-
cussed above Bad phosphorylation is thought to be one of the many down-
stream actions of the PI3K/Akt pathway (Datta et al., 1997).
How the injected BMMNCs activated the RISK pathway remains to be
determined, but there is evidence as proposed in the thesis hypothesis that
the mechanism is related to release of paracrine factors. Two general ob-
servations support this view: firstly, the RISK pathway with subsequent
infarct size reduction can be activated by a wide variety triggers includ-
ing cytokines and growth factors, e.g., TGFβ-1 (Baxter et al., 2001b), IGF-1
(Otani et al., 2000; Yamashita et al., 2001), FGF-2 (Jiang et al., 2002), G-CSF
(Ueda et al., 2006), and Erythropoietin (Bullard et al., 2005; Hanlon et al.,
2005); secondly, BMMNCs and the MSC sub-population have been docu-
mented to release, or up-regulate in local tissues, an increasingly large list
of cytokines and growth factors. For example, the genes for VEGF, FGF-
2, HGF, IGF-1, and TB4 were all found to be up-regulated within MSCs
transfected with Akt. Both FGF-2 and IGF-1 have been documented to acti-
vate the RISK pathway. Additionally, this study demonstrated infarct size
reduction with Akt-MSC or Akt-MSC conditioned media. This strongly
supports a paracrine mediated mechanism for myocardial protection in
AMI, such as activation of the RISK pathway and reduction of reperfusion
injury (Gnecchi et al., 2006). To date the following other factors have been
derived from BMMNCs and MSCs: VEGF, bFGF, Ang-1, IL-1β, IL-1, IL-6,
TNF-α, IGF, Akt, eNOS, TGF-β, PIGF, PDGF, G-CSF and HGF (Kamihata
et al., 2001; Kinnaird et al., 2004b,c; Rehman et al., 2003; Uemura et al.,
2006). If we combine the list of factors known to activate the RISK path-
way and the factors released by BMMNCs or MSC this gives a combined
list of potential factors that could be responsible for RISK pathway activa-
tion seen in the model used here, namely: TGFβ, IGF-1, FGF, and G-CSF.
As discussed in §4.8, another component of the amelioration of reper-
fusion injury, aside from activation of the RISK pathway, could be a di-
rect effect on ROS. MSCs in particular can reduce ROS generation. MSCs
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express the enzymes required to manage ROS, in particular high levels
of glutathione peroxidase (Valle-Prieto & Conget, 2010), and have been
shown to to produce superoxide dismutase (SOD) (Kemp et al., 2010).
In summary, it is now possible to postulate the following scenario:
BMMNCs injection immediately upon reperfusion activates the RISK
pathway by release of paracrine factors — possibly one of TGFβ, IGF-1,
FGF, or G-CSF — which up-regulate anti-apoptotic systems and inhibit
mPTP opening thus reducing infarct size; a direct effect on ROS reduction
may also contribute to reduced infarct size.
7.4 Chronic Studies
As previously discussed, the hypothesis for the mechanism of benefit of
BMMNC treatment in chronic cardiac dysfunction is considered to be dif-
ferent from that in AMI, such that transdifferentiation with myogenesis
and vasculogenesis is considered the only possible mechanism able to re-
store chronic cardiac dysfunction.
To investigate such a possible mechanism of de novo myogenesis and
vasculogenesis in the adult heart, in situ hybridisation was used to detect
X and Y chromosomes within ex-planted human sex-mismatched hearts,
thus we used female donor hearts transplanted into male hosts. Host de-
rived cells, identified by the Y chromosome, were found in donor hearts,
most frequently within neointimal lesions, suggesting ongoing cardiac tis-
sue repair by cells originating outside the donor heart, but in this case
contributing to a pathological process. Despite that fact of the undesirable
contribution to neo-intimal hyperplasia seen, clear evidence for de novo
cell formation was found, supporting the hypothesis of transdifferentia-
tion in chronic cardiac dysfunction.
The repair phenomenon seen was of a very low frequency, as noted by
a considerable number of other studies. Therefore this mechanism proba-
bly lacks the capacity to effectively respond to major cell loss events such
as myocardial infarction; to treat chronic cardiac dysfunction, methods for
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increasing this low-level intrinsic repair process must be found. One op-
tion would be to transplant an exogenous supply of cells capable of myo-
genesis and vasculogenesis into the myocardium instead of relying on the
native process.
Hence, the capacity of the human immortalised MSC line V54.1 to sup-
plement endogenous cardiac repair was examined in vitro, and in the
same rat model of IR injury as used in the previously discussed exper-
iments. No tendency for the MSCs to form cardiomyocytes was noted
when cultured with 5-azacytidine or with ascorbic acid. Furthermore, the
injected MSCs failed to home to the ischaemic rat heart or improve cardiac
function in the rat IR model. Failure to demonstrate any in vitro myoge-
nesis or functional benefit in vivo may have been due to the inter-species
nature of the experiment or because of changes induced in the MSCs dur-
ing the immortalisation process. The failure documented here is not a
lone finding, as others have also documented failure to transdifferentiate
MSCs into cardiomyocytes in vitro using 5-azacytidine (Liu et al., 2003).
However, others have reported success in transdifferentiating MSCs into
cardiomyocytes under the same conditions with 5-azacytidine (Antonitsis
et al., 2008; Kadivar et al., 2006; Xu et al., 2004; Zhang et al., 2005). MSCs
have many characteristics that make them an ideal choice for use in car-
diac stem cell treatments. They are relatively straightforward to isolate and
are stable in culture (allowing genetic manipulation if needed). They also
have the potential to release factors that reduce ROS generation and to
modify reperfusion injury. Thus, despite the negative results found here,
there is good reason to continue investigation of the potential of MSCs to
contribute to cardiac repair.
7.5 Future Work
The work performed here could be improved in several ways. The in
vitro co-culture experiments were not an ideal model of IR injury and
this could be improved by implementing hypoxic tissue culture methods.
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Also, no attempt was made to identify what factors BMMNCs released
in the tissue culture experiments, this information could have strength-
ened the hypothesis of paracrine factor release. With respect to the in vivo
IR injury model experiments, two significant limitations were, firstly, the
lack of a cellular control. Thus it is not entirely clear if the effects demon-
strated were due to the special characteristics of BMMNCs or would the
same effects be seen with the injection of an equivalent dose of a non-
progenitor cell type, e.g., cardiac fibroblasts. Secondly, further evidence
for a paracrine effect would have been demonstrated if the same benefit
in infarct size reduction could have been demonstrated with the injection
of BMMNC conditioned media in the IR injury model. This experiment
was not performed. More weight for the hypothesis of a paracrine effect
could also have been obtained by quantifying the expression of the pro-
posed cytokines and growth factors capable of activating the RISK path-
way. Finally, the study would also have been improved by assessing the
end effectors of the RISK pathway, providing further evidence of func-
tional activation of this pathway.
Future work should attempt to correct the above deficiencies. Thus,
the in vitro co-culture work should be repeated under hypoxic conditions
modelling IR injury. The ability of BMMNCs to release paracrine factors
in vitro and in the IR model should be assessed. The IR model should be
repeated with two additional treatment arms, these being BMMNC condi-
tioned media and a non-progenitor cell line injection arm, e.g., cardiac fi-
broblasts. Further assessment of activation of the RISK pathway should be
performed, especially with respect to evaluation of the end effectors, these
being inhibition of the mPTP opening and activation of anti-apoptotic
signalling systems effecting proteins such as BAX, BAD, caspase 3 and
p70s6K. If further clarity is obtained regarding the paracrine factors re-
sponsible for the infarct size reduction after the above work, then gain
and loss of function studies using the identified paracrine factors would
be important to underline the biological importance of the findings.
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7.6 Conclusion
In summary, the endogenous repair process within the native adult my-
ocardium appears to be quantitatively inadequate to compensate for large
cell loss events such as AMI. Supplementing this process with exogenous
BMMNCs in a rat IR model provided a significant benefit to infarct size
and LV function. The mechanism of benefit appears to be induced by
paracrine effects rather than myogenesis, and is likely to represent activa-
tion of the RISK pathway with reduction in reperfusion injury. This is the
first time evidence for such a mechanism has been presented. Thus, this
thesis progresses understanding of the role of bone marrow derived stem
cells, highlighting paracrine effects, in ameliorating cardiac injury in a rat
IR model and provides new basic science insights into the acute mecha-
nisms of benefit. These findings have significant implications for clinical
research, especially with respect to the optimal timing of BMMNC deliv-
ery in AMI.
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